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40.1 Abstract
The norovirus genotype GII.4 is a leading cause of human gastroenteritis worldwide and
has caused six pandemics since the mid-1990s. In this thesis, we use phylogenetic anal-
yses to investigate the evolutionary history of the GII.4 genotype and the sources and
drivers of norovirus pandemics.
We first examine the early history of GII.4 and suggest that the increased prevalence
of GII.4 concomitant with the first pandemic was a ‘perfect storm’ where a virus capable
of accommodating a high level of amino acid change with a high mutation rate enabling
efficient transmission acquired a highly stable viral capsid and/or an increased susceptible
population size by expanding its receptor-binding repertoire.
We next reconstruct the temporal history of GII.4 and demonstrate that each pan-
demic strain circulated undetected within poorly sampled reservoir populations for years
prior to pandemic emergence. Over several years prior to pandemic emergence, the strain
diversifies into a large number of lineages and spatiotemporal reconstruction suggests the
strain undergoes low-level worldwide circulation. This indicates that the viral genetic
changes important for pandemic emergence are acquired years prior to the pandemic and
are therefore not the proximal driver of pandemic spread; we hypothesise that genetic
changes pre-adapt the strain for future emergence by shifting the virus to a new region
of antigenic space. We demonstrate significant amino acid diversity within pandemic
strains, with highly diverse sites within a strain often coinciding with immune epitopes
and/or receptor-binding regions. This diversity begins to be accumulated prior to pan-
demic emergence. We hypothesise that increasing host population immunity curtails cir-
culation of the preceding pandemic strain and results in a new pandemic by opening a
niche into which many closely related but subtly different viral lineages can emerge.
Finally, we examine two newly emerging norovirus strains and demonstrate that they
share polymerase substitutions that may enable increased transmission.
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Chapter 1
Introduction
1.1 Norovirus gastroenteritis and global prevalence
1.1.1 Norovirus prevalence and disease burden
The report of Zahorsky in 1929 described the ‘winter vomiting disease’, an illness
characterised by the rapid onset of self-limiting vomiting and diarrheoa that exhibited
peaks in winter months (Zahorsky, 1929). It was not until 1972 that Kapikian et al iden-
tified the aetiological agent likely responsible for winter vomiting disease in a gastroen-
teritis outbreak in an elementary school in Norwalk, Ohio (Kapikian et al., 1972). This
Norwalk agent was the first causative agent of acute infectious nonbacterial gastroenteritis
to be identified (Kapikian et al., 1972) and is the prototype virus for the Norovirus genus,
one of five genera within the Caliciviridae. While the disease burden of norovirus was
initially hard to assess due to a lack of simple diagnostic tests (Widdowson et al., 2005),
the cloning of the norovirus genome in 1990 and the advent of reverse transcription-
polymerase chain reaction (RT-PCR) enabled assessment of the contribution of norovirus
to the global burden of gastroenteritis (Xi et al., 1990; Widdowson et al., 2005; Lopman
et al., 2016). Norovirus is now estimated to cause roughly 684 million episodes of di-
arrheoal disease annually, afflicting close to 1 in 10 of the world’s population each year
(Kirk et al., 2015; Pires et al., 2015; Lopman et al., 2016). Norovirus is ubiquitous and
is associated with gastroenteritis in low-, middle- and high-income countries and within
community, outpatient and inpatient settings (Ahmed et al., 2014; Lopman et al., 2016;
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Mans et al., 2016). Prevalence estimates suggest that norovirus is the leading cause of
diarrhoeal cases in patients of all age groups (Pires et al., 2015; Lopman et al., 2016),
causing roughly 18% of acute gastroenteritis cases and 50% of gastroenteritis outbreaks
worldwide (Patel et al., 2009; Ahmed et al., 2014). Seroprevalence studies suggest that
almost all adults have been exposed to at least one norovirus (Donaldson et al., 2010).
The majority of norovirus sampling is carried out in outbreak environments, typi-
cally in hospitals and aged care facilities, and little is known about norovirus prevalence
and epidemiology in outbreaks and sporadic gastroenteritis in the community (Inns et al.,
2017). The prevalence of norovirus in the community is therefore thought to be sub-
stantially underestimated (Inns et al., 2017). The Infectious Intestinal Disease studies
(IID1 and IID2) were carried out in the UK from 1993-1996 and 2008-2009 and esti-
mated the community prevalence of norovirus (Wheeler et al., 1999; Tam et al., 2012).
The IID2 study estimated that roughly 3 million clinically significant norovirus cases
(defined as detection of norovirus with a cycle threshold (ct) value of 30 of less) occur
in the UK annually (Tam et al., 2012). More recently, Harris et al. (2017) used a less
stringent, but diagnostically relevant, ct cutoff of 40 to define norovirus cases and re-
estimated norovirus prevalence in the UK at 3.7 million (95% confidence interval (CI)
3.3-4.1 million) annual infections. While norovirus is associated with gastroenteritis in
all age groups, age-specific incidence rates from the IID2 study demonstrated that the
infection rate is significantly higher in children under five years of age compared with
other age groups in both the community (142.6 cases per 1000 person years (95% CI
99.8-203.9) versus 37.6 (95% CI 31.5-44.7)) and presenting to primary healthcare (14.4
cases per 1000 person years (95% CI 8.5-24.5) versus 1.4 (95% CI 0.9-2.0)).
There has been significant progress in reducing global diarrhoeal deaths, with a 50%
reduction from 2.6 million deaths in 1990 to 1.3 million deaths in 2013 (GBD 2013 Mor-
tality and Causes of Death Collaborators, 2015). However, diarrhoeal deaths remain sig-
nificant and still represent the fourth most common cause of mortality (GBD 2013 Mor-
tality and Causes of Death Collaborators, 2015). Norovirus is estimated to cause roughly
212,000 deaths annually, with the vast majority of these deaths occurring in countries de-
fined as middle- or high-mortality by the World Health Organisation (Pires et al., 2015).
Most deaths occur in children under five years of age and norovirus is the second most
frequent cause of diarrheoal death in this age group, in addition to being the most fre-
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quent cause of diarrheoal death in children over the age of five (Lopman et al., 2016).
While the number of deaths in developed countries is far lower, norovirus has resulted in
fatalities within young children, the immunocompromised and elderly patients. Annually,
norovirus is estimated to result in 64,000 episodes of diarrheoa requiring hospitalisation
and 900,000 clinic visits in children from developed countries (Patel et al., 2008). Addi-
tionally, with the introduction of rotavirus vaccination, noroviruses are now the most fre-
quent cause of diarrheoal illness requiring medical attention in children under five years
of age in the USA (Payne et al., 2013). Recent estimates suggest norovirus has a global
economic cost of US$60.3 billion in societal costs and US$4.2 billion in direct health sys-
tem costs annually, with most of this economic burden due to disease in children under
five years of age (Bartsch et al., 2016).
1.1.2 Symptoms of norovirus gastroenteritis
Norovirus infection has a typical incubation period of 24-48 hours (median 1.2 days)
(Patel et al., 2009; Lee et al., 2013). Symptoms can vary from individual to individual,
but often consist of vomiting and/or non-bloody diarrheoa, which may be accompanied
by nausea, stomach cramps and muscle pain (Lopman et al., 2004b; Patel et al., 2009;
Robilotti et al., 2015). The symptomatic period typically lasts 12-72 hours, but there
is evidence of a longer symptomatic period in hospitalised patients and young children
(Lopman et al., 2004b; Patel et al., 2009; Robilotti et al., 2015). In most individuals,
disease is self-limiting and patients recover fully after the symptomatic period. However,
more prolonged and severe disease has been noted in immunocompromised patients, who
can be infected persistently for up to several years, and occasionally in the elderly and
other otherwise healthy individuals (Bok and Green, 2012; Robilotti et al., 2015).
While norovirus is highly prevalent in symptomatic gastroenteritis cases, it has be-
come clear that large numbers of individuals are asymptomatically infected (Teunis et al.,
2015; Ahmed et al., 2014). Indeed, in some studies in low income countries the propor-
tion of norovirus-positive patients is similar in symptomatic and asymptomatic groups
(Kotloff et al., 2013). In a systematic review of norovirus prevalence, Ahmed et al esti-
mated a total prevalence of 7% in asymptomatic control patients compared with 20% in
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symptomatic patients in the same studies (Ahmed et al., 2014), while volunteer studies
suggest that up to 50% of exposed individuals will not exhibit any symptoms (Patel et al.,
2009). Additionally, patients can shed virus in stool for up to several months after the res-
olution of symptoms, with similar periods of shedding being estimated for symptomatic
and asymptomatic individuals (Teunis et al., 2015).
1.2 Norovirus molecular and cellular biology
1.2.1 Genome organisation
The Caliciviridae are a family of small nonenveloped positive sense single stranded
RNA viruses (Green, 2007). The family consists of five accepted genera: Norovirus,
Sapovirus, Lagovirus, Nebovirus and Vesivirus, of which Norovirus and Sapovirus are
known to infect humans. There are also three proposed genera that are yet to be ap-
proved: Recovirus, Valovirus and chicken calicivirus (Smits et al., 2012). The linear
nonsegmented norovirus genome is 7.3-7.7 kilobases (Kb) in length and is bound by a vi-
rally encoded protein VPg (Viral Protein genome-linked) at the 5’ end and is polyadeny-
lated at the 3’ end (Green, 2007; Thorne and Goodfellow, 2014) (Figure 1.1). The 5’
and 3’ untranslated regions (UTRs) are short, with the 5’ UTR consisting of just four
nucleotides in human noroviruses and five nucleotides in murine noroviruses (MNVs)
(Thorne and Goodfellow, 2014) (Figure 1.1). The norovirus genome encodes three open
reading frames (ORFs), with the exception of MNVs which encode an additional fourth
ORF (Figure 1.1). ORF1 is more than 5Kb in length and encodes an approximately
200 kiloDalton nonstructural polyprotein that is co- and post-translationally cleaved by
a virally-encoded protease into six proteins (Belliot et al., 2003; Sosnovtsev et al., 2006),
which are typically given different names for human noroviruses and MNVs: p48 (NS1/2
in MNV), NTPase (NS3), p22 (NS4), VPg (NS5), protease (NS6) and RNA-dependent
RNA polymerase (RdRp, NS7) (Figure 1.1). ORF2 is roughly 1.8Kb in length, over-
laps with ORF1 by roughly 20 nucleotides and encodes the major capsid protein VP1,
180 copies of which form the viral particle (Prasad et al., 1999; Green, 2007). The cap-
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Figure 1.1: Norovirus genome organisation. A schematic of the norovirus genome is shown
depicting the open reading frames (ORFs). The complete genome is between 7.3
and 7.7 kilobases in length depending on genogroup. ORF1 encodes a nonstructural
polyprotein that is co- and post-translationally cleaved by the virally encoded protease
into six proteins: p48, NTPase, p22, VPg, protease and RdRp. The NS name shown
below each protein is the name of the protein in MNV. ORF2 encodes the VP1 capsid
protein that is subdivided into the shell domain and two protruding subdomains P1 and
P2. The P2 subdomain (shown in yellow) is an insert into the P1 subdomain (shown
in orange), with the P1 subdomain being encoded on either side of the P2 subdomain.
ORF3 encodes the minor structural protein VP2. ORF4 is present only in MNVs
and encodes virulence factor 1 (VF1), an antagonist of the innate immune response.
The genome has a very short 5’ UTR (sequence GTGA in GII viruses) and a short 3’
UTR. The 5’ end of the genome is bound by the viral protein VPg, which acts as a
cap substitute for translation and the 3’ end of the genome is poly-adenylated. ORFs 2
and 3 are produced as a subgenomic RNA that is identical to the corresponding region
in the full length genome, is bound by VPg at the 5’ end and is polyadenylated.
sid protein is divided into the shell and protruding domains, with the protruding domain
being further subdivided into the P1 and P2 subdomains (Figures 1.1, 1.2). ORF3 is ap-
proximately 0.6Kb in length and encodes a small basic protein VP2, a small number of
copies of which are incorporated into the viral particle (Vongpunsawad et al., 2013). The
ORF3 start codon overlaps with the stop codon of ORF2 by a single nucleotide (Figure
1.1). The second and third ORFs are also produced as a subgenomic RNA that is iden-
tical to the corresponding region in the complete genome and is bound by VPg at the 5’
end and polyadenylated at the 3’ end (Figure 1.1) (Thorne and Goodfellow, 2014). The
fourth ORF in MNVs encodes virulence factor 1 (VF1), an antagonist of the innate im-
mune response that is translated from an alternative reading frame located within ORF2
(McFadden et al., 2011).
The norovirus particle is roughly 38nm in diameter and is formed from 180 copies
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Figure 1.2: The structure of the norovirus capsid protein. (A) The capsid is formed from 90
dimers. The structure of the dimer is shown with one monomer in grey and the other
monomer in blue-white. Interactions occur between the monomers in each subdomain
of the capsid. (B) The capsid is divided into the shell and protruding domains, with the
protruding domain being further subdivided into the P1 and P2 subdomains. The shell
domain forms the interior of the viral particle and the P2 domain is surface exposed.
of the VP1 capsid protein, organised into 90 dimers with a T=3 icosahedral symmetry
(Prasad et al., 1999). The particle also contains a small number of copies of VP2 (Vong-
punsawad et al., 2013). The shell domain is found on the interior face of the viral particle
(Figure 1.2). The shell domain forms the icosahedral shell and when expressed alone
can form smooth icosahedral particles, while the P domain forms four regions of dimeric
interactions that stabilise the particle (Prasad et al., 1999; Bertolotti-Ciarlet et al., 2002;
Cao et al., 2007). The shell domain is formed from capsid residues 1-221 (site numbers
relative to the GII.4 capsid) and is connected to the protruding domain by a flexible hinge
approximately ten residues in length (Prasad et al., 1999). The protruding domain con-
sists of residues 222-540 and multiple studies have demonstrated that the P2 subdomain
(residues 275-417) is an insertion in the P1 subdomain (residues 222-274 and 418-540)
(Prasad et al., 1999). The P2 subdomain is found on the surface of the viral particle (Fig-
ure 1.2). The shell domain exhibits a high level of conservation, while the P2 domain
exhibits the highest level of variability within the norovirus genome (Bull et al., 2010).
1.2.2 Norovirus classification
Until recently, most noroviruses could not be cultured and therefore classification
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has been based on seqeuence and phylogenetic analyses (Zheng et al., 2006; Kroneman
et al., 2013). While classification was initially based on percentage amino acid similarity
(Zheng et al., 2006), this method was recently shown to be unreliable and so phylogenetic
clustering is now used (Kroneman et al., 2013). Recombination has been demonstrated
to occur frequently at the ORF1-ORF2 boundary, enabling novel combinations of the
nonstructural and structural proteins (Bull et al., 2005, 2007; Eden et al., 2013). This re-
combination likely occurs through a mechanism involving the full length and subgenomic
RNAs, whereby the RdRp reaches a RNA stem loop structure at the start of ORF2, losses
processivity, falls off the full length genome and reattaches at the stem loop structure
of a different subgenomic RNA molecule (Bull et al., 2005). Due to this frequent re-
combination, a dual-typing nomenclature system has been proposed where the RdRp and
capsid are classified independently into genogroups and further into genotypes (Figure
1.3) (Zheng et al., 2006; Kroneman et al., 2013). There are currently seven genogroups,
termed GI-GVII (Figure 1.3) (Vinje, 2015). There are 9 recognised genotypes in GI, 23
in GII, 2 in GIII, 2 in GIV, 1 in GV, 2 in GVI and 1 in GVII (Figure 1.3) (Vinje, 2015).
The genotypes GI.3, GI.5, GI.7, GII.3 and GII.6 are further subdivided into multiple sub-
clusters (Vinje, 2015). Under the dual-typing system (Kroneman et al., 2013), a virus
classified as GII.P1-GII.4 would have a RdRp in genotype 1 and a capsid in genotype
4, both within genogroup II. Human norovirus infections are predominantly caused by
viruses within genogroups GI and GII, with a smaller number of infections with GIV.1
viruses (Vinje, 2015). However, the majority of human norovirus cases and outbreaks
are caused by a single capsid genotype called GII.4 (Kroneman et al., 2008; de Graaf
et al., 2016). The rapid evolution of viruses within the GII.4 genotype has necessitated
the subdivision of this genotype into strains (Figure 3.1), each of which is named after
the geographical location and year in which the strain was first detected (Siebenga et al.,
2009; Parra et al., 2017). The other genogroups are associated with infection of different
animal species: GIII with infection of sheep and cows, GIV.2 with infection of cats, dogs
and lion, GV with infection of mice and rats and GVI and GVII with infection of dogs
(Figure 1.3) (Liu et al., 1999; Ando et al., 2000; Oliver et al., 2003; Karst, 2003; Wobus
et al., 2006; Park et al., 2007; Wolf et al., 2009; Martella et al., 2008, 2009; Mesquita
et al., 2010; Tse et al., 2012; Vinje, 2015). While most of the GII genotypes are associ-
ated with human infection, the genotypes GII.11, GII.18 and GII.19 infect swine (Sugieda
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Figure 1.3: Classification of the Caliciviridae. The hierarchical classification of the Caliciviri-
dae family is shown, with Norovirus being one of five accepted genera within the fam-
ily. There are currently seven genogroups of norovirus, with five of these genogroups
being further subdivided into multiple genotypes. The species known to be infected
by each genogroup are shown. Rapid evolution within the GII.4 genotype has neces-
sitated further subdivision of this genotype into strains.
et al., 1998; Wang et al., 2005; Wolf et al., 2009; Vinje, 2015). There have been individual
studies that have reported norovirus infection of dolphin (de Graaf et al., 2017), bat (Wu
et al., 2016) and sea lion (Li et al., 2011), indicating that noroviruses likely have a wide
host spectrum.
1.2.3 Cell culture and tropism
Until recently, there was no reproducible and robust cell culture system for human
noroviruses and MNVs were the only members of the genus that could be cultivated
in vitro (Wobus et al., 2004; Vashist et al., 2009; Jones et al., 2014; Ettayebi et al.,
2016). This has greatly hampered understanding of the viral life cycle, host-pathogen
interactions and the mechanisms employed by noroviruses to infect the intestinal tract.
MNVs replicate efficiently in the murine macrophage cell line RAW264.7 and in primary
macrophages and dendritic cells isolated from mice, suggesting a tropism for haematopoi-
etic cells (Wobus et al., 2004). This is supported by the detection of MNV antigen in vivo
in cells that morphologically resemble macrophages and dendritic cells (Wobus et al.,
2004; Ward et al., 2006). However, despite human norovirus antigens being detected in
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cells resembling macrophages and dendritic cells in chimpanzee and immunodeficient
mouse models (Bok et al., 2011; Taube et al., 2013), efforts to culture human noroviruses
in these cell types have been unsuccessful (Lay et al., 2010).
However, recently B cells have been identified as a target cell for both human and
murine noroviruses, leading to the development of a human norovirus cell culture sys-
tem employing the BJAB B cell line (Jones et al., 2014, 2015). Interestingly, replica-
tion of a GII.4 Sydney 2012 virus within this system was decreased upon stool filtration
but restored by co-culture with enteric bacteria expressing histo blood group antigens
(HBGAs), suggesting that enteric bacteria may act as a stimulatory factor for norovirus
infection (Jones et al., 2014, 2015). Infection of B cells in vivo is supported by the detec-
tion of MNV genomes and nonstructral protein in B cells of infected mice (Jones et al.,
2014) and by a decrease in viral titre in mice (Jones et al., 2014) and humans (Brown
et al., 2016a) lacking B cells. However, patients lacking B cells can still exhibit high viral
loads, demonstrating infection of another tissue type must occur in vivo (Brown et al.,
2016a).
A recent study detected the presence of the VP1 capsid protein, VPg and RdRp in
enterocytes from the duodenum and jejunum of immunocompromised transplant patients
(Karandikar et al., 2016). Importantly, the detection of nonstructural proteins suggests
productive infection of enterocytes occurs in vivo. This is also supported by a recently
developed cell culture system that has demonstrated human norovirus replication in hu-
man intestinal enteroids (HIEs) (Ettayebi et al., 2016). This cell culture system is de-
veloped from stem cells isolated from human intestinal crypts and forms a multicellular,
differentiated and physiologically active culture containing enterocytes, enteroendocrine
cells, goblet cells and Paneth cells (Sato et al., 2011; Ettayebi et al., 2016). Replication of
human noroviruses from genotypes GI.1, GII.3, GII.4 and GII.17 has been demonstrated
in this system, with enterocytes being the only cell type within the system to be infected
(Ettayebi et al., 2016). Interestingly, while GII.4 viruses replicate within HIEs without
the need for additional factors, GI.1, GII.3 and GII.17 viruses require a nonproteinaceous
component of bile to support replication, with this component likely acting upon the cells
to support infection. The addition of bile also enhanced GII.4 infection. Both GII.3
and GII.4 viruses replicate in HIEs from the duodenum, jejunum and ileum, suggesting
noroviruses can productively infect enterocytes in each region of the small intestine. Stud-
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ies examining GII.4 norovirus infection of gnotobiotic pigs and GIII.1 infection of calves
have also found evidence of in vivo infection of enterocytes (Cheetham et al., 2006; Otto
et al., 2011).
The VP1 capsid protein was also detected in macrophages, T cells and dendritic
cells in the lamina propria of immunocompromised transplant patients, although VPg and
RdRp were not detected in T cells or dendritic cells and the presence of these nonstruc-
tural proteins in macrophages was likely due to phagocytosis of a productively infected
enterocyte (Karandikar et al., 2016). Together, the current evidence suggests that entero-
cytes are a major site of human norovirus replication in vivo, with additional replication
in B cells and potentially in other immune system cell types (Jones et al., 2014; Ettayebi
et al., 2016; Karandikar et al., 2016; Green, 2016; Brown et al., 2016a).
1.2.4 VLPs and expression systems
Due to the lack of a human norovirus cell culture system until recently (Jones et al.,
2014; Ettayebi et al., 2016), many laboratory assays have taken advantage of the fact
that the VP1 capsid protein self-assembles to form virus like particles (VLPs) upon in
vitro expression (Baric et al., 2002; Donaldson et al., 2008). Two recombinant expres-
sion systems have been developed that enable the production of large quantities of VLPs
that are antigenically highly similar to native particles but lack the viral genome: the
baculovirus system and the Venezuelan equine encephalitis (VEE) replicon system (Jiang
et al., 1992; Baric et al., 2002; Donaldson et al., 2008, 2010). In the baculovirus system,
wild type baculovirus DNA is co-transfected with a transfer vector DNA containing the
norovirus capsid gene as a cDNA copy (Jiang et al., 1992). In the VEE replicon sys-
tem, the VEE structural genes are provided in trans but are replaced in the genome by
the norovirus capsid gene under the control of a subgenomic 26S promoter (Baric et al.,
2002). The VEE expression system has the advantage of employing mammalian rather
than insect cells which may result in more physiological post-translational modifications
(Baric et al., 2002). VP2 increases the stability of VLPs but is not required for VLP
formation (Bertolotti-Ciarlet et al., 2003).
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1.2.5 The norovirus replication cycle
The first stage of the viral replication cycle is entry into a susceptible target cell. Vi-
ral entry is typically a multistep process that involves binding of the viral particle to one
or more attachment factors to concentrate the viral particles on the cell surface followed
by interaction with one or more receptors that promote uptake into the cell (Mercer et al.,
2010; Bartnicki et al., 2017). While norovirus entry is incompletely understood, a similar
multistep entry process has been hypothesised (Figure 1.4) (Bartnicki et al., 2017). The
attachment factors for human noroviruses are HBGAs, small carbohydrate molecules that
are expressed on the surface of intestinal epithelial cells and are secreted into body flu-
ids, including saliva (Figure 1.4) (Lindesmith et al., 2008; Thorne and Goodfellow, 2014).
HBGAs can be found on a variety of N- and O-linked glycoproteins and on several groups
of glycosphingolipids (GSLs), the latter of which are major components of cellular mem-
branes (Taube et al., 2010). Noroviruses bind to HBGAs from the A/B/H and Lewis
antigens in a genotype- and strain-specific manner (Lindesmith et al., 2008; Singh et al.,
2015). The expression of HBGAs is under the control of fucosyl and glycosyltransferases
encoded by the FUT2, FUT3 and ABH genes (Figure 1.5) (Ruvoe¨n-Clouet et al., 2013;
Singh et al., 2015). Polymorphisms in these genes result in differential HBGA expression
in saliva and on the surface of gastrointestinal cells. The frequency of such polymor-
phisms varies greatly depending on ethnicity (Lindesmith et al., 2003; Nordgren et al.,
2016). Of particular importance for norovirus infection are several inactivating polymor-
phisms in the FUT2 gene, including the G428A nonsense mutation which is homozygous
in roughly 20% of the European and North American populations (Lindesmith et al.,
2003; Le Pendu et al., 2006; Carlsson et al., 2009; Kindberg and Svensson, 2009; Kamb-
hampati et al., 2015). The FUT2 enzyme adds a fucose moeity to carbohydrate chains
and is required for the expression of multiple HBGAs on the surface of gastrointesti-
nal cells (Figure 1.5). Individuals with a nonfunctional FUT2 enzyme only express the
LeA and LeX HBGAs and are termed non-secretors, while individuals with a functional
FUT2 enzyme are termed secretors and express a greater range of HBGAs (Figure 1.5)
(Lindesmith et al., 2003; Ruvoe¨n-Clouet et al., 2013). Non-secretor individuals account
for 5%-50% of individuals in different populations worldwide (Nordgren et al., 2016).
Different norovirus genotypes are associated with different host susceptibility patterns.
28 Chapter 1. Introduction
For example, the GI.1 Norwalk virus is unable to infect non-secretors as it binds only
to HBGA types A and H and Lewis antigen B (Lindesmith et al., 2003; Le Pendu et al.,
2006). Multiple studies have also demonstrated non-secretors are resistant to infection
with the globally dominant GII.4 genotype (Bucardo et al., 2009; Carlsson et al., 2009;
Nordgren et al., 2013; Liu et al., 2014; Currier et al., 2015; Lopman et al., 2015; Ettayebi
et al., 2016). However, certain GII.4 strains can bind non-secretor HBGAs in vitro (Singh
et al., 2015) and rare cases of GII.4 infection of non-secretors have been reported (Carls-
son et al., 2009; Nordgren et al., 2013). There are, however, multiple genotypes that can
infect both secretors and non-secretors, including GI.3 and GII.2 (Lindesmith et al., 2005;
Rockx et al., 2005; Nordgren et al., 2010), although non-secretor-specific genotypes have
not been identified. While there is strong support for HBGAs acting as norovirus attach-
ment factors, the existence of additional attachment factors has been suggested due to the
identification of strains with weak affinity for all tested HBGAs (Lindesmith et al., 2008,
2012a), although the specific molecules are yet to be described.
The HBGA-binding site has been mapped in the capsid of several norovirus geno-
types (Figure 1.5) (Cao et al., 2007; Singh et al., 2015; Koromyslova et al., 2015; Singh
et al., 2016b). Capsid dimerisation is essential for HBGA-binding, with the binding site
being close to the dimerisation interface and formed by residues in both monomers (Cao
et al., 2007). Therefore each capsid dimer contains two HBGA-binding sites (Singh et al.,
2015). Five capsid residues are key for the binding of each tested HBGA with GII.4 VLPs
from multiple strains: T344, R345 and D374 in one monomer and G443 and Y444 in the
other monomer (Figure 1.5) (Cao et al., 2007; Singh et al., 2015). These residues interact
with the fucose in both ABH and Lewis HBGAs (Singh et al., 2015). Additional residues
are important for binding to specific HBGAs, including S343, Y390, C441, S442 and
the loop containing residues 391-395 (Figure 1.5) (Donaldson et al., 2008; Singh et al.,
2015). Specifically, the 391-395 loop is repositioned to enable binding to HBGA type B,
LeB and LeY (Singh et al., 2015). Additionally, residue T338 is predicted to be essential
for HBGA binding through hydrogen bonds formed between this residue and R345 (Cao
et al., 2007; Donaldson et al., 2008). The mode of interaction between the capsid and
HBGA receptor differs between GI and GII noroviruses; in the GI.1 Norwalk virus cap-
sid, residues D327, H329, S377 and S380 interact with the N-acetylglucosamine of the
HBGA type A (Bu et al., 2008).
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Capsid site Function Additional information Reference
294 Blockade epitope A Lindesmith et al. (2012b)
296 Blockade epitope A/site A Allen et al. (2008); Lindesmith et al. (2012b)
297 Blockade epitope A/site A Allen et al. (2008); Lindesmith et al. (2012b)
298 Blockade epitope A/site A Allen et al. (2008); Lindesmith et al. (2012b)
310 Access to ‘universal epitope’ Lindesmith et al. (2014)
316 Access to ‘universal epitope’ Glutamic acid within GII.4 Lindesmith et al. (2014)
333 Epitope B Lindesmith et al. (2012b)
338 HBGA-binding Hydrogen bonds to residue R345, Cao et al. (2007)
threonine within GII.4
340 Epitope C Lindesmith et al. (2012b)
343 HBGA-binding site, specific Serine within GII.4 Cao et al. (2007); Singh et al. (2015)
344 HBGA-binding site, required Threonine within GII.4 Cao et al. (2007); Singh et al. (2015)
345 HBGA-binding site, required Arginine within GII.4 Cao et al. (2007); Singh et al. (2015)
355 May contribute to blockade epitope E Lindesmith et al. (2012b)
356 May contribute to blockade epitope E Lindesmith et al. (2012b)
357 May contribute to blockade epitope E Lindesmith et al. (2012b)
368 Blockade epitope A Lindesmith et al. (2012b)
372 Blockade epitope A Lindesmith et al. (2012b)
373 Blockade epitope A Debbink et al. (2013); Allen et al. (2014)
374 HBGA-binding site, required Aspartic acid within GII.4 Cao et al. (2007); Singh et al. (2015)
376 Epitope C Lindesmith et al. (2012b)
382 Epitope B Lindesmith et al. (2012b)
390 HBGA-binding site, specific Tyrosine within GII.4 Singh et al. (2015)
391-395 loop HBGA binding site, specific Repositioning of this loop is required Singh et al. (2015)
to bind HBGA type B, LeB and LeY
393 Blockade epitope D/site B Allen et al. (2008); Lindesmith et al. (2012b)
394 Blockade epitope D/site B Allen et al. (2008); Lindesmith et al. (2012b)
395 Blockade epitope D/site B Allen et al. (2008); Lindesmith et al. (2012b)
407 Blockade epitope E Lindesmith et al. (2012b)
412 Blockade epitope E Lindesmith et al. (2012b)
413 Blockade epitope E Lindesmith et al. (2012b)
441 HBGA-binding site, specific Cysteine within GII.4 Cao et al. (2007); Singh et al. (2015)
442 HBGA-binding site, specific Serine within GII.4 Cao et al. (2007); Singh et al. (2015)
443 HBGA-binding site, required Glycine within GII.4 Cao et al. (2007); Singh et al. (2015)
444 HBGA-binding site, required Tyrosine within GII.4 Cao et al. (2007); Singh et al. (2015)
484 Access to ‘universal epitope’ Arginine within GII.4 Lindesmith et al. (2014)
493 Access to ‘universal epitope’ Lysine within GII.4 Lindesmith et al. (2014)
Table 1.1: Summary of epitopes and HBGA-binding sites in the GII.4 capsid. Each site within
the GII.4 capsid suggested to form part of an epitope region or contribute to HBGA-
binding is shown. Sites listed as ’HBGA-binding site, required’ are required for bind-
ing to all HBGAs, while sites listed as ’HBGA-binding site, specific’ are only required
for binding to specific HBGAs. Site 338 is essential for HBGA-binding due to a hy-
drogen bond formed by this residue to R345. Numbering relative to the post-US95/96
GII.4 capsid (i.e. after the insertion at site 394).
The interaction between the capsid P2 domain and HBGAs is thought to result in
clustering of the GSLs to form a lipid raft (an organised lipid microdomain), leading to
local invagination of the membrane (Bartnicki et al., 2017). Binding of norovirus to HB-
GAs is not sufficient to mediate entry into target cells and, while no receptor for human
norovirus has yet been described, two groups recently independently identified CD300lf
as a proteinaceous receptor for MNV (Orchard et al., 2016; Haga et al., 2016). CD300lf
knockout mice are resistant to MNV infection and the expression of murine CD300lf
in cells from other species makes these usually non-permissive cell types permissive to
MNV infection (Orchard et al., 2016; Haga et al., 2016). While CD300ld was also demon-
strated to be a receptor for MNV (Orchard et al., 2016; Haga et al., 2016), the lack of viral
replication in CD300lf knockout mice suggests that CD300lf is the primary MNV recep-
tor (Figure 1.4) (Orchard et al., 2016). The entry process of norovirus into cells is de-
pendent on dynamin, cholesterol and ceramide (Thorne and Goodfellow, 2014; Bartnicki
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et al., 2017). A recently proposed model of norovirus entry suggests that binding to one
or more GSLs enables attachment of the viral particle to the cell surface. The GSLs are
either already in lipid rafts or are recruited into a new lipid raft where the CD300 protein
receptors are located. The lipid rafts are dependent on cholesterol and interactions within
the lipid raft may result in invagination of the plasma membrane followed by dynamin
II-mediated scission of the invagination (Figure 1.4) (Bartnicki et al., 2017).
After entry into host cells, the viral capsid disassembles in a process known as un-
coating, resulting in release of the VPg-linked viral genome into the cytoplasm where it
acts as the template for the ‘pioneer round’ of protein translation (Figure 1.4) (Thorne
and Goodfellow, 2014). Noroviruses do not encode their own translational machinery
and translation is therefore dependent on the recruitment of host cell factors and ribo-
somes. VPg acts as a substitute for 5’ cap that is found on cellular mRNAs and acts in
the same way to recruit cellular eukaryotic translation initiation factors (eIFs), including
eIF3, eIF4e, eIF4G and cap binding protein (Figure 1.4) (Thorne and Goodfellow, 2014;
Chung et al., 2014; Alhatlani et al., 2015). Therefore linkage of the viral genome to VPg
is essential for infectivity. Binding of these cellular factors by VPg results in recruitment
of the 43S ribosomal pre-initiation complex (Thorne and Goodfellow, 2014). Addition-
ally, highly conserved RNA structures at the 5’ and 3’ ends of the viral genome interact
with cellular proteins and, while the exact function(s) of most of these interactions are yet
to be elucidated, they likely enable circularisation of the genome and efficient translation
(Thorne and Goodfellow, 2014; Alhatlani et al., 2015). These interactions may also result
in a gradual switch from translation in the early phase of infection to replication in the
late phase of infection via recruitment of the cellular protein PTB; mutation of the PTB-
binding site in the MNV genome resulted in viral attenuation in vivo, demonstrating the
essential role of host cell proteins in infection (Alhatlani et al., 2015).
Translation of the VP1 capsid protein and VP2 occurs primarily from the subgenomic
RNA, which is likely a strategy to enable efficient production of the high levels of these
proteins required to form new viral particles (Thorne and Goodfellow, 2014). The subge-
nomic RNA is polycistronic and translation of VP2 occurs by a termination-reinitiation
mechanism. In this mechanism, ribosomes remain associated with the RNA after termi-
nation of ORF2 translation and reinitiate translation at the start of ORF3 (Napthine et al.,
2009). Cellular RNA is typically present at far higher levels than the incoming viral RNA
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Figure 1.4: The norovirus replication cycle. Each stage in the replication cycle is described
in more detail in the text. Briefly, the viral particle interacts with cellular attach-
ment factors that enable interaction with additional receptors and entry into the cell.
After cell entry, the genome is released from the viral particle and acts as the tem-
plate for the ‘pioneer’ round of translation. This translation is carried out by host
ribosomes recruited through interactions between VPg and cellular eukaryotic trans-
lation initiation factors (eIFs). The virally encoded protease cleaves the nonstructural
polyprotein into six proteins. The replication of the viral genome is carried out by the
virally-endoded RdRp and occurs on membranes that are recruited by p48 and p22.
Genome replication occurs via a negative strand intermediate and results in the pro-
duction of genomic RNA and subgenomic RNA. These RNA molecules are used for
additional translation, with high levels of the capsid protein and VP2 being translated
from subgenomic RNA. The capsid and VP2 assemble to form viral particles, with
VP2 likely recruiting the viral genome and these viral particles are released from the
cell.
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Figure 1.5: The HBGA receptors used by noroviruses as attachment factors. (A) The biosyn-
thesis pathway for HBGA receptors. Gal - galactose, GlcNAc - N-acetlyglucosamine,
Fuc - fucose. The synthesis of HBGAs is under the control of fucosyl- and glyco-
syltransferases encoded by the FUT2, FUT3 and ABH genes. The type 1 and type
2 precursor molecules differ by the nature of the link between the Gal and GlcNAc
moities, with the type 1 precursor exhibiting a β1,3 link and the type 2 precursor ex-
hibiting a β1,4 link. The enzyme that catalyses each step in the synthesis pathway
is shown by the corresponding arrow and the sugar group added by each enzyme is
shown in the same colour as the enzyme. LeA and LeX differ by only the linkages
between the sugar groups, as do LeB and LeY. The structure of LeY is not shown
for simplicity. The HBGAs in the grey shaded area require the action of a functional
FUT2 enzyme to be produced and so are only expressed in secretor individuals. Non-
secretor individuals can only express LeA and LeX. The HBGAs shown are terminal
structures, the rest of the chain is shown by the R group. (B) The HBGA-binding site
is highlighted on the GII.4 Sydney 2012 dimeric P domain structure 4WZT. This is
a top view of the capsid with one monomer shown in grey and the other monomer
shown in blue-white. The HBGA (in this case HBGA type A) is shown in cyan.
Residues T344, R345, D374, G443 and Y444 that are required for binding to all HB-
GAs are shown in purple. Residues S343, Y390, C441, S442 and the 391-395 loop
that are required for binding to specific HBGAs are shown in blue.
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and many viruses have evolved mechanisms to promote translation of viral proteins over
that of cellular proteins (Firth and Brierley, 2012). A recent study demonstrated that the
norovirus protease cleaves the cellular protein PABP to enable the preferential translation
of viral mRNA and a reduction in translation of cellular proteins (Emmott et al., 2017b).
This has the additional benefit of inhibiting translation of interferon-stimulated genes and
may therefore act as a mechanism of immune evasion (Emmott et al., 2017b). The viral
protease cleaves the nonstructural polyprotein in a co- and post-translational fashion to re-
lease free forms of each of the nonstructural proteins as well as stable intermediate forms
(Figure 1.4) (Belliot et al., 2003; Thorne and Goodfellow, 2014; Emmott et al., 2017a).
These intermediate forms can be functional, with, for example, the protease-RdRp in-
termediate exhibiting polymerase activity (Belliot et al., 2005). The protease active site
consists of a catalytic triad of H30, E54 and C139, with E54 likely determining substrate
specificity (Someya et al., 2002, 2008; Zeitler et al., 2006; Thorne and Goodfellow, 2014).
The replication of the norovirus genome occurs in association with cellular mem-
branes, in particular those of the endoplasmic reticulum (ER), Golgi apparatus and endo-
somes that form the secretory pathway (Hyde et al., 2009; Thorne and Goodfellow, 2014).
While the mechanisms by which cellular membranes are recruited are not completely un-
derstood, p48 (NS1/2) and p22 (NS4) have been implicated in this process, with both
proteins localising to components of the secretory pathway (Figure 1.4) (Bailey et al.,
2010; Hyde and Mackenzie, 2010; Thorne and Goodfellow, 2014). The ER-export signal
in p22 is thought to promote the uptake of p22 into COPII-coated vesicles in transit from
the ER to the Golgi, resulting in mislocalisation of COPII-coated vesicles and Golgi disas-
sembly. As MNV NS4 does not contain this ER-export signal, it likely acts via a different
mechanism. The p48 protein is thought to act via interaction with SNARE regulator vesi-
cle associated membrane protein-associated protein A (VAP-A) and VAP-B, proteins that
regulate cellular vesical transport (McCune et al., 2017). Interaction with these proteins
results in Golgi disassembly and is essential for efficient replication of murine norovirus
(McCune et al., 2017).
As with other positive strand RNA viruses, replication of the genome occurs via
a negative-sense intermediate (Figure 1.4). There are two mechanisms by which the
norovirus RdRp can initiate synthesis of a new RNA strand: de novo and VPg-dependent
(Rohayem et al., 2006; Subba-Reddy et al., 2011). Both mechanisms have been demon-
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strated in vitro (Rohayem et al., 2006). It has been proposed that the norovirus RdRp syn-
thesises the negative-sense genomic and sub-genomic RNA by de novo initiation (Figure
1.4) (Subba-Reddy et al., 2012). The active site of the RdRp consists of residues R182,
D242, Y243, D247, S300, N309, D343 and D344 (Ng et al., 2004; Zamyatkin et al., 2008)
and the RdRp is thought to function as a homodimer (Ho¨gbom et al., 2009). Specific loops
within the shell domain of the VP1 capsid protein enhance de novo initiation in a species-
specific manner (Subba-Reddy et al., 2012). This has been proposed to enhance genome
replication when levels of the VP1 capsid protein are low early in the replication cycle.
As more copies of VP1 are present, they form higher order capsid structures which pre-
vents RdRp-binding, thereby decreasing genome replication (Subba-Reddy et al., 2012;
Thorne and Goodfellow, 2014). Species-specific interaction between p48 and RdRp also
enhances RdRp activity, while VP2 interaction with RdRp inhibits RdRp activity (Subba-
Reddy et al., 2011).
Synthesis of the negative-sense RNA strand results in formation of a double-stranded
replicative form. Synthesis of the positive-sense genomic RNA is thought to occur via
VPg-dependent initiation (Figure 1.4) (Chaudhry et al., 2006; Thorne and Goodfellow,
2014). The first step of this synthesis involves VPg nucleotidylation (also called VPg
guanylation), where the RdRp covalently attaches a conserved tyrosine residue in VPg
(Y27 in human norovirus and Y26 in murine norovirus) to the initiating nucleotide, which
is guanine throughout the noroviruses (Subba-Reddy et al., 2011). The nucleotidylation
process has been suggested to be enhanced by an element at the 3’ end of the genome
(Belliot et al., 2005). Two potential, and non-mutually exclusive, mechanisms by which
the subgenomic RNA molecules may be transcribed have been suggested. Both positive-
sense and negative-sense genomic and subgenomic RNAs have been identified in infected
cells (Green et al., 2002). In the first mechanism, the RdRp reaches a termination signal
at the 5’ end of VP1 while transcribing the negative-sense RNA strand, thereby resulting
in negative-sense subgenomic RNA molecules from which positive-sense subgenomic
RNAs can be transcribed. In the second mechanism, a promoter sequence exists in the
genomic negative-sense RNA at the start of VP1 and the RdRp transcribes positive-sense
subgenomic RNA starting at this promoter (Thorne and Goodfellow, 2014). The existence
of a conserved RNA stem loop structure close to the start of the subgenomic RNA supports
this second mechanism, although whether this loop has a direct role in synthesis of the
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subgenomic RNA is unknown (Simmonds et al., 2008).
Additional rounds of RNA replication and viral protein translation occur (Figure
1.4). That the VP1 capsid protein self-assembles into virus-like particles in vitro suggests
that cellular factors are unlikely to be required for formation of the viral particle (Baric
et al., 2002). VP2 is located on the interior face of the viral particle and contains a basic
domain that may recruit the viral genome into the particle (Vongpunsawad et al., 2013).
Such a basic domain is not present in the VP1 capsid protein. Alternatively, it is possible
that an interaction between VPg and either VP1 or VP2 may recruit the genome into the
particle and a possible interaction between VPg and VP1 has been observed in the related
feline calicivirus (Kaiser et al., 2006). While studies of the mechanism(s) employed by
noroviruses to exit host cells are largely lacking, apoptosis is induced by murine norovirus
and apoptotic cells have been noted in intestinal biopsies from infected patients (Bok et al.,
2009; Furman et al., 2009; Karandikar et al., 2016). Damaged sites in intestinal biopsies
correlate with the expression of viral antigens (Karandikar et al., 2016). Induction of
apoptosis by MNV is associated with downregulation of the cellular pro-survival factor
survivin (Bok et al., 2009; Furman et al., 2009) and inhibition of apoptosis reduces the
production of MNV particles, suggesting the importance of this mechanism in the viral
replication cycle (Figure 1.4) (Furman et al., 2009).
1.3 Transmission and epidemiology
1.3.1 Norovirus transmission
Noroviruses transmit exceptionally efficiently between susceptible individuals via
the faecal-oral or oral-oral route (de Graaf et al., 2016). Part of the reason explaining
this success may be a low infectious dose, with the estimated ID50 (number of viral par-
ticles required to infect 50% of exposed individuals) being as low as 18 viral particles
for the GI.1 Norwalk virus (Teunis et al., 2008). Additionally, the same study suggested
that exposure to a single virus particle results in a 50% probability of infection (Teunis
et al., 2008). In context, a single gram of faeces from an infected patient can contain up
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to 1011 virus particles, with the estimated median peak of shedding containing 9.5x1010
genome copies per gram of faeces (Atmar et al., 2008). Therefore just one gram of faeces
can contain more than 5 billion infectious doses (Hall, 2012). However, more recent es-
timates have suggested the Norwalk virus ID50 to be 1320 genome equivalents (95% CI
440-3760) (Atmar et al., 2014). To date, no study has estimated the ID50 of the dominant
GII.4 genotype. Given the high prevalence of GII.4, it is possible that the infectious dose
for this genotype may be lower than that of other genotypes. Noroviruses are thought to
withstand freezing, heating and many commonly used detergents, although the lack of a
cell culture system for human noroviruses has made it difficult to assess whether treated
viruses remain infectious (Donaldson et al., 2008; Hall, 2012; Lopman et al., 2012). MNV
and feline calicivirus have therefore been used as surrogates for human norovirus and have
been demonstrated to be inactivated by UV, high temperatures and high pressure (Lop-
man et al., 2012). The recent development of human norovirus culture systems (Jones
et al., 2014; Ettayebi et al., 2016) may enable determination of whether the same is true
for human noroviruses. It has been demonstrated that norovirus can persist on surfaces
for up to two weeks and even longer persistence has been demonstrated in water, where
virus particles spiked into ground water remained infectious in humans for at least 61
days (Seitz et al., 2011; Lopman et al., 2012). Intact viral particles containing genomic
RNA remained detectable in ground water for more than three years, although whether
these particles were infectious was not determined (Seitz et al., 2011). This long envi-
ronmental persistence is exacerbated by the ability of vomiting to aerosolise the virus,
thereby spreading the virus to a large area (Lopman et al., 2012). While the highest levels
of contamination occur on surfaces that have been in direct contact with faeces or vomit,
contamination of a large variety of objects has been demonstrated and vomiting is likely
to accelerate the spread of the virus (Cheesbrough et al., 2000; Gallimore et al., 2006,
2008). In addition, the short incubation time coupled with the long period of shedding
after the resolution of symptoms means that infected patients have a long period of time
during which they are potentially infectious (Patel et al., 2009; Lee et al., 2013; Lopman
et al., 2012; Teunis et al., 2015). However, symptomatic patients have been suggested to
be responsible for most transmission within norovirus outbreaks (de Graaf et al., 2016).
While most transmission in outbreaks and sporadic disease is thought to occur
through direct person to person transmission (Lopman et al., 2012), noroviruses can be
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transmitted indirectly via faecal or vomit contamination of food, water, the environment
or fomites. However, outbreaks can involve multiple transmission routes and can be ex-
tended and perpetuated by contaminated fomites (Lopman et al., 2012). Outbreaks also
frequently occur through contaminated food and these outbreaks can be large and inter-
national due to the global nature of food production (Lopman et al., 2012; de Graaf et al.,
2016). Different genotypes appear to exhibit different preferences for different transmis-
sion routes, with a greater proportion of non-GII.4 genotype outbreaks being foodborne
compared with GII.4 genotype outbreaks (Verhoef et al., 2015). In total, roughly 14%
of norovirus outbreaks are attributed to food (Verhoef et al., 2015). The contamination
of food products can occur through irrigation with contaminated sewage or exposure of
shellfish to faecal discharge, but contamination by food handlers is likely the main mech-
anism (Lopman et al., 2012; de Graaf et al., 2016). Foodborne outbreaks are commonly
contaminated with multiple genotypes, providing a mechanism by which recombination
may occur between different strains (de Graaf et al., 2016). While numerous waterborne
outbreaks have been reported, these likely account for only a small percentage of total
norovirus outbreaks (Lopman et al., 2012).
1.3.2 Seasonality
Norovirus cases and outbreaks exhibit peaks in the winter months and troughs in
summer months in temperate regions of the Northern hemisphere (Ahmed et al., 2013).
While seasonality in Oceania has been less clear, a recent study suggested norovirus out-
breaks peak during the southern hemisphere winter (Eden et al., 2014), similar to temper-
ate countries in South America (da Silva Polo´ et al., 2016). Of the limited studies carried
out in Africa, no clear seasonal pattern of infection has been identified (Mans et al., 2016).
1.3.3 Norovirus epidemiology
While there are close to 30 genotypes known to infect humans, the vast majority
of both human cases and human outbreaks of norovirus are caused by a single capsid
genotype, termed GII.4, with this genotype causing up to 82% of outbreaks annually
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(Siebenga et al., 2007; Kroneman et al., 2008; Siebenga et al., 2009). While the GII.3
genotype is prevalent in children (Boon et al., 2011; Brown et al., 2016c), the other non-
GII.4 genotypes are typically rare (Parra et al., 2017). The GII.4 genotype has also caused
six pandemics of gastroenteritis since the mid-1990s (Figure 1.6) (Siebenga et al., 2009;
Bull and White, 2011; van Beek et al., 2013). Each of the pandemics has been associated
with a phylogenetically distinct GII.4 strain and pandemics have occurred in the Northern
hemisphere winters of 1995-1996 (US95/96 strain), 2002-2003 (Farmington Hills 2002),
2004-2005 (Hunter 2004), 2006-2007 (Den Haag 2006), 2009-2010 (New Orleans 2009)
and 2012-2013 (Sydney 2012) (Figure 1.6) (Noel et al., 1999; Lopman et al., 2004a; Bull
et al., 2006; Tu et al., 2008; Vega et al., 2011; van Beek et al., 2013; Siebenga et al.,
2007, 2009). Additional epidemic GII.4 strains have been identified that either cause out-
breaks within a more restricted geographical region, or that cause widespread but only
sporadic outbreaks, including the Lanzhou 2002, Kaiso 2003, Asia 2003, Yerseke 2006,
Osaka 2007 and Apeldoorn 2007 strains (Figure 1.6) (Siebenga et al., 2009; Eden et al.,
2014). The first GII.4 pandemic in 1995-1996 coincided with an increase in norovirus
outbreaks in USA, Europe and Australia and the Farmington Hills 2002 pandemic was
associated with an unprecedented number of norovirus outbreaks (Wright et al., 1998;
Lopman et al., 2004a; Bull and White, 2011). While the first pandemic coincided with
an increase in norovirus surveillance, raising the possibility of additional earlier pan-
demics that remained undetected, phylodynamic analysis suggests that there was an in-
crease in GII.4 norovirus prevalence in the mid-1990s (Siebenga et al., 2010). The most
recent common ancestor of the GII.4 capsid has been dated to 1966, suggesting that this
genotype was present for at least 30 years prior to the first pandemic (Bok et al., 2009).
There are very few studies of norovirus molecular epidemiology prior to the emergence
of the first GII.4 pandemic. However, each of the studies carried out to our knowledge to
date that have genotyped norovirus samples collected in the 1970s and 1980s have sug-
gested that GII.4 was one of a number of lower prevalence genotypes at this time (Boon
et al., 2011; Siqueira et al., 2017; Mori et al., 2017b,a). GII.4 was only present in 17%
of norovirus-positive samples collected from children in a Washington hospital between
1974 and 1991 (Bok et al., 2009; Boon et al., 2011), while in Northern Brazil GII.4 was
detected at comparable frequencies to GII.6 and GII.7 between 1982 and 1986, to GII.3,
GII.6 and GII.7 between 1990 and 1992 and to GII.3 between 1992 and 1994 (Siqueira
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Figure 1.6: Pandemic and epidemic GII.4 strains. The main period of pandemic (purple) or
epidemic (blue) circulation is shown for each of the major GII.4 strains. The pandemic
strain labels are in bold font.
et al., 2017). Importantly, following the emergence of US95/96, this strain dominated
norovirus-positive samples in Northern Brazil between 1998 and 2000 (Siqueira et al.,
2017). GII.4 was identified in only 6.9% of norovirus foodborne outbreaks in Tokyo
between 1966 and 1983 (Mori et al., 2017b) and in 2.3% of norovirus sporadic gastroen-
teritis cases in Tokyo between 1985 and 1992 (Mori et al., 2017a). This lower historical
prevalence of GII.4 is also supported by a study examining serological samples collected
from children in the Netherlands in 1963, 1983 and 2006/2007 (Van Beek et al., 2016).
Here, the prevalence of sera reactive against GI viruses decreased through time, while
sera reactive against GII.4 increased in prevalence in the 2006/2007 serum samples com-
pared with those from 1963 and 1983 (Van Beek et al., 2016). However, this study has
the caveat that serum reactivity against GII.4 was measured against a virus collected in
1995 and if the virus had undergone antigenic drift between 1963 and 1995, the ability of
the 1963 serum to bind to the 1995 virus would have been reduced. However, the current
evidence suggests that GII.4 first became dominant in the mid-1990s, correlating with an
increase in norovirus activity (Siebenga et al., 2010).
The mechanisms underlying the high prevalence of GII.4 in recent times are not well
understood, but previous proposals include broader HBGA binding (Lindesmith et al.,
2008), a faster mutation rate enabling more efficient transmission and/or rapid evasion
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of host immunity (Bull et al., 2010; Arias et al., 2016) and reduced capsid constraints
resulting in a greater ability to accomodate change (Boon et al., 2011; Donaldson et al.,
2010; Parra et al., 2017). As discussed previously, GII.4 viruses are not thought to infect
nonsecretors individuals, with rare exceptions (Carlsson et al., 2009). The US95/96 pan-
demic strain was demonstrated to bind to secretor-positive sera from individuals of blood
types A, B and O, representative of roughly 80% of the European and North American
populations (Lindesmith et al., 2008; Singh et al., 2015). The US95/96 capsid also binds
to the A, B, H3, LeB and LeY HBGAs (Lindesmith et al., 2008). This is a greater range
of binding than in the majority of other genotypes, suggesting that GII.4 may be highly
prevalent due to the ability to infect a greater proportion of individuals (Lindesmith et al.,
2008; Donaldson et al., 2010). However, the Hunter 2004 pandemic strain does not bind
efficiently to any tested HBGA under experimental conditions (Lindesmith et al., 2012a)
and therefore broad HBGA-binding does not appear to be universal in pandemic GII.4
strains (Lindesmith et al., 2008). Additionally, broad HBGA-binding is not sufficient
for high prevalence, as the rarely detected GII.10 capsid exhibits broad HBGA binding
(Hansman et al., 2011).
The GII.P4 RdRp was demonstrated to have a higher mutation rate in vitro than the
GII.Pb (now reclassified as GII.P21 (Kroneman et al., 2013)) and GII.P7 RdRps (Bull
et al., 2010). Here, the number of transversion and transition mutations introduced upon
transcription from a poly-C template RNA was several fold higher for GII.P4. It was
suggested that this higher mutation rate enables more efficient generation of viral diver-
sity (Bull et al., 2010). It was recently demonstrated that RdRp fidelity is an important
component of MNV fitness, with a mutation conferring increased RdRp fidelity reducing
the efficiency of transmission (Arias et al., 2016). While there has been no study to date
examining the influence of RdRp fidelity on human norovirus transmission, these stud-
ies together suggest that the higher mutation rate of the GII.P4 RdRp may enable more
efficient transmission.
In a study comparing GII.3 and GII.4 capsid evolution over a similar time period,
both genotypes exhibited an accumulation of nucleotide change through time (Boon et al.,
2011). However, while GII.4 exhibited an accumulation of amino acid change through
time, the GII.3 capsid remaining relatively constant at the amino acid level (Boon et al.,
2011). A recent study examined a greater number of norovirus genotypes and found
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that the non-GII.4 genotypes remain ‘static’ through time and segregate into only a small
number of distinct variants, each of which circulates with few amino acid changes for
long time periods (Parra et al., 2017). For example, the GII.6 genotype segregates into
three variants that have each circulated with few nonsynonymous changes for more than
40 years (Parra et al., 2017). In contrast, GII.4 exhibits rapid change at the amino acid
level with a greater number of variants that each persists for a much shorter period of time
(Siebenga et al., 2007; Boon et al., 2011; Parra et al., 2017). This has led to suggestions
that GII.4 is genetically robust and can accumulate amino acid changes while maintaining
important functions, while the non-GII.4 genotypes are genetically fragile and cannot
tolerate amino acid change (Parra et al., 2017). This hypothesis therefore suggests that
the GII.4 capsid can structurally tolerate changes in a way that the capsid from other
genotypes cannot. A similar mechanism has been proposed for the higher prevalence
of GII viruses compared with GI viruses (Donaldson et al., 2010), where the GII capsid
is larger with more flexible surface loops and can therefore tolerate a greater amount of
change than the GI capsid. However, as the GII.4 capsid is not larger than the capsid of
other GII genotypes, size alone cannot explain the higher prevalence of GII.4.
1.3.4 Emergence of GII.4 pandemic strains
Since the first GII.4 pandemic in 1995, a new pandemic GII.4 strain has emerged
within the human population every 2-7 years (Figure 1.6) (Siebenga et al., 2009; van
Beek et al., 2013). The emergence of a new pandemic strain is often, but not always,
associated with an increase in norovirus outbreaks (Lopman et al., 2004a; Siebenga et al.,
2009; Allen et al., 2014). The onset of a new pandemic is marked by rapid global strain re-
placement, with the new pandemic strain dominating outbreaks worldwide within several
months of its first detection (Eden et al., 2014). For example, the most recent pandemic
strain Sydney 2012 was first detected in Australia in March 2012 and between Novem-
ber 2012 and January 2013 replaced the previous pandemic strain New Orleans 2009 as
the dominant cause of norovirus outbreaks in Europe, North America, Asia and Ocea-
nia (Allen et al., 2014; Giammanco et al., 2013; Hasing et al., 2013; Vega et al., 2014a;
Kim et al., 2013; White, 2014). The pattern of GII.4 strain emergence is consistent with
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epochal evolution, with periodic rapid emergence of a new strain followed by a period of
stasis where that strain dominates (Siebenga et al., 2007; Lindesmith et al., 2008).
The emergence of a new pandemic GII.4 strain is thought to be driven by escape from
herd immunity raised against the preceding pandemic strain (Lindesmith et al., 2008; Can-
non et al., 2009; Lindesmith et al., 2012a; Debbink et al., 2012a; Lindesmith et al., 2013;
Debbink et al., 2013). Multiple studies have demonstrated the occurrence of amino acid
substitutions through time within the GII.4 genotype, with the majority of these substitu-
tions localising to the P2 domain (Siebenga et al., 2007; Lindesmith et al., 2008; Siebenga
et al., 2009; Bull et al., 2010; Lindesmith et al., 2011; Parra et al., 2017). Genetic changes
within the capsid have been demonstrated to result in antigenic variation through time
(Lindesmith et al., 2011), with newly emerging GII.4 strains exhibiting antigenic dif-
ferences relative to their temporal predecessor (Lindesmith et al., 2013; Debbink et al.,
2013). These antigenic differences were demonstrated using a combination of mouse
monoclonal antibodies (mAbs) (Lindesmith et al., 2008, 2011), human mAbs (Lindesmith
et al., 2012a), mouse polyclonal sera (Lindesmith et al., 2008) and human polyclonal sera
(Lindesmith et al., 2008, 2013; Debbink et al., 2013). Antibody binding to a VLP is not
indicative of neutralisation of infection. In the absence of a human norovirus cell culture
system, a surrogate neutralisation assay has been developed that measures the ability of
mAbs or sera to block the binding of a VLP to a HBGA binding partner (Lindesmith
et al., 2008). Antibodies that block such an interaction are termed blockade antibodies
and the presence of these antibodies in sera correlates with protection from infection in
chimpanzees (Bok et al., 2011) and humans (Reeck et al., 2010). This surrogate neutral-
isation assay has been demonstrated to be highly sensitive and can distinguish VLPs too
similar to be separated by antibody binding alone (Lindesmith et al., 2008).
Epitopes within the GII.4 genotype were initially proposed by identification of
rapidly evolving regions on the surface of the viral particle (Figure 1.7) (Allen et al.,
2008; Lindesmith et al., 2012a). Three blockade epitopes (so called because changes at
these sites alter binding of blockade antibodies) termed A, D and E have been identified
(Figure 1.7) and experimentally verified by switching of these epitopes between GII.4
strains (Lindesmith et al., 2012a; Debbink et al., 2012a; Lindesmith et al., 2013; Debbink
et al., 2013). Epitope A is a conformational epitope consisting of residues 294, 296-298,
368 and 372 and has been verified as a blockade epitope in multiple GII.4 strains (Linde-
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smith et al., 2012a; Debbink et al., 2012a; Lindesmith et al., 2013; Debbink et al., 2013).
This epitope has been proposed to be immunodominant and is estimated to account for
between 40 and 55% of the total blockade antibody response (Lindesmith et al., 2013;
Debbink et al., 2013). Previous studies have suggested that epitope A actually consists of
several overlapping epitopes and have demonstrated that different antibodies can interact
with different residues within this region (Lindesmith et al., 2013). Epitope D consists
of residues 393-395 and therefore coincides with the 391-395 loop important for bind-
ing to certain HBGAs (Lindesmith et al., 2012a; Singh et al., 2015). Correspondingly,
changes within epitope D have been demonstrated to have the ability to alter antigenicity
and HBGA-binding (Lindesmith et al., 2008, 2012a). In particular, substitutions at site
393 can alter binding to HBGA type B, while substitutions at site 395 can alter binding
to HBGA type A (Lindesmith et al., 2008). Interestingly, changes within epitope D can
therefore increase the size of the susceptible population by two mechanisms; evasion of
existing immunity or infection of a new part of the population (Lindesmith et al., 2008;
Donaldson et al., 2008). Epitope E is a conformational epitope consisting of residues
407, 412 and 413 and was initially identified as a Farmington Hills 2002 blockade epi-
tope (Lindesmith et al., 2012b). Residues 355-357 also likely contribute to this epitope
(Lindesmith et al., 2012b). Two additional epitopes, B and C, have been proposed based
on their high variability and surface location, but are yet to be confirmed experimentally
(Lindesmith et al., 2012a). Epitopes B and C consist of residues 333 and 382 and residues
340 and 376, respectively (Lindesmith et al., 2012a). Each of these five epitopes likely
also includes additional sites close to the variable sites (Lindesmith et al., 2012a). Im-
portantly, there is at least one more blockade epitope present in the GII.4 capsid that has
not been identified to date (Lindesmith et al., 2012a). Additionally, previous studies have
identified blockade epitopes on the basis of HBGA binding, raising the possibility of addi-
tional blockade epitopes that influence binding to the as yet undiscovered major norovirus
receptor.
One of the human mAbs (NVB 71.4) isolated by Lindesmith et al. (2012a) blocks
the interaction of a wide range of GII.4 VLPs collected from 1987-2012 with the corre-
sponding HBGA, indicating the presence of a conserved epitope (Lindesmith et al., 2012a,
2014). However, the capacity of the NVB 71.4 mAb to block this interaction differs be-
tween the GII.4 strains, suggesting the epitope consists of both conserved and variable
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Monomer A Monomer B 
Figure 1.7: Immune epitopes on the surface of the GII.4 capsid. Epitopes are shown on the
Sydney 2012 dimeric P domain structure 4WZT. One monomer is shown in grey
and the other monomer is shown in blue-white. This is a top view of the capsid.
The epitopes are coloured in both monomers but are only labelled in monomer A for
clarity. Neutralising epitopes A, D and E are shown in red and putative epitopes B
and C are shown in brown. The residues within each epitope are shown by the dashed
circle.
residues (Lindesmith et al., 2012a). The exact epitope targeted by NVB 71.4 is yet to
be identified, but access to the epitope is conformation and temperature dependent and
is regulated by several amino acids, including E316, R484 and K493 (Lindesmith et al.,
2014). While sites 316, 484 and 493 are highly conserved within GII.4, site 310 varies in
New Orleans 2009 and Sydney 2012 and variation at this site has been demonstrated to
alter access to the conserved epitope (Lindesmith et al., 2014).
Several studies have examined the antigenic changes between temporally adjacent
pairs of pandemic strains in more detail (Lindesmith et al., 2008, 2012b, 2013; Debbink
et al., 2013). While subtle antigenic differences between the Camberwell 1994-like and
US95/96 strains have been demonstrated (Lindesmith et al., 2012a), these strains appear
to be very similar antigenically, supporting suggestions for a non-immunity driven mech-
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anism for the increase in prevalence of the GII.4 capsid in the mid-1990s (Lindesmith
et al., 2008, 2011). Epitope E and site 395 within epitope D have been implicated as
important in the emergence of Farmington Hills 2002 (Lindesmith et al., 2008, 2012b).
Epitope A was demonstrated to change between the Den Haag 2006 and New Orleans
2009 strains, with sites 294, 368 and 372 within epitope A differing between the strains
(Lindesmith et al., 2013). Sydney 2012 changed in epitopes A and D compared with its
temporal predecessor, New Orleans 2009 (Debbink et al., 2013). Only roughly 30% of
the polyclonal blockade response against New Orleans 2009 was retained against Sydney
2012, with a substantial percentage of this reduction being due to changes at sites 294 and,
in particular, 368 (Debbink et al., 2013). New Orleans 2009 and Sydney 2012 also differ
in epitope D and substitutions at site 373 next to epitope A and site 396 next to epitope D
may also have had a role in immune escape (Debbink et al., 2013; Allen et al., 2014). The
conserved epitope recognised by the human mAb NVB 71.4 likely also changed between
New Orleans 2009 and Sydney 2012 (Debbink et al., 2013; Lindesmith et al., 2014).
Recombination has also been suggested to have a role in the emergence of GII.4
pandemic strains (Eden et al., 2013). Prior to their respective pandemic emergence, New
Orleans 2009 acquired a Yerseke 2006-like ORF1, while Sydney 2012 acquired a GII.Pe
ORF1 by recombination (Eden et al., 2013). Such recombination events have the poten-
tial to enable acquisition of an advantageous ORF1 which could, for example, be able to
evade T cell immune responses raised against non-structural proteins (White, 2014). Ad-
ditional recombination events at the ORF1/ORF2 and ORF2/ORF3 boundaries have been
identified leading to epidemic GII.4 strains, leading to suggestions of the importance of
recombination in GII.4 evolution (Eden et al., 2013). However, to date no studies have
been conducted comparing the properties of non-structural proteins found with the dif-
ferent pandemic GII.4 strains and there is little information available of T cell immunity
against these proteins. Therefore, while recombination has clearly occured leading to cer-
tain GII.4 strains, the importance of this recombination is unknown. The Sydney 2012
pandemic strain circulated with both the GII.P4 and GII.Pe ORF1s (Wong et al., 2013).
The first four pandemic GII.4 strains were suggested to have evolved from their tem-
poral predecessor, with the exception of Den Haag 2006 which was proposed to have
evolved from Farmington Hills 2002 (Siebenga et al., 2007; White, 2014). However, a
recent phylogenetic analysis demonstrated that the New Orleans 2009 and Sydney 2012
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strains last shared a common ancestor close to the start of the Apeldoorn 2007 epidemic
and therefore neither of these strains evolved from a previously circulating pandemic
strain (Eden et al., 2014). Pre-pandemic forms of New Orleans 2009 and Sydney 2012
were identified circulating one and two years prior to the onset of the respective pandemic,
leading to suggestions that these strains circulated at low level until acquiring substitutions
within the capsid P2 domain that drove global emergence (Eden et al., 2014). Several ad-
ditional studies have now identified individual cases and/or outbreaks caused by GII.4
pandemic strains over several years prior to the onset of their pandemic (Siebenga et al.,
2009; Sdiri-Loulizi et al., 2009; Mans et al., 2016; Allen et al., 2016). In a recent study
of UK community gastroenteritis cases from the mid 1990s, Allen et al. (2016) identified
four of the pandemic strains between eight and 18 years prior to the onset of their respec-
tive pandemics and suggest the importance of surveillance of sporadic gastroenteritis in
the community (Allen et al., 2016).
Exactly where GII.4 noroviruses may be circulating when they acquire their pan-
demic enabling mutations has been a topic of active discussion (Karst and Baric, 2015).
Immunocompromised patients have been suggested to be a potential reservoir for new
GII.4 strains due to the diverse viral population that has been detected within these pa-
tients (Bull et al., 2012; Vega et al., 2014b; Karst and Baric, 2015). This diversity is in
stark contrast to the limited diversity detected in infections of immunocompetent indi-
viduals (Bull et al., 2012; Karst and Baric, 2015) and changes acquired during chronic
infection of immunocompromised patients can alter viral antigenicity (Debbink et al.,
2014). However, a recent study developed a mathematical model of transmission that in-
corporates immunocompetent and immunocompromised patients and suggested that im-
munocompromised patients do not greatly contribute to norovirus evolutionary dynamics
due to the rarity and isolation of such hosts (Eden et al., 2017). The potential for elderly
or malnourished hosts to act as reservoirs for new strains has also been mooted as these
individuals have diminished, but not absent, immune responses (Hickman et al., 2014;
Karst and Baric, 2015). Malnourished mice exhibited a more diverse murine norovirus
quasispecies, but again there is no evidence that this could result in new variants that
are onwardly transmissible (Hickman et al., 2014). Importantly, few studies of norovirus
epidemiology have been carried out in developing countries where malnutrition is more
common (Mans et al., 2016). GII.4 viruses have been detected in faeces from cows, pigs
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and dogs, raising the possibility of zoonotic transmission (Mattison et al., 2007; Summa
et al., 2012; Caddy et al., 2015). However, norovirus genotypes typically exhibit strict
species tropism and, while inter-species transmissions have clearly occurred in the past,
no zoonotic transmission has yet been observed (Karst and Baric, 2015).
1.3.5 Emergence of the GII.P17-GII.17 Kawasaki 2014 lineage in
Asia in Winter 2014-2015
In the Winter of 2014-2015, a novel GII.17 lineage replaced GII.4 Sydney 2012 as
the dominant cause of norovirus outbreaks in East Asia (Matsushima et al., 2015; De
Graaf et al., 2015; Lu et al., 2015; Fu et al., 2015; Lee et al., 2015). Until this time, the
GII.17 genotype had only rarely been detected (De Graaf et al., 2015). The novel GII.17
lineage, termed GII.17 Kawasaki 2014, was first detected in wastewater samples in Kenya
in 2012 and 2013 (Kiulia et al., 2014; De Graaf et al., 2015) and the origins of this lineage
were traced back to Africa, with a single introduction into Asia (Lu et al., 2016). GII.17
Kawasaki 2014 caused a large peak in norovirus outbreaks in Japan, Hong Kong and
Jiangsu province, China in Winter 2014-2015 (Matsushima et al., 2015; Fu et al., 2015;
Chan et al., 2015), similar to increases associated with the emergence of new pandemic
GII.4 strains (Lopman et al., 2004a). The GII.17 Kawasaki 2014 lineage is associated
with a novel GII.P17 ORF1 and the surface of the capsid exhibits two insertions and
multiple substitutions relative to other GII.17 viruses, including at sites within and close
to known epitopes within the GII.4 capsid (Chan et al., 2015; De Graaf et al., 2015; Singh
et al., 2016a). It was recently demonstrated that the GII.17 Kawasaki 2014 lineage is
antigenically distinct from other GII.17 viruses and sites 393-396 were identified as an
important epitope in GII.17 (Lindesmith et al., 2017a). Additionally, GII.17 Kawasaki
2014 was demonstrated to bind to HBGA types A, B and O, suggesting the ability to
infect a large proportion of the population (Chan et al., 2015). While sporadic cases of
GII.17 Kawasaki 2014 were detected in multiple countries worldwide, this lineage has
not replaced GII.4 Sydney 2012 as the dominant norovirus strain in most countries and is
therefore largely restricted to East Asia (Chan et al., 2017a).
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1.3.6 Emergence of viruses with the GII.P16 ORF1 in Winter 2016-
2017
Two novel lineages containing the GII.P16 ORF1 emerged as a major cause of
norovirus outbreaks in Winter 2016-2017 (Niendorf et al., 2017; Ao et al., 2017; Lu et al.,
2017; Liu et al., 2017; Bidalot et al., 2017). The emergence of these lineages was associ-
ated with a large increase in norovirus outbreaks compared with recent years in Germany
(Niendorf et al., 2017), China (Ao et al., 2017) and France (Bidalot et al., 2017). While
the two lineages each have the GII.P16 ORF1, one lineage has the GII.4 Sydney 2012
capsid, while the other has the rarely detected GII.2 capsid (Matsushima et al., 2016;
Niendorf et al., 2017; Chan et al., 2017b). The GII.P16-GII.2 lineage was dominant in
Taiwan in late 2016, with outbreaks caused by this lineage predominantly occurring in
schools (Liu et al., 2017).
1.4 Human norovirus immunity and immune escape
1.4.1 Innate immunity against noroviruses
Innate immunity has been suggested to be critical for controlling norovirus infection,
due to the short duration of symptomatic infections in immunocompetent patients (Karst
et al., 2014). Type I interferon (IFN) responses are particularly important for control of
MNV infection and mice lacking type I interferon receptor, type I and type II interferon
receptors or STAT1 exhibit far higher MNV viral titres compared with wild-type mice and
succumb to lethal infection (Karst, 2003; Thackray et al., 2012). In the absence of type
I IFN, MNV infection can be controlled by a mechanism involving type II IFN (Karst,
2003; Karst et al., 2014). Additionally, MNV strongly induces a type I IFN response in
cultured macrophages and dendritic cells (Thackray et al., 2012) and replicates to higher
titres in cultured macrophages and dendritic cells from mice lacking components of the
IFN pathway, including STAT1-/-, IRF3-/-, MDA5-/- and IFNAR1-/- mice, indicating a key
role for IFN in control of MNV infection (Wobus et al., 2004; McCartney et al., 2008;
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Thackray et al., 2012). However, a single cycle of Norwalk virus replication and replica-
tion of a GII.3 virus in human cells able to mount strong IFN responses does not result
in an IFN response (Qu et al., 2016). These human noroviruses do not block induction of
IFN by co-transfection of Sendai virus, indicating that human noroviruses do not induce
IFN (Qu et al., 2016). Additionally, the ability of p48 and p22 to alter protein secretory
pathways potentially inhibits the ability of infected cells to mount effective innate immune
responses (Roth and Karst, 2016). Interestingly, a single substitution within the MNV p48
homologue NS1/2 is sufficient to enable persistent infection of the colon, consistent with
an inhibition of the innate immune response (Nice et al., 2013; Niendorf et al., 2016).
1.4.2 Adaptive immunity against noroviruses
There is evidence of a role for B cells, CD4+ T cells and CD8+ T cells in the con-
trol of norovirus infections (Karst et al., 2014). Mice lacking B cells do not clear MNV
infections, while the transfer of immune serum or B cells into persistently infected RAG1
knockout mice results in clearance of infection (Chachu et al., 2008b). The presence of
long term protective humeral immunity against human noroviruses has been controversial
(Debbink et al., 2012b). Volunteer studies have demonstrated the development of short-
term immunity against GI.1 norovirus, but also identified that some individuals could be
re-infected with the same strain, suggesting infection did not result in long-term protective
immunity (Parrino et al., 1977). However, this was challenged by the detection of immune
responses in norovirus challenged but uninfected volunteers, leading to suggestions that
the high inoculum titres used in early studies were unrealistic and potentially resulted in
less protective immunity than would be mounted against a, more realistic, small infec-
tious dose (Lindesmith et al., 2003, 2005, 2012a). An increase in Norwalk virus-specific
IgA between one and five days after exposure correlated with protection from infection,
in contrast to infected individuals who exhibited an increase in IgA only more than five
days after exposure (Lindesmith et al., 2003). The Norwalk virus-specific IgA level had
returned to baseline by eight days after exposure, indicating a rapid immunological re-
sponse and the presence of pre-existing immunity (Lindesmith et al., 2003). The presence
of long-term immunity is also supported by the complex binding patterns of human mAbs
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against GII.4 strains (Lindesmith et al., 2012a). Mathematical modelling indicates that the
duration of human norovirus immunity is 4.1-8.7 years (Simmons et al., 2013). Recently,
Parra et al suggested that the GI and GII genogroups could be divided into immunotypes,
with each immunotype consisting of one or more closely related genotypes (Parra et al.,
2017). Importantly, re-infection within an immunotype is rare, suggesting both protective
immunity and antigenic similarity of related genotypes (Parra et al., 2017). Similar to
other viruses, the magnitude and duration of norovirus immunity is boosted by multiple
exposures, as demonstrated by multiple MNV infections in mice and GI.1 infections of
chimpanzees (Chachu et al., 2008a; Bok et al., 2011).
GI- and GII-reactive antibodies are high in acute sera (Reeck et al., 2010; Lindesmith
et al., 2010). Cross reactivity patterns differ between the genogroups, with GI sera being
cross reactive within the genogroup but not with GII viruses (Debbink et al., 2012b).
In contrast, GII sera are far more strain-specific and do not exhibit broad GII-blocking
responses (Rockx et al., 2005; Debbink et al., 2012b). Interestingly, there is evidence
that even closely related MNV strains can greatly differ in their ability to generate robust
immunity (Zhu et al., 2013; Karst et al., 2014). MNV-3 elicits a more robust antiviral
antibody and CD4+ T cell response compared with MNV-1, with this robust response
resulting in protection from reinfection (Zhu et al., 2013). This difference was due to
VP2, with exchange of VP2 between the strains switching the phenotypes, although the
mechanism behind this remains unknown (Zhu et al., 2013; Roth and Karst, 2016).
The role of T cells in norovirus infection has not been as well characterised as that
of B cells. However, infection or vaccination with human norovirus leads to induction
of a primarily CD4+ Th1 cell response, leading to production of IFN-gamma and IL-2
(Lindesmith et al., 2005, 2010). Indeed, an early Th1 response correlated with protection
against infection with a GII.2 virus (Lindesmith et al., 2005). T cell responses have been
suggested to be cross reactive between closely related genotypes (Lindesmith et al., 2005,
2010). Mice infected with MNV develop an intestinal T cell response by eight days post-
infection (Tomov et al., 2013). While mice deficient in CD4+ or CD8+ T cells do clear
infection, transfer of immune CD4+ or CD8+ T cells into RAG1 knockout mice reduced
chronic viral load and transfer of immune CD4+ T cells into either wild-type of RAG1
knockout mice protects from primary infection (Chachu et al., 2008a; Tomov et al., 2013;
Zhu et al., 2013).
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1.4.3 Vaccine development against human noroviruses
There is currently no widely accepted treatment for norovirus infection, although
compounds targeting various viral and cellular components are under development
(Thorne et al., 2016). There has been progress towards the development of a norovirus
vaccine, with early clinical trials demonstrating vaccine protection against experimen-
tal challenge (Atmar et al., 2011; Bernstein et al., 2015; Nordgren et al., 2016; Cortes-
Penfield et al., 2017). Given the high prevalence of norovirus disease, a vaccine eliciting
protective immunity in a high proportion of recipients has the potential to provide eco-
nomic and public health benefits (Bartsch et al., 2012). Several correlates of protection for
human norovirus infection have been identified (Ramani et al., 2016) and provide insights
into the immunity that an effective vaccine may need to elicit. The presence of blockade
antibodies in sera prior to exposure to Norwalk virus was associated with a lower risk of
illness in a human challenge study (Reeck et al., 2010). Such antibodies were also associ-
ated with protection from infection and disease following vaccination (Atmar et al., 2011,
2015). A key role for IgA in protection from infection and illness is suggested by the
results of several studies. Pre-exposure levels of salivary IgA correlate with protection
from illness (Ramani et al., 2015), while post-exposure levels correlate with protection
from infection as previously discussed (Lindesmith et al., 2003). Additionally, the level
of fecal IgA pre-exposure exhibits an inverse relationship with peak virus shedding, while
fecal IgA levels seven days post-exposure inversely correlates with the duration of virus
shedding (Ramani et al., 2015). A role for IgG is also supported by the presence of virus-
specific memory IgG cells correlating with protection from illness (Ramani et al., 2015).
Two vaccines employing different strategies have entered clinical trials and have each
demonstrated a degree of protection against experimental infection with the genotype(s)
included in the vaccine (Nordgren et al., 2016; Cortes-Penfield et al., 2017). Additional
vaccines are in pre-clinical trials. One vaccine in clinical trials is a VLP-based bivalent
vaccine containing GI.1 and a consensus GII.4, while the other uses a recombinant ade-
novirus that expresses the GI.1 capsid (Cortes-Penfield et al., 2017). Lindesmith et al.
(2017b) recently showed that while the bivalent vaccine elicited a peak blockade anti-
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body avidity against GI.1 35 days after exposure, evidities against heterotypic GI VLPs
were not sustained 35 days after vaccination, nor after the same time period following
exposure in volunteer studies. As only secretor-positive individuals retined high avidity
blockade antibodies 180 days post-exposure, host genetics can influence vaccine response
(Lindesmith et al., 2017b). Interestingly, avidity to the consensus GII.4 VLP peaked ear-
lier at day seven and remained elevated through to day 180. Unlike GI.1, this avidity was
not dependent on secretor status.
However, the high genetic and antigenic diversity of human noroviruses presents
a serious challenge to vaccine development. As previously discussed, genogroup-specifc
immunity has been suggested to be elicited by natural infection, with little cross-reactivity
between GI and GII noroviruses (Malm et al., 2014, 2015). Additionally, available evi-
dence indicates that newly emerging pandemic GII.4 strains are capable of evading im-
munity raised against previous pandemic strains (Lindesmith et al., 2012b, 2013; Debbink
et al., 2013). However, a recent study suggested that serum from many individuals pos-
sesses cross-reactive blockade antibodies that can recognise GII.4 strains years before the
strain emerges (Sharma et al., 2017). Avidity against the GII.4 Sydney 2012 strain was
induced by the bivalent GI.1 and consensus GII.4 vaccine, despite this strain not emerging
until one year after the vaccine trial (Lindesmith et al., 2017b). Therefore this vaccine has
the potential to protect individuals against future GII.4 strains.
As previously discussed, norovirus infection rates are particularly high in children
under the age of five (O’Brien et al., 2016). It has been suggested that immunisations
that elicit robust immunity in adults may not be equally efficacious in children (Cortes-
Penfield et al., 2017), raising a potential challenge in vaccine development. Addition-
ally, immunocompromised patients and the elderly are at higher risk of morbidity and
mortality from norovirus infection. Both of these groups exhibit differing degrees of im-
mune system impairment that may limit vaccine efficacy. Finally, as previously discussed,
norovirus immunity may be short lived. A vaccine would need to elicit long lasting im-
munity to be cost-effective (Cortes-Penfield et al., 2017).
1.4.4 Thesis aims and organisation
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The emergence of pandemic GII.4 strains has been well documented and multiple
studies have suggested immune evasion as a mechanism enabling the emergence of these
strains. However, the sources of new pandemic strains and the process by which these
strains emerge remain poorly understood. In this thesis, we aim to answer: Where do new
pandemic GII.4 strains come from? How do new GII.4 strains emerge within the popu-
lation and spread pandemically? Which genetic changes enable new pandemic strains to
emerge? Why do new GII.4 pandemics occur? In chapter 2, we examine the mechanisms
that drove the emergence of GII.4 as the dominant genotype in the mid-1990s. In chapter
3, we reconstruct the temporal evolutionary history of the GII.4 genotype to investigate
the sources of subsequent pandemic GII.4 strains and suggest mechanisms responsible
for norovirus pandemics. We next reconstruct the spatiotemporal history of individual
norovirus strains in chapter 4 to investigate their early spread and characterise global
circulation. In this chapter, we also identify capsid substitutions that may have been im-
portant for the pandemic emergence of the five most recent pandemic strains. Finally,
in chapter 5, we demonstrate the worldwide circulation of a newly emerging norovirus
lineage and identify the genetic substitutions that may be responsible for the increased
circulation of this lineage.

Chapter 2
The GII.4 lineage became pandemic in
the mid-1990s due to substitutions in
the capsid and/or VP2
2.1 Abstract
Despite the large diversity of norovirus genotypes infecting humans, the GII.4 capsid
genotype causes the majority of cases and outbreaks and has caused six pandemics since
the mid-1990s. Current evidence suggests that prior to the first pandemic, GII.4 was far
less prevalent. While several hypotheses have been suggested for the high prevalence of
GII.4, no previous study has examined the viral genetic changes that occured within this
genotype as it transitioned from low frequency to high frequency. Here, we carry out
phylogenetic analyses on each region of the viral genome and suggest that changes within
the capsid and/or VP2 likely drove the increase in GII.4 prevalence. The substitutions
leading to the common ancestor of the pandemic GII.4 viruses suggest two mechanisms
by which this increase could have been driven: an increase in capsid stability and/or an
increase in the range of HBGA-binding. The ORF1 regions found with pandemic GII.4
capsids last shared a common ancestor in the 1970s and this region is therefore very
unlikely to have driven pandemic emergence in the mid-1990s. We find evidence for an
increase in substitution rate in the RdRps associated with the GII.4 capsid, consistent
with an increase in mutation rate. However, this is shared with other RdRp genotypes not
found with the GII.4 capsid and was likely acquired by 1906, indicating that an increased
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mutation rate was not the driver of pandemic emergence. We demonstrate that GII.4 is
the only GII capsid genotype that exhibits an accumulation of change at the amino acid
level, consistent with previous results that non-GII.4 genotypes remain ‘static’ through
time. This accumulation of amino acid change was already occurring within GII.4 prior
to pandemic emergence. We therefore hypothesise that the GII.4 capsid was pre-adapted
for pandemic emergence due to an inherent ability to accommodate amino acid change
and the associated RdRps enabling rapid mutation to aid transmission and evasion of
host immunity. The increase in capsid stability and/or increase in HBGA-binding range
then enabled more efficient transmission and/or infection of a larger proportion of the
population, respectively, which drove the actual increase in prevalence of GII.4.
2.2 Introduction
While the GII.4 genotype currently accounts for the majority of human norovirus
cases and outbreaks (Kroneman et al., 2008; Siebenga et al., 2009), this high prevalence
likely began with the onset of the first GII.4 pandemic in the mid-1990s (Donaldson et al.,
2008; Siebenga et al., 2010). To date there have only been limited studies on norovirus
molecular epidemiology from prior to the onset of this first pandemic. However, each
of the studies including surveillance undertaken prior to 1995 have suggested GII.4 to be
one of a number of low prevalence genotypes (Boon et al., 2011; Siqueira et al., 2017;
Mori et al., 2017b,a). These studies have been undertaken in both children and adults and
within community, hospital and foodborne outbreak settings, suggesting a universally
lower prevalence.
Previous studies have resulted in several hypotheses for the high prevalence of the
GII.4 genotype. HBGA-binding studies have demonstrated the US95/96 GII.4 pandemic
strain can bind to a wider range of HBGAs than other genotypes (Lindesmith et al., 2008;
Donaldson et al., 2010). Specifically, US95/96 can bind to HBGAs expressed by secretor
positive individuals with A, B and O blood groups and is therefore thought to be able
to infect roughly 80% of the human population, a greater proportion than other geno-
types (Lindesmith et al., 2008). However, this wide range of HBGA-binding has not been
demonstrated for all GII.4 strains, as would be expected if this were the major determi-
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nant of high prevalence. For example, the Hunter 2004 pandemic strain does not bind ef-
ficiently to any tested synthetic HBGAs under experimental conditions (Lindesmith et al.,
2008; Donaldson et al., 2010; Lindesmith et al., 2012a).
The GII.P4 RdRp associated with the majority of pandemic GII.4 strains exhibits
a higher mutation rate than the lower prevalence GII.Pb and GII.P7 RdRps (Bull et al.,
2010). This has led to suggestions that the GII.4 capsid may be highly prevalent due to the
associated GII.P4 RdRp enabling faster change and thereby rapid evasion of existing host
immunity (Bull et al., 2010; Bull and White, 2011). Alternatively, a higher mutation rate
may increase transmissibility, as recently demonstrated for murine norovirus (Arias et al.,
2016). Boon et al demonstrated that while the GII.4 capsid has accumulated amino acid
change through time, the GII.3 capsid has remained relatively constant at the amino acid
level (Boon et al., 2011). It is therefore possible that the GII.4 capsid is able to accomo-
date increased amino acid variation compared to the other genotypes, while maintaining
important capsid functions (Boon et al., 2011). This is supported by a recent study that
demonstrated a wide range of non-GII.4 genotypes have remained static at the amino acid
level through time (Parra et al., 2017). However, whether this accumulation of amino acid
change within the GII.4 genotype is a cause or consequence of its high prevalence is yet to
be determined. The large size of the genogroup GII capsid compared with capsids in the
GI genogroup has been suggested be of importance for the ability of GII to accomodate
change (Donaldson et al., 2010). In particular, the presence of large loops on the surface
of the capsid may enable accomodation of rapid change.
Previous studies have not examined the viral genetic changes that occurred leading to
the highly prevalent GII.4 viruses. Here, we carry out phylogenetic analyses and demon-
strate that substitutions within either the capsid and/or VP2 likely drove the increase in
GII.4 prevalence in the mid-1990s. We identify two potential mechanisms based on the
substitutions within the capsid region: increased capsid stability and expansion of the
HBGA-binding range. We demonstrate that the common ancestor of pandemic ORF1 se-
quences occurred in the 1970s, indicating that ORF1 was highly unlikely to have driven
pandemic emergence. Phylogenetic data do support a higher substitution rate within the
RdRps associated with the GII.4 capsid, consistent with an increased mutation rate, al-
though this is not unique to the RdRps found with the GII.4 capsid and was likely ac-
quired by the early 1900s. Therefore the increase in GII.4 prevalence was not driven by
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the acquisition of a higher mutation rate. While most GII capsid genotypes exhibit an
accumulation of nucleotide change through time, GII.4 is the only GII genotype to ex-
hibit accumulation of amino acid change. This accumulation of amino acid change was
already evident in the pre-pandemic GII.4 lineages. We conclude that the GII.4 capsid
was pre-adapted to become pandemic due to its ability to accomodate amino acid change
and the high mutation rate of the associated RdRps, and an increase in capsid stability
and/or increase in HBGA-binding range were the final steps that enabled the pandemic
emergence and subsequent dominance of this genotype.
2.3 Materials and Methods
2.3.1 GII.4 capsid dataset assembly and phylogenetic analyses
To obtain a dataset of all available norovirus GII.4 capsid sequences, we searched
GenBank with the term ‘norovirus’ and sequence length 400-10000 nucleotides. We
genotyped each of these sequences using the norovirus genotyping tool (Kroneman et al.,
2011) and retained all sequences with the GII.4 capsid that contained more than 800 nu-
cleotides in the capsid region. We removed sequences that within their GenBank record
are associated with a patent or a laboratory host and sequences that were listed as a syn-
thetic construct, a laboratory strain, a passaged virus, a cloned sample or an unverified
sequence. Any of these associations may have resulted in changes to the sequence after
the isolation of the virus from an infected patient and can therefore mislead evolutionary
analyses. We also removed sequences that exhibited a frameshift within the capsid region
and sequences that contained a stop codon within each frame in the capsid region as these
changes will likely have resulted in a non-functional capsid. We removed sequences for
which a collection date could not be obtained. We additionally removed one sequence
that was listed as having a non-functional capsid. Where multiple longitudinal sequences
from the same patient are present, only the earliest collected sequence from the patient
was retained.
The root-to-tip distance accumulated by each sequence in a phylogenetic tree rela-
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tive to its date of collection gives a measure of the amount of change accumulated per
unit time (Rambaut et al., 2016). Sequences that are overly divergent (i.e. exhibit a large
root-to-tip distance relative to their collection date) are often spurious sequences, poten-
tially due to sequencing error. Any such sequences should therefore be removed from
further phylogenetic analyses. We aligned the GII.4 capsid dataset at the amino acid level
using MUSCLE (Edgar, 2008) and reconstructed a nucleotide maximum likelihood tree
using RAxML v8.1 (Stamatakis, 2014) with the GTR substitution model and gamma rate
heterogeneity with four gamma classes. We assessed topological robustness using 1000
bootstrap replicates. We examined the temporal signal within this tree using TempEst v1.5
(Rambaut et al., 2016) and did not find any sequences that were overly divergent based on
their collection date. This phylogenetic tree was therefore used for further analyses. The
final GII.4 capsid dataset contained 2198 capsid sequences and included sequences from
all of the major GII.4 strains (Table 2.1).
To calculate the date of the common ancestor of the pandemic GII.4 clade and the
date of the increase in prevalence of the GII.4 capsid, we extracted the CHDC 1970s,
Tokyo 1980s, Bristol 1993, Camberwell 1994-like, Kaiso 2003, US95/96 and Osaka 2007
sequences from the GII.4 dataset (Table 2.1). This dataset contains all of the available se-
quences from the early part of the GII.4 phylogenetic tree, with it being well supported
that Osaka 2007 is the first strain that diverges after US95/96. There is a correlation
between root-to-tip distance and sampling date within this dataset, as calculated using
a nucleotide maximum likelihood tree reconstructed with RAxML as above. We recon-
structed the temporal evolutionary history of the early GII.4 lineage using BEAST v.2.4.2.
We used the SRD09 substitution model, where the alignment is partitioned into codon po-
sitions 1 and 2 and codon position 3, with a separate HKY substitution model with gamma
rate heterogeneity and four gamma classes being applied to each partition. We used the
relaxed lognormal clock model and applied a lognormal prior to the substitution rate with
mean 6.83x10-3 and standard deviation 0.1. This prior was chosen based on the mean and
95% HPD posterior estimates of the GII.4 substitution rate estimated in chapter 3 (Table
3.2). We applied a coalescent Bayesian skyline tree prior. Three replicate runs were car-
ried out and run until convergence, as assessed using Tracer v1.5. The replicate runs were
combined with removal of suitable burnin using LogCombiner v2.2.1 and the maximum
clade credibility (MCC) phylogenetic tree was identified using TreeAnnotator v2.2.1.
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GII.4 strain Number of capsid Number of VP2
sequences sequences
CHDC1970s 8 8
Tokyo 1980s 2 2
Bristol 1993 3 3
Camberwell 1994-like 7 5
US95/96 79 5
Farmington Hills 92 61
2002
Lanzhou 2002 11 2
Asia 2003 42 16
Kaiso 2003 5 0
Hunter2004 59 17
Den Haag 2006 858 629
Yerseke 2006 46 18
Apeldoorn 2007 69 36
Osaka 2007 30 4
New Orleans 2009 396 158
Sydney 2012 480 157
GII.4 could not 22 6
assign strain
Table 2.1: Summary of the GII.4 capsid and VP2 datasets. All sequences were genotyped
using the norovirus genotyping tool (Kroneman et al., 2011). There is currently no
genotyping system for VP2 and each VP2 sequence was therefore assigned to a strain
on the basis of its capsid strain, as assigned using the norovirus genotyping tool (Kro-
neman et al., 2011). Phylogenetic analysis confirmed that the majority of sequences
clustered similarly in the capsid and VP2, with the exception of Osaka 2007 where the
11 sequences with the Osaka 2007 capsid clustered within two separate clades within
the VP2 phylogenetic tree. Four of the sequences cluster with the US95/96 VP2, while
the other seven sequences cluster within the Den Haag 2006 clade. We classified the
four sequences that cluster with US95/96 as having the Osaka 2007 VP2, as this is
consistent with the clustering of the RdRp classified as Osaka 2007. The other seven
sequences were included in the Den Haag 2006 clade. Pandemic strains are labelled in
bold font.
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We calculated the date at which the pandemic GII.4 clade diverged from the pre-
pandemic GII.4 lineages from the date of the node immediately upstream of the common
ancestor of the pandemic GII.4 clade in all trees in the posterior distribution. We calcu-
lated the date of the increase in GII.4 prevalence using information from the Bayesian
skyline plot in each sampled step in the MCMC chain. The Bayesian skyline plot is a
piecewise constant model to estimate relative genetic diversity (estimated by the effective
population size multiplied by generation time, Neτ) through time. Here, Neτ can change
between time windows but is constant within a window. We employed a Bayesian skyline
plot consisting of five time windows. The value of Neτ within each window and the length
of each window are integrated over during the MCMC chain. We initially calculated the
date at which each sampled step supported an increase in Neτ of more than 100% relative
to that in the first time window. Most sampled steps supported an increase in the 1990s,
while a small number of steps supported an earlier increase between the 1960s and 1980s
(Figure S2.1). Examination of the steps supporting an early increase demonstrated that
these steps supported a small early increase in Neτ followed by another, larger, increase
in Neτ in the mid-1990s (Figure S2.1). We therefore defined the time of pandemic onset
in these steps as the time at which Neτ increased by more than 400% relative to base-
line. We combined the date at which these steps supporting a small early increase in Neτ
increased by more than 400% relative to baseline with the time at which the remaining
steps support an increase in Neτ of more than 100% relative to baseline to obtain a single
distribution for the time of the increase in GII.4 capsid prevalence (Figure S2.1). As this
distribution is not normally distributed (see Figure 2.2 panel D), we used the median as
the point estimate of the date of the increase in frequency. The date at which the median
Neτ begins to increase in frequency in the Bayesian skyline plot reconstructed on all sam-
pled steps using Tracer v1.5 (October 1994) is very similar to our estimate of the median
date of the increase in GII.4 prevalence (December 1994).
We inferred the nonsynonymous substitutions that occurred leading to the pandemic
GII.4 clade common ancestor using the nucleotide maximum likelihood tree reconstructed
on the 2198 sequence GII.4 capsid dataset and ten bootstrap tree topologies reconstructed
during bootstrapping of this dataset. We used multiple tree topologies to assess the ro-
bustness of the inferred substitutions to tree topology. We used RAxML v8.1 (Stamatakis,
2014) to optimise branch lengths to the amino acid alignment using the translated GII.4
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alignment and the WAG substitution model with optimised base frequencies. We carried
out ancestral reconstruction at the amino acid level with PAML v4.9 (Yang, 2007) using
the WAG substitution matrix and optimised base frequencies. We identified nonsynony-
mous substitutions by comparing the amino acid sequence of the pandemic GII.4 clade
common ancestor with that of the upstream node. Each of the nonsynonymous substi-
tutions inferred to have occurred leading to the pandemic GII.4 clade common ancestor
occurred with each tested tree topology, with the exception of T534A which occurred
in 9 of 11 tested tree topologies. We verified the identified changes using SubRecon
(available at https://github.com/chrismonit/SubRecon) which calculates the probability of
each nonsynonymous substitution occurring at each site along a branch of interest. We ran
SubRecon on the maximum likelihood tree topology with WAG-optimised branch lengths
and employed the WAG substitution matrix incorporating the base frequencies optimised
by RAxML. The same nonsynonymous substitutions were identified using SubRecon as
through ancestral reconstruction with PAML. SubRecon identified the probability of each
substitution to be 1.0 with the exception of T534A, the probability of which was 0.86.
The conservation of sites of interest was assessed using the coloured trees method, where
each tip within the nucleotide maximum likelihood phylogenetic tree was coloured by the
amino acid residue within that sequence at the site.
We identified sites under different selective constraints in the pandemic GII.4 clade
compared with the pre-pandemic GII.4 lineages using TdG v1.1.2 (Tamuri et al., 2009).
Briefly, this method identifies amino acid sites that are evolving differently within two
or more subclades. A substitution matrix is optimised for each subclade independently
at each site and a likelihood ratio test performed to determine whether the two subclade-
specific rate matrices fit the data significantly better than a single rate matrix optimised on
the entire dataset. Two matrices fitting the data significantly better than one is indicative
of the two clades evolving differently at the site. We used the maximum likelihood tree
reconstructed on the 2198 GII.4 sequence dataset with WAG-optimised branch lengths
and optimised base frequencies. We labelled the viruses from the CHDC 1970s, Tokyo
1980s, Bristol 1993, Camberwell 1994-like and Kaiso 2003 strains as pre-pandemic and
the viruses within the pandemic GII.4 clade were labelled as pandemic.
We carried out homology modelling using two methods: SWISS-MODEL (Biasini
et al., 2014) and I-TASSER (Zhang, 2008). We constructed homology models of the
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common ancestor of the pandemic GII.4 clade and the immediately upstream ancestor
using the sequences of these nodes reconstructed by PAML. We modelled the structure of
the P domain excluding the last nine residues because currently available GII.4 structures
consist of this region. These ancestral sequences therefore differ at sites 285, 294, 309,
333, 340, 395, 459, 497 and 505. We identified the best fitting template structure using
SWISS-MODEL, which in each case was a dimeric US95/96 P domain structure in com-
plex with HBGA type B (Cao et al., 2007), PDB identifier 2OBT. We used structure 2OBT
as the template for SWISS-MODEL. However, I-TASSER does not model the structure of
dimeric complexes and instead models monomeric structures. While structure 2OBT was
solved as a dimer, the PDB structure file only contains a single monomeric capsid. We
therefore used structure 5IYQ as the template for homology modelling with I-TASSER,
which is a CHDC 1970s structure in complex with HBGA type A. Here, prior to mod-
elling, we altered the PDB structure file for this sequence to convert the two chains of the
dimer into a single chain, with all atoms retaining the same spatial position. Analysis of
the resulting structures was carried out using PyMol v1.74.
We investigated the hydrogen bond network formed by site 459 in the capsid us-
ing PyMol. We examined interactions within two hydrogen bonds of site 459 in nine
solved crystal structures and four homology models. We used six P domain crystal struc-
tures from three pandemic GII.4 strains: Farmington Hills 2002 not bound to a HBGA
(PDB identifier 400V), Farmington Hills 2002 bound to Lewis antigen B (4OPS), Den
Haag 2006 bound to Lewis antigen A (4WZL), Den Haag 2006 bound to HBGA type B
(4X06), Sydney 2012 bound to HBGA type A (4WZT) and Sydney 2012 bound to HBGA
type B (4OP7). Each of these six structures has glutamine at site 459, enabling compari-
son of the interaction network formed by this residue in different structures from different
pandemic strains. We additionally examined the interaction network in three P domain
structures from a pre-pandemic GII.4 virus in the CHDC 1970s strain, either not bound
to a HBGA (PDB identifier 5IYN), bound to HBGA type A (5IYP) or bound to HBGA
type B (5IYQ). These structures have serine at site 459. We also investigated the interac-
tion network in the homology models of the pandemic GII.4 clade common ancestor and
the immediately upstream ancestor constructed using SWISS-MODEL and I-TASSER.
The common ancestor of the pandemic GII.4 clade has glutamine at site 459 while the
immediately upstream ancestor has leucine at site 459.
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2.3.2 RdRp and ORF1 dataset assembly and phylogenetic analyses
We collected a dataset containing all of the 1248 available norovirus RdRp sequences
using the same approach as in collation of the capsid dataset, but in this case retained se-
quences from all genogroups (Table 2.2). We aligned the RdRp dataset at the amino
acid level using MUSCLE (Edgar, 2008) and screened for recombination using the single
breakpoint (SBP) method in HyPhy (Kosakovsky Pond et al., 2005; Pond et al., 2006).
Briefly, this method splits the alignment at each variable site and reconstructs a phylo-
genetic tree on either side of the breakpoint. The fit of these two phylogenetic trees to
the two alignments is compared with the fit of a single phylogenetic tree for the whole
alignment using the Akaike information criteria (AIC). A significantly better fit of the
two trees to the split alignment is taken as evidence of recombination, with one or more
sequences having a different evolutionary history on either side of the breakpoint. No re-
combination was identified in the RdRp dataset. We therefore reconstructed a nucleotide
maximum likelihood tree using RAxML (Stamatakis, 2014) as above. To analyse the
accumulation of nucleotide change through time, we midpoint rooted the maximum like-
lihood tree, which results in the GV genogroup diverging from the root. We obtain the
same root location when rooting to maximise the correlation between root-to-tip distance
and collection date with TempEst v1.5 (Rambaut et al., 2016), although there is no appre-
ciable correlation between these values. We calculated the total distance from the root of
the tree to each tip in nucleotide substitutions/site and divided by the collection date of
the tip to obtain a measure of the accumulation of nucleotide change per unit time. The
observed division in the nucleotide change per unit time within the GII genogroup was
also identified in a maximum likelihood nucleotide phylogenetic tree reconstructed on all
GII RdRp sequences and rooted on a single GIV.1 outgroup sequence (accession number
of outgroup JQ613567.1).
We calculated the substitution rate within the RdRp of the GII.P4 lineage and the
rest of the GII clade independently using BEAST v2.4.2 (Bouckaert et al., 2014). Due
to the large number of sequences in our dataset from several strains (Table 2.2), we took
five random sequences from the Farmington Hills 2002, Hunter 2004, Den Haag 2006,
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Genotype Number of sequences Number of sequences
in ORF1 dataset in RdRp dataset
GII.P1 6 6
GII.P2 1 1
GII.P3 5 5
GII.P4 852 836
GII.P5 1 1
GII.P6 3 3
GII.P7 42 40
GII.P8 2 2
GII.P11 1 1
GII.P12 36 27
GII.P13 1 1
GII.P15 1 1
GII.P16 9 9
GII.P17 56 55
GII.P18 1 1
GII.P20 1 1
GII.P21 29 29
GII.P22 17 17
GII.Pa 2 2
GII.Pc 3 3
GII.Pe 85 85
GII.Pg 17 16
GII.Pj 1 1
GII.Pm 2 2
GII.Pp 1 1
GII could not assign genotype 4 4
GI NA 28
GIII NA 7
GIV 4 4
GV NA 57
GVI NA 2
Table 2.2: Summary of ORF1 and RdRp datasets. We assembled datasets containing all avail-
able norovirus RdRp or ORF1 sequences and genotyped each sequence using the
norovirus genotyping tool (Kroneman et al., 2011). The number of sequences included
from each genotype is shown for the ORF1 dataset and the RdRp dataset. We only
retained sequences in the GII or GIV genogroups in the ORF1 dataset.
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New Orleans 2009, Yerseke 2006 and Apeldoorn 2007 GII.P4 strains and five random
sequences from the GII.Pe clade associated with the GII.4 Sydney 2012 capsid. We used
the SRD09 model of nucleotide substitution and a relaxed lognormal clock model. We
employed a diffuse prior on the substitution rate with mean 6.73x10-3 and standard de-
viation 0.79, chosen to encompass our estimate of the substitution rate within the RdRps
found with the GII.4 capsid in chapter 3 (Table 3.2). The results were highly similar when
employing an alternative lognormal prior on the substitution rate with mean 3x10-3 and
standard deviation 0.79. We applied a coalescent Bayesian skyline tree prior. Three repli-
cate runs were carried out for each dataset and were run until convergence, as assessed
with Tracer v1.5. We combined the replicate runs after removal of suitable burnin using
LogCombiner v2.2.1 and identified the MCC tree using TreeAnnotator v2.2.1.
We calculated the distribution of the substitution rate parameter in the GII.P4 lineage
and the rest of the GII clade using the posterior estimates of the mean and standard devi-
ation of the lognormal distribution of substitution rates within each clade. We used a two
sample Kolmogorov Smirnov test to calculate the statistical significance of the difference
between these lognormal distributions.
To test for a difference in the substitution rate at the third codon position in each
clade, we ran BEAST on the third codon position only. We used the HKY substitution
model with amongst site rate variation accomodated by a gamma distribution with four
gamma categories. We used a lognormal clock model and employed a lognormal prior
distribution with mean 6.673x10-3 and standard deviation 0.79 for the mean substitution
rate. A difference in subsitution rate was tested for using the two sample Kolmogorov
Smirnov test as above.
To identify the nonsynonymous substitutions that occurred within the RdRp leading
to the GII.P4 lineage, we initially optimised branch lengths within the RdRp maximum
likelihood phylogenetic tree with RAxML (Stamatakis, 2014) using the translated RdRp
alignment, the WAG substitution matrix and optimised base frequencies. Ancestral re-
construction was carried out at the amino acid level using PAML v4.9 (Yang, 2007) as
above and nonsynonymous substitutions that occurred leading to the GII.P4 lineage were
identified by comparing the sequence at the common ancestor of the GII.P4 lineage with
that at the upstream node. We identified sites under different selective constraints in the
GII.P4 lineage and the rest of the GII clade using TdG (Tamuri et al., 2009) as described
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above. With TdG, the GII.P4 lineage was labelled as one clade and the rest of the GII
clade was labelled as the second clade.
The divergence date between the GII.Pe-Sydney 2012 RdRps and the pandemic
GII.P4 RdRps was calculated using the posterior distribution of trees for the GII.P4 lin-
eage BEAST runs. We identified the date of the most recent common ancestor of these
sequences in each tree in the posterior distribution and calculated the mean and 95% HPD
of this distribution.
We reconstructed the nonsynonymous substitutions that occurred leading to the pan-
demic GII.P4 and GII.Pe clades using a dataset containing all 1183 GII and GIV ORF1
sequences available (Table 2.2), collated as described for the capsid dataset above. We
included the GIV sequences to enable accurate rooting of the GII clade. We aligned
the ORF1 dataset at the amino acid level using MUSCLE (Edgar, 2008). However, the
5’ end of P48 and a region within P22 do not align well between the more distantly
related genotypes within GII or between GII and GIV. It was therefore not possible to
accurately identify homologous sites within these regions across all of the genotypes.
Mis-alignment would result in the inclusion of non-homologous sites, which may mis-
lead ancestral reconstruction. At sites which could not be accurately aligned across all
genotypes, we retained the site in GII.P4, GII.Pe and all other genotypes that aligned
well with GII.P4 and GII.Pe, but removed the site from genotypes that could not accu-
rately be aligned with GII.P4 and GII.Pe. As expected, the genotypes that cluster more
closely with GII.P4 and GII.Pe in the ORF1 phylogenetic tree could be aligned within
these regions, while the more distantly related genotypes could not be aligned. Therefore
at certain sites within P48 and P22, the genotypes more distantly related to GII.P4 and
GII.Pe had gap characters. As the genotypes closely related to GII.P4 and GII.Pe did not
have residues deleted, we would expect the nonsynonymous substitutions reconstructed
close to GII.P4 and GII.Pe to remain reliable. Genotypes GIV.1, GIV.2, GII.P6, GII.P7,
GII.P8, GII.P11, GII.P15, GII.P18, GII.P20 and GII.P22 had residues deleted at the 5’
end of P48 and within P22. Genotype GII.Pp had residues deleted at the 5’ end of P48
but could be aligned within P22 and so did not have residues deleted in this region.
We found no evidence of recombination within the ORF1 dataset as screened for
using SBP. We reconstructed a maximum likelihood phylogenetic tree of the ORF1 dataset
using RAxML (Stamatakis, 2014) and optimised branch lengths within this tree using the
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translated ORF1 alignment as described above. We carried out ancestral reconstruction at
the amino acid level as above and identified nonsynonymous substitutions close to GII.P4
and GII.Pe by comparing the reconstructed sequences at the relative ancestal nodes. To
ensure the identified substitutions were robust to tree topology, we carried out the same
analysis on ten bootstrap tree topologies in addition to the maximum likelihood tree.
2.3.3 GII.4 VP2 dataset assembly and phylogenetic analyses
We collected a dataset containing all of the available VP2 sequences from viruses
with a GII capsid as described in the collation of the capsid dataset above (Table 2.1).
There is currently no genotyping system for VP2, with genotyping instead being car-
ried out on the RdRp and capsid (Zheng et al., 2006; Kroneman et al., 2013). While
recombination has been noted close to the boundary between ORFs 2 and 3 (Eden et al.,
2013), to our knowledge there are no reported instances of inter-genogroup recombina-
tion in this region. It is therefore very likely that viruses with a GII capsid will also be
found with a VP2 that can be classified as GII based on phylogenetic clustering. We also
included four VP2 sequences where the ORF1 and capsid regions were not sequenced.
We reconstructed a nucleotide maximum likelihood phylogenetic tree of this 1387 se-
quence dataset using RAxML (Stamatakis, 2014) as described above, which confirmed
that the VP2 sequences found with the GII.4 capsid form a well supported monophyletic
clade. Two of the viruses where the ORF1 and capsid were not sequenced were identified
within the GII.4 VP2 clade: sequence EF635440.1 clusters with Asia 2003 and sequence
EU876893.1 clusters with Yerseke 2006.
We inferred the nonsynonymous substitutions leading to the pandemic GII.4 clade
using the GII nucleotide maximum likelihood VP2 tree. We optimised branch lengths
within this tree and carried out ancestral reconstruction as described above. Nonsynony-
mous substitutions were identified by comparing the sequence at the common ancestor of
the pandemic GII.4 clade with the sequence at the immediately upstream node.
To reconstruct the evolutionary dynamics of the early part of the GII.4 clade, we
used the sequences that cluster within the CHDC 1970s, Bristol 1993, Camberwell 1994-
like, US95/96, Farmington Hills 2002 and Osaka 2007 clades. The VP2 sequences from
2.3. Materials and Methods 69
viruses with the Osaka 2007 capsid cluster within two regions of the GII.4 clade, with
four sequences clustering with US95/96 and seven sequences clustering with Den Haag
2006. Here, we included only the four Osaka 2007 sequences that cluster with US95/96.
We initially reconstructed a maximum likelihood phylogenetic tree of this dataset us-
ing RAxML (Stamatakis, 2014) and confirmed the dataset exhibited accumulation of
nucleotide change through time using TempEst v1.5 (Rambaut et al., 2016). We used
BEAST v2.4.2 (Bouckaert et al., 2014) to reconstruct the temporal evolutionary history
of the early GII.4 VP2 lineage, using the SRD09 nucleotide substitution model and a re-
laxed lognormal clock model. We employed a lognormal prior distribution on the mean
substitution rate with mean 6.11x10-3 and standard deviation 0.1, chosen to encompass
the mean and 95% HPD posterior estimates of the GII.4 VP2 substitution rate estimated
in chapter 3 (Table 3.2).
2.3.4 Comparison of accumulation of change between GII.4 and
other GII genotypes
We collected datasets for each GII capsid genotype containing all of the available
capsid sequences from that genotype. The GII.1, GII.2, GII.3, GII.5, GII.6, GII.7, GII.12,
GII.13, GII.14, GII.17 and GII.21 contained sufficient sequences for further analysis (Ta-
ble 2.3), in addition to the GII.4 dataset assembled previously. Sequences were aligned
within each dataset at the amino acid level using MUSCLE (Edgar, 2008). We screened
each of the genotype datasets for recombination using SBP (Kosakovsky Pond et al.,
2005; Pond et al., 2006). In cases where a breakpoint was found (p< 0.05 in the Kishino-
Hasegawa (KH) test), we reconstructed a nucleotide maximum likelihood tree on either
side of the proposed breakpoint using RAxML (Stamatakis, 2014) as described above
and identified sequences that clustered differently on either side of the breakpoint with
strong bootstrap support. These sequences were considered to be putative recombinants
and were removed from further analyses. Potentially recombinant sequences were iden-
tified in the GII.12, GII.14 and GII.21 datasets (Table 2.3); the sequences removed are
listed in Table S2.1. As our aim was to remove potentially recombinant sequences rather
than to identify recombination, we did not carry out any further analyses to confirm these
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Genotype Number of Date span Putative recombinant
sequences of sequences sequences
GII.1 22 1971-2014 No
GII.2 103 1975-2011 No
GII.3 134 1975-2014 No
GII.5 23 1978-2013 No
GII.6 63 1975-2014 No
GII.6 clade 1 21 1976-2012 NA
GII.6 clade 2 21 1975-2013 NA
GII.6 clade 3 21 1977-2014 NA
GII.7 15 1976-2010 No
GII.12 28a 1990-2010 Yes
GII.13 47 1983-2013 No
GII.14 16a 1978-2013 Yes
GII.17 178 1978-2015 No
GII.21 19a 2005-2015 Yes
Table 2.3: Summary of genotype datasets. The number and time span of sequences within each
genotype dataset is shown. Genotypes were screened for recombination using SBP,
putative recombinant sequences are listed in Table S2.1. NA - recombination was
not tested for within the GII.6 subclades as recombination was not present within the
complete GII.6 dataset. a The number of sequences following removal of putatively
recombinants is shown for GII.12, GII.14 and GII.21.
recombination events.
We reconstructed a nucleotide maximum likelihood tree for each genotype using
RAxML (Stamatakis, 2014) as described above. The temporal signal for each genotype
was investigated using TempEst v1.5 (Rambaut et al., 2016). We identified the best fitting
root location by minimising the heuristic residual mean squared score for the correla-
tion between root-to-tip distance and sampling date. We divided the GII.6 genotype into
three subclades due to a lack of temporal signal within the complete genotype dataset and
reconstructed a nucleotide maximum likelihood tree on each subclade independently.
To calculate the accumulation of amino acid change through time, we used the tree
reconstructed on the complete capsid nucleotide dataset. We only carried out this analy-
sis for genotypes that exhibited a correlation between nucleotide root-to-tip distance and
collection date. We optimised branch lengths within the tree with RAxML using the trans-
lated capsid alignment and the WAG substitution matrix with optimised base frequencies.
We rooted the tree on the branch where it was rooted to maximise the correlation between
nucleotide root-to-tip distance and collection date. As the root could have occurred at any
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point along this branch, we rooted at ten equally spaced intervals along this branch and
used the root location that maximised the R2 correlation between root-to-tip distance and
collection date. To compare the accumulation of amino acid change within the pandemic
GII.4 clade and the pre-pandemic GII.4 lineages, we extracted the respective clade from
the GII.4 nucleotide tree and optimised branch lengths independently using the respective
amino acid alignments and the WAG substitution model with optimised base frequencies.
We plotted the amino acid root-to-tip distance versus collection date for each sequence
and calculated the best fit regression line usig TempEst. Both datasets exhibit a correlation
between amino acid root-to-tip distance and collection date.
2.4 Results
2.4.1 The first GII.4 pandemic likely began in the mid-1990s
We reconstructed a phylogenetic tree containing 2198 GII.4 capsid sequences from
all of the major GII.4 strains (Figure 2.1). All of the GII.4 strains associated with pan-
demics or large epidemics since the mid-1990s form a well-supported monophyletic clade
downstream of the US95/96 common ancestor (starred node in Figure 2.1). We therefore
defined the sequences downstream of the US95/96 common ancestor as forming the pan-
demic GII.4 clade and those lineages that branch prior to the US95/96 common ancestor
as the pre-pandemic GII.4 lineages. The sequences in the pre-pandemic lineages belong
to the CHDC 1970s, Tokyo 1980s, Bristol 1993, Camberwell 1994-like and Kaiso 2003
strains (Figure 2.1). The only sequences that branch prior to the US95/96 common ances-
tor that were collected after 1994 are those belonging to the Kaiso 2003 strain, with Kaiso
2003 likely evolving from the Bristol 1993 strain (Figure 2.1). The common ancestor of
the pandemic GII.4 clade occurred in July 1992 (95% HPD December 1990-August 1993)
and the lineage leading to the pandemic GII.4 clade diverged from other sampled GII.4
capsid sequences in April 1987 (95% HPD December 1983-September 1989) (Figure 2.2
panel A). The GII.4 capsid most likely increased in prevalence in late 1994 (95% HPD
January 1994-October 1996), although there is significant support on the increase occur-
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Figure 2.1: Maximum likelihood phylogenetic tree of the GII.4 capsid. A nucleotide max-
imum likelihood tree was reconstructed for 2198 GII.4 capsid sequences using
RAxML. Major GII.4 strains are collapsed for clarity. Branches are coloured by strain
to match the colour of the strain label. Pandemic strains are labelled in bold font. The
starred node is the common ancestor of the pandemic GII.4 clade. Bootstrap supports
are shown on trunk nodes, with the colour of the bootstrap support at strain root nodes
matching the colour of the strain label. The scale bar shows the expected number of
nucleotide substitutions per site.
ring earlier in 1994 and in either 1995 or 1996 (Figure 2.2 panels C and D). However, there
is very little support on an increase in relative genetic diversity prior to 1994, supporting
previous epidemiological and phylodynamic data suggesting that US95/96 was the first
GII.4 pandemic and coincided with increased prevalence of the GII.4 capsid (Siebenga
et al., 2010; Donaldson et al., 2008).
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Figure 2.2: Temporal evolutionary history of the early GII.4 lineage. (A) Maximum clade
credibility tree of the early sequences from the GII.4 lineage: CHDC 1970s, Tokyo
1980s, Bristol 1993, Camberwell 1994-like, Kaiso 2003, US95/96 and Osaka 2007.
The starred node is the common ancestor of the pandemic GII.4 clade. The nonsyn-
onymous substitutions that occurred leading to the common ancestor of the pandemic
clade are labelled. Branches are coloured by the corresponding strain and match the
colour of the strain label. Posterior supports are shown at nodes along the trunk of
the tree. The pandemic US95/96 strain is labelled in bold font. (B) The correla-
tion between root-to-tip distance and collection date within the early GII.4 lineage,
calculated from a nucleotide maximum likelihood tree reconstructed using the same
sequences in the MCC tree in panel A. The strong correlation between root-to-tip dis-
tance and collection date enabled reconstruction of the temporal evolutionary history
of the lineage. (C) Bayesian skyline plot of the early GII.4 lineage, plotting a measure
of the relative genetic diversity (Neτ) through time. The increase in relative genetic
diversity indicates an increase in prevalence. The dashed line represents the start of
the increase in relative genetic diversity in October 1994. (D) The distribution of the
date of onset of the first GII.4 pandemic, estimated using the date of the first increase
in Neτ at each sampled step in the MCMC chain. The red dashed line represents the
median date of the increase in frequency. All values within the 95% HPD of the date
of pandemic onset are within the range shown; there are a small number of steps that
support an earlier increase in frequency; these steps are not shown here for clarity but
are shown in Figure S2.1.
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2.4.2 Capsid substitutions that may have been important for the pan-
demic emergence of the GII.4 genotype
We would expect that capsid sites important for the increase in prevalence of GII.4
in the mid-1990s would have undergone a substituion leading to the common ancestor of
the pandemic GII.4 clade and would exhibit different amino acid residues in the pandemic
GII.4 clade and the pre-pandemic GII.4 sequences. We infer that 17 nonsynonymous
substitutions occurred leading to the pandemic GII.4 clade common ancestor: S6N, A15T,
I47V, S93A, V119I, H172N, L176I, N285T, V294A, S309N, L333M, A340G, H395N,
L459Q, I497V, Y505H and T534A (Figures 2.2 panel A, 2.3). Of these, sites 6, 15, 47,
93, 119, 172 and 176 are located within the shell domain, sites 459, 497, 505 and 534
are located within the P1 domain and sites 285, 294, 309, 333, 340 and 395 are located
within the P2 domain (Figure 2.3). The substitutions at sites 6, 15, 47, 119, 309 and 534
are unlikely to have been important for the increase in prevalence of the GII.4 capsid as
these sites exhibit the same amino acid residues in the pandemic GII.4 clade and the pre-
pandemic GII.4 sequences (Figure 2.3). Using TdG (Tamuri et al., 2009), we identify two
capsid sites that are evolving under different selective constraints in the pandemic GII.4
clade compared with the pre-pandemic GII.4 viruses with a false discovery rate < 0.05:
sites 333 and 459 (Figure 2.3). Site 333 is located within the P2 domain, while site 459 is
in the P1 domain.
The two sites that were identified as evolving under different selective constraints
in the pandemic GII.4 clade versus the pre-pandemic GII.4 viruses (sites 333 and 459)
are both located within the dimerisation interface. Four regions of inter-monomer inter-
actions have been identified within the P domain (Cao et al., 2007). Site 333 is located
within region I, in which the capsid monomers interact via hydrophobic interactions (Cao
et al., 2007). This site is conserved as leucine within the pre-pandemic GII.4 viruses
and changes regularly between methionine and valine within the pandemic GII.4 lineage
(Figure 2.4). While leucine is intermediate between methionine and valine in size and
hydrophobocity (Kyte and Doolittle, 1982), it has been suggested that valine and me-
thionine exhibit a greater propensity to form beta sheet secondary structure than leucine
(Koehl and Levitt, 1999). Site 333 is located close to the center of beta strand β4 within
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Figure 2.3: Nonsynonymous capsid substitutions leading to the pandemic GII.4 clade. (A)
Location within the capsid of the 17 nonsynonymous substitutions that occurred lead-
ing to the common ancestor of the pandemic GII.4 clade. Sites 333 and 459 that
change leading to the common ancestor of the pandemic GII.4 clade and are under
different selective constraints in the pandemic GII.4 clade and pre-pandemic GII.4
lineages are shown in red. The sites that change leading to the common ancestor of
the pandemic GII.4 clade and were not inferred to be under different selective con-
straints are shown in black. (B) Amino acid residue distribution in the pandemic GII.4
clade versus the pre-pandemic GII.4 lineages at each site inferred to have undergone
a substitution leading to the pandemic GII.4 clade but exhibits the same amino acid
residues in the pre-pandemic GII.4 lineages and the pandemic GII.4 clade. Amino
acid residues at each site are shown between the respective pie charts and residues
with similar properties are shown in similar colours. (C) As in panel B but sites that
exhibit a convergent substitution leading to the pandemic GII.4 clade and the Kaiso
2003 epidemic strain are shown. (D) As in panel B but sites that underwent a substi-
tution leading to the pandemic GII.4 clade and exhibit a different amino acid residues
in the pre-pandemic GII.4 lineages and pandemic GII.4 clade are shown.
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the P2 domain beta barrel structure.
Site 459 is located within region IV of the dimerisation interface and this region
contains a hydrophilic center formed by the side chains of multiple residues (Cao et al.,
2007). Site 459 is largely conserved as leucine within the pre-pandemic GII.4 lineages
and is conserved as glutamine within the pandemic GII.4 clade (Figure 2.5 panel A). In
solved P domain crystal structures from pandemic GII.4 strains, glutamine 459 forms a
hydrogen bond network through its main chain and side chain atoms (Figures 2.5, S2.2).
It is unfortunately not possible to directly compare the hydrogen bond networks formed
by glutamine 459 and leucine 459 as the only pre-pandemic GII.4 virus with a solved
P domain crystal structure has serine at site 459, a rare residue at this site within GII.4.
However, the hydrogen bond network formed by glutamine 459 in pandemic GII.4 viruses
is more extensive than that formed by serine 459 in a pre-pandemic GII.4 virus (Figures
2.5, S2.2). To enable comparison of the interaction network formed by glutamine 459
and leucine 459, we constructed P domain homology models of the common ancestor
of the pandemic GII.4 clade (glutamine at site 459) and the immediately upstream node
(leucine at site 459). Homology models support glutamine 459 forming an increased
number of hydrogen bonds compared with leucine 459, due to side chain interactions
formed by glutamine 459 that are not possible with the hydrophobic leucine 459 side chain
(Figure 2.5). However, the exact interaction network differs between homology models
constructed with different methods. Together, the solved crystal structures and homology
models indicate the possibility for an increased number of inter-monomer contacts with
glutamine at site 459 compared with the ancestral leucine residue at this site.
It has previously been suggested that an expansion in the range of bound HBGAs
may have been responsible for the increase in GII.4 prevalence (Lindesmith et al., 2008;
Donaldson et al., 2008, 2010). Site 395 mutated leading to the common ancestor of the
pandemic GII.4 clade and is located within a flexible loop that undergoes a structural
rearrangement to allow binding to certain HBGAs (Singh et al., 2015). While site 395 has
not been demonstrated to directly bind to HBGAs (Singh et al., 2015), previous studies
have demonstrated that mutations at this site can influence HBGA binding, in particular
binding to HBGA type A (Lindesmith et al., 2008). Site 395 is conserved as histidine
within the pre-pandemic GII.4 lineages, with the exception of the Kaiso 2003 strain which
has arginine at this position (Figure 2.6). Site 395 mutated from histidine to asparagine
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Figure 2.4: Variation at capsid site 333. Shown is the distribution of amino acid residues at site
333 throughout the GII.4 genotype. The early GII.4 lineage (consisting of the CHDC
1970s, Tokyo 1980s, Bristol 1993 and Camberwell 1994-like strains) and Kaiso 2003
strain have leucine at this site. The site underwent a substitution from leucine to
methionine leading to the common ancestor of the pandemic GII.4 clade (the starred
node) and was then variable between methionine and valine within the pandemic GII.4
clade. The distribution of residues is shown for each major strain within the pandemic
GII.4 clade and demonstrates that multiple substitutions occurred between methionine
and valine at this site. The tree shown is the same as that in Figure 2.1.
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Figure 2.5: The interaction network at site 459. (A) The distribution of amino acid residues at
site 459 within the pre-pandemic GII.4 lineages and the pandemic GII.4 clade. (B-
G) The interaction network formed by site 459 in solved crystal structures (B,C) and
homology models (D-G). The residue at site 459 is shown in red in each case and
residues that hydrogen bond with site 459 either directly or through a single water
molecule intermediate are shown in grey if the residue is in the same monomer or
brown if the residue is in the other monomer. Water molecules are shown as blue
circles and each hydrogen bond is shown as a black dashed line. (B) The interaction
network formed by glutamine 459 in a solved Farmington Hills 2002 crystal structure,
PDB identifier 400V. The interaction network formed by glutamine 459 is compared
between six solved crystal structures from the pandemic GII.4 clade in Figure S2.2.
(C) The interaction network formed by serine 459 in a solved CHDC 1970s crys-
tal structure, PDB identifier 5IYP. The interaction network formed by serine 459 is
compared between three solved crystal structures from a CHDC 1970s virus in Fig-
ure S2.2. (D-E) Homology models of the pandemic GII.4 clade common ancestor
(D) and the immediately upstream ancestor (E) as determined by SWISS-MODEL.
(F-G) Homology models of the pandemic GII.4 clade common ancestor (F) and the
immediately upstream ancestor (G) as determined by I-TASSER.
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leading to the pandemic GII.4 clade and was conserved as asparagine in the US95/96
strain (Figure 2.6). However, the Hunter 2004, Den Haag 2006, New Orleans 2009 and
Sydney 2012 pandemic strains have threonine conserved at this site and site 395 is largely
conserved as threonine in Farmington Hills 2002. Of the epidemic strains, Yerseke 2006
and Osaka 2007 have threonine, Apeldoorn 2007 has alanine and Asia 2003 is variable
between alanine and threonine at site 395 (Figure 2.6). Interestingly, it was mutation of
alanine to threonine that was previously demonstrated to alter binding to HBGA type A
(Lindesmith et al., 2008). The residues at site 395 in the pandemic GII.4 clade (alanine,
asparagine and threonine) are all smaller than the histidine residue present in the pre-
pandemic GII.4 lineages. Given the importance of movement of the 391-395 loop for
HBGA-binding, it is possible that a decrease in residue size at site 395 may have resulted
in a more flexible loop, enabling more efficient binding to a greater range of HBGAs.
Alternatively, both residues found within the pre-pandemic GII.4 viruses are positively
charged and the loss of the positive charge at this position may have had the same effect.
To test this hypothesis, we suggest future experiments to validate whether VLPs with
alanine, asparagine or threonine at site 395 exhibit broader HBGA-binding compared to
VLPs with histidine at this site. In particular, we would test the HBGA-binding profile of
the common ancestor of the pandemic GII.4 clade and upon mutation of site 395 to A, T
and H within this ancestral sequence.
Of the sites that change leading to the common ancestor of the pandemic GII.4 clade,
site 294 is located within blockade epitope A, site 333 is located within putative epitope
B, site 340 is located in putative epitope C and site 395 is located within blockade epitope
D (Lindesmith et al., 2012a). Sites 294 and 340 are highly variable within the pandemic
GII.4 clade and site 294 is also highly variable within the pre-pandemic GII.4 sequences
(Figures 2.3, 2.7).
The potential importance of substitutions at sites 93, 172, 176, 285, 497 and 505 is
less clear, as these sites are not located within a part of the capsid with known function.
However, each of these sites is highly conserved within the pandemic GII.4 clade, with the
only substitutions occurring either in individual tip viruses or within small clades where
the viruses within the clade were sampled over a very short time period (Figure 2.7).
Therefore there is no evidence that viruses within the pandemic GII.4 clade that mutate
at any of these six sites can persist and transmit within the population. It is therefore
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Figure 2.6: Substitution at site 395 within the HBGA-binding loop. Shown is the distribution
of amino acid residues at site 395 throughout the GII.4 genotype. The early GII.4
lineage (consisting of the CHDC 1970s, Tokyo 1980s, Bristol 1993 and Camberwell
1994-like strains) has histidine at this site, while the Kaiso 2003 strain has arginine.
The site underwent a substitution from histidine to asparagine leading to the common
ancestor of the pandemic GII.4 clade (the starred node) and was then variable between
alanine, asparagine and threonine within the pandemic GII.4 clade. The distribution
of residues is shown for each major strain within the pandemic GII.4 clade. The tree
shown is the same as that in Figure 2.1.
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Figure 2.7: Conservation of sites within the pandemic GII.4 clade. Coloured trees for sites
93, 172, 176, 285, 294, 340, 497 and 505. The substitution at each site leading to the
pandemic GII.4 clade is labelled. Sites 93, 172, 176, 285, 497 and 505 are largely con-
served within the pandemic GII.4 clade, while sites 294 and 340 are highly variable.
Black indicates that the site was not sequenced within that sample.
possible that either these sites have important functions within the pandemic GII.4 clade
and/or that these sites cannot easily mutate away from the consensus residue without
destabilising the capsid structure. Sites 285 and 505 exhibit convergent changes along
the branches leading to the pandemic GII.4 clade and the Kaiso 2003 common ancestor
(Figure S2.3), indicating that the substitutions at these sites are not sufficient to enable
pandemic spread.
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2.4.3 The RdRps found with pandemic GII.4 capsids last shared a
common ancestor in the 1970s
The first five pandemic GII.4 strains contained the GII.P4 ORF1. However, the most
recent pandemic GII.4 strain, Sydney 2012, circulated most commonly with the GII.Pe
ORF1 and less frequently with the GII.P4 ORF1 (van Beek et al., 2013; Wong et al.,
2013). Therefore any substitutions in ORF1 that are essential for pandemicity must have
either been acquired by the common ancestor of the GII.P4 and GII.Pe genotypes, or have
been acquired convergently along the lineages leading to the pandemic GII.P4 and GII.Pe
clades. GII.P4 and GII.Pe last shared a common ancestor in August 1972 (95% HPD
October 1966-March 1978). We do not find evidence of convergent changes leading to
the pandemic clades within the GII.P4 and GII.Pe genotypes (Figure 2.8). Additionally,
while several substitutions occur convergently leading to GII.P4, GII.Pe or the pandemic
subclades within these genotypes (Figure S2.4), the residues at these sites within the pan-
demic clades are additionally found in other genotypes (Figure S2.5) and so are unlikely
to have driven pandemic spread. Therefore substitutions within ORF1 required for pan-
demicity were most likely acquired by the early 1970s and so are unlikely to have driven
the increase in prevalence of the GII.4 lineage in the mid-1990s.
2.4.4 An increase in substitution rate leading to the GII.P4 lineage
It has previously been suggested that the high mutation rate associated with the
GII.P4 RdRp has contributed to the high prevalence of the GII.4 capsid (Bull et al., 2010).
If the underlying mutation rate is different for different RdRps, this would likely leave a
pattern in the RdRp phylogenetic tree, with those viruses with an increased mutation rate
accumulating greater nucleotide change through time. In a RdRp phylogeny containing
sequences from all norovirus genogroups, a group of GII sequences have accumulated
more change relative to their sampling date compared with the rest of the GII clade (Fig-
ure 2.9). We confirmed this using a phylogenetic tree reconstructed on the GII clade
with a single outgroup species (Figure 2.9). The sequences that have accumulated more
change form a monophyletic clade within the RdRp phylogenetic tree that includes the
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via ancestral reconstruction. Only a subclade from the tree is shown for clarity and
branches within this subclade are coloured by genotype or strain, with the colour
matching that of the genotype or strain label. Part of the pandemic GII.P4 clade has
been collapsed for clarity. Bootstrap supports are shown on trunk nodes. The GII.Pe
sequences are divided into those found with either the GII.4 Osaka 2007 capsid or
the GII.17 capsid (both non-pandemic) and those found with the GII.4 Sydney 2012
capsid (pandemic). (B) The lineages close to the pandemic GII.P4 clade and the pan-
demic GII.Pe-GII.4 Sydney 2012 clade are shown. The nonsynonymous substitutions
that occurred along the branch leading to the pandemic GII.P4 clade (branch 1) and
along the branch leading to the pandemic GII.Pe-GII.4 Sydney 2012 clade (branch 2)
are shown.
genotypes GII.P1, GII.P4, GII.P12, GII.Pa, GII.Pc, GII.Pe, GII.Pg, GII.Pj and GII.Pm
(Figures 2.9, 2.10). This clade therefore contains each of the RdRp genotypes that are
associated with the GII.4 capsid (GII.P1, GII.P4, GII.P12 and GII.Pe) as well as several
‘orphan’ genotypes, so called because they are not the dominant RdRp found with any of
the capsid genotypes (Bull and White, 2011; Kroneman et al., 2013). We therefore named
this monophyletic clade the GII.P4 lineage. The RdRp tree suggests that the GII.Pm geno-
type evolved from GII.P1 viruses that persisted through to the 1990s and 2000s, while the
GII.Pa genotype evolved from GII.P4 US95/96 viruses that persisted through to 2010
(Figure 2.10). The GII.P4 lineage may have accumulated more change due to either a
higher substitution rate within the clade or a single long branch leading to the common
ancestor of the clade. We infer that the substitution rate within the GII.P4 lineage is sig-
nificantly higher than that in the rest of the GII clade (p < 0.001 Kolmogorov Smirnov
test), with a general elevation in the substitution rate along branches within the GII.P4
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lineage (Figure 2.11). We estimate the mean substitution rate within the GII.P4 lineage to
be 6.30x10-3 compared with 4.74x10-3 in the rest of the GII clade. The substitution rate
is determined by a combination of mutation rate, replication dynamics and transmission
dynamics and can also be influenced by selection, with positive selection increasing the
substitution rate and purifying selection reducing the substitution rate. The GII.P4 lineage
exhibits a higher substitution rate at the third codon position compared with the rest of the
GII clade (8.24x10-3 in the GII.P4 lineage versus 5.68x10-3 in the rest of the GII clade,
p < 0.001 Kolmogorov Smirnov test), suggesting that at least part of the difference in
substitution rate is due to a neutral process, such as an increase in mutation rate, faster
replication rate or increased transmission rate.
The common ancestor of the GII.P4 lineage occurred in 1906 (95% HPD 1872-1937,
Figure 2.10) and it is therefore likely that the increase in substitution rate had been ac-
quired by this date. We would expect that sites in the RdRp that may be responsible for the
increase in substitution rate would change leading to the common ancestor of the GII.P4
lineage. We infer that four nonsynonymous substitutions occurred along the branch in the
phylogenetic tree leading to the GII.P4 lineage: Y105F, S189A, F426S and S463T (Fig-
ure 2.12). Additionally, we identify four sites that are evolving under different selective
constraints within the GII.P4 lineage compared with the rest of the GII clade: 105, 266,
330 and 463. Site 105 is completely conserved as phenylalanine in the GII.P4 lineage and
completely conserved as tyrosine in the rest of the GII clade (Figure 2.12), suggesting
there is a strong selective constraint to retain the respective residue within each clade.
Site 189 is also highly conserved as alanine within the GII.P4 lineage, with the rest of the
GII clade having either glycine or serine at this site (Figure 2.12). Sites 426 and 463 are
variable within the GII.P4 lineage. Site 426 is mostly serine in the GII.P4 lineage, with
serine also being found in the GII.P3, GII.P13 and GII.P17 genotypes. Site 463 varies
between alanine, serine and threonine within the GII.P4 lineage, with the rest of the GII
clade having either alanine, asparagine or serine at this site. Sites 266 and 330 are vari-
able within the GII.P4 lineage and exhibit residues within the GII.P4 lineage that are also
present in the rest of the GII clade (Figure 2.12). Therefore the substitutions at sites 266,
330, 426 and 463 are unlikely to have been responsible for the increase in substitution rate
leading to the GII.P4 lineage. None of the sites that either change leading to the common
ancestor of the GII.P4 lineage or are under different selective constraints in the GII.P4
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Figure 2.9: The GII.P4 lineage exhibits an excess of change compared with the other GII
genotypes. (A) The scaled phylogenetic distance was calculated for each sequence
in an all genogroups RdRp phylogenetic tree by dividing the root-to-tip distance by
the collection date of each tip to give a measure of accumulation of nucleotide change
per unit time. The sequences within the GII.P4 lineage are labelled in blue. (B)
A nucleotide maximum likelihood phylogenetic tree of the GII RdRp with a GIV.1
outgroup. The GII.P4 lineage is indicated in blue. Bootstrap supports are shown at
trunk nodes. The scale bar represents the expected nucleotide substitutions/site. In
panels A and B, a dataset where the GII.P4 and GII.Pe-GII.4 Sydney 2012 sequences
have been randomly subsampled is shown for clarity. The same results are obtained
using the complete dataset.
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Figure 2.10: Temporal evolutionary history of the GII.P4 lineage. (A) Correlation between
root-to-tip distance and collection date in a nucleotide maximum likelihood tree of
the GIII.P4 lineage. The correlation enabled reconstruction of the temporal evolu-
tionary history of the lineage. (B) MCC tree of the GII.P4 lineage reconstructed
using BEAST. Branches are coloured by RdRp genotype with the colour matching
that of the corresponding genotype label. Posterior supports are shown on trunk
nodes.
lineage relative to the rest of the GII clade are close to the active site of the RdRp (Figure
2.13). Sites 105 and 189 are located close together in the fingers domain of the RdRp
(Figure 2.13).
2.4.5 VP2 substitutions leading to the pandemic GII.4 lineage
As in the capsid phylogenetic tree, the VP2 regions found with each of the GII.4
strains associated with pandemics and large epidemics since the mid-1990s evolve from
a single common ancestor that diverged from the Camberwell 1994-like sequences (Fig-
ure 2.14). Therefore, as with the capsid, the GII.4 sequences can be divided into the
pandemic GII.4 clade and the pre-pandemic GII.4 lineages. The common ancestor of
the pandemic GII.4 clade in the VP2 region occurred in July 1992 (95% HPD February
1991-March 1994, Figure 2.14), the same month as the capsid common ancestor (Figure
2.2). The pandemic GII.4 clade diverged from the pre-pandemic GII.4 viruses in October
1988 (95% HPD January 1988-July 1990). Ten nonsynonymous substitutions occurred
along the branch leading to the common ancestor of the pandemic GII.4 clade: Q72K,
L78M, T93E, V148A, P155S, P156S, A162T, G187S, N199S and N230S (Figure 2.14).
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Figure 2.11: The GII.P4 lineage has an elevated substitution rate compared with the rest of
the GII clade. A MCC tree was reconstructed for the GII.P4 lineage and the rest of
the GII clade using BEAST under a relaxed lognormal clock model. The distribu-
tion of branch substitution rates is plotted for the respective MCC trees. The mean
substitution rate estimated for each dataset from the complete posterior distribution
of trees is indicated with a red vertical line.
However, sites 155 and 199 undergo a back substitution along the branch leading to the
common ancestor of the pandemic GII.4 clade, with the dominant residue within the pan-
demic GII.4 clade matching that in the early pre-pandemic GII.4 sequences (Figure 2.15).
It is therefore unlikely that these sites contributed to the increase in frequency of the GII.4
genotype. Additionally, site 156 exhibits the same residue in the pre-pandemic GII.4
sequences as in the Asia 2003 epidemic strain and a large clade within the Den Haag
2006 pandemic strain, while site 162 exhibits the same residue in the pre-pandemic GII.4
sequences as in the Hunter 2004 and Den Haag 2006 pandemic strains (Figure 2.15).
Site 230 exhibits the same residue in the pandemic GII.4 clade as in the Bristol 1993
pre-pandemic clade (Figure 2.15). It is therefore unlikely that any of these sites were re-
sponsible for the increase in frequency of the GII.4 genotype in the mid-1990s. Sites 72,
78 and 93 are largely conserved as K, M and E, respectively within the pandemic GII.4
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Figure 2.12: Sites changing leading to and under different selective constraints within the
GII.P4 lineage. Coloured trees for sites that change leading to the GII.P4 lineage
(105, 189, 426 and 463) and sites that are under different selective constraints within
the GII.P4 lineage compared with the rest of the GII clade (105, 266, 330 and 463).
The branch leading to the common ancestor of the GII.P4 lineage is indicated in each
tree and the substitution along that branch is indicated for the four sites that change
along that branch.
clade, with changes away from the dominant residue in the pandemic GII.4 clade typically
only occurring along tip branches within the tree, or leading to small clades containing
viruses that were sampled over a short period of time (Figure 2.16). There is therefore
no evidence that viruses within the pandemic GII.4 clade with changes away from the
dominant residue at sites 72, 78 and 93 can persist. This suggests that viruses within the
pandemic GII.4 clade have a constraint to retain the dominant residue at these positions.
Site 148 is highly variable within the pandemic clade, with alanine, aspartic acid and thre-
onine at this site, compared with the pre-pandemic viruses in which valine is conserved.
Site 187 also varies between asparagine, arginine and serine within the pandemic GII.4
clade, each of which differs from the glycine that is dominant in the pre-pandemic GII.4
viruses (Figure 2.16).
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Figure 2.13: Location of sites 105 and 189 in the RdRp structure. (A) The RdRp active site
residues (blue), sites that change leading to the common ancestor of the GII.P4 lin-
eage (red) and sites under different selective constraints in the GII.P4 lineage com-
pared with the rest of the GII clade (magenta) are shown on the GII.P4 RdRp struc-
ture 1SH0. (B) Side view of the fingers domain of the RdRp, showing sites 105 and
189 in close apposition.
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Figure 2.14: Temporal history of the early GII.4 VP2 lineage. (A) MCC tree reconstructed
using BEAST of the early GII.4 lineage VP2, consisting of the CHDC 1970s, Tokyo
1980s, Bristol 1993, Camberwell 1994-like, US95/96 and Osaka 2007 strains, with
Farmington Hills 2002 included as an early strain within the pandemic GII.4 clade.
Branches are coloured by strain, with the colour matching that of the correspond-
ing strain label. As there is currently no genotyping system established for VP2,
one of the sequences with a Tokyo 1980s capsid clusters within the Bristol 1993
clade within VP2, as shown by the purple branch within the Bristol 1993 clade. The
starred node is the common ancestor of the pandemic GII.4 clade. Posterior supports
are shown at trunk nodes. The nonsynonymous substitutions that occurred leading
to the common ancestor of the pandemic GII.4 clade are labelled. (B) The corre-
lation between root-to-tip distance and collection date calculated using a maximum
likelihood tree reconstructed on the same sequences as in panel A. The correlation
between these values enabled the reconstruction of the temporal evolutionary history
of the lineage.
2.4.6 The GII.4 capsid exhibits an accumulation of amino acid
change through time
We next investigated whether the evolutionary process within the GII.4 genotype is
different to that within other GII genotypes. We reconstructed nucleotide phylogenetic
trees of the GII.1, GII.2, GII.3, GII.5, GII.6, GII.7, GII.12, GII.13, GII.14, GII.17 and
GII.21 capsid genotypes, in addition to the GII.4 phylogenetic tree used in our previous
analyses. Most of the capsid genotypes exhibit strong temporal signal at the nucleotide
level, with a correlation between nucleotide root-to-tip distance and collection date (Fig-
ure 2.17). The GII.14 capsid exhibits only weak temporal signal, indicating the lack of a
steady accumulation of change through time in this genotype (Figure 2.17). The GII.17
capsid exhibits little temporal signal, consistent with previous suggestions that different
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Figure 2.15: VP2 sites that change leading to the pandemic GII.4 clade but were unlikely
to have driven an increase in prevalence. Coloured trees of sites 155, 156, 162,
199 and 230. The starred node in each tree is the common ancestor of the pandemic
GII.4 clade. The pandemic GII.4 clade after the divergence of the US95/96 and Os-
aka 2007 strains has been collapsed in the trees for sites 155, 199 and 230 for clarity.
Sites 155 and 199 exhibit back substitutions leading to the common ancestor of the
pandemic GII.4 clade, with the dominant resiude in the pandemic GII.4 clade also
being dominant in the early GII.4 sequences. Sites 156 and 162 undergo back sub-
stitutions within pandemic GII.4 strains to the dominant residue in the pre-pandemic
GII.4 sequences. The dominant residue in the pandemic GII.4 clade at site 230 was
also present in the pre-pandemic Bristol 1993 clade.
GII.17 lineages may evolve at different rates (Lu et al., 2016). The GII.6 genotype also
does not exhibit temporal signal when all GII.6 sequences are included (Figure 2.17).
However, the GII.6 genotype clusters into three well diverged subclades, with each of
these clades being separated by a long branch within the phylogenetic tree (Figure S2.6)
(Vinje, 2015). Each of these three subclades does exhibit temporal signal (Figure S2.6),
suggesting the lack of temporal signal within the GII.6 genotype as a whole is due to ei-
ther differences in substitution rate leading to the clade common ancestors, differences in
substitution rate within each of the GII.6 clades, or both.
The non-GII.4 genotypes that exhibit a strong temporal signal at the nucleotide level
exhibit only a weak temporal signal, or no temporal signal, at the amino acid level and
do not exhibit an accumulation of amino acid change through time (Figure 2.18). The
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Figure 2.16: VP2 sites that change leading to the pandemic GII.4 clade and exhibit residue
differences between the pandemic GII.4 clade and pre-pandemic GII.4 se-
quences. Coloured trees for sites 72, 78, 93, 148 and 187. The starred node in
each tree is the common ancestor of the pandemic GII.4 clade. Sites 72, 78 and
93 are conserved within the pandemic GII.4 clade. Sites 148 and 187 are variable
within the pandemic GII.4 clade, with each common residue within the pandemic
GII.4 clade being different to that in the pre-pandemic GII.4 sequences.
GII.4 capsid, however, exhibits a strong temporal signal at the amino acid level. This
accumulation of amino acid change is evident in both the pandemic GII.4 clade and the
pre-pandemic GII.4 lineages (Figure 2.18), although the magnitude of the accumulation
appears greater within the pandemic GII.4 clade (Figure S2.7).
2.5 Discussion
The GII.4 capsid genotype has dominated norovirus outbreaks since the mid-1990s and
during this time has caused six pandemics and additional epidemics (Siebenga et al.,
2009; van Beek et al., 2013). Our results support previous suggestions that the pandemic
caused by US95/96 was the first GII.4 pandemic and coincided with a large increase in
prevalence of this genotype (Figure 2.2) (Donaldson et al., 2008; Siebenga et al., 2010),
although reconstruction of the evolutionary dynamics of the early GII.4 lineage suggests
that this first pandemic may have begun as early as 1994 (Figure 2.2 panels C, D). The
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Figure 2.17: Accumulation of nucleotide change within GII capsid genotypes. A nucleotide
maximum likelihood phylogenetic tree was reconstructed for each genotype. Here,
the nucleotide root-to-tip distance in the phylogenetic tree is plotted against the col-
lection date for each sequence. The root location was identified as the position that
minimised the heuristic residual mean squared of the root-to-tip distance versus col-
lection date, as calculated with TempEst v1.5 (Rambaut et al., 2016). The dashed line
is a linear regression between root-to-tip distance and collection date and is shown
for genotypes that exhibit a correlation between these values. The R2 correlation
between root-to-tip distance and collection date is shown for each genotype.
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Figure 2.18: Accumulation of amino acid change within GII capsid genotypes. The amino
acid root-to-tip distance versus collection date is plotted for each sequence within
each genotype that exhibited a correlation between nucleotide root-to-tip distance
and collection date. The dashed line is a linear regression between root-to-tip dis-
tance and sampling date. The R2 correlation between amino acid root-to-tip distance
and collection date is shown for each genotype. As the GII.5 genotype exhibits a
negative correlation between amino acid root-to-tip distance and collection date, the
R2 correlation was not calculated for this genotype.
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timing of the first pandemic has the caveat that there was an increase in norovirus sam-
pling in the mid-1990s that may have resulted in an artificial increase in the estimated
relative genetic diversity at this time. It is unlikely that a change in the host population
could have selectively driven the emergence of only a single norovirus genotype. Instead,
the transition of GII.4 from one of a number of low prevalence genotypes to the dom-
inant genotype is most likely to have been driven by one or more changes in the viral
genome. Importantly, the continued high prevalence of GII.4 through to the present day
suggests that the change(s) important for the increase in frequency have been retained, at
least phenotypically if not genotypically. The structure of the GII.4 capsid and VP2 phy-
logenetic trees demonstrates that each of the strains associated with pandemics or large
epidemics since the mid-1990s cluster downstream of a single node (Figures 2.1, 2.14).
Therefore GII.4 transitioned from being one of a number of low frequency genotypes to
being the dominant genotype along a single branch within the respective phylogenetic
trees. Conversely, the ORF1 regions found with pandemic strains last shared a common
ancestor in the 1970s (Figure 2.10). Therefore there was not a single branch in the ORF1
phylogenetic tree where the transition from low frequency to high frequency occurred
and we find no evidence of convergent changes occurring along branches leading to high
frequency ORF1 clades (Figures 2.8, S2.4, S2.5). This has the caveat that changes at
different sites within ORF1 proteins may result in phenotypically similar outcomes; this
is hard to assess with the currently limited knowledge of the functions of ORF1 proteins
and functionally important sites. However, our results argue that genetic changes within
the capsid and/or VP2 drove the increase in frequency of GII.4. The capsid and VP2 sub-
stitutions that occurred leading to the pandemic GII.4 clade were most likely acquired by
July 1992 (Figures 2.2, 2.14) and therefore GII.4 likely circulated with these changes for
at least two years prior to increasing in frequency.
Our results suggest two potential mechanisms by which the GII.4 capsid could have
increased in prevalence in the mid-1990s: an increase in capsid stability and an increased
range of HBGA-binding. Sites 333 and 459 were the only two sites identified as evolving
under different selective constraints in the pandemic GII.4 clade and the pre-pandemic
GII.4 lineages, although the small number of sequences in the pre-pandemic GII.4 clade
raises the possibility of false negatives. We infer that the leucine to glutamine substitu-
tion at site 459 may have increased the interaction network within region IV of the capsid
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dimer interface (Figure 2.5, S2.2); future crystallographic studies to examine the structure
in this region with leucine at site 459 would be useful to confirm this. The potential influ-
ence of the substitution at site 333 is less clear, although the methionine and valine at this
site in the pandemic GII.4 clade (Figure 2.4) have greater beta sheet propensity than the
leucine found in the pre-pandemic clade (Koehl and Levitt, 1999) and may therefore alter
local protein structure or flexibility. Alternatively, these residues may increase dimer sta-
bility through specific inter-monomer interactions. Clearly, an increase in inter-monomer
interactions is likely to increase the stability of the viral particle. A more stable capsid
would be able to persist for longer on surfaces, in the environment and within an infected
individual, resulting in significantly increased transmission. To date, studies directly com-
paring the environmental stability of different norovirus genotypes are lacking. However,
there is evidence that the Ebola virus responsible for the large 2013-2016 epidemic was
more stable in blood compared with a 1976 Ebola virus that caused only a small outbreak
and there is therefore precedent for more stable variants causing larger outbreaks (Schuit
et al., 2016).
While the majority of GII capsid genotypes exhibit an accumulation of nucleotide
change through time (Figure 2.17), GII.4 was the only genotype to exhibit an accumula-
tion of amino acid change through time (Figure 2.18). These results are consistent with a
concurrent published study that demonstrated that non-GII.4 genotypes remain ‘static’ at
the amino acid level (Parra et al., 2017). Interestingly, the ability to accomodate change
appears to be inherent to the GII.4 capsid, as the pre-pandemic GII.4 lineages also ex-
hibit an accumulation of amino acid change through time (Figure 2.18). However, the
magnitude of this accumulation appears far greater in the pandemic GII.4 clade (Figure
S2.7), indicating an elevated rate of change following pandemic emergence. It is not
clear whether this increase is a cause or consequence of pandemic spread. Future anal-
yses estimating substitutions rates and dN/dS ratios for the pandemic GII.4 clade and
pre-pandemic GII.4 lineages would be useful to confirm our findings. It has previously
been demonstrated that the increased mutational robustness conferred by an increase in
protein stability increases the capacity of a protein to evolve (Bloom et al., 2006). Capsid
sites 93, 172, 176, 285, 497 and 505 changed leading to the pandemic GII.4 clade and are
conserved within this clade (Figure 2.7). While these sites are not currently associated
with a particular function, their conservation within the pandemic GII.4 clade suggests
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a selective constraint. We therefore hypothesise that one or more of these substitutions,
potentially coupled with the substitutions at site 333 and/or 459, may have increased
capsid stability and thereby increased evolvability, enabling accomodation of the amino
acid change necessary to persist at high frequency within the population. Future in silico
studies examining the adaptability of the capsid protein with and without these substitu-
tions would test this hypothesis. Additionally, future studies comparing the environmental
stability of pandemic and pre-pandemic GII.4 capsids would resolve whether there was
indeed an increase in stability leading to the pandemic GII.4 clade.
Previous studies have demonstrated that the US95/96 GII.4 strain binds to a greater
range of HBGAs than other genotypes, providing a mechanism by which this strain can
infect a larger proportion (roughly 80%) of the population (Lindesmith et al., 2008; Don-
aldson et al., 2008). Site 395 is the only site close to the HBGA-binding region that
changed leading to the common ancestor of the pandemic GII.4 clade (Figure 2.2) and it
is therefore likely that any alterations in HBGA binding between the Camberwell 1994-
like and US95/96 strains would be driven by the substitution at this site. Movement of the
391-395 loop is required for binding to HBGA type B, LeB and LeY (Singh et al., 2015)
and substitutions at site 395 can alter binding to HBGA type A (Lindesmith et al., 2008).
Therefore substitutions at site 395 have the potential to alter HBGA binding by both alter-
ing movement of the 391-395 loop and by directly modulating interactions with HBGAs.
Each of the amino acid residues found at site 395 in the pandemic GII.4 clade (alanine,
asparagine and threonine) is smaller in size than the histidine found in the pre-pandemic
GII.4 lineages (Figure 2.4). Interestingly, site 395 is also part of blockade epitope D (Lin-
desmith et al., 2012a) and substitutions at this site within the pandemic GII.4 clade that
enable evasion of antibody responses have retained the small residue size at this site. We
hypothesise that a smaller residue at site 395 results in a more flexible loop and there-
fore more efficient binding to a greater range of HBGAs, enabling infection of a larger
proportion of the population. While there is not a clear difference in the structure of the
391-395 loop in homology models of the pandemic GII.4 clade common ancestor and the
immediately upstream ancestor, under our hypothesis it is movement of this loop that is
important and such movement is not included in the homology models. Therefore future
structural, molecular dynamics and HBGA-binding studies would determine whether the
size of the residue at site 395 alters movement of this loop and HBGA-binding. However,
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the role of wider HBGA-binding in the high prevalence of GII.4 is called into question by
the low efficiency of binding of the Hunter 2004 pandemic strain to synthetic HBGAs in
experimental conditions (Lindesmith et al., 2008, 2012a). If wider HBGA-binding is the
key mechanism enabling the high prevalence of GII.4, it would be expected that this be
maintained in all pandemic GII.4 strains. It is, however, possible that Hunter 2004 may
bind to alternative cell surface receptors.
While sites 294, 333, 340 and 395 are located within blockade epitope A, putative
epitope B, putative epitope C and blockade epitope D, respectively, envoking evasion
of immunity as a mechanism by which the GII.4 capsid increased in prevalence would
require significant population immunity built against pre-pandemic GII.4 viruses from
which the pandemic GII.4 lineage escaped. Given the low prevalence of GII.4 viruses
prior to the mid-1990s it is very unlikely that such immunity existed.
The influence of the substitutions at sites 72, 78, 93, 148 and 187 in VP2 is difficult
to predict due to the lack of knowledge of the functional importance of different VP2
regions. While site 148 is located within the putative capsid-interaction domain (Glass
et al., 2003), variation at this site does not correlate with variation within the capsid shell
domain and is therefore unlikely to greatly alter capsid-VP2 interaction.
The increase in prevalence of the GII.4 capsid is unlikely to have been driven by an
increase in mutation rate (Bull et al., 2010) as, while we do find evidence of an elevated
substitution rate in the GII.P4 lineage, this higher rate was likely acquired by 1906 (Fig-
ure 2.10) and was therefore not newly acquired close to the time of the increase in GII.4
prevalence. Importantly, the accumulation of nucleotide change is relatively constant
throughout the GII.P4 lineage (Figure 2.10 panel A) and this lineage exhibits a gener-
ally elevated substitution rate compared with the rest of the GII clade (Figure 2.11). The
higher substitution rate at the third codon position within the GII.P4 lineage suggests at
least part of the increased substitution rate is due to a neutral process, such as an increase
in mutation rate, replication rate or transmission rate. Several of the genotypes within the
GII.P4 lineage are found with the GII.4 capsid which exhibits a rapid transmission rate,
as evidenced by its high frequency. However, the presence of the rarely detected ‘orphan’
ORF1 genotypes within this lineage (Figure 2.10) suggests that increased transmission
is not the factor driving the higher substitution rate. Additionally, the replication rate of
the GII.P4 RdRp is not higher than that of the GII.Pb or GII.P7 RdRps (genotypes that
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are not within the GII.P4 lineage) (Bull et al., 2010). We therefore hypothesise that the
increased substitution rate is due to an increase in mutation rate. Future studies inves-
tigating the effect of the substitutions at RdRp sites 105 and 189 on the mutation rate
and replication rate using previously developed assays (Bull et al., 2010) would confirm
this. It was recently demonstrated that a more diverse viral quasispecies results in more
efficient transmission of murine norovirus (Arias et al., 2016) and therefore an increased
mutation rate generating a more diverse viral population may enable more efficient trans-
mission between humans. Each of the ORF1 genotypes found with the pandemic (and
pre-pandemic) GII.4 strains is within the GII.P4 lineage (Figure 2.10) and a higher mu-
tation rate may therefore contribute to the rapid transmission of GII.4, although it cannot
be completely responsible for this rapid transmission.
We hypothesise that the GII.4 genotype was pre-adapted to become pandemic due to
its capsid structure inherently being able to tolerate high levels of amino acid variation and
through the associated RdRps from the GII.P4 lineage enabling rapid mutation to enable
efficient transmission and evasion of host immunity. We propose that this combined with
an increase in capsid stability and/or increase in HBGA binding in the mid-1990s resulted
in a highly stable and highly transmissible virus that was capable of infecting a large
proportion of the human population and tolerating the variability that has been required
to persist despite significant population immunity. The combination of these factors has
enabled the GII.4 genotype to dominate gastroenteritis cases and outbreaks worldwide for
the past 20 years.

Chapter 3
Identifying the sources and drivers of
norovirus pandemics
3.1 Abstract
The norovirus genotype GII.4 is a leading cause of human gastroenteritis and has caused
six pandemics since the mid-1990s. Hitherto it has been suggested that pandemics are
driven by the acquisition of viral mutations enabling evasion of existing herd immunity.
However, by reconstructing the evolutionary dynamics of GII.4 norovirus, we demon-
strate that all of the GII.4 strains circulated undetected for years prior to their pandemic
spread. We show that each of the pandemic GII.4 strains diverged into multiple lineages
over years prior to pandemic emergence, indicating that the genetic changes important
for pandemic spread were acquired several years previously. Our results suggest that
GII.4 strains circulate in their pandemic form within one or more currently poorly sam-
pled reservoir populations for years prior to pandemic spread. We hypothesise that new
pandemics are triggered when growing herd immunity against the preceding pandemic
strain opens a niche into which a pre-adapted GII.4 strain can emerge. These results have
implications for surveillance strategies to detect potential future pandemic strains and for
vaccine design.
3.2 Introduction
Despite the large number of norovirus genotypes known to infect humans, all pan-
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demics and up to 80% of annual outbreaks since 1995 have been caused by a single
capsid genotype, GII.4 (Kroneman et al., 2008; Siebenga et al., 2009). To date, there
have been six GII.4 pandemics, occurring in the Northern hemisphere winters of 1995-
1996 (US95/96 strain), 2002-2003 (Farmington Hills 2002), 2004-2005 (Hunter 2004),
2006-2007 (Den Haag 2006), 2009-2010 (New Orleans 2009) and 2012-2013 (Sydney
2012) (Siebenga et al., 2009; van Beek et al., 2013). Each pandemic has been caused
by a phylogenetically distinct GII.4 strain and the replacement of the previous pandemic
strain occurs rapidly, with the new strain dominating outbreaks worldwide within several
months of its emergence (Siebenga et al., 2007, 2009; White, 2014). Here, we define a
pandemic strain as the dominant strain in worldwide outbreaks. There are therefore mul-
tiple pandemic strains within the ‘pandemic GII.4 clade’ defined in the previous chapter
and replacement of the pandemic strain has occurred periodically since the mid-1990s.
Several epidemic GII.4 strains have also been identified and have caused outbreaks either
within more restricted geographical regions, or have caused widespread but only spo-
radic outbreaks, including Asia 2003, Yerseke 2006, Apeldoorn 2007 and Osaka 2007
(Siebenga et al., 2009; Eden et al., 2013).
It has previously been suggested that, analogous to influenza A H3N2, the pandemic
GII.4 strains generally evolve from one of the previous pandemic GII.4 strains (Siebenga
et al., 2007, 2009; van Beek et al., 2013; White, 2014), a process driven by mutations in
the antigenic regions of the capsid P2 domain that enable evasion of population herd im-
munity (Lindesmith et al., 2008; Cannon et al., 2009; Lindesmith et al., 2012a; Zakikhany
et al., 2012; Lindesmith et al., 2013; Debbink et al., 2013). The emergence of new pan-
demic strains being driven by evasion of herd immunity is supported by the observation
that newly emerging pandemic strains are capable of evading mouse monoclonal anti-
bodies, human monoclonal antibodies, mouse polyclonal sera and human polyclonal sera
raised against the preceding pandemic strain (Lindesmith et al., 2008, 2011, 2012a, 2013;
Debbink et al., 2013). However, recent phylogenetic analysis has suggested that the two
most recent pandemic strains, New Orleans 2009 and Sydney 2012, diverged at the start
of the Apeldoorn 2007 epidemic and therefore neither evolved from a previous pandemic
strain (Eden et al., 2014). Further retrospective analyses have identified sporadic commu-
nity cases and/or outbreaks caused by pandemic norovirus strains several years prior to
the pandemic emergence of those strains (Siebenga et al., 2009; Sdiri-Loulizi et al., 2009;
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Eden et al., 2013; Allen et al., 2016). This has led to suggestions that variants of pandemic
strains may persist at low levels until acquiring changes in the capsid P2 domain that drive
pandemic spread (Eden et al., 2014; White, 2014; Allen et al., 2016). While most work
on the drivers of GII.4 pandemics has focused on the capsid, both New Orleans 2009 and
Sydney 2012 acquired new ORF1 regions by recombination, leading to suggestions of a
role for recombination in strain emergence (Motomura et al., 2010; Eden et al., 2013).
Here, we further investigate the origin of pandemic GII.4 viruses by reconstructing
the evolutionary history of the RdRp, capsid and VP2. We demonstrate that each of the
pandemic and epidemic GII.4 strains circulated undetected for years prior to pandemic or
epidemic spread. The simultaneous presence of multiple unobserved co-circulating GII.4
lineages, including future pandemic and epidemic strains, suggests that these viruses can
persist for long periods of time in unsampled reservoir populations. During this time,
the pandemic strains diversify into multiple lineages, with these multiple lineages emerg-
ing simultaneously at the onset of the new pandemic. This demonstrates that the genetic
changes enabling pandemic spread must be acquired years prior to the start of the pan-
demic and emergence is therefore not driven by the acquisition of new viral mutations.
Instead, we hypothesise that new GII.4 pandemics are driven by changes in host herd
immunity that create an immunological niche that allows a pre-adapted strain to emerge.
3.3 Materials and Methods
3.3.1 Analyses using all GII.4 strains
To examine the evolutionary dynamics of the GII.4 genotype, we collected all of the 871
GII.4 norovirus sequences available in GenBank as of 30/10/2015 containing the com-
plete RdRp, capsid and VP2. The strategy of including sequences containing each of
these regions enabled collection of comparable datasets for each genomic region. Se-
quences were removed if their GenBank record was associated with terms that may in-
dicate sequence change after collection from an infected patient (as detailed in chapter
2.3.1) and sequences were retained only if they were associated with a collection date in
either their GenBank record or within primary literature. The RdRp and capsid genotype
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Number of Number of capsid
Strain name RdRp sequences and VP2 sequences Subsampled
GII.4 1970s (GII.P1 RdRp) 6 6 No
Bristol 1993 2 2 No
Camberwell 1994 5 5 No
US95/96 3 3 No
Lanzhou 2001 1 1 No
Farmington Hills 2002 18 18 No
Asia 2003 (GII.P12 RdRp) 15 15 No
Hunter 2004 17 17 No
Yerseke 2006 12 12 No
Den Haag 2006 551 559 Yes, 41 sequences
Osaka 2007 (GII.Pe RdRp) 5 5 No
Apeldoorn 2007 37 31 No
New Orleans 2009 141 134 Yes, 41 sequences
Sydney 2012 (GII.Pe RdRp) 36 41 No
GII.4 could not assign strain 3 3 No
Table 3.1: Summary of the GII.4 strains included in this study and the number of sequences
from each strain. The number of sequences from each strain is shown following the
removal of potentially recombinant samples. The RdRp genotype is shown in paren-
theses for each GII.4 strain that is not found with the GII.P4 RdRp. Den Haag 2006
and New Orleans 2009 were randomly subsampled to the number of sequences present
in the third most prevalent strain. Sydney 2012 and Osaka 2007 are found with the
GII.Pe RdRp, therefore there are 41 GII.Pe samples in the RdRp dataset. Pandemic
strains are labelled in bold font.
of each sequence was confirmed using the norovirus genotyping tool (Kroneman et al.,
2011), which was also used for initial strain typing (Table 3.1). All capsid sequences in
the dataset clustered with a bootstrap score of 100 in a capsid phylogeny including viruses
from all GII genotypes indicating that each sequence contains the GII.4 capsid. However,
the dataset includes sequences with the GII.P1, GII.P4, GII.P12 and GII.Pe RdRp, due to
intergenotype recombination events (Table 3.1) (Eden et al., 2013). The strain names used
are those returned by the norovirus genotyping tool (Table 3.1). The RdRp, capsid and
VP2 datasets were aligned independently at the amino acid level using MUSCLE (Edgar,
2008).
3.3.2 Recombination analysis
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The presence of recombination was screened for using the Single Breakpoint (SBP)
method in HyPhy (Kosakovsky Pond et al., 2005; Pond et al., 2006). SBP was run on the
alignment for the RdRp, capsid and VP2 separately with the GTR model of nucleotide
substitution. No recombination was detected in the RdRp or VP2. Recombination was
detected in the capsid (p < 0.01 in the Kishino-Hasegawa (KH) test). We identified the
most likely breakpoint as the nucleotide position with the greatest gain in AIC when the
alignment was split at that position compared with the null model and reconstructed a
maximum likelihood tree on either side of this position using RAxML (Stamatakis, 2014)
with the GTR model of nucleotide substitution and gamma rate heterogeneity with four
gamma classes. We assessed topological robustness using 1000 bootstrap replicates. As
SBP identifies putative recombination events to the nearest variable site, the identified
breakpoint may not be the true breakpoint position. Sequences that clustered separately
on either side of the breakpoint with strong bootstrap support (here defined as 70 or above)
were considered putative recombinants and were removed from the dataset and from fur-
ther analyses. SBP was then run on the alignment again to ensure the signal for recombi-
nation at that position had been removed. In total, there were 19 putatively recombinant
capsid sequences with the most likely breakpoint at either position 314 or 537 (Table
S3.1). These recombination events predominantly occurred between Den Haag 2006 and
Apeldoorn 2007, Den Haag 2006 and New Orleans 2009 or Apeldoorn 2007 and New
Orleans 2009, strains that cocirculated within the human population (Eden et al., 2014),
providing the opportunity for coinfection.
3.3.3 Assessing clock-like signal
Methods employing sampling dates to infer divergence times and evolutionary rates
are valid only if there is a temporal evolutionary signal in the dataset, i.e. if there is
an accumulation of nucleotide change through time (Rambaut et al., 2016). To assess
whether there is a clock-like signal in our datasets, we reconstructed maximum likelihood
trees for the RdRp, capsid and VP2 using RAxML as described above. The best fitting
root position was inferred using TempEst v1.5 (Rambaut et al., 2016). We calculated
the R2 correlation between root-to-tip distance and sampling date and assessed statistical
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significance using a bootstrapping approach whereby the sampling dates were randomly
resampled and the R2 correlation recalculated 1000 times.
3.3.4 Bayesian reconstruction of evolutionary dynamics
We used the Bayesian Markov chain Monte Carlo approach implemented in BEAST
version 2.2.1 (Bouckaert et al., 2014) to reconstruct the evolutionary dynamics of the
GII.4 genotype. Analyses were run separately on the RdRp, capsid and VP2. As Den
Haag 2006 and New Orleans 2009 have a greater number of samples compared with the
other strains (Table 3.1), we took 3 random subsamples of 41 sequences (chosen to match
the number of sequences from the next most numerous strain in each dataset) from each
of these strains and combined these with the sequences from the other strains to form 3
subsampled datasets for each genomic region. These datasets contained 241 sequences
for the capsid and VP2 and 242 sequences for the RdRp. Each of the subsampled datasets
was analysed separately and results were insensitive to the subsampled dataset (Figure
S3.1, Table S3.2). Each sample was labelled with the most accurate date possible; the
day of collection if available, the middle of the month of collection if the sampling day
was not available or the middle of the year of collection if the sampling month was not
available. Each dataset was analysed with the GTR substitution model and partitioned
so codon positions 1 and 2 shared a substitution model while codon position 3 had its
own substitution model. Amongst site rate heterogeneity was accounted for using gamma
rate heterogeneity with 4 gamma classes. We applied a coalescent Bayesian skyline tree
prior. We used the strict clock and relaxed lognormal clock models to assess variation in
substitution rate within each dataset. The priors on the substitution rate were chosen to
encompass the 95% highest probability density (HPD) of previously published estimates
(Bok et al., 2009; Siebenga et al., 2010). We employed a lognormal prior on the cap-
sid substitution rate with mean 4.3x10-3 substitutions/site/year and standard deviation 0.1
(Bok et al., 2009), while for the RdRp we used a lognormal prior on the substitution rate
with mean 4.32x10-3 substitutions/site/year and standard deviation 0.1 (Siebenga et al.,
2010). At the time of our analyses, there was no previously published estimate of the VP2
substitution rate across the entire GII.4 clade. We therefore applied the same substitution
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rate prior to VP2 as the capsid. We performed three replicate runs with different start-
ing parameters for each dataset and clock model and ran until convergence, as assessed
using Tracer v1.5. We combined the three replicate runs with removal of suitable burnin
using LogCombiner v2.2.1. Maximum clade credibility (MCC) trees were obtained with
TreeAnnotator v2.2.1. The MCC trees obtained with BEAST consistently exhibited the
same overall topology as the maximum likelihood trees reconstructed using RAxML.
3.3.5 Calculation of parameter estimates and 95% confidence inter-
vals
All estimates of divergence dates, branch lengths and recombination dates were cal-
culated by combining the complete posterior distribution of trees from each of the sub-
sampled datasets. We inferred the date of divergence between each pair of strains by
calculating the date of the most recent common ancestor of the two strains in each tree
within the posterior distribution and then calculating the mean and 95% HPD of this dis-
tribution. We calculated the date at which a recombination event occurred by identifying
the branch in the tree along which the recombination event occurred in each tree in the
posterior distribution. We combined the dates of the start and end of this branch into a
distribution of times for that branch and calculated the mean and 95% HPD of this distri-
bution.
3.3.6 Acquisition of strain-specific datasets
We examined the evolutionary dynamics of the New Orleans 2009 and Sydney 2012
strains using datasets containing all of the P2 domain sequences with a known collection
date available for the strain as of 30/10/2015. All analyses were carried out on the New
Orleans 2009 dataset and the Sydney 2012 dataset independently. The datasets for each
strain were aligned at the amino acid level using MUSCLE (Edgar, 2008). Each of the
datasets exhibited a significant (p< 0.001) temporal signal, as assessed using a maximum
likelihood tree as described above. The evolutionary dynamics of the P2 domain datasets
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were reconstructed with BEAST v2.2.1. We applied the HKY substitution model with
gamma rate heterogeneity with four gamma classes. We used the strict clock and relaxed
lognormal clock models to test for variation in the substitution rate within the strain. In
each case, there was strong support (log10 Bayes factor > 100) to reject the strict clock
model in favour of the relaxed lognormal clock model. We employed a lognormal prior
on the substitution rate with mean 6.83x10-3 and standard deviation 0.1 to accomodate the
mean and the 95% HPD of our estimate of the substitution rate of the complete GII.4 cap-
sid clade. Triplicate runs were carried out for each dataset and were run until convergence,
as assessed with Tracer v1.5. Runs were combined with removal of suitable burnin using
LogCombiner v2.2.1. Maximum clade credibility trees were obtained using TreeAnnota-
tor v2.2.1. Bayesian skyline plots were reconstructed using Tracer v1.5. We used the date
at which the Bayesian skyline plot exhibits a large increase in relative genetic diversity as
the date of the onset of the pandemic. To determine the number of lineages present at the
onset of the pandemic, we calculated the number of lineages present at this point in time
in each tree in the posterior distribution.
3.3.7 Identification of pre-pandemic and pre-epidemic sequences
We defined pre-pandemic/pre-epidemic sequences as sequences that cluster with
a pandemic/epidemic strain but were collected prior to the year of onset of the pan-
demic/epidemic. We initially obtained all GII.4 capsid sequences present on GenBank
containing more than 400 nucleotides and genotyped each sequence using the norovirus
genotyping tool (Kroneman et al., 2011). We identified 50 sequences that were as-
sociated with a collection date that was earlier than the year in which the respective
pandemic/epidemic strain emerged. We assessed whether each of these putative pre-
pandemic/pre-epidemic sequence had accumulated close to the expected amount of nu-
cleotide change given its reported collection date by reconstructing a maximum likeli-
hood tree of the P2 domain with RAxML (Stamatakis, 2014) as described above and
assessed this tree using TempEst v1.5 (Rambaut et al., 2016). We estimated the collection
date of each putative pre-pandemic/pre-epidemic sequence using BEAST v2.4.2 (Bouck-
aert et al., 2014). We used the capsid subsample 1 dataset assembled in section 3.3.4
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and added to this dataset the putative pre-pandemic/pre-epidemic sequences in batches of
five. The collection dates of the capsid subsample 1 dataset were fixed to the most accu-
rate date possible, while we employed a uniform prior distribution on the collection date
of the putative pre-pandemic/pre-epidemic sequences with minimum 1974.5 and maxi-
mum 2015.446575, the earliest and latest collection dates within the capsid subsample 1
dataset. We then estimated the collection date of each of these sequences as part of the
MCMC chain. We used the SRD09 model of nucleotide substitution and a relaxed log-
normal clock model. We assumed a lognormal prior on the substitution rate with mean
6.83x10-3 and standard deviation 0.1, chosen to encompass the mean and 95% HPD es-
timates of the GII.4 capsid substitution rate estimated in the BEAST runs described in
section 3.3.4 (Table 3.2). We carried out triplicate runs and run until convergence as
assessed using Tracer v1.6. Replicate runs were combined using LogCombiner v2.2.1.
3.4 Results
3.4.1 The GII.4 capsid emerged by the 1940’s
We collected datasets for the GII.4 capsid, VP2 and associated RdRps and screened
these datasets for potential recombinants (Table S3.1). The GII.4 capsid, VP2 and as-
sociated RdRps each exhibit a significant correlation between root-to-tip distance and
sampling date, indicating there has been an accumulation of nucleotide change through
time in each genomic region (Figure 3.1). We therefore reconstructed the evolutionary
dynamics of each of the genomic regions using BEAST (Figure 3.1, Table 3.2). There is
strong support to reject the strict clock model in favour of the relaxed lognormal clock
model in each genomic region (Table 3.2). The substitution rate is very similar for the
RdRp, capsid and VP2 (Table 3.2). Previous estimates have placed the common ancestor
of the GII.4 capsid in the 1960s (Bok et al., 2009). In our dataset, the GII.4 capsid com-
mon ancestor occurred in the 1940s, due to the inclusion of a sequence collected from
Malaysia in the 1970s that branches from the root of the GII.4 clade (Figure 3.1) and was
not included in the previous study. The proposed GII.4 root in the previous study falls
110 Chapter 3. Identifying the sources and drivers of norovirus pandemics
Genome region Log10 BF rejecting Substitution rate, x10-3 Root date GII.P4 RdRp
strict clock substitutions/site/year (95% HPD) ancestor date
(95% HPD) (95% HPD)
RdRp 54.89 6.67 (5.84,7.53) 1941 (1922,1958) 1979 (1975,1982)
Capsid 122.97 6.83 (6.03,7.68) 1943 (1919,1965) N/A
VP2 44.23 6.11 (5.35,6.93) 1949 (1934,1963) N/A
Table 3.2: Summary of Bayesian MCMC results. Mean values and 95% HPD intervals were
calculated by combining the complete posterior distributions for each parameter of
interest from each of the subsampled datasets. The log10 Bayes factor (BF) is the
support for rejecting the strict clock model in favour of the relaxed lognormal clock
model.
within our phylogeny at a similar date (node P in Figure 3.1). Given the paucity of GII.4
sequences from and prior to the 1970s, it is possible that the GII.4 capsid common an-
cestor occurred earlier than our estimate. The GII.4 viruses collected in the 1970s are not
monophyletic in the capsid tree. However, each of these samples has the GII.P1 RdRp,
suggesting that the GII.4 capsid common ancestor was found with the GII.P1 RdRp. The
GII.P4 RdRp found with the majority of more recent GII.4 capsids arose by the late 1970s
(Figure 3.1, Table 3.2).
3.4.2 GII.4 pandemic strains are present for years prior to causing
the pandemic
Each of the pandemic and epidemic GII.4 strains was present for years prior to caus-
ing their respective pandemic or epidemic, as evidenced by the occurrence of the common
ancestor of each strain years prior to pandemic/epidemic spread (Table 3.3). However, the
common ancestor is the ancestor of the subset of diversity represented in our datasets and
is unlikely to represent the true common ancestor of the strain. Indeed, the branch leading
to the common ancestor of each of the pandemic GII.4 strains typically accounts for sev-
eral years of unsampled diversity (Figure 3.1, Table 3.3) and the true common ancestor
of the strain could have occurred at any point along this branch. If a GII.4 strain evolved
from one of the preceding pandemic strains, the new strain would diverge from its prede-
cessor during the time at which that previous strain was circulating. However, the GII.4
strains exhibit deep divergence times, years prior to the emergence of either of the strains
(Figure 3.2, Table 3.4), demonstrating that (with the possible exception of emergence
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Figure 3.1: Temporal evolutionary history of the GII.4 capsid, VP2 and associated RdRps.
Maximum clade credibility (MCC) trees are shown for the RdRp, capsid and VP2 as
reconstructed using BEAST. Poorly supported (posterior support< 0.75) trunk nodes
have been collapsed. Branches within each tree are coloured by the corresponding
strain, with the colours matching the strain label. Pandemic strains are labelled in
bold font. Posterior supports are shown on trunk nodes and strain root nodes. The
posterior support on the US95/96 strain root node in the RdRp tree is 0.76. Node
P within the capsid tree corresponds to the root node of the GII.4 capsid clade in a
previous analysis (Bok et al., 2009). The date of node P is very similar to the root
date estimated in this previous analysis. The correlation between root-to-tip distance
and collection date is shown for sequences within each genomic region. The p-value
on the R2 correlation was calculated using a bootstrapping approach whereby the
sampling dates were randomised and the R2 correlation recalculated 1000 times. The
significant correlation enabled reconstruction of the temporal evolutionary history of
each genomic region.
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Figure 3.2: Comparison of divergence and emergence times. Shown is a representation of the
capsid tree in Figure 3.1. The black vertical line occurs at the mean time of diver-
gence and the orange shaded area represents the 95% HPD on the divergence time.
The triangle represents the start of the year in which the strain emerged either pan-
demically (red) or epidemically (yellow). If a GII.4 strain evolved from a preceding
strain, the divergence would occur after the emergence (triangle) of the preceding
strain, as illustrated by the (unobserved) dashed green line. In all cases, divergence
occurs earlier: Hunter 2004 diverged from Farmington Hills 2002 and Asia 2003 be-
fore either the Farmington Hills 2002 pandemic or the Asia 2003 epidemic, Den Haag
2006 diverged from Hunter 2004 before the Hunter 2004 pandemic, etc.
from US95/96 for which we have very few sequences) none of the pandemic or epidemic
GII.4 strains evolved from a previous pandemic or epidemic strain. Rather, GII.4 strains
diverge from and coexist with other pandemic and pre-pandemic strains for years prior
to causing the pandemic in the human population. The fact that each of the strains exists
for years before emergence, while only rarely being sampled, suggests that the strains
circulate within one or more populations that is hidden from current surveillance.
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GII.4 Strain Common ancestor date Years of unsampled diversity leading to strain common
ancestor
RdRp (95% HPD) Capsid (95% HPD) VP2 (95% HPD) RdRp (95% HPD) Capsid (95% HPD) VP2 (95% HPD)
US95/96 December 1993 December 1993 April 1995 1.2 (0.0, 2.9) 1.8 (0.1, 4.1) 1.4 (0.2, 2.9)
(November 1991 - (June 1991 - (September 1993 -
January 1996) April 1996) September 1996)
Farmington Hills July 2000 December 2000 September 2000 3.2 (1.5, 5.1) 3.2 (1.4, 5.1) 2.5 (1.0, 4.1)
2002 (August 1999 - (February 2000 - (October 1999 -
April 2001) September 2001) July 2001
Asia 2003 August 2002 February 2001 March 2002 29.1 (19.0, 40.2) 3.7 (1.6, 5.9) 3.8 (1.8, 5.8)
(June 2001 - (May 1999 - (November 2000 -
August 2003) November 2002 April 2003
Hunter 2004 September 2002 December 2002 April 2002 0.9 (0.0, 2.2) 1.7 (0.6, 3.0) 1.3 (0.3, 2.4)
(August 2001 - (March 2002 - (September 2000 -
August 2002) September 2003) August 2003)
Yerseke 2006 June 2002 July 2003 April 2003 1.5 (0.3, 2.8) 2.3 (0.8, 3.8) 1.0 (0.0, 2.1)
(January 2001 - (April 2002 - (April 2002 -
October 2003) October 2004) April 2004)
Den Haag 2006 March 2004 February 2004 January 2004 4.4 (2.6, 6.4) 5.6 (2.7, 8.4) 4.3 (2.2, 6.5)
(February 2003 - (October 2002 - (October 2002 -
April 2005) April 2005) April 2005
Osaka 2007 February 2006 September 2005 December 2005 5.4 (1.5, 10.6) 10.2 (4.8, 13.9) 1.3 (0.3, 2.5)
(January 2005 - (June 2004 - (November 2004 -
January 2007) November 2006) November 2006)
Apeldoorn 2007 April 2005 January 2006 April 2006 2.5 (1.2, 3.7) 1.9 (0.6, 3.3) 1.0 (0.3, 1.8)
(April 2004 - (December 2004 - (June 2005 -
March 2006) December 2006) January 2007)
New Orleans 2009 April 2005 December 2005 October 2006 1.5 (0.4, 2.6) 1.7 (0.5, 3.0) 1.5 (0.6, 2.5)
(December 2003 - (October 2004 - (November 2005 -
July 2006) February 2007) August 2007)
Sydney 2012 October 2009 February 2007 May 2006 9.0 (5.0, 14.4) 2.9 (1.1, 4.8) 1.7 (0.2, 3.4)
(August 2008 - (April 2005 - (August 2004 -
September 2010) October 2008) April 2008
Table 3.3: Strain common ancestor dates and unsampled diversity. The common ancestor
date of each GII.4 strain is shown for the RdRp, capsid and VP2. The number of
years of unsampled diversity is the branch length leading to the common ancestor of
each GII.4 strain. The common ancestor of the Sydney 2012 RdRp is the common
ancestor of the GII.Pe RdRps found with the Sydney 2012 capsid (Figure 3.1 RdRp).
Asia 2003 has a GII.P12 RdRp, which is also found with capsids from multiple other
genotypes. As only GII.P12 RdRps associated with the GII.4 capsid were included
here, the years of unsampled diversity leading to the Asia 2003 RdRp ancestor is larger
than would be obtained if RdRps associated with other capsid genotypes were also
included. 95% HPD intervals were calculated by combining the posterior distributions
for each subsampled dataset. Pandemic strains are labelled in bold font.
GII.4 strain US95/96 Farmington Asia 2003 Hunter 2004 Yerseke Den Haag Osaka 2007 Apeldoorn New Sydney
Hills 2002 2006 2006 2007 Orleans 2009 2012
US95/96 - 1992 (1989, 1992 (1989, 1992 (1989 1992 (1989, 1992 (1989, 1992 (1989, 1992 (1989, 1992 (1989, 1992 (1989,
1994) 1994) 1994) 1994) 1994) 1994) 1994) 1994) 1994
Farmington - - 1997 (1995, 1996 (1994, 1996 (1994, 1997 (1994, 1994 (1991, 1996 (1994, 1996,1994, 1996 (1994,
Hills 2002 1999) 1998) 1998) 1999) 1996) 1998) 1998) 1998)
Asia 2003 - - - 1996 (1994, 1996 (1994, 1996 (1994, 1994 (1991, 1996 (1994, 1996 (1994, 1996 (1994,
1998) 1998) 1998) 1996) 1998) 1998) 1998)
Hunter 2004 - - - - 2001 (1999, 1997 (1995, 1994 (1991, 1999 (1996, 1999 (1996, 1999 (1996,
2002) 1999) 1996) 2001) 2001) 2001)
Yerseke 2006 - - - - - 1997 (1995, 1994 (1991, 1999 (1996, 1999 (1996, 1999 (1996,
1999) 1996) 2001) 2001) 2001)
Den Haag - - - - - - 1994 (1991, 1997 (1995, 1997 (1995, 1997 (1995,
2006 1996) 2000) 2000) 2000)
Osaka 2007 - - - - - - - 1994 (1991, 1994 (1991, 1994 (1991,
1996) 1996) 1996)
Apeldoorn - - - - - - - - 2004 (2002, 2003 (2002,
2007 2005) 2005)
New Orleans - - - - - - - - - 2004 (2002,
2009 2005)
Sydney 2012 - - - - - - - - - -
Table 3.4: Summary of strain divergence times. The mean divergence time for each pair of
strains in the capsid posterior distribution of trees is shown. The 95% HPD of the
divergence time is shown in parentheses. Pandemic strains are labelled in bold font.
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3.4.3 Pandemic strains diverge into multiple lineages over several
years prior to emergence
We next reconstructed the evolutionary dynamics of the two most recent pandemic
strains, New Orleans 2009 and Sydney 2012, using a larger dataset of P2 domain se-
quences. New Orleans 2009 and Sydney 2012 underwent a large increase in relative
genetic diversity in 2009 and 2012, respectively, coinciding with the time at which they
emerged pandemically and replaced the preceding pandemic strain (Figure 3.3). However,
by the time of the increase in relative genetic diversity, each strain had already diverged
into multiple lineages; approximately 67 lineages (95% HPD 41-100 lineages) in the case
of New Orleans 2009 and approximately 88 lineages (95% HPD 59-113 lineages) in the
case of Sydney 2012 (Figure 3.3). Each of the other pandemic strains also exhibits this
pre-divergence into multiple lineages prior to pandemic emergence, as evidenced by the
occurrence of the strain common ancestor years prior to pandemic onset. However, the in-
terval between common ancestor and emergence is largest for the New Orleans 2009 and
Sydney 2012 pandemics than for the other pandemic strains, a finding that likely reflects
more thorough surveillance from a greater number of countries in recent times. This sug-
gests that the interval between common ancestor and pandemic or epidemic emergence
for other strains is likely to be underestimated. These observations suggest that consid-
erable and long-standing diversity of pandemic and epidemic strains exists within the
hidden populations prior to their pandemic or epidemic emergence.
3.4.4 Recombination in the GII.4 genotype
There are topological differences between the RdRp, capsid and VP2 trees in well
supported regions, indicating substantial recombination close to ORF boundaries (Figures
3.1, 3.4). In addition to the previously reported acquisition of a Den Haag 2006-like VP2
by the Osaka 2007 capsid (Eden et al., 2013), we also find that the Apeldoorn lineage ac-
quired a Yerseke 2006-like VP2 in 2003, prior to diverging into the Apeldoorn 2007, New
Orleans 2009 and Sydney 2012 strains (Figures 3.1, S3.2, Table 3.5). Multiple recom-
bination events have occurred between the RdRp and capsid (Figure 3.4). In agreement
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Figure 3.3: Evolutionary dynamics of New Orleans 2009 and Sydney 2012. Summary of phy-
lodynamic analysis of the P2 domains of New Orleans 2009 (A and C) and Sydney
2012 (B and D). (A and B) MCC tree of the New Orleans 2009 and Sydney 2012
P2 domain datasets as reconstructed using BEAST. (C and D) Bayesian skyline plots
showing the population dynamics of New Orleans 2009 and Sydney 2012 through
time. The solid black line is the median value and the shaded grey area is the 95%
HPD. An increase in Neτ indicates an increase in the relative number of viral infec-
tions and therefore in this case indicates the onset of the pandemic. The red and blue
vertical dashed lines represent the time of the large increase in Neτ for New Orleans
2009 and Sydney 2012, respectively, by which time the strains had diverged into a
large number of lineages.
with previous results, we find that Asia 2003 acquired a GII.P12 RdRp and Osaka 2007
acquired a GII.Pe RdRp (Eden et al., 2013). A common ancestor of the New Orleans 2009
and Sydney 2012 (and possibly the Apeldoorn 2007) strains acquired a Yerseke 2006-like
RdRp in 2004 (95% HPD 2003-2006) (Figure S3.2, Table 3.5). Multiple recombination
events are required to explain the acquisition of RdRp and VP2 regions by the Apeldoorn
2007 lineage capsid (consisting of the Apeldoorn 2007, New Orleans 2009 and Sydney
2012 strains) (Figure S3.2). The Sydney 2012 capsid sequences in our dataset are found
with a New Orleans 2009-like RdRp and a GII.Pe RdRp. At least three independent re-
combination events are required to explain the distribution of the GII.Pe RdRps in the
Sydney 2012 clade in the capsid tree (Figure S3.3). The clustering of the GII.Pe RdRps
in the RdRp and capsid trees indicates the cocirculation of the Sydney 2012 viruses with
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Figure 3.4: Comparison of the temporal evolutionary history of the GII.4 capsid and associ-
ated RdRps. Representations of the capsid (blue) and RdRp (red) trees from Figure
3.1 are shown. Nodes with posterior support less than 0.75 have been collapsed. For
each strain, the boxed area represents the time from the common ancestor of the strain
to the start of the year in which the strain emerged pandemically or epidemically, with
the triangle representing time after the strain has emerged. The pandemic GII.4 strains
are labelled in bold font.
Capsid strain RdRp or VP2 acquired Time of recombination event (95% HPD)
Asia 2003 GII.P12 RdRp March 1999 (March 1996-October 2001)
Osaka 2007 GII.Pe RdRp June 2000 (October 1994-January 2006)
Osaka 2007 Den Haag 2006-like VP2 March 2005 (December 2003-August 2006)
Apeldoorn lineage Yerseke 2006-like VP2 March 2004 (February 2003-April 2005)
Apeldoorn lineage Yerseke 2006-like RdRp July 2004 (January 2003-November 2005)
Sydney 2012 GII.Pe RdRp May 2010 (July 2009-February 2011)
January 2012 (July 2011-May 2012)
February 2012 (August 2011-July 2012)
Table 3.5: Summary of recombination events in the GII.4 lineage. Shown are the dates at
which the capsid gene acquired a new RdRp or VP2. Recombination events were
initially identified on the basis of well-supported topological differences between the
capsid tree and the RdRp or VP2 tree. The date of the recombination event was calcu-
lated from the complete posterior distribution of trees in the corresponding dataset by
identifying the branch along which the recombination event occurred in each tree. Syd-
ney 2012 acquired the GII.Pe RdRp in at least three independent recombination events.
Additional recombination events likely occurred within the Apeldoorn lineage. Further
information on recombination within the Apeldoorn lineage is shown in Figures S3.2
and S3.3.
both GII.P4 New Orleans 2009-like and GII.Pe RdRps, consistent with previous results
(Wong et al., 2013). Importantly, each of the recombination events where the two con-
tributing strains can be identified occurred years prior to the emergence of either of the
contributing strains (Table 3.5).
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3.4.5 Identification of pre-pandemic GII.4 viruses
We next identified publically available pre-pandemic/pre-epidemic sequences, de-
fined here as sequences that cluster with a GII.4 strain but were collected prior to the
year of onset of the respective pandemic or epidemic. We identified 50 putative pre-
pandemic/pre-epidemic sequences that were genotyped as either Farmington Hills 2002,
Hunter 2004, Osaka 2007, New Orleans 2009 or Sydney 2012 (Tables 3.6, 3.7). To
validate whether the reported collection dates for these sequences were plausible, we
estimated the collection date of each sequence using BEAST (Figure S3.4, Tables 3.6,
3.7). The posterior estimate of the collection date overlapped with the reported collec-
tion date for 31 sequences (Figures 3.5, S3.4, Table 3.6). Each of these sequences also
exhibits close to the expected accumulation of nucelotide change given their reported col-
lection date (Figure S3.5). Our analysis therefore supports, but does not confirm, the
reported collection date for these sequences and suggests that these sequences are true
pre-pandemic/pre-epidemic sequences. We therefore find evidence for pre-pandemic se-
quences from the Farmington Hills 2002, Hunter 2004 (Sdiri-Loulizi et al., 2009), New
Orleans 2009 (Eden et al., 2014) and Sydney 2012 (Eden et al., 2014) strains as well as
pre-epidemic sequences from the Osaka 2007 strain (Figure 3.5). Of the 19 sequences
where the reported and estimated collection dates do not overlap, 18 have an earlier re-
ported collection date than that estimated by our analysis (Table 3.7). Possible reasons
for this include mis-reporting of the collection date (most of these sequences are not as-
sociated with a publication and it is therefore not possible to verify the collection date in
primary literature) or sample contamination or mis-labelling.
3.5 Discussion
The suggestion that each of the pandemic GII.4 strains evolved from one of the pre-
vious pandemic or epidemic strains (Siebenga et al., 2007; van Beek et al., 2013) has
recently come into question with the demonstration that New Orleans 2009 and Sydney
2012 diverged from a common ancestor close to the start of the Apeldoorn 2007 epidemic
(Eden et al., 2014). We demonstrate here that this finding can be generalised. None of
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Figure 3.5: Pre-pandemic and pre-epidemic GII.4 sequences. We collected and genotyped all
available norovirus sequences from GenBank and identified 50 GII.4 sequences with a
reported collection date earlier than the year of onset of the pandemic/epidemic caused
by the strain to which the sequence was genotyped. We estimated the collection date
of each of these sequences using BEAST and found 31 sequences where the estimated
collection date overlapped with the reported collection date; this analysis supports, but
does not confirm, the reported collection date for these sequences and suggests that
these sequences are true pre-pandemic/pre-epidemic sequences. The reported collec-
tion date for each of these sequences is shown here as a diamond coloured by the
continent on which the sequence was collected. The putative pre-pandemic Sydney
2012 sequences LC005721.1, LC005722.1, LC005723.1 and LC005724.1 were all
collected in December 2011 in the same study (Kumazaki and Usuku, 2015) (Table
3.6); a single diamond is shown for these four sequences for clarity. The period of
pandemic (purple) or epidemic (blue) circulation is shown for each GII.4 strain. Fur-
ther information on the putative pre-pandemic and pre-epidemic sequences is shown
in Figures S3.4, S3.5 and Table 3.6.
the pandemic GII.4 strains evolved from a previous pandemic or epidemic strain (with
the possible exception of evolving from US95/96); once a GII.4 strain has emerged pan-
demically or epidemically, it does not give rise to any future strains. Instead, the GII.4
phylogenetic trees indicate that future pandemic strains circulate and evolve within one
or more poorly sampled reservoirs containing substantial genetic diversity. For exam-
ple, during the late 1990s when US95/96 was the pandemic strain, we estimate that there
were at least six other distinct lineages of GII.4 capsid present (Farmington Hills 2002,
Asia 2003, Den Haag 2006, Osaka 2007, the Hunter lineage (leading to Hunter 2004 and
Yerseke 2006) and the Apeldoorn lineage (leading to Apeldoorn 2007, New Orleans 2009
3.5. Discussion 119
Accession number Strain Capsid region present Country of collection Reported collection Estimated collection
date date (95% HPD)
EU078408.1 Farmington Hills 2002 Complete USA 2001 2000 (1998-2003)
GU937448.1 Farmington Hills 2002 P domain USA 2000 2000 (1998-2003)
EU916961.1 Hunter 2004 Complete Tunisia 11-January-2003 2004 (2003-2006)
EU916960.1 Hunter 2004 Complete Tunisia 11-September-2003 2003 (2002-2005)
EU916959.1 Hunter 2004 Complete Tunisia 05-April-2003 2004 (2003-2006)
EU916957.1 Hunter 2004 Complete Tunisia 17-October-2003 2004 (2003-2006)
EU876890.1 Hunter 2004 Complete France 2002 2004 (2002-2006)
GQ845367.2 New Orleans 2009 Complete Australia November-2008 2008 (2006-2010)
GQ845345.2 New Orleans 2009 Complete Australia August-2008 2008 (2006-2009)
KR131773.1 New Orleans 2009 Complete India 2008 2009 (2008-2010)
KJ735099.1 Sydney 2012 Missing first 25 AA Morocco 14-September-2011 2011 (2009-2012)
KF509947.2 Sydney 2012 Complete Canada September-2011 2010 (2007-2012)
AB972499.1 Sydney 2012 Complete Japan 2011 2012 (2011-2013)
LC005724.1 Sydney 2012 Complete Japan December-2011 2012 (2010-2014)
LC005723.1 Sydney 2012 Complete Japan December-2011 2011 (2010-2013)
LC005722.1 Sydney 2012 Complete Japan December-2011 2011 (2010-2013)
LC005721.1 Sydney 2012 Complete Japan December-2011 2011 (2010-2012)
LC005720.1 Sydney 2012 Complete Japan November-2011 2012 (2010-2015)
KR904236.1 Sydney 2012 Complete South Africa 19-December-2011 2009 (2006-2012)
KR904215.1 Sydney 2012 Complete South Africa 06-July-2010 2009 (2006-2011)
KR904214.1 Sydney 2012 Complete South Africa 19-May-2010 2009 (2006-2012)
KC962462.3 Sydney 2012 Complete South Africa November-2011 2010 (2007-2013)
KF870711.1 Sydney 2012 AA 299-end Spain Febuary-2011 2010 (2008-2015)
KF668567.1 Sydney 2012 Complete Italy 01-November-2011 2011 (2010-2013)
KF060124.1 Sydney 2012 Complete New Zealand September-2010 2009 (2006-2012)
KF060123.1 Sydney 2012 Complete New Zealand September-2010 2009 (2006-2011)
KF060122.1 Sydney 2012 Complete New Zealand September-2010 2009 (2006-2012)
KX354057.1 Sydney 2012 Complete USA 26-October-2011 2012 (2010-2015)
FJ411171.1 Osaka 2007 Complete USA 2005 2003 (1999-2007)
EU876884.1 Osaka 2007 Complete Egypt November-2006 2004 (2000-2008)
EU876882.1 Osaka 2007 Complete Egypt September-2006 2004 (2000-2008)
Table 3.6: Summary of pre-pandemic and pre-epidemic GII.4 sequences. We collected and
genotyped all available norovirus sequences and identified 50 GII.4 sequences with a
reported collection date earlier than the year of onset of the pandemic/epidemic caused
by the strain to which the sequence was genotyped. We estimated the collection date
of each of these 50 sequences using BEAST. The 31 sequences where the 95% HPD
of the estimated collection date overlaps with the reported collection date were taken
to be true pre-pandemic/pre-epidemic sequences. These sequences are summarised
here. The strain is the strain as genotyped by the norovirus genotyping tool (Kroneman
et al., 2011); all assignments were supported by phylogenetic clustering in a nucleotide
maximum likelihood phylogenetic tree. Note that while the estimated collection date
is given to the year, we compared the estimated and reported collection dates to the
most precise value possible; therefore where the reported collection date was given to
the nearest day or month, the 95% HPD of the estimated collection date overlaps with
that day or month. AA - amino acid.
and Sydney 2012)) that had not yet been sampled. This high diversity present in reser-
voirs is also supported by recombination events between multiple GII.4 strains prior to
their pandemic or epidemic emergence (Table 3.5). Interestingly, our results suggest that
the majority of the diversity that has seeded pandemics and epidemics post-US95/96 had
been generated by the year 2000. As discussed and demonstrated in the previous chapter,
US95/96 was likely the first GII.4 pandemic and the onset of this pandemic likely coin-
cided with GII.4 transitioning from one of a number of relatively low frequency geno-
types to the dominant genotype in the human population (Donaldson et al., 2008, 2010;
Siebenga et al., 2010). This first pandemic therefore likely resulted in a large popula-
tion expansion for GII.4 noroviruses and appears to have resulted in the generation of
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Accession number Strain Capsid region present Country of collection Reported collection Estimated collection
date date (95% HPD)
KU312299.1 Farmington Hills 2002 P2 domain UK 1994 2002 (2001-2004)
EU916958.1 Hunter 2004 Missing first 3 AA Tunisia 02-January-2003 2004 (2003-2005)a
KU182476.1 Hunter 2004 Complete Tunisia 2002 2004 (2003-2006)
KU182477.1 Hunter 2004 Complete Tunisia 2002 2004 (2003-2005)
KU182478.1 Hunter 2004 Complete Tunisia 2002 2004 (2003-2006)
KU182479.1 Hunter 2004 Complete Tunisia 2002 2004 (2003-2006)
KU182480.1 Hunter 2004 Complete Tunisia 2002 2004 (2003-2006)
KU182481.1 Hunter 2004 Complete Tunisia 2002 2004 (2003-2006)
KU182482.1 Hunter 2004 Complete Tunisia 2002 2004 (2003-2006)
KU182483.1 Hunter 2004 Complete Tunisia 2002 2004 (2003-2006)
KU312301.1 Hunter 2004 P2 domain UK 1995 2004 (2002-2007)
KU312302.1 Hunter 2004 P2 domain UK 1995 2004 (2002-2006)
KU312303.1 Hunter 2004 P2 domain UK 1995 2004 (2002-2007)
AB972505.1 Sydney 2012 Complete Japan 2011 2013 (2012-2014)
AB972504.1 Sydney 2012 Complete Japan 2011 2013 (2012-2014)
AB972503.1 Sydney 2012 Complete Japan 2011 2013 (2012-2015)
AB972502.1 Sydney 2012 Complete Japan 2011 2013 (2012-2014)
KU312300.1 Sydney 2012 P2 domain UK 1994 2013 (2011-2015)
FJ411172.1 Osaka 2007 Complete USA 2006 2001 (1997-2004)
Table 3.7: Summary of putative pre-pandemic and pre-epidemic sequences where the re-
ported collection date was not supported by phylogenetic analyses. We collected
and genotyped all available norovirus sequences and identified 50 GII.4 sequences
with a reported collection date earlier than the year of onset of the pandemic/epidemic
caused by the strain to which the sequence was genotyped. We estimated the collection
date of each of these 50 sequences using BEAST. The 19 sequences where the 95%
HPD of the estimated collection date does not overlap with the reported collection
date were not taken to be pre-pandemic/pre-epidemic sequences. Rather, we suggest
that the collection date for these sequences was likely mis-reported or that the samples
were contaminated or mislabelled. These sequences are summarised here. While the
estimated collection date of 18 of these sequences is later than the reported collection
date, the estimated collection date of sequence FJ411172.1 is earlier than the reported
collection date. The strain is the strain as genotyped by the norovirus genotyping tool
(Kroneman et al., 2011); all assignments were supported by phylogenetic clustering in
a nucleotide maximum likelihood phylogenetic tree. a The 95% HPD of the estimated
collection date of sequence EU916958.1 does not overlap with the reported collection
date to the level of the day. AA - amino acid.
a high level of diversity within a short space of time. Multiple studies have suggested
that different pandemic strains may infect different sections of the human population via
interactions with different HBGA receptors (Lindesmith et al., 2008; Donaldson et al.,
2008). It will be interesting in the future to test the HBGA-binding profile of ancestral
viruses from each of the lineages that diverged in the late 1990s to determine whether this
rapid generation of diversity may have been driven by adaptation of different lineages to
different HBGA-binding niches and therefore different parts of the human population.
From our observations, two questions arise. First, what drives a strain that has been
circulating undetected for many years to spread rapidly, cause global outbreaks and re-
place the previous pandemic strain. Second, where are what are the reservoirs in which
future pandemic strains spread and diversify but remain undetected? Our results suggest
that the emergence of a new pandemic GII.4 strain occurs in three stages (Figure 3.6).
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The predivergence into multiple lineages over years prior to the pandemic suggests that
the mutations and/or recombination events required for pandemic spread (e.g. for evasion
of herd immunity) occur years prior to pandemic spread, as otherwise the same change
would need to occur independently many times. Therefore we predict that pandemic
strains acquire all of the genetic changes necessary to cause a future pandemic while they
are circulating within the unsampled reservoir population (stage 1). The pre-pandemic
strains continue to diversify within these reservoirs (stage 2), resulting in multiple lin-
eages containing the important pandemic-enabling changes. During this diversification,
the strain may remain within a single geographical reservoir or may undergo limited
spread to multiple geographically distinct reservoirs (Figure 3.6). Finally, the related
lineages emerge concurrently, spreading rapidly to cause the new pandemic and replacing
the previous pandemic strain (stage 3). While we have depicted these stages as discrete
time steps, in reality the acquisition of changes and diversification is likely a continuous
process, with many low level viruses being in stages 1 and 2 at any point in time.
While viral genetic changes are vital for pandemic emergence, their occurrence mul-
tiple years before pandemic spread indicates that these changes are not the proximate
driver of the new pandemic, in constrast with previous suggestions (Eden et al., 2014).
Rather, viral genetic changes enable the strain to emerge as a pandemic in the future.
Given the very high number of GII.4 norovirus cases annually (Kirk et al., 2015; Pires
et al., 2015; Lopman et al., 2016), it is very unlikely that stochastic factors could drive
the emergence of a large number of lineages of one strain of one genotype. Similarly, it is
hard to conceive of an event or set of environmental factors that could be responsible for
this emergence. We therefore suggest that the emergence of a new pandemic GII.4 strain
is most likely to be driven by a change in the host population. Given current evidence
of the importance of herd immunity in GII.4 strain emergence (Lindesmith et al., 2008,
2012a; Debbink et al., 2013), we hypothesise that growing herd immunity against the pre-
vious pandemic strain may open a niche into which multiple lineages of the new strain can
emerge. We therefore hypothesise that it is changes in the host immunity profile, rather
than changes in the virus, that are the drivers of norovirus pandemic emergence. In the
future, mathematical models incorporating viral antigenicity and transmission will be key
to provide support for this hypothesis.
Multiple studies have suggested immunocompromised patients as a potential reser-
122 Chapter 3. Identifying the sources and drivers of norovirus pandemics
Diversification Reservoir of GII.4 strains 
Acquires 
changes 
Diversification in 
a single reservoir 
region 
Onward spread 
of multiple 
lineages from 
single reservoir 
Transmission 
Infection 
2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 
Acquisition of changes Pandemic spread 
Acquires 
changes 
Spread to and diversification in 
multiple geographically distinct 
reservoirs 
Onward spread 
from multiple 
reservoirs 
A 
B 
Figure 3.6: Three stage emergence of new pandemic GII.4 strains. The strain that will emerge
as a pandemic is a component of an unsampled reservoir of GII.4 strains. The pan-
demic emergence of the new strain occurs in three stages. In the first stage, the strain
acquires the genetic changes that will be essential for it to spread pandemically, with
example changes shown in blue in the capsid P2 domain (PDB structure 2OBR). This
acquisition occurs years prior to emergence, leaving the strain pre-adapted for future
spread. In the second stage, the strain continues to diversify within the reservoir or
reservoirs resulting in multiple lineages that share the pre-adaptation. The strain at
this stage may be within a single reservoir region (A) or may undergo limited spread
to multiple geographically distinct reservoir regions (B). Multiple lineages that share
the pre-adaption then emerge concurrently in stage 3. Here, the three stages of strain
emergence are shown with reference to the Sydney 2012 phylogenetic tree in Fig-
ure 3.3B. The red lineages that branch from the root of the Sydney 2012 tree did not
persist and do not contain changes that have been suggested to be important for the
pandemic emergence of Sydney 2012 (Debbink et al., 2013; Allen et al., 2014).
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voir for GII.4 viruses due to the diverse viral population often found in these patients
(Debbink et al., 2014; Vega et al., 2014b; Karst and Baric, 2015). There is also evi-
dence of GII.4 infection of swine, cattle (Mattison et al., 2007) and dogs (Summa et al.,
2012; Caddy et al., 2015), suggesting the possibility of an animal reservoir. Both of these
options are possible. However, a single immunocompromised patient cannot be the reser-
voir for a new strain due to the diversification of the virus into multiple lineages prior to
emergence and it is difficult to explain how immunocomprised patients could form the
interconnected transmission network required for this strain diversification. Similarly, the
emergence of the multiple lineages concurrently from an animal reservoir would require
a large number of zoonotic transmissions at the onset of the pandemic; no such trans-
missions have yet been observed. Instead we propose that the future pandemic/epidemic
strains are likely to circulate undetected in the human population in either the community
or in undersampled geographical regions for at least several years prior to their emer-
gence as a new pandemic, even if they initially arise in an immunocompromised patient
or animal reservoir. While a recent study by Allen et al detected multiple pandemic GII.4
strains in community cases of sporadic diarrhoea in the UK 8-18 years before their emer-
gence as a pandemic (Wheeler et al., 1999; Allen et al., 2016), our phylogenetic analysis
did not support the reported collection dates for these sequences (Table 3.7). However,
we do identify pre-pandemic sequences from the Farmington Hills 2002, Hunter 2004,
New Orleans 2009 and Sydney 2012 pandemic strains, as well as pre-epidemic sequences
from Osaka 2007 (Figure 3.5, Table 3.6). Interestingly, there are more pre-pandemic se-
quences from the Sydney 2012 pandemic strain compared with the other strains (Figure
3.5), correlating with increased and more widespread surveillance in recent times. It is
interesting, however, that pre-pandemic samples of Hunter 2004 and Sydney 2012, as
well as pre-epidemic sequences from Osaka 2007, have been identified in Africa, despite
this region only being sparsely sampled (Sdiri-Loulizi et al., 2009; Kamel et al., 2009;
Mans et al., 2016). Capsid sequences that fail to cluster within any of the major GII.4
strains have also been described, a feature that would be expected if Africa were a GII.4
reservoir (Mans et al., 2015, 2016). Importantly, current norovirus surveillance focuses
on sequencing of outbreak strains, predominantly in hospital and institutional settings
in middle and high income countries, a strategy that would miss community and low-
income-country reservoirs. The majority of norovirus sampling is currently carried out
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in outbreak settings, with few studies examining norovirus in the community (Inns et al.,
2017). However, the studies of Infectious Intestinal Disease (IID1 and IID2) in the UK
suggested norovirus is highly prevalent in community settings (Tam et al., 2012; Harris
et al., 2017). It is therefore possible that the community could function as a reservoir of
norovirus strains and could also be the location of the diversification we observe prior to
emergence (Figure 3.6).
Our results suggest that the GII.4 strains that will become pandemic in the future are
already circulating at low level, and may already be in their pandemic form. If regions
of early circulation can be identified, it may be possible to identify strains currently at
low level that are antigenically distinct from the currently dominant strain and therefore
identify strains that have the potential to become pandemic in the future. Phylogeographic
studies may identify the reservoir regions in which pre-pandemic circulation occurs and
determine whether there is a single geographical reservoir, as has been demonstrated for
for influenza A H3N2 (Bedford et al., 2015), or whether strains circulate widely prior
to emergence. We employ a phylogeographic analysis to assess the potential for source
regions in chapter 4. Recombination events occurring between multiple GII.4 strains
years prior to the emergence of either strain (Table 3.5) argue for a single reservoir region
as these recombination events require coinfection of individual patients with multiple low
level strains. Alternatively, these viruses may come into contact during food or waterborne
infections as these can be contaminated with multiple viruses (de Graaf et al., 2016).
Our hypothesis that new pandemics are not driven by viral genetic changes but by
changes in host immunity represents a shift in our understanding of the drivers of new
pandemics. We have discussed the importance of our results in developing surveillance
strategies for the detection of new pandemic strains, but these results also have impli-
cations for the design of vaccines. Under the previous hypothesis where new pandemic
strains typically evolve from previous pandemic strains, a vaccine targeting the current
pandemic may help prevent future pandemics. If, however, the emergence of a new pan-
demic is driven by changes in host immunity, the targeting of a vaccine against the current
strain may have the paradoxical effect of hastening the next pandemic. Therefore under
our hypothesis it is essential that norovirus vaccines provide broad immunity against GII.4
noroviruses.
Chapter 4
Characterisation of global circulation
and important substitutions for
norovirus pandemics
4.1 Abstract
In the previous chapter, we suggested a three stage process of pandemic GII.4 strain
emergence where the strain acquires the genetic changes that will be important for pan-
demic spread years prior to the pandemic and then undergoes diversification into multiple
pre-adapted lineages that emerge concurrently to cause the pandemic. Here, we carry
out phylogeographic analyses and demonstrate that the New Orleans 2009 and Sydney
2012 pandemic strains circulated widely and consistently during the diversification phase
of strain emergence. We find no evidence for a single source region for pandemic GII.4
strains, but instead suggest that strains undergo low level worldwide spread over several
years prior to the pandemic. At the onset of the pandemic strains therefore emerge from
multiple geographical regions, strengthening our previous suggestions that strain emer-
gence is driven by changes in host factors. We carry out an analysis of amino acid change
to identify nonsynonymous substitutions that occurred leading to each of the pandemic
GII.4 strains and resulted in a different amino acid residue(s) to that in the preceding pan-
demic strain, thereby identifying potential pandemic-enabling substitutions. We demon-
strate that a high level of amino acid diversity exists within each of the pandemic GII.4
strains and that sites of diversity often coincide with epitope sites and/or HBGA-binding
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sites. This suggests that viruses within a pandemic strain may exhibit subtly different
phenotypes. In New Orleans 2009 and Sydney 2012, this diversity began to be accumu-
lated prior to the pandemic emergence of the strains. These results strongly suggest that
viruses within each pandemic strain share one or more phenotypic characteristics that are
acquired by the strain root node and are vital to enable pandemic emergence. We extend
our three stage model of strain emergence to suggest that strains move to a new region
of antigenic space in the acquisition of changes phase and then undergo local movements
within this new region of antigenic space in the diversification phase. We hypothesise
that changes in host immunity enable each of the lineages within this region of antigenic
space to emerge at the onset of the new pandemic.
4.2 Introduction
In the previous chapter, we provided evidence that each of the pandemic GII.4 strains
circulated within one or more hidden reservoir populations for years prior to causing their
respective pandemic. We demonstrated that each pandemic strain diverged into multiple
lineages over years prior to pandemic onset, indicating that the genetic changes essential
for pandemic spread are acquired years prior to the pandemic. Our results are supported
by the detection of multiple pandemic strains in sporadic cases and outbreaks of gas-
troenteritis over several years prior to pandemic emergence (Sdiri-Loulizi et al., 2009;
Siebenga et al., 2009) and by publically available putative ‘pre-pandemic’ sequences, the
validity of which we established in the previous chapter (Figure 3.5, Table 3.6). These
data raise the questions of where pandemic strains circulate during the years prior to
pandemic spread and why we do not regularly observe these strains over the years prior
to their emergence. Extensive studies on influenza have demonstrated that epidemic in-
fluenza A H3N2 strains originate in South East Asia (Bedford et al., 2015), from where
they are spread worldwide via airplane travel (Lemey et al., 2014). In contrast, no consis-
tent source region has been observed for influenza A H1N1 or influenza B, with multiple
continents acting as source regions for new viral lineages (Bedford et al., 2015). Previous
studies examining norovirus diversity have suggested Africa to harbour a particularly di-
verse norovirus population, with this high diversity being correlated with the broad range
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of HBGAs expressed by different individuals on this continent (Nordgren et al., 2013,
2016). However, this high diversity is defined as the presence of a large range of different
genotypes, rather than as a high diversity of different GII.4 variants. GII.4 sequences that
do not cluster within any of the main GII.4 strains have been identified in Africa (Mans
et al., 2016), despite this region only being sparsely sampled, and this is a characteristic
that would be expected of a reservoir region. Additionally, the Hunter 2004 and Sydney
2012 strains were identified in Northern and Southern Africa, respectively, prior to their
pandemic emergence (Sdiri-Loulizi et al., 2009; Mans et al., 2016). However, norovirus
prevalence is high in all countries worldwide and with the potential for very rapid trans-
mission and links between distant locations via airplane travel and the global food trade,
transmission can in theory occur between even distant locations very quickly (de Graaf
et al., 2016) and therefore any region could potentially act as a source.
Previous studies have identified individual amino acid changes that alter antigenicity
and may have had a role in strain emergence (Lindesmith et al., 2012a; Debbink et al.,
2013). For example, the A368E, N373H and G393S substitutions were suggested to be
important for the pandemic emergence of Sydney 2012 (Debbink et al., 2013; Allen et al.,
2014). However, these studies have typically employed single viruses as representatives
of each strain and the conservation of antigenic sites within individual pandemic strains
is largely unexplored. Should antigenic sites vary within a pandemic strain, the examina-
tion of a single viral sequence cannot result in an accurate picture of strain antigenicity,
particularly because different viruses from the same pandemic strain can have different
properties (Lindesmith et al., 2008; Debbink et al., 2014). The genetic changes that are
essential for the emergence of a pandemic strain are likely those acquired leading to the
common ancestor of the strain, as these changes differentiate the viruses within that pan-
demic cluster from those in other, closely related, clusters that did not cause a pandemic
at that point in time. Crucially, our phylogenetic analysis in the previous chapter strongly
suggested that the GII.4 strain that emerges to cause a new pandemic is one of a number
of low level strains present at that point in time.
Here, we employ phylogeographic methods to trace the spatiotemporal history of the
New Orleans 2009 and Sydney 2012 pandemic strains. We demonstrate that each of these
strains circulated widely across multiple continents over several years prior to pandemic
emergence. There is therefore no evidence for a consistent source region from which
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pandemic GII.4 strains emerge and spread. This suggests that environmental factors are
very unlikely to drive emergence of new pandemic strains and strengthens our previous
suggestion that pandemics are caused by a change in host factors. After the emergence
of the pandemic, viruses tend to persist within a continent for long periods of time with
a low inter-continental transmission rate, consistent with individuals with symptomatic
norovirus infection being unlikely to travel long distances. We show that there is a high
level of amino acid diversity within each of the pandemic GII.4 strains and that variable
sites often coincide with known epitope sites and/or HBGA-binding regions. It is there-
fore likely that viruses within a pandemic strain exhibit subtle phenotypic differences.
However, viruses within a pandemic strain are likely to exhibit one or more unifying and
important phenotypic characteristics. We highlight sites that potentially determine these
characteristics by identifying the substitutions that occurred leading to each of the pan-
demic GII.4 strains. Together, our results suggest extensions to the three stage process
of pandemic GII.4 strain emergence proposed in the previous chapter whereby the pre-
pandemic strain moves to a new region of antigenic space in the acquisition of changes
phase and then circulates widely and acquires subtle antigenic diversity during the diver-
sification phase prior to emerging to cause the new pandemic.
4.3 Materials and Methods
4.3.1 Phylogeographic analyses
We collected datasets containing all of the available capsid sequences on GenBank as
of 09/02/2017 for the two most recent pandemic strains, New Orleans 2009 and Syd-
ney 2012. We retained sequences that contained the P2 domain only, as this region is
typically highly variable providing phylogenetic signal, but did not retain sequences con-
taining only a small region of the shell domain, as this region is typically conserved and
therefore contains little phylogenetic signal. We also removed sequences for which no
collection date could be obtained and sequences that were overly divergent based on their
sampling date. Sequences overly divergent based on their collection date may contain
sequencing errors or have an incorrectly classified date and can therefore mislead tem-
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poral evolutionary analyses (Rambaut et al., 2016). There were 565 sequences in the
New Orleans 2009 dataset and 708 sequences in the Sydney 2012 dataset. Each dataset
exhibited a correlation between root to tip distance and sampling date in a maximum like-
lihood phylogenetic tree reconstructed using RAxML (Stamatakis, 2014) with the GTR
model of nucleotide substitution and gamma rate heterogeneity with four gamma classes.
We assessed topological robustness with 1000 bootstrap replicates. Examination of the
sampling locations showed that there was typically only a small number of sequences
sampled from each country (Table 4.1). We therefore used the continent of collection as
the label for each sequence. Labelling each sequence with the continent of collection will
enable us to determine the broad location of the virus and the broad patterns of spread
while maximising the number of sequences with each label. The Sydney 2012 dataset
contains many more sequences from Asia compared with the other continents, while the
New Orleans 2009 dataset contains a large number of sequences from Asia and Oceania
relative to the other continents (Table 4.1). Should sequences from the same continent
typically cluster, continents with more intense sampling are unlikely to artifactually influ-
ence estimates of ancestral locations. However, if sequences from different continents are
typically interspersed within the tree, an excess of sequences from one continent is likely
to artifactually increase support for that continent at ancestral nodes. To assess the cluster-
ing of sequences from each continent, we used a maximum likelihood tree for each strain
reconstructed with RAxML as above (Figure 4.1). The Sydney 2012 sequences from
Asia and the New Orleans 2009 sequences from Asia and Oceania are spread throughout
the respective trees, suggesting the more intense sampling in these regions may alter the
estimations of ancestral locations. We therefore randomly subsampled 115 of the Syd-
ney 2012 Asia sequences and 95 of each of the New Orleans 2009 Asia and Oceania
sequences (with 115 and 95 chosen to match the number of sequences from the next most
prevalent region in the respective strain dataset). We carried out three random subsamples
and performed all analyses on each of the subsampled datasets. Results were insensitive
to the subsampled dataset.
We used the Markov chain Monte Carlo approach implemented in BEAST v2.4.2
(Bouckaert et al., 2014) to reconstruct the phylogeographic history of New Orleans 2009
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Country Number of Number of Continent
New Orleans 2009 Sydney 2012
sequences sequences
Albania 1 0 Europe
Australia 144 56 Oceania
Bangladesh 8 4 Asia
Brazil 65 0 South America
Canada 6 6 North America
China 21 234 Asia
Denmark 15 23 Europe
France 1 7 Europe
Germany 0 11 Europe
Hungary 1 0 Europe
India 10 3 Asia
Italy 10 4 Europe
Japan 44 87 Asia
Morocco 0 1 Africa
Netherlands 2 2 Europe
New Zealand 0 32 Oceania
Russia 8 2 Europe
Singapore 16 0 Asia
Slovenia 0 56 Europe
South Africa 18 16 Africa
South Korea 29 6 Asia
Spain 5 3 Europe
Sweden 12 0 Europe
Taiwan 16 27 Asia
UK 19 0 Europe
USA 89 109 North America
Vietnam 26 7 Asia
Continent Number of Number of
New Orleans 2009 Sydney 2012
sequences sequences
Africa 18 17
Asia 170 368
Europe 74 108
North America 95 115
Oceania 144 88
South America 65 0
Table 4.1: Summary of sequence countries and continents in the New Orleans 2009 and Syd-
ney 2012 datasets. The number of sequences from each country and from each con-
tinent are shown within the New Orleans 2009 and Sydney 2012 datasets. The Asia
and Oceania sequences within the New Orleans 2009 dataset and the Asia sequences
within the Sydney 2012 dataset were subsampled to create the respective phylogeo-
graphic datasets.
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Figure 4.1: Interspersion of seqeunces from each continent in New Orleans 2009 and Sydney
2012. Maximum likelihood trees were reconstructed for the New Orleans 2009 and
Sydney 2012 strains. Tips are coloured by the continent on which the sequence was
collected. Sequences from different continents are interspersed within each strain.
The scale bar represents the expected number of nucleotide substitutions per site.
and Sydney 2012. Sequences were labelled with the most accurate collection date possi-
ble; the day of collection if available, the middle of the month of collection if the sampling
day was not available and the middle of the year of collection if the month of sampling
was not available. We modelled the nucleotide substitution process using the HKY substi-
tution model with amongst site rate variation accomodated with gamma rate heterogeneity
with 4 gamma classes. We applied the strict and relaxed lognormal clock models to test
for variation in the substitution rate within each clade. In each case, there was strong
support to reject a strict clock model in favour of a relaxed lognormal clock model (log10
Bayes factor 66-83) and we therefore used the relaxed lognormal clock model for our
inferences. However, the results with the strict clock model are qualitatively very similar,
suggesting that potential over-parameterisation due to the large number of branch-specific
rate parameters with the relaxed lognormal clock model has not influenced the results. We
used a lognormal distribution as the prior on the substitution rate with mean 7x10-3 for
New Orleans 2009 and 6.4x10-3 for Sydney 2012 and standard deviation 0.1 in each case.
The mean value was set to the mean posterior estimate of the strain substitution rate from
our previous analyses (chapter 3.3.6) and the standard deviation was set to incorporate
the 95% HPD of our previous estimate. We used a Bayesian coalescent skyline tree prior
for each dataset. We applied a discrete phylogeographic model to describe lineage migra-
tions within each dataset (Lemey et al., 2009). The model includes a symmetric transition
matrix for the migration rates, where the rate of migration from location A to location B
is the same as that from location B to location A. Relaxation of this constraint will be dis-
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cussed below. Each of the parameters within the location transition matrix had a Bayesian
stochastic search variable selection (BSSVS) indicator variable, enabling each rate to be
either ‘on’ or ‘off’. We set the prior on the number of on rate classes to a Poisson prior
with mean 5 for the New Orleans 2009 datasets and mean 4 for the Sydney 2012 datasets,
which places 50% of the prior probability on the smallest possible number of location
transitions and places high prior probability on a small number of transition rates being
on. We assumed an exponential prior with mean 1.0 migration event per lineage per year
for the overall rate of geographical transition, and a gamma prior with shape 1.0 and scale
1.0 to each of the relative geographical transition rates in the rate matrix. Three replicate
runs were carried out on each dataset with different starting parameters and were run until
convergence, as assessed in Tracer v1.6. Runs were combined using LogCombiner v2.2.1
after removal of sufficient burnin and subsampled to obtain between 1500 and 2500 trees
which formed the posterior distribution. The MCC tree was identified using TreeAnno-
tator v2.2.1. Bayesian skyline plots were reconstructed for each strain using Tracer v1.5.
We carried out additional runs with New Orleans 2009 without subsampling to compare
the length of sample persistence. The models and priors used for these runs were the same
as those for the subsampled datasets.
We identified the date of first import into each continent by calculating either the
date of the root node if the continent was inferred as the root location or the date of the
earliest branch midpoint where the downstream node was inferred to be within the conti-
nent. We calculated this date for each continent in each tree in the posterior distribution
and calculated the median and 95% HPD of each distribution. We obtain similar results
when using the date of the earliest non-root node inferred to be within the continent (i.e.
when assuming that the import event occurred at the end of the branch). We used the
program posterior analysis of coalescent trees (PACT) v0.9.4 to compute the proportion
of viral lineages on each continent through time, the length of persistence of viral lineages
within each continent (measured as the average length of time each virus takes to leave
its sampled location walking backwards from the tip of the tree), the total and annual mi-
gration rates and the proportion of lineages sampled on each continent that were present
on each continent going back in time. In each case, estimates were based on the complete
posterior distribution of trees.
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To identify connected continents, we carried out a Bayes factor test as implemented
in SPREAD v1.0.7. Briefly, this test calculates the support for a rate (in our case a sym-
metric rate) contributing to viral migration by calculating the ratio between the posterior
odds of the rate being non zero divided by the prior odds of the rate being non zero. We
considered migration rates with Bayes factor support greater than three of being non zero
to be well supported (Lemey et al., 2009). We assessed whether New Orleans 2009 and
Sydney 2012 have similar global connectivity networks by measuring the Spearman rank
correlation coefficient of the migration rates between pairs of continents that are present
in each strain dataset.
To determine whether each continent acted as a source or sink of viral lineages, we
combined the posterior distribution of trees for each subsampled dataset into a single
posterior distribution and counted the total number of import events into the continent
and the total number of export events from the continent in each tree in the posterior
distribution. We used the ratio of export to import events as a measure of whether each
continent donated or received more viral lineages.
4.3.2 Examination of the Sydney 2012 Bayesian skyline plot
To determine whether the two stage increase in the Sydney 2012 Bayesian skyline plot
may have been influenced by the addition of the phylogeographic model, we ran BEAST
v2.4.2 on the Sydney 2012 subsampled dataset 1 without the inclusion of the phylogeo-
graphic model. The other models and priors used were the same as for the phylogeogra-
phy runs described above, but the sampling locations of each sequence and inference of
ancestral locations were not included in the model.
We examined the Bayesian skyline plot at each sampled step in the MCMC chain
of the Sydney 2012 subsampled dateset 1 relaxed lognormal clock runs. The two stage
increase in relative genetic diversity evident in the Sydney 2012 Bayesian skyline plot
could be caused by each sample from the MCMC chain exhbiting this two stage increase
or by different sampled steps supporting an increase in relative genetic diversity at dif-
ferent points in time. We therefore divided the MCMC steps into two groups based on
whether the first increase in relative genetic diversity (here defined as an increase of more
than 100% relative to the population size in the first time slice) occurred before or after
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1st January 2012. We reconstructed Bayesian skyline plots for each of these groups us-
ing Tracer v1.5. We identified parameters exhibiting a significant difference between the
groups using a two sample Kolmogorov Smirnov test.
4.3.3 Identification of potential pandemic enabling substitutions and
examination of diversity within GII.4 strains
To identify genetic changes that likely occurred leading to each strain common ancestor,
we used the dataset assembled in chapter 2.3.1 containing 2198 GII.4 capsid sequences
across all GII.4 strains. We used the nucleotide maximum likelihood phylogenetic tree re-
constructed using RAxML (Stamatakis, 2014) and ten bootstrap tree topologies obtained
in chapter 2.3.1 for this analysis. Branch lengths within each tree were optimised using
the amino acid alignment and the WAG substitution matrix with optimised base frequen-
cies in chapter 2.3.1. In chapter 2.3.1, we also carried out ancestral reconstruction in
each tree at the amino acid level using PAML v4.9 (Yang, 2007). We identified the non-
synonymous substitutions that occurred leading to each pandemic strain by identifying
the substitutions that occurred leading to each strain common ancestor in the maximum
likelihood tree and each of the bootstrap tree topologies.
Strain-specific datasets were assembled to contain all of the available capsid se-
quences for the strain as of 09/02/2017. Viruses were removed if they contained only
a small region of the shell domain but retained if they only contained the P2 domain.
The sequences from each strain were aligned at the amino acid level using MUSCLE. We
reconstructed a nucleotide maximum likelihood phylogenetic tree for each strain using
RAxML (Stamatakis, 2014) as above.
For each site inferred to change along the branch leading to a pandemic strain, we cal-
culated the amino acid distribution at this site in that pandemic strain and in the previous
pandemic strain. This distribution was calculated using the alignment from the respec-
tive strains and so does not take into account the phylogenetic relationships between se-
quences. The amino acid conservation at each site was also examined using the coloured
trees technique, where each tip in the phylogenetic tree is coloured by the amino acid
residue in that sequence at the amino acid site of interest. This technique visualises the
distribution of amino acids at a single site and enables determination of whether genetic
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changes likely occurred on a single occassion, with sequences with the genetic change
sharing a common ancestor, or whether there have been multiple independent changes at
the site. Homology models were reconstructed for each strain common ancestor and the
upstream node using SWISS-MODEL (Bordoli et al., 2008; Biasini et al., 2014). The
upstream node was defined as the sequence of the strain common ancestor with each of
the substitutions inferred to have occurred leading to the strain common ancestor incor-
porated. As each of the currently available GII.4 capsid structures consists of only the P
domain, we only used the P domain of the reconstructed sequences in the structural mod-
elling. The best fitting template structure was identified using SWISS-MODEL and this
single structure was used as the template for homology modelling. Structural analyses
were carried out using PyMol v1.74. To visualise residue properties we coloured each
residue based on its hydropathy score in the Kyte and Doolittle scale (Kyte and Doolit-
tle, 1982), with more polar residues being shown in blue and more hydrophobic residues
being shown in red.
Variable sites were initially identified using the coloured trees technique. Coloured
trees were created for each amino acid site in each strain using the capsid strain phy-
logeny. Variable sites were identified as those sites that exhibited either different amino
acid residues in different large clades within the strain or that required multiple nonsyn-
onymous substitutions to explain the distribution of amino acids across the tree at that site.
We also used Shannon’s entropy to quantify the diversity at each amino acid site in the
alignment. The sites identified as highly variable via examination of coloured trees were
consistently the sites with the highest Shannon’s entropy. As Shannon’s entropy does not
take the structure of the phylogenetic tree into account, it is possible to obtain compara-
ble diversity estimates from situations requiring vastly different numbers of changes to
explain the pattern of residues within the coloured trees. Variable sites, epitope regions
(Lindesmith et al., 2012a) and HBGA binding sites (Cao et al., 2007; Singh et al., 2015)
were mapped onto the Sydney 2012 P domain structure 4WZT (Singh et al., 2015), which
is bound to HBGA type A.
To calculate the diversity at each variable site in New Orleans 2009 and Sydney 2012
through time, we used the MCC tree from the phylogeographic analysis of that strain. We
optimised branch lengths within the strain using the amino acid alignment and the WAG
substitution matrix with optimised base frequencies using RAxML (Stamatakis, 2014).
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We carried out ancestral reconstruction using PAML. The amino acid residue at each site
of interest was mapped onto the MCC nucleotide temporally resolved tree as a ‘location’
label and PACT v0.7.4 was used to reconstruct the proportion of lineages with each amino
acid residue through time, as with the geographical location labels described above.
4.4 Results
4.4.1 The two most recent pandemic GII.4 strains circulated widely
over several years prior to pandemic emergence
Our results in chapter 3 suggested that each of the pandemic GII.4 strains were present
for years prior to causing their respective pandemics. We investigated where the two most
recent pandemic GII.4 strains, New Orleans 2009 and Sydney 2012, circulated over the
years prior to their pandemic emergence using a phylogeographic analysis (Figure 4.2).
The common ancestors of New Orleans 2009 and Sydney 2012 occurred approximately
four and seven years prior to pandemic emergence (Figure 4.2), respectively, although
as previously discussed it is possible that the true common ancestors of these strains oc-
curred significantly earlier. It is well supported that both strains were imported into each
continent prior to the onset of their respective pandemic (Figure 4.3 panels A and B). New
Orleans 2009 was likely imported into Africa, Asia and Oceania more than two years prior
to the onset of the pandemic, with introduction into North America roughly one year prior
to the pandemic onset and into Europe and South America several months prior to pan-
demic onset. Sydney 2012 was likely imported into Africa, Europe and Oceania more
than four years prior to the pandemic onset and into Asia and North America two years
or more prior to pandemic onset. These dates, in particular for Sydney 2012, have large
confidence intervals on the lower bound of importation due to uncertainty regarding the
location of the virus close to the root of tree, likely due to the large time interval between
the root and the collection dates of the first viruses to be sampled in each strain. After
initial introduction into a continent, it is well supported that New Orleans 2009 and Syd-
ney 2012 continued to circulate within that continent up until the time of pandemic onset
and throughout the period in which sequences are available from that continent during the
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Figure 4.2: Spatiotemporal evolutionary history of New Orleans 2009 and Sydney 2012.
Temporal and location resolved MCC trees are shown for the New Orleans 2009 and
Sydney 2012 pandemic strains, as reconstructed with BEAST. Branches are coloured
by continent. The vertical dashed lines represent the date of the onset of the respective
pandemic.
pandemic (Figure 4.3 panels C and D). These results suggest that New Orleans 2009 and
Sydney 2012 circulated widely and consistently over several years prior to pandemic on-
set, despite the respective Bayesian skyline plots suggesting each strain was at low level
during this period (Figure 4.3 panels C and D).
The Sydney 2012 Bayesian skyline plot exhibits a two stage increase in relative ge-
netic diversity, with an initial increase in early 2011 followed by another increase in early
2012 coinciding with the onset of the Sydney 2012 pandemic (Figures 4.3, 4.4). This
population history may indicate that Sydney 2012 emerged in a two stage process. This
two stage increase is not due to the inclusion of the phylogeographic model, as we ob-
serve the same results with the same dataset without including the phylogeographic model
(Figure 4.4). Indeed, this two stage increase was also evident in our previous Sydney
2012 Bayesian skyline plots (Figure 3.3), although the phylogeographic dataset exhibits
a greater increase in relative genetic diversity in the first stage compared with our pre-
vious analysis. We examined the skyline of each sampled step in the MCMC chain and
identified two major patterns in the relative genetic diversity through time. Most sampled
steps (roughly 75%) exhibit a two stage increase in relative genetic diversity, as is the
case in the Bayesian skyline plot calculated on all MCMC chain samples (Figure 4.4).
We therefore defined this pattern as scenario 1. A smaller number of sampled steps ex-
hibit a single increase in relative genetic diversity in 2012, coinciding with the time of
the second increase in scenario 1 (Figure 4.4). We defined this pattern as scenario 2. The
138 Chapter 4. Characterising global circulation and pandemic-enabling substitutions
0
10
20
30
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Time
M
ed
ian
statistic
pro_Africa
pro_Asia
pro_Europe
pro_NorthAmerica
pro_Oceania
0
10
20
30
40
50
2007 2008 2009 2010 2011 2012 2013 2014 2015
Time
M
ed
ian
statistic
pro_Africa
pro_Asia
pro_Europe
pro_NorthAmerica
pro_Oceania
pro_SouthAmerica
0
2
4
6
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Median
St
ar
t
0
2
4
6
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Median
Sta
rt
Import date Import date 
2004 2006 2008 2010 2012 2002 2004 2006 2008 2010 2012 2014 
South America 
Oceania 
Africa 
Asia 
North America 
Europe 
Oceania 
Africa 
Asia 
North America 
Europe 
A B 
Relative genetic 
diversity, Neτ 
Date 
0 
10 
20 
30 
40 
50 
2007 2009 2011 2013 2015 
Relative genetic 
diversity, Neτ 
0 
10 
20 
30 
Date 
2007 2009 2011 2013 2015 
Africa 
Asia 
Europe 
North America 
Oceania 
South America 
Africa 
Asia 
Europe 
North America 
Oceania 
C D 
Figure 4.3: New Orleans 2009 and Sydney 2012 circulated widely and consistently over sev-
eral years prior to pandemic emergence. (A and B) Summary of continent impor-
tation dates for New Orleans 2009 and Sydney 2012. The distribution of the first date
of importation was calculated for each continent for New Orleans 2009 (A) and Syd-
ney 2012 (B). The vertical line represents the mean date and the shaded area the 95%
HPD. (C and D) Summary of the spatial distribution of New Orleans 2009 and Syd-
ney 2012 lineages through time. The proportion of viral lineages on each continent
is plotted through time for New Orleans 2009 (C) and Sydney 2012 (D) and is scaled
to the relative genetic diversity (Neτ) from the Bayesian skyline plot for each strain.
The locations through time are plotted as a stacked area plot.
Bayesian skyline plot consists of a number of time slices (in this case five) with a dif-
ferent scaled effective population size in each time slice. During the MCMC chain, the
length of each time slice and the scaled effective population size in each time slice are in-
tegrated over in the form of bGroupSizes and bPopSizes parameters, respectively. There
is a significant difference (p < 0.05) between scenario 1 and scenario 2 in the posterior
distributions of the four earliest bGroupSizes parameters and between the three earliest
bPopSizes parameters. Therefore there is a significant difference between the scenarios in
the length of time of the four earliest time slices in the Bayesian skyline plot and between
the scaled effective population size within the three earliest time slices. In particular, the
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Figure 4.4: The population history of Sydney 2012. Bayesian skyline plots reconstructed for the
Sydney 2012 pandemic strain. (A) Bayesian skyline plot of the subsampled Sydney
2012 dataset with phylogeography. (B) Bayesian skyline plot of the subsampled Syd-
ney 2012 dataset without phylogeography. (C) Bayesian skyline plot of MCMC chain
samples that exhibit the first increase in relative genetic diversity pre-2012, defined
here as scenario 1. Here, we defined an increase in relative genetic diversity as an in-
crease in Neτ of more than 100% relative to the baseline value. (D) Bayesian skyline
plot of MCMC chain samples that exhibit an increase in relative genetic diversity in
or after 2012, defined here as scenario 2.
earliest bGroupSizes parameter is significantly larger in scenario 2, meaning there are
more coalescent events within the first time slice and therefore delaying the time at which
the second time slice begins. As the population size increases in the second time slice,
this delays the time of the increase in population size. In contrast, the second time slice
occurs earlier in scenario 1, with this time slice having an intermediate population size
between that in time slices one and three, resulting in the two stage increase in relative
genetic diversity. This second time slice in scenario 1 has a very similar scaled effective
population size to that in the first time slice in scenario 2 (Figure 4.4). There is, however,
no significant difference between the distributions of posterior probability or likelihood
of scenario 1 and scenario 2. Therefore there is no siginificant difference in how well
these two scenarios fit the data and, despite more MCMC steps supporting scenario 1,
there is not strong support in favour of a two stage increase in relative genetic diversity
(one pre-pandemic and one at the onset of the pandemic) over a single stage increase in
relative genetic diversity at the onset of the pandemic.
4.4.2 Phylogeography supports rare intercontinental transmission
with long intracontinental persistence
Both maximum likelihood (Figure 4.1) and Bayesian phylogenies (Figure 4.2) demon-
strate that sequences sampled from the same geographical region do not always clus-
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ter together. There are sequences sampled from each continent spread throughout the
New Orleans 2009 and Sydney 2012 phylogenies, indicating historical intercontinental
transmission events. Indeed, each continent contains a high diversity of lineages from
each pandemic strain, with viruses from multiple clades within a strain often being found
within a continent in a single season (Figure 4.2). However, viral lineages typically persist
within a continent for a long period of time, with the average persistence of New Orleans
2009 and Sydney 2012 on a continent being more than two years (Figure 4.5). The aver-
age persistence of New Orleans 2009 lineages is similar for each continent, although this
strain typically persisted for longer within Asia compared with the other continents. The
average persistence of Sydney 2012 lineages is also similar for most continents, with evi-
dence of shorter persistence in Oceania. However, the majority of Sydney 2012 sequences
in our dataset sampled in Oceania were collected during the 2012-2013 season, with very
few sequences from Oceania in 2014, which is likely to have decreased persistence in
this continent. In total, 86% and 85% of New Orleans 2009 and Sydney 2012 lineages,
respectively, were imported into their continent of sampling more than one year prior
to sampling (Figure S4.1). If viruses from different continents are interspersed within
the phylogenetic tree, subsampling these viruses may inflate persistence estimates due to
reducing the number of migration events. However, the length of persistence is very simi-
lar within each subsampled New Orleans 2009 dataset and in a New Orleans 2009 dataset
without subsampling (Figure S4.2), indicating that subsampling is unlikely to have greatly
influenced estimates of sample persistence. There is no correlation between the average
persistence in each continent between New Orleans 2009 and Sydney 2012 (Figure S4.3).
The intercontinental transmission rate is similar for New Orleans 2009 (0.2946 mi-
grations/lineage/year) and Sydney 2012 (0.2561 migrations/lineage/year). This rate cor-
responds to roughly one in four lineages migrating to a different continent each year, sug-
gesting that intercontinental transmission is not a very frequent event. Estimates of the
annual migration rate indicate that the highest rate of viral migration occurs in the year of
and the years preceding pandemic spread, with the migration rate decreasing during the
pandemic period (Figure 4.6).
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Figure 4.5: Summary of lineage persistence within each continent. For each tip virus, we cal-
culated the length of time it took to leave the sampling continent walking backwards
up the phylogenetic tree. The continental persistence was calculated by combining the
length of persistence of each tip virus from that continent in each tree in the posterior
distribution. The mean of the distribution is shown by the vertical line and the 95%
HPD is shown by the shaded area. The total persistence is the average persistence
across all continents.
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Figure 4.6: Annual migration rates for New Orleans 2009 and Sydney 2012. The annual mi-
gration rate was calculated as the rate at which the location label changes within each
year. The point represents the mean migration rate for the year and the error bars
represent the 95% HPD.
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4.4.3 Identification of frequent inter-continental transmission path-
ways and Asia as a source of viral lineages
We next investigated the global connectivity network within the New Orleans 2009 and
Sydney 2012 strains (Figure 4.7). Continents are generally well-connected, with each
continent having at least one well supported connection in each dataset and most con-
tinents having more than one well supported connection (Figure 4.7). Therefore while
the inter-continental transmission rate is low overall, there is evidence for occasional mi-
gration events between a large number of continents. We do not find evidence for New
Orleans 2009 and Sydney 2012 sharing the same global connectivity network (Spearman
rank correlation coefficient 0.4704), although this estimate may be biased by the New Or-
leans 2009 dataset additionally containing sequences from South America. While several
continent pairs exhibit greatly different migration rates when comparing New Orleans
2009 and Sydney 2012, the migration rate is high between Europe and North America
and between Asia and Oceania in both strains (Figure 4.8).
We next identified whether each continent acted as a source (i.e. exports more viral
lineages than it imports) or a sink of viral lineages or whether the number of import and
export events is roughly equal (Figure 4.9). While most continents export and import a
similar number of viral lineages or act as lineage sinks, Asia acted as a source of viral
lineages in both New Orleans 2009 and Sydney 2012 (Figure 4.9).
4.4.4 Identification of potential pandemic-enabling substitutions
The phylogenetic trees reconstructed as part of the phylogeographic analysis exhibit the
same pattern as those reconstructed in chapter 3 where New Orleans 2009 and Sydney
2012 diversify into a large number of lineages prior to pandemic emergence. In chapter 3
we demonstrated that this is true of the five most recent pandemic strains and introduced
a model of strain emergence where the viral genetic changes that enable the pandemic to
occur are acquired years prior to pandemic onset (Figure 3.6, stage 1).
We next aimed to identify substitutions that may have been important for the pan-
demic emergence of each strain by carrying out a thorough examination of amino acid
change across the GII.4 tree. This work was carried out as part of a collaboration and
aimed to identify substitutions that could be tested experimentally to determine their ef-
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Figure 4.7: The global connectivity network for New Orleans 2009 and Sydney 2012. Lines
are shown between continents with support (Bayes factor > 3) for connection in at
least two of the three subsampled datasets. The thickness of the line is proportional to
the median estimate of the migration rate between the pair of continents.
fect on viral antigenicity. We would expect substitutions important for pandemic emer-
gence to occur along the branch in the phylogenetic tree leading to the pandemic clade
and result in a different amino acid residue(s) to that in the previous pandemic strain.
In chapter 3, we demonstrated that there are multiple low level GII.4 lineages present
through time and that multiple low level GII.4 strains were present at the emergence of
each pandemic strain, for example at the onset of the Hunter 2004 pandemic, the lineages
leading to Den Haag 2006, Yerseke 2006, Apeldoorn 2007, New Orleans 2009 and Syd-
ney 2012 were likely all present but at low level (Figure 3.1, Table 3.4). The substitutions
that occurred leading to the pandemic clade are specific to that pandemic cluster and are
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Figure 4.8: Comparison of inter-continental migration rates in New Orleans 2009 and Syd-
ney 2012. The median migration rate is plotted for each pair of continents in New
Orleans 2009 and Sydney 2012. Only continent pairs that are present in both datasets
are included.
therefore likely to have enabled the emergence of that cluster over the other lineages that
were also present at the time. We therefore identified the nonsynoymous substitutions that
occurred leading to the common ancestor of each of the pandemic clusters and compared
the distribution of residues at each of these sites to that in the preceding pandemic strain.
As the topology of the GII.4 tree is poorly supported in several regions, we carried out
our analyses on the maximum likelihood tree and ten bootstrap tree topologies from the
capsid dataset assembled in chapter 2.3.1.
Sydney 2012
The topology of the Sydney 2012 clade has been consistent in each of our analyses
with this strain, with the common ancestor predicted to occur in late 2004 (95% HPD late
2001-mid 2007). However, there are two clades of sequences collected in South Africa
and New Zealand that branch from or close to the root of the clade (Figure 4.10). The se-
quences within these clades were mostly collected in 2010 and 2011 and there is therefore
no evidence that these viruses contributed to the Sydney 2012 pandemic. All of the viruses
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Figure 4.9: Asia acted as a source of New Orleans 2009 and Sydney 2012 lineages. We
counted the total number of viral lineage import and export events for each conti-
nent and calculated the export/import ratio. This ratio is plotted for each continent for
New Orleans 2009 (red) and Sydney 2012 (blue). The horizontal dashed line at the
export/import ratio of 1 shows an equal number of export and import events. There-
fore continents with ratios under this line are sinks while continents with ratios above
this line are sources. NE - not estimated due to sequences from that continent not
being included in the dataset.
that contributed to the Sydney 2012 pandemic form a monophyletic cluster that coalesces
to a common ancestor in late 2008 (95% HPD mid 2007-late 2009) (Figure 4.10). We
therefore defined two nodes within the Sydney 2012 clade: node 1 which is the common
ancestor of all Sydney 2012 viruses and node 2 which is the common ancestor of the
pandemic Sydney 2012 viruses (Figure 4.10). It is possible that pandemic-enabling sub-
stitutions were acquired leading to node 1 and the South Africa and New Zealand clades
became extinct due to stochastic factors. However, it is also possible that substitutions
important for the pandemic emergence of Sydney 2012 were acquired leading to node
2 and the South Africa and New Zealand clades did not contribute to the Sydney 2012
pandemic because they did not have one or more of the important substitutions. Each of
the clades downstream of node 2 persisted throughout the pandemic, with no evidence of
one or more lineages outcompeting other lineages, suggesting that important substitutions
had been acquired by node 2 (Figure 4.10).
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Figure 4.10: Nonsynonymous substitutions leading to the Sydney 2012 clade. (A) MCC tree
of the Sydney 2012 strain, as in figure 4.2 but without the branches labelled by
location. We identified node 1 as the common ancestor of all Sydney 2012 viruses
and node 2 as the common ancestor of the pandemic GII.4 viruses. All of the viruses
that contributed to the Sydney 2012 pandemic are downstream of node 2. The South
Africa and New Zealand clades that diverge from or close to the root of the tree
are labelled in red. The nonsynonymous substitutions that occurred leading to node
1 and node 2 are labelled on the respective branch. (B) Comparison of the amino
acid distribution at each of the sites that change leading to node 2 in New Orleans
2009 and Sydney 2012. Amino acid residues at each site are shown between the
distributions and residues with similar properties are shown in similar colours. The
same residues are found in New Orleans 2009 and Sydney 2012 at sites 297, 393,
395, 539 and 540.
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We infer that a single nonsynonymous substitution occurred along the branch leading
to node 1: T15A (Figure 4.10). Site 15 is located in the shell domain and has been
identified as evolving under positive selection in GII.4 (Bok et al., 2009), although the
functional importance of substitutions at this site is unknown. As this site is located
within the shell domain, it is very unlikely that substitutions at this site would alter viral
antigenicity.
We infer that eight nonsynonymous substitutions occurred along the branch leading
to node 2 (Figure 4.10). However, the amino acid residues at sites 297, 393, 395, 539 and
540 in Sydney 2012 are the same as those in the preceding pandemic strain, New Orleans
2009 (Figure 4.10). This suggests that substitutions at these sites were not the key drivers
of pandemic emergence of Sydney 2012, but rather the key substitution was one or more
of S310N, A368E and N373H (Figure 4.11). Sites 368 and 373 are located within block-
ade epitope A (Lindesmith et al., 2012a) and site 310 has previously been demonstrated to
alter viral antigenicity, potentially through regulating antibody access to an epitope (Lin-
desmith et al., 2014). Sites 310 and 368 are largely conserved as asparagine and glutamic
acid, respectively, within the Sydney 2012 pandemic clade, while site 373 is largely con-
served as histidine but with arginine also frequently present at this site in the pandemic
clade (Figures 4.10, 4.11). However, both residues present at site 373 in Sydney 2012 are
different to the residue at this site in New Orleans 2009 (Figure 4.10). The substitutions
at sites 368 and 373 have previously been suggested to be important for the emergence of
the Sydney 2012 pandemic (Debbink et al., 2013; Allen et al., 2014) and homology mod-
elling suggests that the substitutions at these sites resulted in a change in the structure
of blockade epitope A (Figure 4.11). We therefore hypothesise that substitutions within
blockade epitope A may have contributed to the pandemic emergence of Sydney 2012
and identify the substitutions S310N, A368E and N373H for experimental validation of
their effect on viral antigenicity.
New Orleans 2009
There were three nonsynonymous substitutions that occurred leading to the com-
mon ancestor of the New Orleans 2009 pandemic strain in the majority of tested tree
topologies: T294A, A340T and A359S (Figure 4.12). Each of these sites has a different
distribution of amino acid residues in New Orleans 2009 compared with that in the previ-
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Figure 4.11: Sites that may have enabled the pandemic emergence of Sydney 2012. (A) Con-
servation of sites 310, 368 and 373 within the Sydney 2012 strain. Each tip within
a maximum likelihood tree of 782 Sydney 2012 capsid sequences is coloured by the
residue at the respective site. The common amino acid residues present at each site
are labelled next to the respective tree. The site was not sequenced in tips coloured
black. Sites 310 and 368 are largely conserved, while site 373 is mostly histidine
with arginine also present at this site. (B) The change within epitope A between
Sydney 2012 node 1 and node 2. Residues within 12 A˚ of site 368 are shown, with
sites in this region forming blockade epitope A (Lindesmith et al., 2012a). Residues
are coloured by hydrophobicity on the Kyte and Doolittle scale (Kyte and Doolit-
tle, 1982), with blue residues being more polar and red residues more hydrophobic.
Sites 368 and 373 that are located within blockade epitope A and change between
node 1 and node 2 are highlighted. The substitution at site 368 results in a change
in residue size and polarity, while the substitution at site 373 results in a change in
residue size.
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ous pandemic strain, Den Haag 2006 (Figure 4.12). Sites 294 and 340 are located within
blockade epitope A and putative epitope C (Lindesmith et al., 2012a), respectively.
While site 294 changes leading to the New Orleans 2009 common ancestor, it is
highly variable within the New Orleans 2009 clade, with multiple substitutions between
adenine, proline and serine (Figure 4.13). Interestingly, site 294 was largely conserved as
adenine in Den Haag 2006 (Figure 4.12) and New Orleans 2009 lineages with adenine at
this site appeared to circulate at lower prevalence during the pandemic than viruses with
proline or serine at this site (Figure 4.13). If site 294 was vital to enable the pandemic
emergence of New Orleans 2009, we would not expect to see New Orleans 2009 viruses
with adenine at this site. The lower prevalence of lineages with adenine at site 294 sug-
gests that this site may have had a more minor role in, or very little influence on, strain
emergence.
Site 340 is largely conserved as threonine in the New Orleans 2009 clade in con-
trast to the glycine residue dominant at this site in Den Haag 2006 (Figures 4.12, 4.13).
However, a convergent adenine to threonine substitution occurred early in the pandemic
Sydney 2012 clade and Sydney 2012 viruses with threonine at site 340 were likely present
at the onset of the New Orleans 2009 pandemic. This suggests that either site 340 did not
have a major influence on the pandemic emergence of New Orleans 2009, or that Sydney
2012 had acquired additional changes that decreased the advantage provided by the sub-
stitution at site 340. Site 359 is conserved as serine in New Orleans 2009 which differs to
the adenine and threonine found at this site in other strains. While site 359 is not within a
previously characterised epitope, it is close to epitope A (Figure 4.13). Therefore, while
there is no clear candidate substitution for driving the New Orleans 2009 pandemic, we
identify sites 294, 340 and 359 for experimental investigation.
Den Haag 2006
The clustering of Den Haag 2006 within the GII.4 clade is uncertain. In particular,
the clustering of Farmington Hills 2002, Lanzhou 2002, Asia 2003, Den Haag 2006, the
Hunter lineage (leading to Hunter 2004 and Yerseke 2006) and the Apeldoorn lineage
(leading to Apeldoorn 2007, New Orleans 2009 and Sydney 2012) is typically poorly
supported (Figure 2.1). This poorly supported topology is likely partly due to convergent
amino acid substitutions and correspondingly several substitutions occurred leading to the
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Figure 4.12: Nonsynonymous substitutions leading to the New Orleans 2009 clade. (A) MCC
tree of the New Orleans 2009 strain, as in figure 4.2 but without the branches labelled
by location. The nonsynonymous substitutions that occurred leading to the common
ancestor of the New Orleans 2009 strain are labelled. (B) Comparison of the amino
acid distribution at each of the sites that changed leading to the common ancestor
of New Orleans 2009 with that in the previous pandemic strain, Den Haag 2006.
Amino acid residues at each site are shown between the distributions and residues
with similar properties are shown in similar colours.
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Figure 4.13: Sites that may have enabled the pandemic emergence of New Orleans 2009. (A)
Conservation of sites 294, 340 and 359 within the New Orleans 2009 strain. Each
tip within a maximum likelihood tree of 540 New Orleans 2009 capsid sequences
is coloured by the residue at the respective site. The common amino acid residues
present at each site are labelled next to the respective tree. Tips coloured black in-
dicate that the site was not sequenced in that sample. Sites 340 and 359 are largely
conserved while site 294 is variable. (B) The proportion of New Orleans 2009 lin-
eages with each residue at site 294 through time. The proportion of lineages with A,
P, S and T at site 294 is plotted through time. This was calculated from ancestral re-
construction on a temporally-resolved phylogenetic tree. Therefore all lineages and
not only tip viruses are considered. The proportions are shown as a stacked area plot.
(C) The location of site 359 (blue) relative to epitope A (red). The capsid structure
linking site 359 to residues in epitope A is shown in grey, while the rest of the capsid
structure is partially transparent.
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common ancestor of Den Haag 2006 in some but not all bootstrap tree topologies. Due to
the poorly supported tree topology, we examined the distribution of amino acids across the
GII.4 clade at each site that was inferred to change leading to the Den Haag 2006 common
ancestor in one or more of the 11 tested tree topologies. There is strong support that the
substitutions T15A, Q306L, H357P, N372E and G378H occurred leading to the Den Haag
2006 common ancestor, with the residues at sites 306, 357, 372 and 378 in Den Haag 2006
being unique within the GII.4 clade (Figure 4.14). Additionally, the substitutions P174S,
H297R, R339K, S352Y, V356A, N407S and G413V were inferred to occur leading to the
Den Haag 2006 common ancestor in more than half of the tested tree topologies (Figure
4.14). Each of these sites has a convergent substitution in one or more other strains, likely
explaining why they only occurred leading to the Den Haag 2006 common ancestor in a
subset of the tested topologies. There are additional substitutions that occurred leading to
the Den Haag 2006 common ancestor in a small number of tested tree topologies, with
these sites exhibiting the same residue in Den Haag 2006 as in several of the other strains.
We further considered the 12 sites that changed leading to the Den Haag 2006 com-
mon ancestor in more than half of the tested tree topologies. Each of these sites exhibits
a different distribution of residues in Den Haag 2006 compared with the previous pan-
demic strain, Hunter 2004 (Figure 4.14). With the exception of site 357, each of these
sites is largely conserved in the Den Haag 2006 clade (Figure 4.14). Sites 15 and 174 are
located in the shell domain and are therefore unlikely to alter the antigenicity of the virus.
However, sites 297, 339, 352, 356, 357, 372, 378, 407 and 413 are all surface exposed
(Figure 4.15). Sites 297 and 372 are in blockade epitope A, while sites 407 and 413 are
in blockade epitope E (Lindesmith et al., 2012a) and sites 352, 356 and 357 are located
close to both blockade epitopes A and E. Homology models of the common ancestor of
the Den Haag 2006 strain and the upstream ancestor suggest that these substitutions may
have altered the structure of blockade epitope A, blockade epitope E and the region in
between these epitopes (Figure 4.16). Additionally, while site 306 is not surface exposed,
it is located close to site 310 which can regulate antibody access an as yet unidentified
epitope (Lindesmith et al., 2014). While site 306 is conserved as leucine within Den Haag
2006, this site is completely conserved as glutamine in all other GII.4 strains.
Our results therefore suggest that there was a large change in surface structure lead-
ing to Den Haag 2006, with the potential for changes in at least two blockade epitope re-
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Figure 4.14: Nonsynonymous substitutions leading to the Den Haag 2006 clade. (A) Maxi-
mum likelihood tree of 1137 Den Haag 2006 capsid sequences. The nonsynonymous
substitutions that occurred leading to the common ancestor of the Den Haag 2006
clade in more than half of the tested tree topologies are labelled. (B) Comparison
of the amino acid distribution at each of the sites that change leading to the com-
mon ancestor of the Den Haag 2006 clade with that in the previous pandemic strain,
Hunter 2004. Amino acid residues at each site are shown between the distributions
and residues within similar properties are shown in similar colours.
gions. Experimental investigation of subsets of the substitutions H297R, Q306L, R339K,
S352Y, V356A, H357P, N372E, G378H, N407S and G413V may determine which sub-
stitutions truly enabled the pandemic emergence of Den Haag 2006.
Hunter 2004
While it is well supported that the Hunter 2004 pandemic strain clusters with the
Yerseke 2006 epidemic strain (Figure 2.1), the exact phylogenetic relationship within
this cluster is not well supported (Figure 4.17). In particular, the clustering of three se-
quences sampled in Paraguay and South Africa and classified as Hunter 2004 viruses
by the norovirus genotyping tool is uncertain. We therefore examined the Paraguay and
South Africa sequences and the early changes within the Hunter 2004/Yerseke 2006 clade
to determine whether antigenic changes likely occurred within the early part of this clade
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Figure 4.15: Surface location of sites that change leading to the Den Haag 2006 common
ancestor. Two views are shown of the Den Haag 2006 capsid structure in which the
surface-exposed sites that change leading to the common ancestor of the Den Haag
2006 strain are labelled in blue. Sites 297, 339, 352, 356, 357, 372, 378, 407 and
413 are labelled.
and therefore which node likely represented the true common ancestor of Hunter 2004.
While the Paraguay sequences were typed as Hunter 2004 viruses by the norovirus
genotyping tool, they were reported as a new strain by Galeano et al because they did
not clearly cluster with either the Hunter 2004 or Yerseke 2006 reference strains in their
analysis (Galeano et al., 2013). Additionally, they report differences between these se-
quences and Hunter 2004 in blockade epitopes A and E and therefore suggest that they
may be antigenically distinct from Hunter 2004 (Galeano et al., 2013). While our an-
cestral reconstruction results do corroborate these viruses differing in epitope E, we find
no differences in epitope A compared to the common ancestor of the main Hunter 2004
clade (node 3 in Figure 4.17). Galeano et al likely obtained differences at epitope A due
to comparing the Paraguay sequences against only two Hunter 2004 reference sequences.
The South Africa sequence was reported as a Hunter 2004 virus by Mans et al (Mans
et al., 2010). In their phylogenetic analysis, Mans et al included a single reference virus
from each strain and, while the South Africa sequence clusters with the Hunter 2004
and Yerseke 2006 reference sequences in a capsid phylogeny, there is low support on the
exact relationship within this clade. We observe the same in our analysis and ancestral
reconstruction suggests a large number of nonsynonymous substitutions occurred lead-
ing to the South Africa sequence, including substitutions in epitope regions. Therefore
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Figure 4.16: Changes in capsid structure leading to the Den Haag 2006 common ancestor.
We reconstructed a homology model of the Den Haag 2006 common ancestor and
the preceding ancestral sequence (here called mutated Den Haag 2006 ancestor) and
examined the structural changes induced by the substitutions leading to Den Haag
2006. (A) Sites within 12 A˚ of either site 297 or site 352 are shown from two view-
points. View 1 is a top view of the capsid structure, while view 2 is a side view of
the capsid structure. The substitutions at sites 297 and 372 are predicted to result
in a change to the structure of a ridge in blockade epitope A. The substitutions at
sites 352, 356 and 357 are predicted to alter the surface structure between blockade
epitopes A and E. A356 and P357 in the Den Haag 2006 common ancestor result in
a smaller structure along a surface-exposed ridge compared to the V356 and H357 in
the upstream ancestor. Y352 in the Den Haag 2006 common ancestor also increases
the surface area of a nearby ridge compared with S352 in the upstream ancestor.
(B) Sites within 12 A˚ of residue 407 are shown, with residues in this area form-
ing blockade epitope E (Lindesmith et al., 2012a). Two views from the side of the
capsid structure are shown. Small structural changes within blockade epitope E are
predicted due to the N407S and G413V substitutions leading to the Den Haag 2006
common ancestor.
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Figure 4.17: Substitutions leading to the Hunter 2004 clade. (A) The Hunter 2004/Yerseke
2006 clade was extracted from the maximum likelihood tree in Figure 2.1 and
branches coloured by strain, as assigned by the norovirus genotyping tool: orange
- Hunter 2004, green - Yerseke 2006. Bootstrap supports are shown on key nodes.
We defined three nodes that may have been the common ancestor of Hunter 2004:
node 1 which is the common ancestor of the Hunter 2004 and Yerseke 2006 clades,
node 2 which is the common ancestor of the sequences genotyped by the norovirus
genotyping tool as Hunter 2004 and node 3 which is the common ancestor of the
Hunter 2004 sequences excluding the Paraguay and South Africa sequences. Nodes
1 and 3 are well supported, while node 2 is not present in most bootstrap tree topolo-
gies. The nonsynonymous substitutions leading to node 1, leading to the Yerseke
2006 common ancestor and between nodes 1 and 3 are labelled. It is well supported
that the substitutions S425T and A465S occurred leading to node 3. There is lower
support that the substitutions N9T, N407D and G413S occurred between node 1 and
node 3. (B) Comparison of the amino acid residue distribution at each of the sites
that may have changed leading to the common ancestor of the Hunter 2004 clade.
The distribution is shown for Hunter 2004 and for the preceding pandemic strain,
Farmington Hills 2002. The residues present at each site are shown between the
distributions and amino acid residues with similar properties are shown in similar
colours.
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both the Paraguay and South Africa sequences contain substitutions in known epitope
regions relative to the main Hunter 2004 clade. There is, however, no reason to assume
that all substitutions within epitope regions will result in viruses with substantially dif-
ferent antigenic properties and future experimental studies examining the antigenicity of
the Paraguay and South Africa viruses are needed to determine whether they belong to
the Hunter 2004 strain. Therefore the Hunter 2004 common ancestor may have been
the ancestor of the Hunter 2004 and Yerseke 2006 strains (node 1 in Figure 4.17), the
common ancestor of the Hunter 2004 sequences including the Paraguay and South Africa
sequences (node 2 in Figure 4.17) or the common ancestor of the Hunter 2004 sequences
excluding the Paraguay and South Africa sequences (node 3 in Figure 4.17).
If node 1 was the true common ancestor of Hunter 2004, the Paraguay and South
Africa sequences would be Hunter 2004 viruses and the Yerseke 2006 epidemic strain
would have evolved from a Hunter 2004-like virus. It is well supported that five nonsyn-
onymous substitutions occurred leading to node 1: H297Q, N372S, K382R, T412D and
T425S. Sites 297, 372 and 412 exhibit a different distribution of amino acids in Hunter
2004 compared with that in the preceding pandemic strain, Farmington Hills 2002 (Figure
4.17). Sites 297 and 372 are located within blockade epitope A while site 412 is located
within blockade epitope E (Lindesmith et al., 2012a). Homology modelling suggests the
substitutions at sites 297 and 372 may have altered the structure within blockade epitope
A, while the substitution at site 412 resulted in only a small difference in structure (Figure
4.18).
Node 2 is poorly supported and does not exist in seven of the eleven tested tree
topologies. Where node 2 does exist, the N9T and possibly T534A substitutions occurred
leading to this node. The location of these sites within the shell domain and P1 domain,
respectively, suggests that substitutions at these sites are unlikely to alter viral antigenicity,
suggesting that should node 2 have existed, it was likely antigenically indistinguishable
from node 1.
It is well supported that the substitutions S425T and A465S occurred leading to node
3 (Figure 4.17). However, each of these sites is located towards the base of the P1 domain
and is therefore unlikely to alter the viral antigenicity. Therefore it is again unlikely that
there was a change in antigenicity leading to node 3 and the viruses downstream of node
3 are therefore unlikely to contain unique and conserved antigenic changes. However,
158 Chapter 4. Characterising global circulation and pandemic-enabling substitutions
A 
Q297 
S372 
H297 
N372 
D412 N412 
Node 1 Mutated node 1 
B Node 1 Mutated node 1 
Figure 4.18: Substitutions leading to Hunter 2004 node 1. We reconstructed homology mod-
els of the sequence at node 1 in the Hunter 2004 and Yerseke 2006 clade and the
upstream ancestral sequence (here called mutated node 1). Residues are coloured
by their hydrophobicity based of the Kyte and Doolittle scale (Kyte and Doolittle,
1982), with blue residues being more polar and red residues being hydrophobic. (A)
Residues within 12A˚ of site 297 are shown from a top view of the capsid. Sites 297
and 372 are labelled in each structural model and are predicted to result in a small
difference in structure within epitope A. (B) Residues within 12A˚ of site 412 are
shown from a side view of the capsid. The substitution N412D does not result in a
change in residue size or hydrophobicity.
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in 6 of the 11 tested tree topologies, the substitution N407D occurs between node 1 and
node 3, with G413S also occurring in 4 of these 6 tree topologies. Sites 407 and 413 are
both located within blockade epitope E and the substitutions at these sites occur after the
branching of one or both of the Paraguay and South Africa sequences, but not along the
branch leading to node 3 (Figure 4.17). It is therefore possible that there was a change in
antigenicity between node 1 and node 3.
We demonstrated in chapter 3 that node 1 most likely occurred in 2001 (Table 3.4).
The Paraguay and South Africa sequences were not included in the dataset we used
in chapter 3 and the Hunter 2004 common ancestor in Figure 3.1 is therefore node 3,
which we inferred to occur in late 2002 (Table 3.3). Therefore at the onset of the Hunter
2004 pandemic the lineages leading Yerseke 2006, the Paraguay sequences and the South
Africa sequence were already present. However, viruses in the Yerseke 2006 lineage
were not detected as contributing to the Hunter 2004 pandemic and the Paraguay and
South Africa lineages have each been sampled in a single study, with the South Africa
sequence being collected in late 2008, two years after the end of the Hunter 2004 pan-
demic. While it is possible that different clades within a pandemic strain may be sampled
at different frequencies during the pandemic, it is very unlikely that the vast majority of
sampled viruses would come from a single clade in the pandemic strain with no viruses
being sampled from another clade within the pandemic. Therefore it is very unlikely that
the Yerseke 2006 lineage, Paraguay lineage or South Africa lineage contributed greatly to
the Hunter 2004 pandemic and we therefore suggest that these lineages do not have one or
more of the defining features important for the pandemic emergence of Hunter 2004. We
therefore hypothesise that the viruses at node 1 and node 3 differed antigenically. Future
experimental work examining the antigenicity of the reconstructed sequence at each node,
the influence of the substitutions leading to node 1 and the impact of N407D and G413S
substitutions that may have occurred between nodes 1 and 3 is required to verify which
node is the true common ancestor of Hunter 2004 and which substitutions likely enabled
the pandemic emergence of this strain.
Farmington Hills 2002
There are 9 nonsynonymous substitutions that occurred leading to the Farmington
Hills 2002 common ancestor in most tested tree topologies: S9N, D298N, K329R, S355D,
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Figure 4.19: Nonsynonymous substitutions leading to the Farmington Hills 2002 clade. (A)
Maximum likelihood tree of 96 Farmington Hills 2002 capsid sequences. Each of
the nonsynonymous substitutions that occurred leading to the Farmington Hills 2002
clade is labelled. (B) Comparison of the amino acid residue distribution between
Farmington Hills 2002 and the preceding pandemic strain, US95/96 at each site that
change leading to the common ancestor of the Farmington Hills 2002 clade. The
residues at each site are shown between the distributions and residues with similar
properties are shown in similar colours. NP - not present, site 394 was not present in
the US95/96 strain as it arose in an insertion event after divergence from US95/96.
However, this insertion is present in all other pandemic and major epidemic strains
post-US95/96, with the exception of Kaiso 2003.
V365I, T368N, S394G, N407S and A534T (Figure 4.19). Site 9 is the only one of these
sites to not exhibit a different amino acid residue in Farmington Hills 2002 compared with
the preceding pandemic strain, US95/96 (Figure 4.19).
Sites 9 and 534 are located within the shell domain and close to the base of the P1
domain, respectively, and are therefore unlikely to alter viral antigenicity. Each of the
remaining sites that change leading to the Farmington Hills 2002 common ancestor are
found close together within the P2 domain (Figure 4.20). Homology models of the Farm-
ington Hills 2002 common ancestor and the upstream node suggest that these substitutions
may have altered the structure of blockade epitopes A, D and E (Figure 4.20).
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Figure 4.20: Changes in capsid structure leading to the Farmington Hills 2002 clade. (A) The
nonsynonymous substitutions leading to the Farmington Hills 2002 clade occurred
close together within the P2 domain. Sites 298, 329, 355, 365, 368, 394 and 407 are
labelled in blue. The sites are shown on dimeric homology model of the Farmington
Hills 2002 common ancestor, with the monomers shown in different shades and
the structure is shown from a top view and a side view. The blue circle shows the
location of the sites that change leading to the Farmington Hills 2002 clade. The
HBGA Lewis B is shown in magenta. (B) We reconstructed P domain homology
models of the Farmington Hills 2002 common ancestor and the upstream ancestor
(here referred to as mutated Farmington Hills 2002 ancestor), which differ at sites
298, 329, 355, 365, 368, 394 and 407. Residues within 12A˚ of site 298, site 394
or site 407 are shown and are coloured by hydrophobicity based on the Kyte and
Doolittle scale (Kyte and Doolittle, 1982). The substitutions at sites 355, 368, 394
and 407 are predicted to result in changes in surface structure.
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It has previously been suggested that an insertion at site 394 in epitope D resulted
in a large change in antigenicity between US95/96 and Farmington Hills 2002. However,
this insertion is not unique to Farmington Hills 2002 and the common ancestor of viruses
with this insertion occurred in late 1993 (95% HPD early 1991-early 1996) (Figure 2.2).
Therefore at the onset of the Farmington Hills pandemic in 2002 a large number of ad-
ditional lineages with this insertion were also present: the Osaka 2007 lineage, the Asia
2003 lineage, the Den Haag 2006 lineage, the Hunter 2004 lineage, the Yerseke 2006 lin-
eage and the Apeldoorn lineage (Figure 3.1). Therefore this insertion is unlikely to have
been the key change enabling pandemic emergence of Farmington Hills 2002. Lindesmith
et al demonstrated that Farmington Hills 2002 has a different antigenic profile in blockade
epitope E compared with US95/96 and Den Haag 2006 viruses (Lindesmith et al., 2012b).
They mapped this difference to residues 407, 412 and 413 and demonstrated that by engi-
neering these residues into the other strains, they could recapitulate the Farmington Hills
2002 antigenic phenotype. Our analysis suggests that site 407 is the only one of these
three sites that changed leading to the Farmington Hills 2002 common ancestor.
Our results identify sites within several surface-exposed regions of the P2 domain
that may have been important for the pandemic emergence of Farmington Hills 2002 and
highlight the substitutions D298N, K329R, S355D, V365I, T368N, S394G and N407S
for experimental validation of their effect on viral antigenicity.
4.4.5 Comparison of substitutions leading to each pandemic GII.4
strain
The nonsynonymous substitutions leading to each pandemic GII.4 strain are predomi-
nantly strain-specific (Figure 4.21) with no evidence for a particular site that consistently
enables the emergence of new pandemic strains. The majority of these substitutions are
located within the P2 domain, with only a small number of sites located in the S and P1
domains (Figure 4.21). There are four sites that changed leading to more than one pan-
demic clade: 297, 368, 372 and 407. Sites 297, 368 and 372 are located within blockade
epitope A and site 407 is located within blockade epitope E (Lindesmith et al., 2012a).
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Figure 4.21: Location of nonsynonymous capsid substitutions leading to pandemic clades.
The location within the capsid is shown for each of the nonsynonymous substitutions
that occurred leading to the Farmington Hills 2002, Hunter 2004, Den Haag 2006,
New Orleans 2009 and Sydney 2012 clades. For Hunter 2004, the substitutions
leading to node 1 are shown in brown and the substitutions leading to node 3 are
shown in orange. For Sydney 2012, the substitution leading to node 1 is shown in
red and the substitutions leading to node 2 are shown in magenta. The vertical grey
dashed lines demonstrate the domain boundaries.
4.4.6 Validation of substitutions important for the pandemic emer-
gence of Sydney 2012
Under the three stage process of strain emergence introduced in chapter 3 (Figure 3.6),
we expect that the genetic changes required for pandemic spread are acquired by the com-
mon ancestor of the strain. To verify whether this is the case for each of the pandemic
strains and to determine which nonsynonymous substitutions were likely the most impor-
tant for pandemic emergence, we will employ reference sets of monoclonal antibodies
and polyclonal sera raised against individual GII.4 pandemic strains. We have initially
designed three virus like particles (VLPs) to test the antigenic properties of ancestral Syd-
ney 2012 viruses and to test our hypothesis that one or more of the substitutions at sites
310, 368 and 373 were key for enabling the pandemic emergence of Sydney 2012. The
first two VLPs contain the inferred ancestral sequences at Sydney 2012 node 1 and node
2, which differ at eight sites (Figure 4.10). The third VLP (VLP3) contains the node 1 se-
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quence with the three substitutions we hypothesise to have enabled pandemic emergence
of Sydney 2012: S310N, A368E and N373H (Figure 4.11). We will test the reactivity of
each of these VLPs with a panel of monoclonal antibodies and convalescent polyclonal
sera raised against New Orleans 2009 and Sydney 2012 and compare the binding profiles
of these three VLPs with a reference set of New Orleans 2009 and Sydney 2012 VLPs.
Under our hypothesis, we would expect the node 2 VLP and VLP3 to exhibit similar anti-
genic properties to the reference Sydney 2012 VLPs and for the node 2 VLP and VLP3 to
be antigenically distinct from the reference New Orleans 2009 VLPs. We also hypothesise
that the node 2 VLP and VLP3 will be antigenically distinct from the node 1 VLP. This
will enable us to determine whether the node 2 virus had acquired a ‘Sydney 2012-like’
antigenic profile, whether additional important antigenic changes were acquired between
node 1 and node 2, whether the node 1 and node 2 viruses were antigenically distinct from
New Orleans 2009 viruses and whether one or more of the substitutions at sites 310, 368
and 373 resulted in a large change in antigenicity.
Importantly, the panel of monoclonal antibodies were raised against individual VLPs
from New Orleans 2009 and Sydney 2012. Comparison of the node 1 and node 2 se-
quences with the reference VLP (VLPref) used to raise the Sydney 2012 monoclonal an-
tibodies identified sequence differences, namely I119V, I145V, I231V, S/N310D, A340T,
N/H373R and N/S393G (Table 4.2). The VLPref was created from the first Sydney 2012
virus to be identified (accession number JX459908.1), but this virus is not representative
of the complete Sydney 2012 clade at a number of sites. For example, this sequence has
residue D at site 310, which is very rare within the Sydney 2012 clade (Figure 4.11).
Table 4.2 summarises the differences between the VLPref, node 1 VLP and node 2 VLP.
The sites that have a unique residue within the VLPref compared with node 1 and node 2
may influence the ability of the monoclonal antibodies to recognise the node 1 and node
2 VLPs. Unfortunately, the reference Sydney 2012 VLP differs from the node 1 and node
2 VLPs at two of the three sites of interest, 310 and 373. It is therefore possible that the
monoclonal antibodies will not give information on the importance of the substitutions at
these sites. However, the panel of convalescent polyclonal sera should give an accurate
reflection of the antigenicity of the respective VLPs and on the combined importance of
the substitutions at sites 310, 368 and 373.
While we have initially synthesised VLPs based on the Sydney 2012 ancestral se-
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Amino acid site Reference Sydney 2012 Node 1 residue Node 2 residue VLP3 residue
VLP residue
119 V I I I
145 V I I I
231 V I I I
297 R H R H
310 D S N N
340 T A A A
368 E A E E
373 R N H H
393 G N S N
395 T A T A
539 A A V A
540 V L V L
Table 4.2: Variable sites between Sydney 2012 VLPs. Each of the variable sites between any of
the Sydney 2012 VLPs is shown. All other sites are constant between the VLPs. The
reference Sydney 2012 VLP was used in construction of the Sydney 2012 reference
monoclonal antibodies. The node 1 and node 2 VLPs differ at sites 297, 310, 368,
373, 393, 395, 539 and 540. VLP3 has the same sequence as the node 1 VLP with the
exception of sites 310, 368 and 373. Sites 297, 310, 368, 373, 393, 395, 539 and 540
change between node 1 and node 2, while the other sites are included here because they
change between the reference Sydney 2012 VLP sequence and our reconstructed se-
quences. Sites 310, 368 and 373 are shown in bold as these are the sites we hypothesise
to have enabled the pandemic emergence of Sydney 2012.
quences and inferred substitutions, we will carry out the same process for the other pan-
demic GII.4 strains using the ancestral sequences and substitutions identified above.
4.4.7 Strains accumulate diversity during the diversification phase of
strain emergence
We next characterised the diveristy at the amino acid level within the capsid of each of
the pandemic GII.4 strains. We could accurately characterise the diversity in the three
most recent pandemic strains, Den Haag 2006, New Orleans 2009 and Sydney 2012,
due to the large number of capsid sequences available for these strains. We identified
19, 13 and 15 amino acid sites that exhibit a high degree of variability within Den Haag
2006, New Orleans 2009 and Sydney 2012, respectively (Figures 4.22, S4.7-S4.9, Table
4.3). Identifying variable sites within US95/96, Farmington Hills 2002 and Hunter 2004
was more challenging due to the smaller number of capsid sequences available for these
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strains. The total branch length in our nucleotide maximum likelihood trees for US95/96,
Farmington Hills 2002 and Hunter 2004 was far smaller than that for Den Haag 2006, New
Orleans 2009 and Sydney 2012, suggesting that our sample sets capture less diversity
for these earlier pandemic strains. Correspondingly, we find a correlation between the
total nucleotide branch length in the strain phylogenetic tree and the total amino acid
entropy within the strain (Figure 4.22). To reduce the potential for false positives, we
took sites as variable in US95/96, Farmington Hills 2002 and Hunter 2004 only if they
exhibited a greater degree of variability. We identify 3, 2 and 8 variable sites in US95/96,
Farmington Hills 2002 and Hunter 2004, respectively (Figures 4.22, S4.4-S4.6, Table
4.3). As would be expected, most of the variable sites are located within the P2 domain
(Figure 4.22), consistent with this region being able to accomodate a greater degree of
structural variability compared with the shell and P1 domains and the persistent targeting
of this region by host immunity.
The intra-strain variable sites often coincide with epitope positions (Figure 4.23, Ta-
ble 4.3). 11 of the 12 sites in blockade epitopes A, D and E are variable within at least
one of the pandemic strains, with site 394 in epitope D being the exception. Additionally,
each of the sites within putative epitopes B and C is highly variable within at least one
pandemic strain. It was previously suggested that the surface epitopes may include ad-
ditional residues within 8 A˚ of the proposed epitope positions (Lindesmith et al., 2012a).
The intra-strain variable sites include additional positions within 8 A˚ of blockade epitopes
A (site 373), D (site 396) and E (sites 356 and 414) as well as putative epitope C (sites
339, 341 and 377).
Several of the intra-strain variable sites coincide with the HBGA binding region (Fig-
ure 4.24, Table 4.3). The sites in the HBGA binding region can be divided into those that
are required for binding to all HBGAs and those that are required for binding to only
specific HBGAs (Singh et al., 2015). The residues required for binding to all HBGAs
(T344, R345, D374, G443 and Y444) are conserved in all GII.4 strains and throughout
the GII.4 clade. However, the variable sites 393 and 395 are located within a loop that
interacts with specific HBGAs (Singh et al., 2015) and there are multiple sites that exhibit
high intra-strain variability and are located close to the HBGA-specific binding site (Fig-
ure 4.24, Table 4.3). That the intra-strain variable sites often coincide with sites within
or close to epitopes and the HBGA-binding region indicates that this variability has the
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Site Domain Epitope site HBGA binding site Close to Close to Type of variation
epitope site HBGA binding site
US9596
47 Shell No No No No Large clade
333 P2 Epitope B No No additional epitope Site 441 Multiple changes
393 P2 Epitope D Yes No additional epitope N/A Multiple changes
Farmington Hills 2002
382 P2 Epitope B No No additional epitope No Multiple changes
395 P2 Epitope D Yes No additional epitope N/A Multiple changes
Hunter 2004
174 Shell No No No No Multiple changes
296 P2 Epitope A No No additional epitope 296 Multiple changes
329 P2 No No No No Multiple changes
339 P2 No No Epitope C Sites 343, 344, 345 Multiple changes
340 P2 Epitope C No No additional epitopes Site 343 Multiple changes
356 P2 No No Epitope E No Multiple changes
407 P2 Epitope E No No additional epitopes No Multiple changes
413 P2 Epitope E No No additional epitopes No Multiple changes
Den Haag 2006
6 Shell No No No No Multiple changes
9 Shell No No No No Multiple changes
23 Shell No No No No Multiple changes
45 Shell No No No No Large Clade
171 Shell No No No No Large clade
193 Shell No No No No Large clade
255 P1 No No No No Large clade
298 P2 Epitope A No No additional epitope No Multiple changes
333 P2 Epitope B No No additional epitope Site 441 Multiple changes
340 P2 Epitope C No No additional epitopes Site 343 Multiple changes
357 P2 No No No No Multiple changes
368 P2 Epitope A No No additional epitopes No Multiple changes
372 P2 Epitope A No No additional epitopes Site 374 Multiple changes
377 P2 No No Epitope C No Multiple changes
393 P2 Epitope D Yes No additional epitopes N/A Multiple changes
412 P2 Eptiope E No No additional epitopes No Multiple changes
414 P2 No No Epitope E No Multiple changes
425 P1 No No No No Large clade
539 P1 No No No No Multiple changes
New Orleans 2009
54 Shell No No No No Large clade
174 Shell No No No No Multiple changes
231 P1 No No No No Multiple changes
294 P2 Epitope A No No additional epitopes No Multiple changes
297 P2 Epitope A No No additional epitopes No Multiple changes
339 P2 No No Epitope C Sites 343, 344, 345 Multiple changes
341 P2 No No Epitope C Sites 343, 344, 345, 444 Multiple changes
372 P2 Epitope A No No additional epitopes Site 374 Multiple changes
376 P2 Epitope C No No additional epitopes Sites 345, 374 Multiple changes
377 P2 No No Epitope C No Large clade
393 P2 Epitope D Yes No additional epitopes N/A Multiple changes
396 P2 No Yes Epitope D N/A Large clade
413 P2 Epitope E No No additional epitope No Multiple changes
Sydney 2012
119 Shell No No No No Multiple changes
145 Shell No No No No Multiple changes
174 Shell No No No No Multiple changes
231 P1 No No No No Multiple changes
297 P2 Epitope A No No additional epitopes No Multiple changes
309 P2 No No Site 310 No Large clade
333 P2 Epitope B No No additional epitopes Site 441 Multiple changes
340 P2 Epitope C No No additional epitopes Site 343 Multiple changes
372 P2 Epitope A No No additional epitopes Site 374 Multiple changes
373 P2 Epitope Aa No No additional epitopes Sites 345, 374 Multiple changes
377 P2 No No No No Multiple changes
393 P2 Epitope D Yes No additional epitopes N/A Multiple changes
414 P2 No No Epitope E No Large clade
539 P1 No No No No Large clade
540 P1 No No No No Large clade
Table 4.3: Variable sites within each pandemic GII.4 strain. Each of the sites we identify as ex-
hibiting high variability within a pandemic GII.4 strain is shown. The capsid domains
were defined as in Cao et al. (2007). Epitopes were defined as those regions identified
in Lindesmith et al. (2012a), with epitopes A, D and E being blockade epitopes and
epitopes B and C being putative epitopes. The HBGA-binding regions were defined
as those regions identified by Cao et al. (2007) and Singh et al. (2015). We classified
sites as being close to an epitope or HBGA-binding region if the residue at the site
is located within 8A˚ of one or more residues within an epitope or HBGA-binding re-
gion (Lindesmith et al., 2012a) in the Sydney 2012 P domain structure 4WZT (Singh
et al., 2015). The nature of the variation at a site was identified using the coloured trees
method. Sites classified as ‘large clade’ exhibit different amino acids within different
large clades within the tree while sites classified as ‘multiple changes’ change on mul-
tiple occassions within the strain. Sites that change leading to multiple large clades
are classified as multiple changes. Coloured trees are shown for each site in Figures
S4.4-S4.9. a Site 373 was not included in epitope A in Lindesmith et al. (2012a) but
was later included in epitope A by Debbink et al. (2013)
168 Chapter 4. Characterising global circulation and pandemic-enabling substitutions
Shell P1 P2 P1 
US95/96 
Farmington Hills 2002 
Hunter 2004 
Den Haag 2006 
New Orleans 2009 
Sydney 2012 
A 
●
●
●
●
●
●
0
10
20
30
40
50
60
70
0 1 2 3 4 5
Region
En
tro
pyEntropy 
0 
10 
20 
30 
40 
50 
60 
70 
Total nucleotide branch length 
0 1 2 3 4 5 
US95/96 
Farmington Hills 2002 
Hunter 2004 
Den Haag 2006 
New Orleans 2009 
Sydney 2012 
B 
Figure 4.22: Highly diverse sites within individual GII.4 pandemic strains. (A) The location
within the capsid sequence of diverse amino acid sites is shown for each pandemic
strain. The vertical grey dashed lines are the domain boundaries. (B) We recon-
structed a maximum likelihood phylogenetic tree for each of the pandemic GII.4
strains individually. The total nucleotide branch length within the maximum likeli-
hood tree is plotted against the total amino acid entropy within the strain. There is
a correlation, indicating that as nucleotide diversity increases, amino acid diversity
increases.
Number of pandemic strains Sites
1 6, 9, 23, 45, 47, 54, 119, 145, 171, 193, 255, 294, 296, 298, 309,
329, 341, 356, 357, 368, 373, 376, 382, 395, 396, 407, 412, 425, 540
2 231, 297, 339, 413, 414, 539
3 174, 333, 340, 372, 377
4 393
Table 4.4: Summary of variable sites within pandemic GII.4 strains. Each of the sites that
is highly variable in one or more pandemic GII.4 strains is shown. The number of
pandemic strains is the number of pandemic strains that site is variable in.
potential to alter the viral phenotype through altering antigenicity of the HBGA-binding
profile.
The variation at most of the highly variable sites in New Orleans 2009 and Sydney
2012 began to be accumulated prior to the onset of their respective pandemics (Figures
4.25, 4.26).
The variable sites within a strain are typically strain-specific, with only a small num-
ber of sites being variable in more than one strain (Table 2.4).
4.5 Discussion
In chapter 3 we presented a three stage model of pandemic strain emergence where the
strain first acquires the genetic changes that will enable it to emerge pandemically in the
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Figure 4.23: Variable sites are often located within epitope regions. A top view of the GII.4
capsid is shown based on the Sydney 2012 P domain dimer structure 4WZT (Singh
et al., 2015). The monomers are labelled in different shades, with one monomer
labelled in grey and the other labelled in blue-white. Each site in blockade epitopes
A, D and E is shown in red and each site in putative epitopes B and C is shown
in brown. The sites within each epitope region are the coloured residues enclosed
within the respective dashed oval. The dashed ovals are only shown in monomer A
for clarity, but the epitopes exist in each monomer. The HBGA type A bound to the
Sydney 2012 P domain in structure 4WZT is shown in magenta. The same capsid
view is shown with the variable sites within each pandemic strain labelled in orange.
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US95/96 Farmington Hills 2002 Hunter 2004 
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Figure 4.24: Variable sites close to and within the HBGA-binding region. A top view of
the GII.4 capsid is shown based on the Sydney 2012 P domain dimer structure
4WZT (Singh et al., 2015). The monomers are labelled in different shades, with
one monomer labelled in grey and the other labelled in blue-white. Each site in the
HBGA-binding region is labelled in purple. The HBGA type A bound to the Sydney
2012 P domain in structure 4WZT is shown in magenta. The same capsid view is
shown with the variable sites within each pandemic strain labelled in orange.
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Figure 4.25: Variability in New Orleans 2009 began to accumulate prior to pandemic emer-
gence. We carried out ancestral reconstruction on a temporally resolved New Or-
leans 2009 phylogenetic tree to determine how amino acid change was accumulated
through time. Plotted here for each site that exhibits high variability in New Orleans
2009 is the proportion of each residue at that site through time, scaled to the inferred
population history in the form of a Bayesian skyline plot. The increase in Neτ in-
dicates the onset of the New Orleans 2009 pandemic. The residues at each site are
shown next to the respective plot. The residue proportions are shown as a stacked
area plot. As an example, the top right panel shows the temporal history of site 297.
The presence of both histidine (H) and arginine (R) at site 297 prior to the increase
in Neτ indicates diversity was accumulated at this site prior to pandemic onset.
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Figure 4.26: Variability in Sydney 2012 began to accumulate prior to pandemic emergence.
We carried out ancestral reconstruction on a temporally resolved Sydney 2012 phy-
logenetic tree to determine how amino acid change was accumulated through time.
Plotted here for each site that exhibits high variability in Sydney 2012 is the pro-
portion of each residue at that site through time, scaled to the inferred population
history in the form of a Bayesian skyline plot. The increase in Neτ in 2012 indicates
the onset of the Sydney 2012 pandemic. The residues at each site are shown next to
the respective plot. The residue proportions are shown as a stacked area plot. As an
example, the top right panel shows the temporal history of site 297. The presence of
both histidine (H) and arginine (R) at site 297 prior to the increase in Neτ indicates
diversity was accumulated at this site prior to pandemic onset.
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future and then undergoes diversification into a large number of pre-adapted lineages that
emerge to cause the pandemic (Figure 3.6). We proposed that during the diversification
phase the strain could either circulate within a small geographical region with spread from
a single region at the onset of the pandemic or circulate widely and spread outwards from
multiple geographical regions at the onset of the pandemic. The phylogeography results
strongly support this second scenario, with support for New Orleans 2009 and Sydney
2012 circulating widely and consistently over several years prior to their emergence as the
pandemic strain (Figures 4.3, 4.27). Therefore there is low level worldwide circulation
prior to the emergence of the pandemic, explaining how New Orleans 2009 and Sydney
2012 were identified on multiple continents prior to their pandemic emergence (Figure
3.5). This strongly suggests that environmental factors do not play an important role in
strain emergence, as the strain is already present on each continent prior to the pandemic
and the pandemic is not caused by one sublineage from the strain that emerges from a
particular geographical region. There is no support for a single continent having a special
role in the early circulation of either strain (Figure 4.3). However, after the emergence
of the pandemic, Asia acted as a source of viral lineages in both New Orleans 2009 and
Sydney 2012, with this region exporting many more lineages than it imported (Figure 4.9).
Therefore prioritising the Asia region in vaccine strategies may have a greater impact on
the global epidemic compared with the impact of vaccinating other continents.
In most countries, norovirus outbreaks typically exhibit a large Winter peak followed
by far fewer cases in Summer (Ahmed et al., 2013). However, the average persistence of
viral lineages within each continent is much longer than one year (Figure 4.5), suggest-
ing that the large Winter peaks are predominantly caused by viruses that have persisted
within the continent during the Summer, although likely with an additional contribution
from newly imported lineages. This is supported by a low overall inter-continental trans-
mission rate (0.29 and 0.26 migration events/lineage/year for New Orleans 2009 and Syd-
ney 2012, respectively). We do observe greatly different rates of viral migration between
different pairs of continents, with a high migration rate between Europe and North Amer-
ica and between Asia and Oceania (Figures 4.7, 4.8). We here employed a symmetric
rate matrix to model the process of inter-continental migration; studies are underway to
confirm our findings using an asymmetric rate matrix that does not assume the same mi-
gration rate in each direction between each pair of continents. Migration events between
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Figure 4.27: Three stage process of strain emergence including geographical spread and
antigenic changes. The three stage process of strain emergence is depicted as in
figure 3.6, with the strain acquiring the genetic changes that will important for it to
emergence pandemically, undergoing diversification into a large number of lineages
and then emerging to cause the new pandemic. The GII.4 strain that will emerge in
the future is only a subset of the total reservoir of GII.4 strains. The phylogeogra-
phy results strongly suggest that the strain circulates widely and consistently during
the diversification phase, resulting in a period of worldwide circulation prior to pan-
demic emergence. The emergence of a number of closely related lineages exhibiting
genetic variability suggests that these lineages share one or more phenotypic char-
acteristics. We suggest that this characteristic is acquired during the acquisition of
changes phase and moves the virus to a new region of antigenic space. It is not clear
where in antigenic space the virus is prior to acquiring these changes, but after ac-
quiring the changes, the virus is in a distinct region of antigenic space compared with
the current pandemic strain. The diversification results in local movement within the
antigenic space, but the lineages remain within the same general, distinct region of
antigenic space. At the onset of the new pandemic, all of the lineages within the
same region of the antigenic space emerge and cause the new pandemic. Here, this
process is shown with reference to New Orleans 2009 as the current pandemic strain
and Sydney 2012 as the next pandemic strain.
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distant continents suggests that airplane travel is likely a major mode of inter-continental
transmission. However, given the high frequency of flights between the majority of con-
tinents and the very high prevalence of GII.4 norovirus strains, this raises the question
of why inter-continental transmission is not more frequent. While norovirus gastroenteri-
tis is typically short lived, it is unlikely that an individual will be able to travel during
the symptomatic period, which typically lasts 24-48 hours (Lopman et al., 2004a; Patel
et al., 2009). Individuals do, however, shed virus in faeces for up to several months after
resolution of symptoms and there is evidence of frequent asymptomatic infection (Teunis
et al., 2015). There is currently no clear evidence as to whether asymptomatically infected
patients may be infectious (Teunis et al., 2015), although transmission is likely to occur
more frequently during symptomatic infection due to the expulsion of viral particles into
the environment. Therefore we suggest that the low inter-continental transmission rate is
the result of patients being unlikely to travel during the period at which they are most in-
fectious. Inter-continental migration events likely occur through patients who have either
resolved norovirus symptoms or exhibited an asymptomatic infection.
Inter-continental transmission is unlikely to be necessary for a pandemic strain to
persist due to each continent containing a large susceptible population. Current preva-
lence estimates suggest that roughly one in ten individuals worldwide are infected with
norovirus annually (Kirk et al., 2015; Pires et al., 2015; Lopman et al., 2016), with be-
tween 60 and 80% of these cases being caused by the dominant GII.4 strain (Kroneman
et al., 2008). While individuals within the population are likely to be differentially sus-
ceptible to different pandemic strains through their HBGA expression (Lindesmith et al.,
2008), the dominance of each pandemic strain for a typical period of 2-3 years suggests
that even towards the end of the pandemic period, a large number of susceptible individ-
uals will remain within the population. This coupled with efficient transmission (Hall,
2012; de Graaf et al., 2016) enabling infection of susceptible individuals likely therefore
enables a virus to persist within a population for long time periods (Figure 4.5) and means
that frequent inter-continental transmission is not necessary for persistence. Interestingly,
we estimate that the rate of inter-continental transmission is highest prior to and in the
first year of the pandemic and decreases throughout the pandemic (Figure 4.6). This is
unlikely to be explained by a large number of cases within the first year of the pandemic
resulting in more opportunities for migration due to the similarly high rate prior to the
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pandemic, during a time at which the strain is present at low frequency. We therefore hy-
pothesise that increasing herd immunity within the population during the pandemic may
make it harder for a virus to migrate into the population.
We identified the substitutions that potentially enabled the emergence of the five
most recent pandemic GII.4 strains by identifying sites that exhibited a nonsynonymous
substitution leading to the strain common ancestor and a different amino acid residue(s)
in the pandemic strain compared with the preceding pandemic strain (Figures 4.10-4.21).
The emergence of a large number of pre-diversified lineages that likely account for a
small proportion of all of the GII.4 lineages present at that point in time suggests that
there is a phenotypic characteristic that is shared by and unique to these lineages. This
is supported by the lack of evidence of particular lineages outcompeting other lineages
within a pandemic strain (Figure 4.2), indicating each lineage has similar fitness within
the human population. The large number of low level strains present at each point in
time (Figure 3.1) suggests that the lineages that emerge have a phenotypic advantage,
rather than each of the other low level strains having acquired a phenotypic disadvantage.
Together, these observations support our hypothesis that the substitutions important for
pandemic emergence were acquired by the root of the pandemic clade.
We identified three substitutions (S301N, A368E and N373H) that were potentially
important for the pandemic emergence of Sydney 2012 (Figures 4.10, 4.11). Our results
support previous experimental work on Sydney 2012 (Debbink et al., 2013) and further
experiments are under way to validate the importance of these substitutions (as described
in section 4.4.6). We could clearly identify the substitutions that occurred leading to the
common ancestors of the New Orleans 2009 (Figure 4.12) and Farmington Hills 2002
(Figure 4.19) strains. These substitutions included changes at sites within and close to
known epitopes in each case (Figures 4.12, 4.19). It has previously been suggested that
sites close to known epitopes may alter viral antigenicity (Lindesmith et al., 2012a) and
it is therefore possible that sites close to known epitopes may enable pandemic emer-
gence. Identifying the substitutions that occurred leading to the Hunter 2004 and Den
Haag 2006 pandemic strains was challenging due to uncertainty in the tree topology in
each of these regions (Figures 2.1, 4.17). We were not able to conclusively determine
the node that represents the common ancestor of Hunter 2004, although we did identify
the nonsynonymous substitutions that occurred leading to each of the possible ancestors
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(Figure 4.17). Accurate determination of the true Hunter 2004 ancestor will require ex-
perimental testing of the antigenic properties of the reconstructed sequences at nodes 1,
2 and 3 in Figure 4.17 and comparison with sampled viruses within the Hunter 2004 and
Yerseke 2006 strains. We identified a large number of nonsynonymous substitutions that
occurred leading to the Den Haag 2006 common ancestor (Figure 4.14), with these sub-
stitutions localising to multiple regions on the surface of the viral capsid (Figure 4.15).
While we carried out homology modelling to predict the stuctural impact of substitutions
leading to strain common ancestors (Figures 4.11, 4.16, 4.18, 4.20), we emphasise the
importance of experimental validation to test the influence of each substitution on viral
antigenicity. In particular, efforts are underway to reconstruct VLP panels for Farmington
Hills 2002, Hunter 2004, Den Haag 2006 and New Orleans 2009 as described for Syd-
ney 2012 in section 4.4.6. While we expect a change in antigenicity to be a major factor
enabling pandemic emergence, substitutions may have alternative phenotypic effects that
could promote pandemic spread, for example increasing particle stability or adaptability.
Interestingly, each of the pandemic strains exhibits a high degree of variability at
the amino acid level (Figures 4.22, S4.4-S4.9 Table 4.3), with this variation commonly
coinciding with putative epitopes (Figure 4.23) and HBGA-binding sites (Figure 4.24).
New Orleans 2009 and Sydney 2012 began to accumulate diversity, including within epi-
topes and HBGA-binding sites, prior to pandemic emergence (Figures 4.25, 4.26) and the
pandemic therefore involved the emergence of closely related, but genetically distinct,
viruses. The onset of these pandemics therefore involved a soft selective sweep. We
propose an extension to the three stage process of strain emergence where the low level
pre-pandemic strain moves to a new region of antigenic space during the acquisition of
changes phase (stage 1) due to one or more major changes (for example N310S, A368E
and/or N373H in Sydney 2012) (Figure 4.28). It is not clear where in the antigenic space
the pre-pandemic strain was prior to this point, but these important genetic changes result
in movement to an antigenic region that is distinct to that of the current pandemic strain.
The new region of antigenic space does not allow the pre-pandemic strain to emerge at
that point in time, but rather the viruses in this region of the antigenic space will be able
to emerge as a pandemic in the future. We hypothesise that emergence during this period
is prevented by partial cross-reactivity of population immunity raised against the current
pandemic strain and/or preceding pandemic/epidemic strains. During the diversification
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phase, the strain acquires additional diversity that moves individual lineages within the
local antigenic space, but each lineage remains in the same general region of antigenic
space (Figure 4.28). At the onset of the pandemic, we hypothesise that all of the viruses
within a certain region of the antigenic space can emerge, enabling the emergence of a
diverse group of lineages that each share some antigenic characteristic(s). The region of
antigenic space containing the viruses that can emerge will depend upon the immunity
that has been built against the preceding pandemic strain, and potentially the pandemic
and/or epidemic strains preceding that strain. Under this hypothesis, there are multiple
regions of antigenic space that are occupied by low level viruses at any point in time and
at the onset of the new pandemic, the strain with the best fit to the niche opened by the
decline of the previous pandemic strain emerges.
The sites that exhibit high variability within a pandemic strain are typically specific to
each strain, with only a small number of sites exhibiting high variability in more than one
pandemic strain (Table 4.4). This indicates that this variation occurs either due to a strain-
specific relaxation in selective constraints at the site or due to a strain-specific selective
pressure to change at the site. While highly variable sites often coincide with epitope
sites, the accumulation of diversity at such sites prior to pandemic emergence within
New Orleans 2009 and Sydney 2012 suggests that variability is unlikely to be driven
by a selection pressure to escape population immunity. Here, when the strain is present
at low frequency there is likely a large susceptible population size and little population
immunity to provide such a selection pressure. The variation within pandemic strains
does not appear to correlate with geographical region as each of the common changes
in Den Haag 2006, New Orleans 2009 and Sydney 2012 are found in viruses collected
worldwide. Therefore the variation is unlikely to be driven by a selective pressure to
better adapt to a specific geographical host population. However, site 393 is the only site
that is variable in four of the six pandemic strains (Table 4.4) and is located within a loop
required for binding to certain HBGAs (Singh et al., 2015). Indeed, substitutions at this
site can alter HBGA binding (Lindesmith et al., 2008). Site 393 is highly variable between
glycine and serine within Den Haag 2006, New Orleans 2009 and Sydney 2012 (Figures
S4.7-S4.9). While the variation at this site does not correlate with geographical location,
we hypothesise that viruses with glycine or serine at this site will have different HBGA-
binding profiles. As individuals with the same HBGA expression are found worldwide,
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substitutions at site 393 may provide a mechanism by which these strains can increase
their susceptible population size and persist for longer.
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Chapter 5
The emerging GII.P16-GII.4 Sydney
2012 norovirus lineage is circulating
worldwide, arose by late-2014 and
contains polymerase changes that may
increase virus transmission
5.1 Abstract
Noroviruses are the leading cause of human gastroenteritis worldwide. The norovirus
genotype GII.4 causes most human outbreaks and has caused six pandemics of gastroen-
teritis since the mid-1990s. A novel norovirus lineage containing the pandemic GII.4
Sydney 2012 capsid in combination with the GII.P16 polymerase was recently detected
in Asia and Germany. Here, we demonstrate that the GII.P16-GII.4 Sydney 2012 lineage
is also circulating within the UK and USA and has been circulating since October 2014
or earlier. This lineage does not contain unique capsid substitutions but does contain sub-
stitutions in the polymerase that are close to positions known to influence polymerase
function and virus transmission. These polymerase substitutions are shared with another
novel norovirus lineage, GII.P16-GII.2, that also emerged as a major cause of norovirus
outbreaks in Winter 2016-2017. Given the increase in prevalence of two novel lineages
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that share polymerase substitutions but have different capsid genotypes, we suggest that
these polymerase substitutions may have resulted in a more transmissible virus. Addition-
ally we suggest that the combination of an advantageous polymerase with the pandemic
GII.4 Sydney 2012 capsid may result in a highly transmissible virus. Further surveillance
efforts will therefore be required to determine whether the GII.P16-GII.4 Sydney 2012
lineage increases in frequency and replaces the previously dominant GII.Pe-GII.4 Sydney
2012 virus over the coming months.
5.2 Introduction
The norovirus genotype GII.4 has been dominant within the human population since
the mid-1990s, during which time it has caused six pandemics (Siebenga et al., 2007; van
Beek et al., 2013). However, in the 2014-2015 Winter, a novel GII.17 lineage (termed
Kawasaki 2014) emerged as the dominant cause of norovirus outbreaks in Asia (Mat-
sushima et al., 2015; De Graaf et al., 2015; Lu et al., 2015). The origins of this lineage
were traced back to Africa, with a single introduction into Asia (Lu et al., 2016). While
sporadic cases of GII.17 Kawasaki 2014 have been detected from many countries world-
wide since emergence in late 2014 (Chan et al., 2017a), this lineage has not replaced GII.4
Sydney 2012 as the dominant strain in most countries worldwide and therefore appears
to be largely restricted to East Asia. More recently, two more novel norovirus lineages
have emerged as major causes of norovirus outbreaks. The first of these lineages contains
the GII.4 Sydney 2012 capsid with a GII.P16 RdRp, with reports of this lineage circulat-
ing within South Korea, Japan and Germany (Choi et al., 2017; Matsushima et al., 2016;
Niendorf et al., 2017). While the GII.P16 RdRp is not typically prevalent, a GII.P16-GII.2
virus was the dominant strain amongst a large peak of norovirus cases and outbreaks in
Germany in Winter 2016-2017 (Niendorf et al., 2017). Therefore these two novel lineages
each contain the GII.P16 ORF1 but different capsid genotypes. The emergence of new
GII.4 strains has often been associated with increased outbreaks, likely due to a lack of
protective immunity against the new strain within the human population, raising concerns
that the emergence of these novel lineages may result in increased outbreaks. Here, we
demonstrate that the GII.P16-GII.4 Sydney 2012 lineage is also circulating within the
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UK and USA. This lineage does not contain unique capsid substitutions, but does contain
RdRp substitutions that are shared with the GII.P16-GII.2 RdRp and are close to positions
known to influence RdRp function and viral transmission. These RdRp substitutions were
acquired by March 2013. We conclude that these RdRp substitutions (possibly assisted by
other substitutions in ORF1) have likely resulted in a more transmissible virus and have
driven the increase in these novel norovirus lineages.
5.3 Materials and Methods
5.3.1 Sample collection, dataset assembly and sequencing
We identified noroviruses with the GII.P16 RdRp in ten stool samples collected as part
of routine surveillance between June 2015 and April 2016. Samples were collected from
South East and North West England from both sporadic cases and outbreaks. Four of
these faecal specimens were referred to the Virus Reference Department, Public Health
England, as part of a sentinel norovirus strain surveillance programme, which collects
norovirus-positive specimens from geographically disparate regions across England. The
other six faecal specimens were collected from a tertiary referral paediatric hospital in
London, UK. RNA was extracted and whole genome sequencing performed as described
previously (Brown et al., 2016b). For each sample, reads were mapped against a set of
norovirus whole genome reference sequences spanning all known human genotypes to
identify the best matching reference sequence. Whole genome sequences were assem-
bled via reference mapping to this best matching reference. Consensus sequences were
extracted from this mapping and used for all downstream analyses. Sample genotyping
was carried out using the norovirus genotyping tool (Kroneman et al., 2011).
5.3.2 Phylogenetic analyses
Due to the presence of recombination close to ORF boundaries (Bull et al., 2007; Eden
et al., 2013), we carried out all phylogenetic analyses on each ORF separately. We com-
bined our sequences with all of the available sequences from the same genotype or strain
available on GenBank with an available collection date as of 27/01/2017 to create datasets
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for the GII.P16 ORF1 (n=45 including our samples), GII.P16 RdRp (n=179 including our
samples), GII.4 Sydney 2012 capsid (n=717 including our samples) and GII.4 Sydney
2012 VP2 (n=176 including our samples). For samples without an accurate collection
date, effort was made to identify the collection date with reference to the original litera-
ture. We aligned each dataset at the amino acid level using MUSCLE (Edgar, 2008) and
reconstructed a nucleotide maximum likelihood tree for each dataset using RAxML (Sta-
matakis, 2014) with the GTR model of nucleotide substitution and gamma rate variation
with 4 gamma classes. We assessed topological robustness using 1000 bootstrap repli-
cates. Sequences that exhibit an excess of nucleotide change relative to their collection
date may contain sequencing errors or a recombination breakpoint(s) or may have an in-
correct collection date and the inclusion of such sequences can bias estimates of ancestral
dates (Rambaut et al., 2016). Sequences that were overly divergent based on their col-
lection date, as assessed using TempEst v1.5 (Rambaut et al., 2016), were removed from
further analysis. We reconstructed the temporal evolutionary history in the GII.P16 RdRp
and GII.4 Sydney 2012 capsid datasets using BEAST v2.4.2 (Bouckaert et al., 2014). For
the GII.4 Sydney 2012 capsid dataset, we identified a well supported clade within the
maximum likelihood tree (bootstrap support 81) that contains 70 sequences including all
of the GII.P16-GII.4 Sydney 2012 sequences and ran BEAST on this smaller dataset. We
used the most accurate collection date available for each sequence; the day of collection if
available, the middle of the month of collection if the day of collection was not available
or the middle of the year of collection if the month of collection was not available. We
used the HKY model of nucleotide substitution with gamma rate heterogeneity with four
rate classes. We used both the strict and relaxed lognormal clock models to test for varia-
tion in substitution rate across each clade. In each dataset, we employed a lognormal prior
distribution on the substitution rate parameter. For the GII.4 Sydney 2012 capsid dataset,
we set the mean of this prior distribution to 6.4x10-3, which is the point estimate of the
substitution rate parameter for the Sydney 2012 capsid estimated in chapter 3.4.3. For
the GII.P16 RdRp dataset, we set the mean of the lognormal prior distribution to 3.1x10-3
which is the slope of the regression line between root-to-tip distance and sampling date
calculated within TempEst v1.5 (Rambaut et al., 2016). In both cases, the standard devia-
tion on the prior distribution was set to 0.1. We applied a coalescent Bayesian skyline tree
prior. We carried out three replicate runs on each clock model with each dataset and ran
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until convergence, as assessed using Tracer v1.6. The replicate runs were combined with
removal of suitable burnin using LogCombiner v2.2.1 and the maximum clade credibility
tree was identified using TreeAnnotator v2.2.1. To infer the nonsynonymous substitutions
that occurred along branches of interest, we carried out ancestral reconstruction using the
maximum likelihood tree reconstructed for each dataset. Initially, we used RAxML to op-
timise branch lengths in the maximum likelihood tree using the amino acid alignment with
the WAG substitution model. Ancestral reconstruction was carried out using PAML v4.9
with the WAG substitution matrix and the nonsynonymous substitutions along branches
of interest were inferred by comparing the reconstructed sequence at the start and end of
the branch (Yang, 2007). The nonsynonymous substitutions that occurred leading to the
novel GII.P16 clade in the RdRp are the same when using the ORF1 dataset and the RdRp
dataset.
Ancestor dates were calculated using the complete posterior distribution of trees in
each case. To identify the date at which the novel GII.P16 lineage diverged from the other
sampled GII.P16 sequences, we calculated the date of the node immediately upstream
of the common ancestor of the novel GII.P16 lineage in each tree in the posterior distri-
bution and calculated the mean and 95% HPD of the distribution of this node date. To
determine the date at which GII.4 Sydney 2012 acquired the GII.P16 RdRp, we identified
the branch along which this acquisition occurred in each tree in the GII.4 Sydney 2012
capsid posterior distribution. We calculated the start date and end date of this branch and
then calculated the mean and 95% HPD of this distribution of branch times. To identify
whether the GII.P16-GII.3 sequences emerged from the GII.P16-GII.4 Sydney 2012 clade
in the RdRp tree, we identified whether the GII.P16-GII.3 clade emerged from within the
GII.P16-GII.4 Sydney 2012 clade in each tree in the posterior distribution. We defined
the posterior probability as the proportion of trees that supported the GII.P16-GII.3 clade
emerging from the GII.P16-GII.4 Sydney 2012 clade.
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5.4 Results
5.4.1 The novel GII.P16 lineage has been circulating since March
2013 or earlier
Recent real time surveillance studies have identified the increased prevalence of viruses
with the GII.P16 RdRp (Choi et al., 2017; Niendorf et al., 2017). We identified and
whole genome sequenced ten viruses containing the GII.P16 RdRp that were collected in
the UK as part of routine surveillance between June 2015 and April 2016. Genotyping
demonstrated that seven of these viruses contained the GII.4 Sydney 2012 capsid and
three contained the GII.3 capsid. The ten RdRp sequences cluster within a single clade
in a RdRp maximum likelihood tree containing all available reference GII.P16 sequences
(Figure 5.1). This clade also contains GII.P16-GII.4 Sydney 2012 sequences collected in
the USA and Japan, including the GII.P16-GII.4 Sydney 2012 virus collected in 2016 in
Kawasaki City, Japan (Matsushima et al., 2016). These RdRp sequences also cluster with
the GII.P16-GII.2 RdRps collected in Germany in Winter 2016-2017 (Niendorf et al.,
2017). There is a good correlation between root-to-tip distance and sampling date within
the GII.P16 clade (Figure 5.1). We infer that the common ancestor of this GII.P16 clade
occurred in March 2013 (95% HPD January 2012-May 2014, Figure 5.2), however this
clade diverged from the other sampled GII.P16 sequences in January 2008 (95% HPD
October 2004-March 2010). In both the maximum likelihood and Bayesian trees, it is
well supported that the RdRps from the GII.P16-GII.3 and GII.P16-GII.4 Sydney 2012
sequences form a monophyletic cluster (Figure 5.1, 5.2). It is not clear, however, whether
the GII.P16-GII.3 sequences emerged from within the GII.P16-GII.4 Sydney 2012 clade,
with posterior support on this scenario of 0.44.
In a phylogenetic tree containing all GII.4 Sydney 2012 capsid sequences, the
GII.P16-GII.4 Sydney 2012 sequences collected in the UK again cluster with sequences
collected in the USA and Japan containing the GII.P16 RdRp (Figure 5.3). This clade
contains additional capsid sequences collected in the USA where the RdRp was not se-
quenced. However, as all of the RdRps that have been sequenced within this clade are
of the GII.P16 genotype, it is very likely that these samples also have the GII.P16 RdRp,
although without additional sequencing and genotyping this remains speculative. There is
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Figure 5.1: Maximum likelihood tree of the GII.P16 RdRp. (A) Nucleotide maximum likeli-
hood tree of 179 GII.P16 RdRp sequences reconstructed using RAxML. Sequences
within the novel GII.P16 lineage are coloured by capsid genotype: blue - GII.2, ma-
genta - GII.3, red - GII.4 Sydney 2012. Bootstrap supports are shown at key nodes.
(B) Correlation between root-to-tip distance and sampling date for the GII.P16 tree.
a correlation between the root-to-tip distance and sampling date within the GII.4 Sydney
2012 clade containing the GII.P16-GII.4 Sydney 2012 sequences (Figure 5.3). It is not
clear whether GII.4 Sydney 2012 acquired the GII.P16 RdRp along the branch leading
to the node in the tree where sequence KX354140.1 diverged (node A in Figure 5.3) or
whether the GII.P16 RdRp was acquired after the divergence of sequence KX354140.1
(leading to node B in Figure 5.3) as the RdRp region was not sequenced in this sample.
Given the long branch length leading to node A compared with the shorter branch length
leading to node B, it is plausible that the GII.P16 RdRp was more likely acquired leading
to node A. Node B occurred in October 2014 (95% HPD June 2014-February 2015) while
node A occurred in May 2014 (95% HPD October 2013-October 2014). If the GII.P16
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Figure 5.2: Temporal evolutionary history of the GII.P16 lineage. Time tree of 179 GII.P16
RdRp sequences reconstructed using BEAST 2. The sequences within the novel
GII.P16 clade are coloured by the associated capsid genotype: blue - GII.2, magenta
- GII.3, red - GII.4 Sydney 2012. The starred node is the common ancestor of this
clade. Posterior supports are shown at key nodes.
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Figure 5.3: Evolutionary history of the GII.4 Sydney 2012 capsid. (A) A maximum likelihood
phylogenetic tree was reconstructed for 781 GII.4 Sydney 2012 capsid sequences.
From this, a well supported clade (bootstrap support 81) containing the GII.P16-GII.4
Sydney 2012 lineage and several other sequences was selected and a time tree re-
constructed on this smaller dataset using BEAST 2. Node A and node B are the
nodes that could be the common ancestor of the GII.P16-GII.4 Sydney 2012 clade;
the RdRp region was not sequenced in sample KX354140.1 that branches from node
A. The samples within the GII.P16-GII.4 Sydney 2012 lineage are coloured based
on the country from which they were isolated: blue - UK, purple - USA, green -
Japan. Posterior supports are shown at key nodes. (B) Correlation between root-to-tip
distance and sampling date for the clade used in reconstruction of the time tree.
RdRp was acquired leading to node A, it was likely acquired in July 2013 (95% HPD
September 2012-July 2014) while if the GII.P16 RdRp was acquired leading to node B,
it was likely acquired in May 2014 (95% HPD February 2013-December 2014).
5.4.2 The novel GII.P16 lineage acquired substitutions in multiple
ORF1 proteins, including the RdRp
No nonsynonymous substitutions occurred in the capsid leading to the GII.P16-GII.4 Syd-
ney 2012 clade and there are no amino acid changes that are shared by the sequences in
this clade that are not found in other Sydney 2012 capsids. Therefore the capsid sequences
in this clade do not contain unique changes. However, we infer that 14 nonsynonymous
substitutions occurred in ORF1 leading to the common ancestor of the GII.P16-GII.4 Syd-
ney 2012/GII.3 clade (Figure 5.2, Table 5.1), with 11 of these changes being conserved
amongst the sequences within this clade. Five of the sites at which substitutions occurred
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are within the RdRp, with several of the sites occurring close to positions known to impact
RdRp function and virus transmission (Figure 5.4) (Bull et al., 2010; Arias et al., 2016).
Only the partial RdRp was sequenced from ORF1 in the GII.P16-GII.2 samples collected
in Germany in Winter 2016-2017 (Niendorf et al., 2017) and this region only contains
four of the sites that change leading to the common ancestor of the GII.P16-GII.4 Syd-
ney 2012/GII.3 clade. However, all four of these nonsynonymous substitutions were also
found within the GII.P16-GII.2 Germany sequences and these substitutions were there-
fore acquired by the common ancestor of the RdRp clade containing the GII.2, GII.3
and GII.4 Sydney 2012 sequences. We also infer a single nonsynonymous substitution
(S157N) occurred in VP2 along the branch leading to the GII.P16-GII.4 Sydney 2012
clade.
Nonsynonymous change Protein RdRp position Conserved within the
novel GII.P16 clade
N52E P48 (NS1/2) N/A Yes
S53P P48 (NS1/2) N/A No
K165R P48 (NS1/2) N/A Yes
S644P NTPase (NS3) N/A No
R731K P22 (NS4) N/A Yes
K750R P22 (NS4) N/A Yes
P845Q P22 (NS4) N/A Yes
A853T P22 (NS4) N/A Yes
V1057I Protease (NS6) N/A Yes
D1362E RdRp (NS7) 173 Yes
S1482T RdRp (NS7) 293 Yes
V1521I RdRp (NS7) 332 No
K1546Q RdRp (NS7) 357 Yes
T1549A RdRp (NS7) 360 Yes
Table 5.1: Nonsynonymous substitutions in ORF1 leading to the novel GII.P16 clade. Each
of the nonsynonymous substitutions that occurred leading to the common ancestor of
the novel GII.P16 clade is shown with the nonstructural protein in which the site sub-
stitution occurred. Conserved sites have the same residue within each sequence in the
novel GII.P16 clade.
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Figure 5.4: Location of RdRp sites that changed leading to the novel GII.P16 clade. The sites
that changed leading to the novel GII.P16 lineage are shown in red. The sites that
form the RdRp active site are shown in blue. Sites previously demonstrated to alter
RdRp fidelity and/or viral transmission when mutated are shown in magenta (Arias
et al., 2016). Site 291 was previously shown to alter the RdRp incorporation rate and
is shown in orange (Bull et al., 2010). Sites are highlighted on PDB structure 1SH0,
which is a structure of a GII.P4 RdRp (Ng et al., 2004).
5.5 Discussion
It has recently been reported that two novel norovirus lineages have become prevalent in
outbreaks in several countries (Choi et al., 2017; Matsushima et al., 2016; Niendorf et al.,
2017). Interestingly, these two novel lineages contain the GII.P16 ORF1 but different
capsid genotypes. Here, we demonstrate that the GII.P16-GII.4 Sydney 2012 lineage is
circulating within the UK and USA, in addition to the previous reports of circulation in
Asia and Germany. We demonstrate, for the first time, that the same GII.P16 lineage is
circulating in combination with the GII.3 capsid (Figure 5.1). This GII.P16 lineage is
also found with the GII.2 capsid (Figure 5.1) and acquired substitutions in five of the six
nonstructural proteins relative to other GII.P16 sequences (Table 1). Our phylogenetic
analyses suggest that the novel GII.P16 lineage has been circulating since March 2013 or
earlier and has been circulating with the GII.4 Sydney 2012 capsid since at least October
2014. Our analysis therefore suggests that the novel GII.P16 lineage circulated for at least
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two years prior to its first identification. From the phylogenetic trees it is not clear which
capsid genotype is likely to have been found ancestrally with the novel GII.P16 RdRp,
with no clear support for the GII.P16 RdRps with one capsid genotype emerging from
those with another capsid genotype (Figure 5.1, 5.2). However, the clustering in the tree
does support each capsid genotype acquiring the GII.P16 RdRp through a single recom-
bination event. The emergence of viruses with different capsid genotypes but a shared
ORF1 lineage strongly suggests that it is the ORF1 that is important for the emergence of
these strains and that one or more of the nonsynonymous changes that occurred leading to
the common ancestor of the novel GII.P16 lineage may have resulted in a large increase
in viral fitness (Table 5.1).
The increase in prevalence of the GII.P16 ORF1 with several different capsid geno-
types is characteristic of a soft selective sweep driven by the GII.P16 ORF1. While little
is known about the influence of several of the nonstructural proteins on viral transmission,
previous studies have implicated the RdRp as an important component of viral fitness and
it was recently demonstrated that changes in the RdRp can influence viral transmission
by modulating replication fidelity and therefore viral diversity (Bull et al., 2010; Arias
et al., 2016). Several of the substitutions leading to the common ancestor of the novel
GII.P16 lineage are located within the palm domain of the RdRp and it is this region
that contains most of the catalytic residues (Figure 5.4). While only four of the sites that
changed leading to the novel GII.P16 lineage were sequenced in the GII.P16-GII.2 viruses
from Germany, these viruses also contained the substitutions at these sites. We therefore
suggest that the worldwide circulation of the GII.P16-GII.4 Sydney 2012 lineage and the
high prevalence of viruses with the GII.P16 RdRp in the 2016-2017 Winter occurred due
to increased transmissibility driven by RdRp changes in GII.P16. Testing the phenotypic
consequences of the nonsynonymous substitutions acquired leading to the novel GII.P16
lineage in the recently developed human norovirus culture systems (Jones et al., 2014;
Ettayebi et al., 2016) should be a priority.
The GII.2 capsid is typically rare and is therefore unlikely to be as fit as the prevalent
GII.4 capsid. It is therefore possible that the combination of an advantageous RdRp with
the GII.4 Sydney 2012 capsid may result in a highly transmissible virus. However, as
the GII.P16-GII.4 Sydney 2012 lineage does not contain unique substitutions in the cap-
sid region, this lineage is unlikely to be able to evade population immunity that has been
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raised against the Sydney 2012 strain since its emergence as the pandemic strain in 2012.
Whether the GII.P16-GII.4 Sydney 2012 lineage increases in prevalence in the future may
therefore be determined by a balance between the benefit of combining an advantageous
RdRp with a fit capsid and the decreased transmissibility of the Sydney 2012 capsid due
to existing population immunity. Interestingly, since the time of this work GII.P16 viruses
were found to also be prevalent in France, China and Taiwan during Winter 2016-2017
(Lu et al., 2017; Ao et al., 2017; Liu et al., 2017; Bidalot et al., 2017). There is a pattern
emerging whereby the GII.P16-GII.2 strain is dominant in outbreaks amongst younger
individuals (for example within kindergartens and schools), while GII.P16-GII.4 Sydney
2012 is dominant in outbreaks amongst older individuals (for example within nursing
homes). This is consistent with the prevailing hypothesis that non-GII.4 capsid geno-
types remain static through time and cannot therefore infect older individuals, while the
GII.4 genotype has the capacity to evolve to evade host immunity and therefore can infect
older individuals (Parra et al., 2017). The GII.P16-GII.3 viruses we detected were all iso-
lated from children, which is also consistent with this hypothesis. This suggests that the
GII.P16-GII.2 and GII.P16-GII.3 lineages are unlikely to be responsible for an increase
in outbreaks in adults in the future. However, this further highlights the likely importance
of the nonsynonymous substitutions in the GII.P16 ORF1, with the capsid appearing to
act more as a vehicle to enable the virus to infect susceptible individuals.
Further surveillance will be required to determine whether the GII.P16-GII.2,
GII.P16-GII.3 and GII.P16-GII.4 Sydney 2012 strains increase in frequency in the future.
Importantly, surveillance strategies involving capsid genotyping alone will be unable to
distinguish between the GII.P16-GII.4 Sydney 2012 capsid sequences and GII.4 Sydney
2012 capsid sequences circulating with the GII.P4 New Orleans 2009 or GII.Pe RdRps.
It is therefore vital that surveillance efforts genotyping both the capsid and RdRp assess
the prevalence of these strains over the coming months.
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Chapter 6
Conclusions and future directions
The work in this thesis was concerned with understanding the evolution of GII.4
norovirus, the mechanism(s) through which this genotype circulates at high frequency
within the human population and the sources and drivers of norovirus pandemics.
6.1 Understanding why the GII.4 genotype became pan-
demic in the mid-1990s
In chapter 2, we examined the factors that likely drove the increase in prevalence of the
GII.4 capsid in the mid-1990s. While previous studies have suggested mechanisms that
may enable GII.4 to be highly prevalent, this is the first study that has examined the non-
synonymous substitutions that occurred leading to the pandemic GII.4 clade. Crucially, as
these substitutions demarcate the low prevalence GII.4 lineages from the high prevalence
GII.4 clade, they are likely responsible for this discrepancy in prevalence. Our results
provided evidence that substitutions in the capsid and/or VP2 resulted in the increase in
GII.4 prevalence. While we do hypothesise that the associated RdRp may be an important
pre-requisite for high prevalence due to a putative high mutation rate, we demonstrated
that this high mutation rate was likely acquired by 1906 and the RdRps found with pan-
demic GII.4 capsids last shared a common ancestor in the 1970s. Therefore while the
associated RdRps may enable more efficient transmission, they did not drive the increase
in prevalence in the mid-1990s. We identified the sites that were most likely responsible
for the increase in RdRp substitution rate in 1906: 105 and 189. Future experiments to
directly test the influence of F105Y, A189S and A189G mutations on the RdRp mutation
rate and replication rate using previously developed assays (Bull et al., 2010) and/or in
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the newly developed human norovirus culture systems (Jones et al., 2014; Ettayebi et al.,
2016) would verify whether these changes truly drove the increase in substitution rate and
which of the determinants of the substitution rate these RdRp substitutions affect.
The importance of substitutions in VP2 was hard to assess due to the paucity of infor-
mation on VP2 functions and important residues for those functions. We identified sites
72, 78, 93, 148 and 187 in VP2 as being potentially important for the increase in GII.4
prevalence. In the future, the incorporation of the VP2 sequence at the common ancestor
of the pandemic GII.4 clade and the sequence at the node upstream of this common an-
cestor into in vitro assays would enable probing of the functional relevance of changes at
each of these sites. Given current evidence on the functions of VP2, it would be partic-
ularly interesting to test the stability of viral particles produced with each VP2 sequence
and the efficiency of genome recruitment into viral particles.
While VP2 may have had a role in the increase in GII.4 frequency, we hypothesise
that the major driver of this increase was substitutions in the capsid. We identified non-
synonymous substitutions at 17 sites leading to the common ancestor of the pandemic
GII.4 clade, although six of these sites exhibit the same amino acid residues in the pre-
pandemic GII.4 lineages and the pandemic GII.4 clade and are therefore unlikely to be
important. From these substitutions, we hypothesised two mechanisms by which the in-
crease in frequency may have occurred: an increase in capsid stability and an increase
in the range of HBGA-binding. The L333M and L459Q substitutions occurred at sites
located in the dimer interface and we identified an increased interaction network formed
by Q459 compared with S459 in solved crystal structures and inferred an increase in this
network with Q459 compared with L459 in homology models. In the future, obtaining
crystal structures of pre-pandemic GII.4 P domains with L at site 459 would confirm
whether there was indeed an increase in the interaction network in this region leading to
the pandemic GII.4 clade. Additionally, capsid sites 93, 172, 176, 295, 497 and 505 un-
derwent a substitution leading to the pandemic GII.4 clade and then remained conserved
throughout this clade. While these sites are not known to carry out particular functions,
we hypothesised that these substitutions may have increased protein stability, providing
a selective constraint not to change within the pandemic GII.4 clade. Such an increase
in protein stability may have enabled the rapid accumulation of amino acid change we
and others observe within the pandemic GII.4 clade. Our hypothesis of increased capsid
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stability could be tested by measuring the length of time pre-pandemic GII.4 lineage and
pandemic GII.4 clade viruses remain infectious upon surfaces or in groundwater. The
newly developed cell culture systems (Jones et al., 2014; Ettayebi et al., 2016) would en-
able determination of whether the viruses remain replication-competent after set periods
of time. Additionally, measuring the tolerance of sites throughout the capsid to mutation
in the pandemic GII.4 clade and the pre-pandemic GII.4 lineages, either in silico or ex-
perimentally, would determine whether substitutions leading to the pandemic GII.4 clade
enabled greater accumulation of amino acid change.
An increased HBGA-binding range has previously been hypothesised to enable the
high prevalence of GII.4 viruses (Lindesmith et al., 2008; Donaldson et al., 2008), al-
though here we provide a potential mechanism through the increased mobility of the
391-395 loop due to a decrease in residue size at site 395. Molecular dynamics work
to examine the mobility of this loop with the pre-pandemic H residue at this site and the
pandemic A, N and T residues at this site would be useful in the future. However, the
high prevalence of GII.4 through to the present day suggests that the mechanisms respon-
sible for high prevalence have been retained in each pandemic strain. Therefore the low
efficiency of binding of Hunter 2004 to all tested HBGAs calls into question increased
HBGA-binding as a mechanism of increased GII.4 prevalence. Future studies to deter-
mine firstly whether Hunter 2004 was less prevalent than other pandemic GII.4 strains and
whether Hunter 2004 may have used alternate attachment factors are therefore necessary
to determine whether increased HBGA-binding is truly a potential mechanism. While we
identify these two mechanisms that may have resulted in an increase in prevlaence, there
is clear potential for other mechanisms to have assisted in the increase.
In the final section in chapter 2, we compared the accumulation of nucleotide and
amino acid change through time within GII.4 and other GII capsid genotypes. We found
that while most GII genotypes accumulate change through time at the nucleotide level,
GII.4 is the only genotype that accumulates change through time at the amino acid level.
Concurrently with this work, another study was published with similar conclusions (Parra
et al., 2017). However, we infer that the pre-pandemic GII.4 lineages were already accu-
mulating amino acid change, albeit to a lower magnitude than the pandemic GII.4 clade.
This suggests that the GII.4 capsid structure is inherently able to accomodate amino acid
change in a way that the structures of the other GII capsid genotypes are not. This ability
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to accomodate change may have been increased further leading to the pandemic GII.4
clade, as previously discussed. Confirmation of these results through estimation of nu-
cleotide substitution rates and dN/dS ratios would be useful. Future studies examining
exactly where within the capsid structure this amino acid change has been accumulated
coupled with in silico analysis of the tolerance of capsid sequences from different geno-
types to mutation may suggest a mechanism by which this change can be accomodated.
We conclude that the pandemic emergence of the GII.4 capsid genotype was a ‘per-
fect storm’ where a highly adaptable capsid structure found with a RdRp that enables
rapid mutation and therefore efficient transmission acquired additional capsid stability
and/or an increase in the susceptible population size through a broadened HBGA-binding
range.
6.2 Understanding the sources and drivers of norovirus
pandemics
In chapters 3 and 4, we examined the sources and drivers of the frequent norovirus pan-
demics that have occurred since the mid-1990s. Reconstruction of the temporal evolution-
ary history of the GII.4 genotype demonstrated that each of the pandemic and epidemic
GII.4 strains was present and hidden for years prior to causing their respective pandemic
or epidemic. This provided evidence for the first time that none of the pandemic strains
evolved directly from a preceding pandemic strain. Rather, pandemic strains diverge from
other strains years prior to emergence and evolve independently in one or more currently
poorly sampled reservoir populations. This was supported by the identification of pre-
pandemic sequences from multiple pandemic strains. We demonstrated that each of the
pandemic strains diverged into a large number of lineages over several years prior to
pandemic emergence and that the onset of the new pandemic is therefore caused by the
concurrent emergence of a large number of closely related viruses. This indicates that
the pandemic-enabling genetic changes are acquired years prior to pandemic spread and
are therefore not the proximal driver of the pandemic. We instead hypothesised that a
new pandemic is driven by changes in host immunity that enable the emergence of a pre-
adapted GII.4 strain (Figure 6.1). We finished this chapter by proposing a three stage
process of GII.4 pandemic strain emergence where 1) substitutions are acquired that will
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enable pandemic emergence in the future, 2) the strain diversifies into a large number
of lineages containing the pre-adaptation changes and 3) the multiple closely related lin-
eages emerge to cause the new pandemic. Our results suggest that increased surveillance
efforts of the community and poorly sampled geographical regions are required and cou-
pling such surveillance with methods to compare viral antigenicity has the potential to
detect strains that have the potential to become pandemic in the future before they ac-
tually do. These results additionally demonstrate the importance of a broadly targeting
vaccine against GII.4 norovirus as a vaccine targeted against an individual strain may
increase host herd immunity and hasten the onset of the next pandemic.
In chapter 4, we addressed questions raised by our analyses in chapter 3, in particular
examining potential source regions of norovirus pandemics and the viral genetic changes
that may enable a new pandemic to occur. We carried out a phylogeographic analysis of
the New Orleans 2009 and Sydney 2012 strains and demonstrated wide and consistent
circulation prior to pandemic emergence. In particular, each strain was introduced into
each continent prior to pandemic emergence and in most cases was first imported at least
two years prior to the pandemic. After introduction, the strain continued circulating within
the continent until at least the date of the latest sequence in out dataset from that continent.
Therefore these strains underwent consistent low-level worldwide circulation for several
years prior to emerging pandemically. We found no evidence of a consistent source region
for the origin or early circulation of pandemic GII.4 strains but did identify Asia as a net
source of viral lineages in each strain. Our phylogeographic analyses also identified that
viral lineages typically persist within a continent for roughly two years. Therefore we
suggest that the large peak of outbreaks within each winter season in temperate countries
is mostly caused by viruses that have persisted within the region since the previous winter.
We carried out an assessment of the nonsynonymous substitutions that occurred lead-
ing to the common ancestor of the five most recent pandemic GII.4 strains. These sub-
stitutions are very likely to have enabled the pandemic emergence of the strain as they
represent the changes that are specific to that clade of viruses compared with the other low
level pre-pandemic strains that our analysis in chapter 3 suggested are also present through
time. We hypothesised mechanisms that may have enabled the pandemic emergence of
each strain by examining homology models. Future studies employing monoclonal an-
tibodies and polyclonal sera that have been raised against each pandemic strain will be
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Figure 6.1: Changes in strain frequency and population immunity through time. Our results
in chapter 3 suggested that there are a large number of low level distinct GII.4 strains
present through time. Here, different coloured hexagons represent antigenically dis-
tinct GII.4 strains. The different pairs of strains have more or less cross-reactivity
of immunity between them depending on the pair, for example here the orange and
green strains are similar antigenically and so immunity against one strain is highly
cross-reactive against the other strain, while there is little cross-reactivity between the
orange and blue strains. At the start of the figure, the orange strain has recently be-
come pandemic and there is therefore rapidly increasing population immunity against
this strain. Due to the high cross-reactivity of immunity between the orange and green
strains, there is also a rapid increase in immunity against the green strain at this point
in time, even though the green strain is only present at low frequency in the popula-
tion. Due to little cross-reactivity between the orange and blue strains, the immunity
against the blue strain remains low. When population immunity against the orange
strain is high, this curtails the spread of the orange strain, thereby opening a niche
into which another strain can emerge. We hypothesise that the strain that emerges, in
this case the blue strain, is the strain that combines the best opportunity to spread with
the least cross-reactivity of immunity against the preceding pandemic strain, and po-
tentially against the pandemic and epidemic strains preceding that. Immunity against
the blue strain then increases in the population as the blue strain is highly prevalent.
However, as norovirus immunity is likely to be relatively short lasting, the immunity
against the orange and green strains decreases through time. As the immunity against
the blue strain is high, the spread of the blue strain is curtailed, opening the oppor-
tunity for the purple strain, which combines the best opportunity to spread with the
least cross-reactivity of immunity against the blue strain and other previous strains, to
emerge.
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useful to test which of the substitutions we identified alter viral antigenicity and may
have therefore enabled pandemic emergence. Such experiments testing the influence of
sites 310, 368 and 373 in the pandemic emergence of Sydney 2012 are already underway.
We identified significant amino acid variation within each of the pandemic GII.4 strains,
with highly variable sites often coinciding with epitope regions and/or HBGA-binding
sites. It is therefore possible that this variation alters important viral phenotypes, includ-
ing antigenicity and the susceptible population size. Importantly, diversity, including at
antigenic and HBGA-binding sites, began to be accumulated in New Orleans 2009 and
Sydney 2012 prior to pandemic emergence. Future experiments measuring antigeniticy
and HBGA-binding profiles would confirm this; again, these studies are underway for
Sydney 2012.
We incorporated the phylogeographic and analysis of amino acid substitution results
into our three stage process of strain emergence. During the diversification phase, the
lineages undergo spread to multiple geographically distinct reservoirs from which they
emerge at the onset of the pandemic. We hypothesise that one or more of the substitutions
leading to the pandemic strain common ancestor results in a large change in antigenicity
and moves the virus to a new region of antigenic space. The strain then diversifies result-
ing in viruses with subtly different antigenicity but these substitutions do not move the
virus out of the vicinity of the new region of antigenic space. At the onset of the new
pandemic, all of the viruses within the new region of antigenic space emerge to cause the
pandemic. The concurrent emergence of multiple closely related lineages that have been
circulating on different continents adds support to our hypothesis that changes in host
immunity drive new pandemics.
In summary, our results in chapter 3 demonstrated that there are a large number of
low level pre-pandemic and pre-epidemic GII.4 strains that are present through time (Fig-
ure 6.1). Each of these strains is in the process of diversifying into multiple lineages, with
each of these lineages either persisting within the population for a period of time or be-
coming extinct. However, we hypothesise that these low level strains are prevented from
gaining a foothold in the population due to partial cross reactivity of immunity, which is
sufficient to prevent a rare strain from gaining a foothold. Once sufficient immunity has
been built against the current pandemic strain, this strain can no longer spread efficiently
and so begins to decline in prevalence. This decline in prevalence results in a decline in
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immunity against the current pandemic which enables the next pandemic strain to gain a
foothold in the population and increase in prevalence to become the dominant strain in
outbreaks. The low level strain that emerges at that point in time is the one that combines
the best opportunity to emerge with the least cross-reactivity against pre-existing immu-
nity. All of the pre-diversified lineages within the advanatageous region of the antigenic
space can emerge at this point in time. Importantly, due to the universally high prevalence
of GII.4 norovirus, population immunity can build across the world at a relatively constant
rate. In the future, we plan to test this hypothesis using a combination of viral sequences,
phylogenetics, human monoclonal antibodies and polyclonal sera raised against individ-
ual GII.4 pandemic strains, antigenic cartography and mathematical modelling. We will
measure the strength of binding of population sera collected through time against a set
of sequences from each of the pandemic GII.4 strains. This will determine whether there
are antigenic shifts between pandemic GII.4 strains, the magnitude of such shifts and how
much antigenic variation there is within a pandemic GII.4 strain (Figure 6.2). We will
also test the antigenic properties of ancestral viruses from each strain. We would expect
to find a large antigenic difference between each of the pandemic strains, as per the shift
in the region of antigenic space in our hypothesis of strain emergence (Figure 6.2). We
hypothesise that the strain common ancestor, downstream ancestors and sampled tip se-
quences will form a cluster within the antigenic space that is distinct from sequences in
other pandemic strains. As we have demonstrated that the strain common ancestor and
downstream ancestors occurred prior to the onset of the pandemic, this would provide
support that important genetic changes for strain emergence are acquired years prior to
the pandemic and for the local movement within antigenic space during the diversifica-
tion phase of strain emergence. A hypothetical example including the Den Haag 2006,
New Orleans 2009 and Sydney 2012 strains is shown in figure 6.2. We will then incor-
porate these results into a mathematical framework that will incorporate changes in host
immunity through time to test the hypothesis that changes in host immunity can drive the
emergence of new pandemic strains and the circumstances under which that could occur.
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Figure 6.2: Testing the antigenic properties of pandemic GII.4 strains. In the future, we
will test the antigenic relationship between sequences and reconstructed ancestor se-
quences from each of the pandemic strains using population polyclonal sera collected
through time. We will measure the binding affinity of each serum sample against
each viral sequence and map this binding data into an antigenic space using multi-
dimensional scaling. A hypothetical scenario is shown here for Den Haag 2006, New
Orleans 2009 and Sydney 2012. Under our hypothesis, the viruses within a strain are
antigenically similar and this shared antigenic characteristic(s) is acquired by the root
of the pandemic clade, while the different pandemic GII.4 strains are antigenically
distinct. We therefore expect the reconstructed ancestor sequences to cluster with the
tip sequences in antigenic space. We suggested in chapter 4 that an antigenic change
occurred between the common ancestor of all Sydney 2012 sequences and the com-
mon ancestor of the pandemic Sydney 2012 clade. Therefore the common ancestor
of all Sydney 2012 sequences and one of the sequences immediately downstream of
this ancestor are shown in a distinct region of antigenic space to the remainder of the
Sydney 2012 sequences. Such a set of results would provide support for the three
stage process of strain emergence described in chapters 3 and 4. An example set of
reconstructed ancestral sequences and tip sequences whose antigenic properties we
would test is shown on the New Orleans 2009 and Sydney 2012 phylogenetic trees.
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6.3 The pandemic potential of viral lineages with the
GII.P16 ORF1
In chapter 5 we examined two norovirus strains that emerged as major causes of gas-
troenteritis in Winter 2016-2017. These strains each contained the GII.P16 ORF1 but
contained different capsid genotypes; GII.2 and GII.4 Sydney 2012. We demonstrated
that the GII.P16-GII.4 Sydney 2012 lineage is circulating in the UK and USA, in addi-
tion to the previously identified circulation in Asia and Germany. We showed that the
GII.P16 RdRps found within the two novel lineages form a monophyletic clade that also
includes GII.P16-GII.3 sequences from the UK and coalesces to a common ancestor in
March 2013. There were no unique substitutions within the Sydney 2012 capsid in this
lineage, suggesting this strain will not be able to evade existing herd immunity raised
against earlier circulating Sydney 2012 viruses. We did, however, identify substitutions
within ORF1 that are shared between the several strains with the novel GII.P16 ORF1.
Importantly, these substitutions include sites within the RdRp that are close to sites known
to influence RdRp function and viral transmission and so may have resulted in a highly
transmissible virus. In the future, testing the effect of these substitutions on viral repli-
cation in the human norovirus culture systems (Jones et al., 2014; Ettayebi et al., 2016)
would determine the functional importance of these substitutions. Additionally, it is vi-
tal that surveillance targeting ORF1 and ORF2 is carried out to determine whether these
novel GII.P16 lineages increase in prevalence.
Bibliography
Ahmed, S. M., Hall, A. J., Robinson, A. E., Verhoef, L., Premkumar, P., Parashar, U. D.,
Koopmans, M., and Lopman, B. A. (2014). Global prevalence of norovirus in cases of
gastroenteritis: A systematic review and meta-analysis. The Lancet Infectious Diseases,
14(8):725–730.
Ahmed, S. M., Lopman, B. A., and Levy, K. (2013). A Systematic Review and Meta-
Analysis of the Global Seasonality of Norovirus. PLoS ONE, 8(10).
Alhatlani, B., Vashist, S., and Goodfellow, I. (2015). Functions of the 5’ and 3’ ends of
calicivirus genomes. Virus Research, 206:134–143.
Allen, D. J., Adams, N. L., Aladin, F., Harris, J. P., and Brown, D. W. G. (2014). Emer-
gence of the GII-4 norovirus Sydney2012 strain in England, winter 2012-2013. PLoS
ONE, 9(2).
Allen, D. J., Gray, J. J., Gallimore, C. I., Xerry, J., and Iturriza-Go´mara, M. (2008).
Analysis of amino acid variation in the P2 domain of the GII-4 Norovirus VP1 protein
reveals putative variant-specific epitopes. PLoS ONE, 3(1).
Allen, D. J., Trainor, E., Callaghan, A., O’Brien, S. J., Cunliffe, N. A., and Iturriza-
G??mara, M. (2016). Early detection of epidemic GII-4 norovirus strains in UK and
Malawi: Role of surveillance of sporadic acute gastroenteritis in anticipating global
epidemics. PLoS ONE, 11(4).
Ando, T., Noel, J. S., and Fankhauser, R. L. (2000). Genetic classification of ”Norwalk-
like viruses. The Journal of infectious diseases, 181 Suppl(Suppl 2):S336–S348.
Ao, Y., Wang, J., Ling, H., He, Y., Dong, X., Wang, X., Peng, J., Zhang, H., Jin, M.,
206 BIBLIOGRAPHY
and Duan, Z. (2017). Norovirus GII.P16/GII.2Associated Gastroenteritis, China, 2016.
Emerging Infectious Diseases, 23(7):1172–1175.
Arias, A., Thorne, L., Ghurburrun, E., Bailey, D., and Goodfellow, I. (2016). Norovirus
Polymerase Fidelity Contributes to Viral Transmission In Vivo. mSphere, 1(5).
Atmar, R. L., Bernstein, D. I., Harro, C. D., Al-Ibrahim, M. S., Chen, W. H., Ferreira, J.,
Estes, M. K., Graham, D. Y., Opekun, A. R., Richardson, C., and Mendelman, P. M.
(2011). Norovirus Vaccine against Experimental Human Norwalk Virus Illness. New
England Journal of Medicine, 365(23):2178–2187.
Atmar, R. L., Bernstein, D. I., Lyon, G. M., Treanor, J. J., Al-Ibrahim, M. S., Graham,
D. Y., Vinje´, J., Jiang, X., Gregoricus, N., Frenck, R. W., Moe, C. L., Chen, W. H., Fer-
reira, J., Barrett, J., Opekun, A. R., Estes, M. K., Borkowski, A., Baehner, F., Goodwin,
R., Edmonds, A., and Mendelman, P. M. (2015). Serological correlates of protection
against a GII.4 norovirus. Clinical and Vaccine Immunology, 22(8):923–929.
Atmar, R. L., Opekun, A. R., Gilger, M. A., Estes, M. K., Crawford, S. E., Neill, F. H.,
and Graham, D. Y. (2008). Norwalk virus shedding after experimental human infection.
Emerging Infectious Diseases, 14(10):1553–1557.
Atmar, R. L., Opekun, A. R., Gilger, M. A., Estes, M. K., Crawford, S. E., Neill, F. H.,
Ramani, S., Hill, H., Ferreira, J., and Graham, D. Y. (2014). Determination of the 50%
human infectious dose for norwalk virus. Journal of Infectious Diseases, 209(7):1016–
1022.
Bailey, D., Kaiser, W. J., Hollinshead, M., Moffat, K., Chaudhry, Y., Wileman, T., Sos-
novtsev, S. V., and Goodfellow, I. G. (2010). Feline calicivirus p32, p39 and p30 pro-
teins localize to the endoplasmic reticulum to initiate replication complex formation.
Journal of General Virology, 91(3):739–749.
Baric, R., Yount, B., and Lindesmith, L. (2002). Expression and self-assembly of Norwalk
virus capsid protein from Venezuelan equine encephalitis virus replicons. Journal of
Virology, 76(6):3023 – 3030.
Bartnicki, E., Cunha, J. B., Kolawole, A. O., and Wobus, C. E. (2017). Recent advances
in understanding noroviruses. F1000Research, 6:79.
BIBLIOGRAPHY 207
Bartsch, S. M., Lopman, B. A., Hall, A. J., Parashar, U. D., and Lee, B. Y. (2012). The
potential economic value of a human norovirus vaccine for the United States. Vaccine,
30(49):7097–7104.
Bartsch, S. M., Lopman, B. A., Ozawa, S., Hall, A. J., and Lee, B. Y. (2016). Global
economic burden of norovirus gastroenteritis. PLoS ONE, 11(4).
Bedford, T., Riley, S., Barr, I. G., Broor, S., Chadha, M., Cox, N. J., Daniels, R. S.,
Gunasekaran, C. P., Hurt, A. C., Kelso, A., Klimov, A., Lewis, N. S., Li, X., McCauley,
J. W., Odagiri, T., Potdar, V., Rambaut, A., Shu, Y., Skepner, E., Smith, D. J., Suchard,
M. A., Tashiro, M., Wang, D., Xu, X., Lemey, P., and Russell, C. A. (2015). Global
circulation patterns of seasonal influenza viruses vary with antigenic drift. Nature,
523(7559):217–220.
Belliot, G., Sosnovtsev, S. V., Chang, K.-O., Babu, V., Uche, U., Arnold, J. J., Cameron,
C. E., and Green, K. Y. (2005). Norovirus proteinase-polymerase and polymerase
are both active forms of RNA-dependent RNA polymerase. Journal of virology,
79(4):2393–2403.
Belliot, G., Sosnovtsev, S. V., Mitra, T., Hammer, C., Garfield, M., and Green, K. Y.
(2003). In vitro proteolytic processing of the MD145 norovirus ORF1 nonstruc-
tural polyprotein yields stable precursors and products similar to those detected in
calicivirus-infected cells. Journal of virology, 77(20):10957–10974.
Bernstein, D. I., Atmar, R. L., Lyon, G. M., Treanor, J. J., Chen, W. H., Jiang, X., Vinje´,
J., Gregoricus, N., Frenck, R. W., Moe, C. L., Al-Ibrahim, M. S., Barrett, J., Ferreira, J.,
Estes, M. K., Graham, D. Y., Goodwin, R., Borkowski, A., Clemens, R., and Mendel-
man, P. M. (2015). Norovirus vaccine against experimental human GII.4 virus illness:
A challenge study in healthy adults. Journal of Infectious Diseases, 211(6):870–878.
Bertolotti-Ciarlet, A., Crawford, S. E., Hutson, A. M., and Estes, M. K. (2003). The 3’
end of Norwalk virus mRNA contains determinants that regulate the expression and
stability of the viral capsid protein VP1: a novel function for the VP2 protein. Journal
of virology, 77(21):11603–11615.
208 BIBLIOGRAPHY
Bertolotti-Ciarlet, A., White, L. J., Chen, R., Prasad, V., Estes, M. K., and Prasad, B. V. V.
(2002). Structural Requirements for the Assembly of Norwalk Virus-Like Particles.
Journal of Virology, 76(8):4044–4055.
Biasini, M., Bienert, S., Waterhouse, A., Arnold, K., Studer, G., Schmidt, T., Kiefer, F.,
Cassarino, T. G., Bertoni, M., Bordoli, L., and Schwede, T. (2014). SWISS-MODEL:
Modelling protein tertiary and quaternary structure using evolutionary information. Nu-
cleic Acids Research, 42(W1).
Bidalot, M., The´ry, L., Kaplon, J., De Rougemont, A., and Ambert-Balay, K. (2017).
Emergence of new recombinant noroviruses GII.P16-GII.4 and GII.p16-GII.2, France,
winter 2016 to 2017. Eurosurveillance, 22(15).
Bloom, J. D., Labthavikul, S. T., Otey, C. R., and Arnold, F. H. (2006). Protein
stability promotes evolvability. Proceedings of the National Academy of Sciences,
103(15):5869–5874.
Bok, K., Abente, E. J., Realpe-Quintero, M., Mitra, T., Sosnovtsev, S. V., Kapikian, A. Z.,
and Green, K. Y. (2009). Evolutionary dynamics of GII.4 noroviruses over a 34-year
period. Journal of virology, 83(22):11890–901.
Bok, K. and Green, K. (2012). Norovirus gastroenteritis in immunocompromised patients.
New England Journal of Medicine, 119(8):1831–1837.
Bok, K., Parra, G. I., Mitra, T., Abente, E., Shaver, C. K., Boon, D., Engle, R., Yu, C.,
Kapikian, A. Z., Sosnovtsev, S. V., Purcell, R. H., and Green, K. Y. (2011). Chim-
panzees as an animal model for human norovirus infection and vaccine development.
Proceedings of the National Academy of Sciences of the United States of America,
108(1):325–330.
Boon, D., Mahar, J. E., Abente, E. J., Kirkwood, C. D., Purcell, R. H., Kapikian, A. Z.,
Green, K. Y., and Bok, K. (2011). Comparative Evolution of GII.3 and GII.4 Norovirus
over a 31-Year Period. Journal of Virology, 85(17):8656–8666.
Bordoli, L., Kiefer, F., Arnold, K., Benkert, P., Battey, J., and Schwede, T. (2008). Protein
structure homology modeling using SWISS-MODEL workspace. Nature Protocols,
4(1):1–13.
BIBLIOGRAPHY 209
Bouckaert, R., Heled, J., Ku¨hnert, D., Vaughan, T., Wu, C. H., Xie, D., Suchard, M. A.,
Rambaut, A., and Drummond, A. J. (2014). BEAST 2: A Software Platform for
Bayesian Evolutionary Analysis. PLoS Computational Biology, 10(4).
Brown, J. R., Gilmour, K., and Breuer, J. (2016a). Norovirus Infections Occur in B-Cell-
Deficient Patients. Clinical Infectious Diseases, 62(9):1136–1138.
Brown, J. R., Roy, S., Ruis, C., Yara Romero, E., Shah, D., Williams, R., and Breuer,
J. (2016b). Norovirus whole-genome sequencing by SureSelect target enrichment: A
robust and sensitive method. Journal of Clinical Microbiology, 54(10):2530–2537.
Brown, J. R., Shah, D., and Breuer, J. (2016c). Viral gastrointestinal infections and
norovirus genotypes in a paediatric UK hospital, 20142015. Journal of Clinical Vi-
rology, 84:1–6.
Bu, W., Mamedova, A., Tan, M., Xia, M., Jiang, X., and Hegde, R. S. (2008). Struc-
tural basis for the receptor binding specificity of Norwalk virus. Journal of virology,
82(11):5340–7.
Bucardo, F., Kindberg, E., Paniagua, M., Vildevall, M., and Svensson, L. (2009). Genetic
susceptibility to symptomatic norovirus infection in nicaragua. Journal of Medical
Virology, 81(4):728–735.
Bull, R. a., Eden, J.-S., Luciani, F., McElroy, K., Rawlinson, W. D., and White, P. a.
(2012). Contribution of Intra- and Interhost Dynamics to Norovirus Evolution. Journal
of Virology, 86(6):3219–3229.
Bull, R. A., Eden, J. S., Rawlinson, W. D., and White, P. A. (2010). Rapid evolution of
pandemic noroviruses of the GII.4 lineage. PLoS Pathogens, 6(3).
Bull, R. A., Hansman, G. S., Clancy, L. E., Tanaka, M. M., Rawlinson, W. D., and White,
P. A. (2005). Norovirus recombination in ORF1/ORF2 overlap. Emerging Infectious
Diseases, 11(7):1079–1085.
Bull, R. A., Tanaka, M. M., and White, P. A. (2007). Norovirus recombination. Journal
of General Virology, 88(12):3347–3359.
210 BIBLIOGRAPHY
Bull, R. A., Tu, E. T. V., McIver, C. J., Rawlinson, W. D., and White, P. A. (2006).
Emergence of a new norovirus genotype II.4 variant associated with global outbreaks
of gastroenteritis. Journal of Clinical Microbiology, 44(2):327–333.
Bull, R. A. and White, P. A. (2011). Mechanisms of GII.4 norovirus evolution.
Caddy, S. L., de Rougemont, A., Emmott, E., El-Attar, L., Mitchell, J. A., Hollinshead,
M., Belliot, G., Brownlie, J., Le Pendu, J., and Goodfellow, I. (2015). Evidence
for human norovirus infection of dogs in the UK. Journal of Clinical Microbiology,
53(April):JCM.02778–14.
Cannon, J. L., Lindesmith, L. C., Donaldson, E. F., Saxe, L., Baric, R. S., and Vinje´,
J. (2009). Herd immunity to GII.4 noroviruses is supported by outbreak patient sera.
Journal of virology, 83(11):5363–74.
Cao, S., Lou, Z., Tan, M., Chen, Y., Liu, Y., Zhang, Z., Zhang, X. C., Jiang, X., Li, X.,
and Rao, Z. (2007). Structural basis for the recognition of blood group trisaccharides
by norovirus. Journal of virology, 81(11):5949–5957.
Carlsson, B., Kindberg, E., Buesa, J., Rydell, G. E., Lido´n, M. F., Montava, R., Mallouh,
R. A., Grahn, A., Rodrı´guez-Dı´az, J., Bellido, J., Arnedo, A., Larson, G., and Svensson,
L. (2009). The G428A nonsense mutation in FUT2 provides strong but not absolute
protection against symptomatic GII.4 norovirus infection. PLoS ONE, 4(5).
Chachu, K. A., LoBue, A. D., Strong, D. W., Baric, R. S., and Virgin, H. W. (2008a).
Immune mechanisms responsible for vaccination against and clearance of mucosal and
lymphatic norovirus infection. PLoS Pathogens, 4(12).
Chachu, K. A., Strong, D. W., LoBue, A. D., Wobus, C. E., Baric, R. S., and Virgin, H. W.
(2008b). Antibody Is Critical for the Clearance of Murine Norovirus Infection. Journal
of Virology, 82(13):6610–6617.
Chan, M. C., Hu, Y., Chen, H., Podkolzin, A. T., Zaytseva, E. V., Komano, J., Sakon, N.,
Poovorawan, Y., Vongpunsawad, S., Thanusuwannasak, T., Hewitt, J., Croucher, D.,
Collins, N., Vinje´, J., Pang, X. L., Lee, B. E., de Graaf, M., van Beek, J., Vennema,
H., Koopmans, M. P., Niendorf, S., Poljsak-Prijatelj, M., Steyer, A., White, P. A., Lun,
BIBLIOGRAPHY 211
J. H., Mans, J., Hung, T.-N., Kwok, K., Cheung, K., Lee, N., and Chan, P. K. (2017a).
Global Spread of Norovirus GII.17 Kawasaki 308, 20142016. Emerging Infectious
Diseases, 23(8):1359–1354.
Chan, M. C. W., Kwok, K., Hung, T.-N., Chan, L.-Y., and Chan, P. K. S. (2017b). Com-
plete Genome Sequence of an Emergent Recombinant GII.P16-GII.2 Norovirus Strain
Associated with an Epidemic Spread in the Winter of 2016- 2017 in Hong Kong, China.
Genome Announcements, 5(20):16–17.
Chan, M. C. W., Lee, N., Hung, T.-N., Kwok, K., Cheung, K., Tin, E. K. Y., Lai, R.
W. M., Nelson, E. A. S., Leung, T. F., and Chan, P. K. S. (2015). Rapid emergence and
predominance of a broadly recognizing and fast-evolving norovirus GII.17 variant in
late 2014. Nature Communications, 6:10061.
Chaudhry, Y., Nayak, A., Bordeleau, M. E., Tanaka, J., Pelletier, J., Belsham, G. J.,
Roberts, L. O., and Goodfellow, I. G. (2006). Caliciviruses differ in their functional
requirements for eIF4F components. Journal of Biological Chemistry, 281(35):25315–
25325.
Cheesbrough, J. S., Green, J., Gallimore, C. I., Wright, P. a., and Brown, D. W. (2000).
Widespread environmental contamination with Norwalk-like viruses (NLV) detected in
a prolonged hotel outbreak of gastroenteritis. Epidemiology and infection, 125(1):93–8.
Cheetham, S., Souza, M., Meulia, T., Grimes, S., Han, M. G., and Saif, L. J. (2006).
Pathogenesis of a genogroup II human norovirus in gnotobiotic pigs. Journal of virol-
ogy, 80(21):10372–81.
Choi, Y. S., Koo, E. S., Kim, M. S., Choi, J. D., Shin, Y., and Jeong, Y. S. (2017). Re-
emergence of a GII.4 Norovirus Sydney 2012 Variant Equipped with GII.P16 RdRp
and Its Predominance over Novel Variants of GII.17 in South Korea in 2016. Food and
Environmental Virology, 9(2):168–178.
Chung, L., Bailey, D., Leen, E. N., Emmott, E. P., Chaudhry, Y., Roberts, L. O., Curry, S.,
Locker, N., and Goodfellow, I. G. (2014). Norovirus translation requires an interaction
between the C terminus of the genome-linked viral protein VPg and eukaryotic trans-
lation initiation factor 4G. Journal of Biological Chemistry, 289(31):21738–21750.
212 BIBLIOGRAPHY
Cortes-Penfield, N. W., Ramani, S., Estes, M. K., and Atmar, R. L. (2017). Prospects and
Challenges in the Development of a Norovirus Vaccine.
Currier, R. L., Payne, D. C., Staat, M. A., Selvarangan, R., Shirley, S. H., Halasa, N.,
Boom, J. A., Englund, J. A., Szilagyi, P. G., Harrison, C. J., Klein, E. J., Weinberg,
G. A., Wikswo, M. E., Parashar, U., Vinje´, J., and Morrow, A. L. (2015). Innate
susceptibility to norovirus infections influenced by FUT2 genotype in a United States
pediatric population. Clinical Infectious Diseases, 60(11):1631–1638.
da Silva Polo´, T., Peiro´, J. R., Mendes, L. C. N., Ludwig, L. F., de Oliveira-Filho, E. F.,
Bucardo, F., Huynen, P., Melin, P., Thiry, E., and Mauroy, A. (2016). Human norovirus
infection in Latin America.
de Graaf, M., Bodewes, R., van Elk, C. E., van de Bildt, M., Getu, S., Aron, G. I.,
Verjans, G. M. G. M., Osterhaus, A. D. M. E., van den Brand, J. M. A., Kuiken, T.,
and Koopmans, M. P. G. (2017). Norovirus infection in harbor porpoises. Emerging
Infectious Diseases, 23(1):87–91.
de Graaf, M., van Beek, J., and Koopmans, M. P. G. (2016). Human norovirus transmis-
sion and evolution in a changing world. Nature Reviews Microbiology, 14(7):421–433.
De Graaf, M., Van Beek, J., Vennema, H., Podkolzin, A. T., Hewitt, J., Bucardo, F., Tem-
pleton, K., Mans, J., Nordgren, J., Reuter, G., Lynch, M., Rasmussen, L. D., Iritani,
N., Chan, M. C., Martella, V., Ambert-Balay, K., Vinj??, J., White, P. A., and Koop-
mans, M. P. (2015). Emergence of a novel GII.17 norovirus ??? end of the GII.4 era?
Eurosurveillance, 20(26):1–8.
Debbink, K., Donaldson, E. F., Lindesmith, L. C., and Baric, R. S. (2012a). Genetic
Mapping of a Highly Variable Norovirus GII.4 Blockade Epitope: Potential Role in
Escape from Human Herd Immunity. Journal of Virology, 86(2):1214–1226.
Debbink, K., Lindesmith, L. C., Donaldson, E. F., Baric, R. S., and Rosenbaum, P.
(2012b). Norovirus Immunity and the Great Escape. PLoS Pathogens, 8(10):e1002921.
Debbink, K., Lindesmith, L. C., Donaldson, E. F., Costantini, V., Beltramello, M., Corti,
D., Swanstrom, J., Lanzavecchia, A., Vinje´, J., and Baric, R. S. (2013). Emergence of
BIBLIOGRAPHY 213
new pandemic gII.4 sydney norovirus strain correlateswith escape from herd immunity.
Journal of Infectious Diseases, 208(11):1877–1887.
Debbink, K., Lindesmith, L. C., Ferris, M. T., Swanstrom, J., Beltramello, M., Corti, D.,
Lanzavecchia, A., and Baric, R. S. (2014). Within-host evolution results in antigeni-
cally distinct GII.4 noroviruses. Journal of virology, 88(13):7244–55.
Donaldson, E. F., Lindesmith, L. C., Lobue, A. D., and Baric, R. S. (2008). Norovirus
pathogenesis: Mechanisms of persistence and immune evasion in human populations.
Donaldson, E. F., Lindesmith, L. C., Lobue, A. D., and Baric, R. S. (2010). Viral shape-
shifting: norovirus evasion of the human immune system. Nature reviews. Microbiol-
ogy, 8(3):231–241.
Eden, J.-S., Chisholm, R. H., Bull, R. A., White, P. A., Holmes, E. C., and Tanaka, M. M.
(2017). Persistent infections in immunocompromised hosts are rarely sources of new
pathogen variants. Virus Evolution, 3(2):219–22.
Eden, J. S., Hewitt, J., Lim, K. L., Boni, M. F., Merif, J., Greening, G., Ratcliff, R. M.,
Holmes, E. C., Tanaka, M. M., Rawlinson, W. D., and White, P. A. (2014). The emer-
gence and evolution of the novel epidemic norovirus GII.4 variant Sydney 2012. Virol-
ogy, 450-451:106–113.
Eden, J.-S., Tanaka, M. M., Boni, M. F., Rawlinson, W. D., and White, P. A. (2013).
Recombination within the pandemic norovirus GII.4 lineage. Journal of virology,
87(11):6270–82.
Edgar, R. C. (2008). Muscle. BMC Bioinformatics.
Emmott, E., de Rougemont, A., Haas, J., and Goodfellow, I. (2017a). Spatial and tempo-
ral control of norovirus protease activity is determined by polyprotein processing and
intermolecular interactions within the viral replication complex. bioRxiv.
Emmott, E., Sorgeloos, F., Caddy, S. L., and Heesom, K. (2017b). Norovirus-mediated
modification of the translational landscape via virus and host-induced cleavage of trans-
lation initiation factors. Molecular and Cellular Proteomics, pages 1–32.
214 BIBLIOGRAPHY
Ettayebi, K., Crawford, S. E., Murakami, K., Broughman, J. R., Karandikar, U., Tenge,
V. R., Neill, F. H., Blutt, S. E., Zeng, X.-l., Qu, L., Kou, B., Antone, R., Burrin, D.,
Graham, D. Y., Ramani, S., Atmar, R. L., and Mary, K. (2016). Replication of human
noroviruses in stem cell derived human enteroids. Science, 5211(August):1–12.
Firth, A. E. and Brierley, I. (2012). Non-canonical translation in RNA viruses.
Fu, J., Ai, J., Jin, M., Jiang, C., Zhang, J., Shi, C., Lin, Q., Yuan, Z., Qi, X., Bao,
C., Tang, F., and Zhu, Y. (2015). Emergence of a new GII.17 norovirus variant in
patients with acute gastroenteritis in jiangsu, China, september 2014 to march 2015.
Eurosurveillance, 20(24):1–7.
Furman, L. M., Maaty, W. S., Petersen, L. K., Ettayebi, K., Hardy, M. E., and Bothner,
B. (2009). Cysteine protease activation and apoptosis in Murine norovirus infection.
Virology journal, 6:139.
Galeano, M. E., Martinez, M., Amarilla, A. A., Russomando, G., Miagostovich, M. P.,
Parra, G. I., and Leite, J. P. (2013). Molecular epidemiology of norovirus strains in
Paraguayan children during 2004-2005: Description of a possible new GII.4 cluster.
Journal of Clinical Virology, 58(2):378–384.
Gallimore, C. I., Taylor, C., Gennery, A. R., Cant, A. J., Galloway, A., Iturriza-Gomara,
M., and Gray, J. J. (2006). Environmental monitoring for gastroenteric viruses in a pe-
diatric primary immunodeficiency unit. Journal of Clinical Microbiology, 44(2):395–
399.
Gallimore, C. I., Taylor, C., Gennery, A. R., Cant, A. J., Galloway, A., Xerry, J., Adigwe,
J., and Gray, J. J. (2008). Contamination of the hospital environment with gastroenteric
viruses: Comparison of two pediatric wards over a winter season. Journal of Clinical
Microbiology, 46(9):3112–3115.
GBD 2013 Mortality and Causes of Death Collaborators (2015). Global, regional, and
national age-sex specific all-cause and cause-specific mortality for 240 causes of death,
1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet
(London, England), 385(9963):117–71.
BIBLIOGRAPHY 215
Giammanco, G. M., De Grazia, S., Tummolo, F., Bonura, F., Calderaro, A., Buonavoglia,
A., Martella, V., and Medici, M. C. (2013). Norovirus GII.4/Sydney/2012 in Italy,
Winter 20122013. Emerging Infectious Diseases, 19(8):1348–1349.
Glass, P. J., Zeng, C. Q., and Estes, M. K. (2003). Two Nonoverlapping Domains on the
Norwalk Virus Open Reading Frame 3 (ORF3) Protein Are Involved in the Formation
of the Phosphorylated 35K Protein and in ORF3-Capsid Protein Interactions. Journal
of Virology, 77(6):3569–3577.
Green, K. (2007). Caliciviridae: The noroviruses. Fields Virology, 2(v. 1):3177.
Green, K. Y. (2016). Editorial Commentary : Noroviruses and B Cells. Clinical Infectious
Diseases, 62(9):1139–1140.
Green, K. Y., Mory, a., Fogg, M. H., Weisberg, a., Belliot, G., Wagner, M., Mitra,
T., Ehrenfeld, E., Cameron, C. E., and Sosnovtsev, S. V. (2002). Isolation of enzy-
matically active replication complexes from feline calicivirus-infected cells. J.Virol.,
76(17):8582–8595.
Haga, K., Fujimoto, A., Takai-Todaka, R., Miki, M., Doan, Y. H., Murakami, K.,
Yokoyama, M., Murata, K., Nakanishi, A., and Katayama, K. (2016). Functional
receptor molecules CD300lf and CD300ld within the CD300 family enable murine
noroviruses to infect cells. Proceedings of the National Academy of Sciences of the
United States of America, page 201605575.
Hall, A. J. (2012). Noroviruses: The Perfect Human Pathogens? Journal of Infectious
Diseases, 205(11):1622–1624.
Hansman, G. S., Biertumpfel, C., Georgiev, I., McLellan, J. S., Chen, L., Zhou, T.,
Katayama, K., and Kwong, P. D. (2011). Crystal Structures of GII.10 and GII.12
Norovirus Protruding Domains in Complex with Histo-Blood Group Antigens Reveal
Details for a Potential Site of Vulnerability. Journal of Virology, 85(13):6687–6701.
Harris, J. P., Iturriza-Gomara, M., and O’Brien, S. J. (2017). Re-assessing the total burden
of norovirus circulating in the United Kingdom population. Vaccine, 35(6):853–855.
216 BIBLIOGRAPHY
Hasing, M. E., Lee, B. E., Preiksaitis, J. K., Tellier, R., Honish, L., Senthilselvan, A., and
Pang, X. L. (2013). Emergence of a new norovirus GII.4 variant and changes in the
historical biennial pattern of norovirus outbreak activity in Alberta, Canada, from 2008
to 2013. Journal of Clinical Microbiology, 51(7):2204–2211.
Hickman, D., Jones, M. K., Zhu, S., Kirkpatrick, E., Ostrov, D. A., Wang, X., Ukhanova,
M., Sun, Y., Mai, V., Salemi, M., and Karst, S. M. (2014). The effect of malnutrition
on norovirus infection. mBio, 5(2).
Ho¨gbom, M., Ja¨ger, K., Robel, I., Unge, T., and Rohayem, J. (2009). The active form
of the norovirus RNA-dependent RNA polymerase is a homodimer with cooperative
activity. Journal of General Virology, 90(2):281–291.
Hyde, J. L. and Mackenzie, J. M. (2010). Subcellular localization of the MNV-1 ORF1
proteins and their potential roles in the formation of the MNV-1 replication complex.
Virology, 406(1):138–148.
Hyde, J. L., Sosnovtsev, S. V., Green, K. Y., Wobus, C., Virgin, H. W., and Mackenzie,
J. M. (2009). Mouse Norovirus Replication Is Associated with Virus-Induced Vesicle
Clusters Originating from Membranes Derived from the Secretory Pathway. Journal of
Virology, 83(19):9709–9719.
Inns, T., Harris, J., Vivancos, R., Iturriza-Gomara, M., and O’Brien, S. (2017).
Community-based surveillance of norovirus disease: a systematic review. BMC In-
fectious Diseases, 17(1):657.
Jiang, X., Wang, M., Graham, D. Y., and Estes, M. K. (1992). Expression, self-assembly,
and antigenicity of the Norwalk virus capsid protein. Journal of virology, 66(11):6527–
32.
Jones, M. K., Grau, K. R., Costantini, V., Kolawole, A. O., de Graaf, M., Freiden, P.,
Graves, C. L., Koopmans, M., Wallet, S. M., Tibbetts, S. A., Schultz-Cherry, S., Wobus,
C. E., Vinje´, J., and Karst, S. M. (2015). Human norovirus culture in B cells. Nature
Protocols, 10(12):1939–1947.
Jones, M. K., Watanabe, M., Zhu, S., Graves, C. L., Keyes, L. R., Grau, K. R., Gonzalez-
Hernandez, M. B., Iovine, N. M., Wobus, C. E., Vinje, J., Tibbetts, S. A., Wallet,
BIBLIOGRAPHY 217
S. M., and Karst, S. M. (2014). Enteric bacteria promote human and mouse norovirus
infection of B cells. Science, 346(6210):755–759.
Kaiser, W. J., Chaudhry, Y., Sosnovtsev, S. V., and Goodfellow, I. G. (2006). Analysis of
protein-protein interactions in the feline calicivirus replication complex. The Journal
of general virology, 87(Pt 2):363–8.
Kambhampati, A., Payne, D. C., Costantini, V., and Lopman, B. A. (2015). Host Genetic
Susceptibility to Enteric Viruses: A Systematic Review and Metaanalysis. Clinical in-
fectious diseases : an official publication of the Infectious Diseases Society of America,
62:civ873–.
Kamel, A. H., Ali, M. A., El-Nady, H. G., De Rougemont, A., Pothier, P., and Belliot, G.
(2009). Predominance and circulation of enteric viruses in the region of greater Cairo,
Egypt. Journal of Clinical Microbiology, 47(4):1037–1045.
Kapikian, A. Z., Wyatt, R. G., Dolin, R., Thornhill, T. S., Kalica, A. R., and Chanock,
R. M. (1972). Visualization by immune electron microscopy of a 27-nm particle associ-
ated with acute infectious nonbacterial gastroenteritis. Journal of virology, 10(5):1075–
1081.
Karandikar, U. C., Crawford, S. E., Ajami, N. J., Murakami, K., Kou, B., Ettayebi, K.,
Papanicolaou, G. A., Jongwutiwes, U., Perales, M. A., Shia, J., Mercer, D., Finegold,
M. J., Vinje´, J., Atmar, R. L., and Estes, M. K. (2016). Detection of human norovirus in
intestinal biopsies from immunocompromised transplant patients. Journal of General
Virology, 97(9):2291–2300.
Karst, S. M. (2003). STAT1-Dependent Innate Immunity to a Norwalk-Like Virus. Sci-
ence, 299(5612):1575–1578.
Karst, S. M. and Baric, R. S. (2015). What is the reservoir of emergent human norovirus
strains? Journal of virology, 89(11):5756–9.
Karst, S. M., Wobus, C. E., Goodfellow, I. G., Green, K. Y., and Virgin, H. W. (2014).
Advances in norovirus biology.
218 BIBLIOGRAPHY
Kim, H. S., Hyun, J., Kim, H. S., Kim, J. S., Song, W., and Lee, K. M. (2013). Emergence
of GII.4 Sydney norovirus in South Korea during the winter of 2012-2013. Journal of
Microbiology and Biotechnology, 23(11):1641–1643.
Kindberg, E. and Svensson, L. (2009). Genetic basis of host resistance to norovirus
infection. Future Virology, 4(4):369–382.
Kirk, M. D., Pires, S. M., Black, R. E., Caipo, M., Crump, J. A., Devleesschauwer,
B., Do¨pfer, D., Fazil, A., Fischer-Walker, C. L., Hald, T., Hall, A. J., Keddy, K. H.,
Lake, R. J., Lanata, C. F., Torgerson, P. R., Havelaar, A. H., and Angulo, F. J. (2015).
World Health Organization Estimates of the Global and Regional Disease Burden of
22 Foodborne Bacterial, Protozoal, and Viral Diseases, 2010: A Data Synthesis. PLoS
Medicine, 12(12).
Kiulia, N. M., Mans, J., Mwenda, J. M., and Taylor, M. B. (2014). Norovirus GII.17
Predominates in Selected Surface Water Sources in Kenya. Food and Environmental
Virology, 6(4):221–231.
Koehl, P. and Levitt, M. (1999). Structure-based conformational preferences of amino
acids. Proceedings of the National Academy of Sciences, 96(22):12524–12529.
Koromyslova, A. D., Leuthold, M. M., Bowler, M. W., and Hansman, G. S. (2015). The
sweet quartet: Binding of fucose to the norovirus capsid. Virology, 483:203–208.
Kosakovsky Pond, S. L., Frost, S. D. W., and Muse, S. V. (2005). HyPhy: Hypothesis
testing using phylogenies. Bioinformatics, 21(5):676–679.
Kotloff, K. L., Nataro, J. P., Blackwelder, W. C., Nasrin, D., Farag, T. H., Panchalingam,
S., Wu, Y., Sow, S. O., Sur, D., Breiman, R. F., Faruque, A. S., Zaidi, A. K., Saha, D.,
Alonso, P. L., Tamboura, B., Sanogo, D., Onwuchekwa, U., Manna, B., Ramamurthy,
T., Kanungo, S., Ochieng, J. B., Omore, R., Oundo, J. O., Hossain, A., Das, S. K.,
Ahmed, S., Qureshi, S., Quadri, F., Adegbola, R. A., Antonio, M., Hossain, M. J.,
Akinsola, A., Mandomando, I., Nhampossa, T., Aca´cio, S., Biswas, K., O’Reilly, C. E.,
Mintz, E. D., Berkeley, L. Y., Muhsen, K., Sommerfelt, H., Robins-Browne, R. M.,
and Levine, M. M. (2013). Burden and aetiology of diarrhoeal disease in infants and
BIBLIOGRAPHY 219
young children in developing countries (the Global Enteric Multicenter Study, GEMS):
A prospective, case-control study. The Lancet, 382(9888):209–222.
Kroneman, A., Vega, E., Vennema, H., Vinje´, J., White, P. A., Hansman, G., Green, K.,
Martella, V., Katayama, K., and Koopmans, M. (2013). Proposal for a unified norovirus
nomenclature and genotyping. Archives of Virology, 158(10):2059–2068.
Kroneman, A., Vennema, H., Deforche, K., Avoort, H., Pen˜aranda, S., Oberste, M. S.,
Vinje´, J., and Koopmans, M. (2011). An automated genotyping tool for enteroviruses
and noroviruses. Journal of Clinical Virology, 51(2):121–125.
Kroneman, A., Verhoef, L., Harris, J., Vennema, H., Duizer, E., Van Duynhoven, Y.,
Gray, J., Iturriza, M., Bo¨ttiger, B., Falkenhorst, G., Johnsen, C., Von Bonsdorff, C. H.,
Maunula, L., Kuusi, M., Pothier, P., Gallay, A., Schreier, E., Ho¨hne, M., Koch, J.,
Szu¨cs, G., Reuter, G., Krisztalovics, K., Lynch, M., McKeown, P., Foley, B., Cough-
lan, S., Ruggeri, F. M., Di Bartolo, I., Vainio, K., Isakbaeva, E., Poljsak-Prijatelj, M.,
Hocevar Grom, A., Zimsek Mijovski, J., Bosch, A., Buesa, J., Sanchez Fauquier, A.,
Hernande´z-Pezzi, G., Hedlund, K. O., and Koopmans, M. (2008). Analysis of inte-
grated virological and epidemiological reports of norovirus outbreaks collected within
the Foodborne Viruses in Europe network from 1 July 2001 to 30 June 2006. Journal
of Clinical Microbiology, 46(9):2959–2965.
Kumazaki, M. and Usuku, S. (2015). Genetic analysis of norovirus GII.4 variant strains
detected in outbreaks of gastroenteritis in Yokohama, Japan, from the 2006-2007 to the
2013-2014 seasons.
Kyte, J. and Doolittle, R. F. (1982). A simple method for displaying the hydropathic
character of a protein. Journal of Molecular Biology, 157(1):105–132.
Lay, M. K., Atmar, R. L., Guix, S., Bharadwaj, U., He, H., Neill, F. H., Sastry, K. J., Yao,
Q., and Estes, M. K. (2010). Norwalk virus does not replicate in human macrophages
or dendritic cells derived from the peripheral blood of susceptible humans. Virology,
406(1):1–11.
Le Pendu, J., Ruvoe¨n-Clouet, N., Kindberg, E., and Svensson, L. (2006). Mendelian
resistance to human norovirus infections.
220 BIBLIOGRAPHY
Lee, C. C., Feng, Y., Chen, S. Y., Tsai, C. N., Lai, M. W., and Chiu, C. H. (2015).
Emerging Norovirus GII.17 in Taiwan.
Lee, R. M., Lessler, J., Lee, R. A., Rudolph, K. E., Reich, N. G., Perl, T. M., and Cum-
mings, D. A. (2013). Incubation periods of viral gastroenteritis: a systematic review.
BMC Infectious Diseases, 13(1):446.
Lemey, P., Rambaut, A., Bedford, T., Faria, N., Bielejec, F., Baele, G., Russell, C. A.,
Smith, D. J., Pybus, O. G., Brockmann, D., and Suchard, M. A. (2014). Unifying Viral
Genetics and Human Transportation Data to Predict the Global Transmission Dynamics
of Human Influenza H3N2. PLoS Pathogens, 10(2).
Lemey, P., Rambaut, A., Drummond, A. J., and Suchard, M. A. (2009). Bayesian phylo-
geography finds its roots. PLoS Computational Biology, 5(9).
Li, L., Shan, T., Wang, C., Cote, C., Kolman, J., Onions, D., Gulland, F. M. D., and
Delwart, E. (2011). The Fecal Viral Flora of California Sea Lions. Journal of Virology,
85(19):9909–9917.
Lindesmith, L., Moe, C., Le pendu, J., Frelinger, J. A., Treanor, J., and Baric, R. S. (2005).
Cellular and humoral immunity following Snow Mountain virus challenge. Journal of
virology, 79(5):2900–9.
Lindesmith, L., Moe, C., Marionneau, S., Ruvoen, N., Jiang, X., Lindblad, L., Stewart,
P., LePendu, J., and Baric, R. (2003). Human susceptibility and resistance to Norwalk
virus infection. Nature Medicine, 9(5):548–553.
Lindesmith, L. C., Beltramello, M., Donaldson, E. F., Corti, D., Swanstrom, J., Debbink,
K., Lanzavecchia, A., and Baric, R. S. (2012a). Immunogenetic mechanisms driving
norovirus GII.4 antigenic variation. PLoS Pathogens, 8(5).
Lindesmith, L. C., Costantini, V., Swanstrom, J., Debbink, K., Donaldson, E. F., Vinje´, J.,
and Baric, R. S. (2013). Emergence of a norovirus GII.4 strain correlates with changes
in evolving blockade epitopes. Journal of virology, 87(5):2803–13.
Lindesmith, L. C., Debbink, K., Swanstrom, J., Vinje´, J., Costantini, V., Baric, R. S., and
BIBLIOGRAPHY 221
Donaldson, E. F. (2012b). Monoclonal antibody-based antigenic mapping of norovirus
GII.4-2002. Journal of virology, 86(2):873–83.
Lindesmith, L. C., Donaldson, E., Leon, J., Moe, C. L., Frelinger, J. a., Johnston, R. E.,
Weber, D. J., and Baric, R. S. (2010). Heterotypic humoral and cellular immune re-
sponses following Norwalk virus infection. Journal of virology, 84(4):1800–1815.
Lindesmith, L. C., Donaldson, E. F., and Baric, R. S. (2011). Norovirus GII.4 Strain
Antigenic Variation. Journal of Virology, 85(1):231–242.
Lindesmith, L. C., Donaldson, E. F., Beltramello, M., Pintus, S., Corti, D., Swanstrom,
J., Debbink, K., Jones, T. A., Lanzavecchia, A., and Baric, R. S. (2014). Particle
Conformation Regulates Antibody Access to a Conserved GII.4 Norovirus Blockade
Epitope. Journal of Virology, 88(16):8826–8842.
Lindesmith, L. C., Donaldson, E. F., LoBue, A. D., Cannon, J. L., Zheng, D. P., Vinje, J.,
and Baric, R. S. (2008). Mechanisms of GII.4 norovirus persistence in human popula-
tions. PLoS Medicine, 5(2):0269–0290.
Lindesmith, L. C., Kocher, J. F., Donaldson, E. F., Debbink, K., Mallory, M. L., Swann,
E. W., Brewer-Jenson, P. D., and Baric, R. S. (2017a). Emergence of Novel Human
Norovirus GII.17 Strains Correlates with Changes in Blockade Antibody Epitopes. The
Journal of Infectious Diseases.
Lindesmith, L. C., Mallory, M. L., Jones, T. A., Richardson, C., Goodwin, R. R., Baehner,
F., Mendelman, P. M., Bargatze, R. F., and Baric, R. S. (2017b). Impact of pre-exposure
history and host genetics on antibody avidity following norovirus vaccination. Journal
of Infectious Diseases, 215(6):984–991.
Liu, B. L., Lambden, P. R., Gu¨nther, H., Otto, P., Elschner, M., and Clarke, I. N. (1999).
Molecular characterization of a bovine enteric calicivirus: relationship to the Norwalk-
like viruses. Journal of virology, 73(1):819–25.
Liu, L. T.-C., Kuo, T.-Y., Wu, C.-Y., Liao, W.-T., Hall, A. J., and Wu, F.-T. (2017).
Recombinant GII.P16-GII.2 Norovirus, Taiwan, 2016. Emerging Infectious Diseases,
23(7):1180–1183.
222 BIBLIOGRAPHY
Liu, P., Wang, X., Lee, J.-C., Teunis, P., Hu, S., Paradise, H. T., and Moe, C. (2014).
Genetic Susceptibility to Norovirus GII.3 and GII.4 Infections in Chinese Pediatric
Diarrheal Disease. The Pediatric Infectious Disease Journal, 33(11):e305–e309.
Lopman, B., Gastan˜aduy, P., Park, G. W., Hall, A. J., Parashar, U. D., and Vinje´, J. (2012).
Environmental transmission of norovirus gastroenteritis. Current Opinion in Virology,
2(1):96–102.
Lopman, B., Vennema, H., Kohli, E., Pothier, P., Sanchez, A., Negredo, A., Buesa, J.,
Schreier, E., Reacher, M., Brown, D., Gray, J., Iturriza, M., Gallimore, C., Bottiger,
B., Hedlund, K. O., Torv??n, M., Von Bonsdorff, C. H., Maunula, L., Poljsak-Prijatelj,
M., Zimsek, J., Reuter, G., Sz??cs, G., Melegh, B., Svennson, L., Van Duijnhoven, Y.,
and Koopmans, M. (2004a). Increase in viral gastroenteritis outbreaks in Europe and
epidemic spread of new norovirus variant.
Lopman, B. a., Reacher, M. H., Vipond, I. B., Sarangi, J., and Brown, D. W. G. (2004b).
Clinical manifestation of norovirus gastroenteritis in health care settings. Clinical in-
fectious diseases : an official publication of the Infectious Diseases Society of America,
39(3):318–324.
Lopman, B. A., Steele, D., Kirkwood, C. D., and Parashar, U. D. (2016). The Vast and
Varied Global Burden of Norovirus: Prospects for Prevention and Control.
Lopman, B. A., Trivedi, T., Vicun˜a, Y., Costantini, V., Collins, N., Gregoricus, N.,
Parashar, U., Sandoval, C., Broncano, N., Vaca, M., Chico, M. E., Vinje´, J., and Cooper,
P. J. (2015). Norovirus infection and disease in an ecuadorian birth cohort: Association
of certain norovirus genotypes with host FUT2 secretor status. Journal of Infectious
Diseases, 211(11):1813–1821.
Lu, J., Fang, L., Sun, L., Zeng, H., Li, Y., Zheng, H., Wu, S., Yang, F., Song, T., Lin, J.,
Ke, C., Zhang, Y., Vinje´, J., and Li, H. (2017). Association of GII.P16-GII.2 Recombi-
nant Norovirus Strain with Increased Norovirus Outbreaks, Guangdong, China, 2016.
Emerging infectious diseases, 23(7):1188–1190.
Lu, J., Fang, L., Zheng, H., Lao, J., Yang, F., Sun, L., Xiao, J., Lin, J., Song, T., Ni, T.,
Raghwani, J., Ke, C., Faria, N. R., Bowden, T. A., Pybus, O. G., and Li, H. (2016).
BIBLIOGRAPHY 223
The evolution and transmission of epidemic gii.17 noroviruses. Journal of Infectious
Diseases, 214(4):556–564.
Lu, J., Sun, L., Fang, L., Yang, F., Mo, Y., Lao, J., Zheng, H., Tan, X., Lin, H., Ruther-
ford, S., Guo, L., Ke, C., and Hui, L. (2015). Gastroenteritis outbreaks caused by
norovirus GII.17, Guangdong Province, China, 20142015. Emerging Infectious Dis-
eases, 21(7):1240–1242.
Malm, M., Tamminen, K., Lappalainen, S., Uusi-Kerttula, H., Vesikari, T., and Blazevic,
V. (2015). Genotype considerations for virus-like particle-based bivalent norovirus
vaccine composition. Clinical and Vaccine Immunology, 22(6):656–663.
Malm, M., Uusi-Kerttula, H., Vesikari, T., and Blazevic, V. (2014). High serum lev-
els of norovirus genotype-specific blocking antibodies correlate with protection from
infection in children. Journal of Infectious Diseases, 210(11):1755–1762.
Mans, J., Armah, G. E., Steele, A. D., and Taylor, M. B. (2016). Norovirus epidemiology
in Africa: A review.
Mans, J., de Villiers, J. C., du Plessis, N. M., Avenant, T., and Taylor, M. B. (2010).
Emerging norovirus GII.4 2008 variant detected in hospitalised paediatric patients in
South Africa. Journal of Clinical Virology, 49(4):258–264.
Mans, J., Murray, T. Y., Nadan, S., Netshikweta, R., Page, N. A., and Taylor, M. B. (2015).
Norovirus diversity in children with gastroenteritis in South Africa from 2009 to 2013:
GII.4 variants and recombinant strains predominate. Epidemiology and Infection, 22:1–
10.
Martella, V., Decaro, N., Lorusso, E., Radogna, A., Moschidou, P., Amorisco, F., Lucente,
M. S., Desario, C., Mari, V., Elia, G., Banyai, K., Carmichael, L. E., and Buonavoglia,
C. (2009). Genetic heterogeneity and recombination in canine noroviruses. Journal of
virology, 83(21):11391–11396.
Martella, V., Lorusso, E., Decaro, N., Elia, G., Radogna, A., D’Abramo, M., Desario, C.,
Cavalli, A., Corrente, M., Camero, M., Germinario, C. A., Ba´nyai, K., Di Martino, B.,
Marsilio, F., Carmichael, L. E., and Buonavoglia, C. (2008). Detection and molecular
224 BIBLIOGRAPHY
characterization of a canine norovirus. Emerging Infectious Diseases, 14(8):1306–
1308.
Matsushima, Y., Ishikawa, M., Shimizu, T., Komane, A., Kasuo, S., Shinohara, M., Na-
gasawa, K., Kimura, H., Ryo, A., Okabe, N., Haga, K., Doan, Y., Katayama, K.,
and Shimizu, H. (2015). Genetic analyses of GII.17 norovirus strains in diarrheal
disease outbreaks from December 2014 to March 2015 in Japan reveal a novel poly-
merase sequence and amino acid substitutions in the capsid region. Eurosurveillance,
20(26):21173.
Matsushima, Y., Shimizu, T., Ishikawa, M., Komane, A., Okabe, N., Ryo, A., Kimura,
H., Katayama, K., and Shimizu, H. (2016). Complete Genome Sequence of a Recom-
binant GII.P16-GII.4 Norovirus Detected in Kawasaki City, Japan, in 2016. Genome
Announcements, 4(5):e01099–16.
Mattison, K., Shukla, A., Cook, A., Pollari, F., Friendship, R., Kelton, D., Bidawid, S.,
and Farber, J. M. (2007). Human noroviruses in swine and cattle. Emerging Infectious
Diseases, 13(8):1184–1188.
McCartney, S. A., Thackray, L. B., Gitlin, L., Gilfillan, S., Virgin IV, H. W., and Colonna,
M. (2008). MDA-5 recognition of a murine norovirus. PLoS Pathogens, 4(7).
McCune, B. T., Tang, W., Lu, J., Eaglesham, J. B., Thorne, L., Mayer, A. E., Condiff, E.,
Nice, T. J., Goodfellow, I., Krezel, A. M., and Virgin, H. W. (2017). Noroviruses Co-
opt the Function of Host Proteins VAPA and VAPB for Replication via a Phenylalanine-
Phenylalanine-Acidic-Tract-Motif Mimic in Nonstructural Viral Protein NS1/2. mBio,
8(4):1–17.
McFadden, N., Bailey, D., Carrara, G., Benson, A., Chaudhry, Y., Shortland, A., Heeney,
J., Yarovinsky, F., Simmonds, P., Macdonald, A., and Goodfellow, I. (2011). Norovirus
regulation of the innate immune response and apoptosis occurs via the product of the
alternative open reading frame 4. PLoS Pathogens, 7(12).
Mercer, J., Schelhaas, M., and Helenius, A. (2010). Virus Entry by Endocytosis. Annual
Review of Biochemistry, 79(1):803–833.
BIBLIOGRAPHY 225
Mesquita, J. R., Barclay, L., Nascimento, M. S. J., and Vinje´, J. (2010). Novel norovirus
in dogs with diarrhea. Emerging Infectious Diseases, 16(6):980–982.
Mori, K., Chu, P. Y., Motomura, K., Somura, Y., Nagano, M., Kimoto, K., Akiba, T.,
Kai, A., and Sadamasu, K. (2017a). Genomic analysis of the evolutionary lineage of
Norovirus GII.4 from archival specimens during 1975???1987 in Tokyo. Journal of
Medical Virology, 89(2):363–367.
Mori, K., Nagano, M., Kimoto, K., Somura, Y., Akiba, T., Hayashi, Y., Sadamasu, K.,
and Ka, A. (2017b). Detection of enteric viruses in fecal specimens from nonbacterial
foodborne gastroenteritis outbreaks in Tokyo, Japan between 1966 and 1983. Japanese
Journal of Infectious Diseases, 70(2):143–151.
Motomura, K., Yokoyama, M., Ode, H., Nakamura, H., Mori, H., Kanda, T., Oka, T.,
Katayama, K., Noda, M., Tanaka, T., Takeda, N., and Sato, H. (2010). Divergent
evolution of norovirus GII/4 by genome recombination from May 2006 to February
2009 in Japan. Journal of virology, 84(16):8085–8097.
Napthine, S., Lever, R. A., Powell, M. L., Jackson, R. J., Brown, T. D. K., and Brierley, I.
(2009). Expression of the VP2 protein of murine norovirus by a translation termination-
reinitiation strategy. PLoS ONE, 4(12).
Ng, K. K. S., Penda´s-Franco, N., Rojo, J., Boga, J. A., Machı´n, A´., Martı´n Alonso,
J. M., and Parra, F. (2004). Crystal Structure of Norwalk Virus Polymerase Reveals
the Carboxyl Terminus in the Active Site Cleft. Journal of Biological Chemistry,
279(16):16638–16645.
Nice, T. J., Strong, D. W., McCune, B. T., Pohl, C. S., Virgin, H. W., Thackray, L. B.,
Smith, T. J., and Virgin, H. W. (2013). A Single-Amino-Acid Change in Murine
Norovirus NS1/2 Is Sufficient for Colonic Tropism and Persistence. Journal of vi-
rology, 86(6):327–334.
Niendorf, S., Jacobsen, S., Faber, M., Eis-Hu¨binger, A. M., Hofmann, J., Zimmermann,
O., Ho¨hne, M., and Bock, C. T. (2017). Steep rise in norovirus cases and emergence
of a new recombinant strain GII.P16-GII.2, Germany, winter 2016. Euro surveillance :
226 BIBLIOGRAPHY
bulletin Europeen sur les maladies transmissibles = European communicable disease
bulletin, 22(4).
Niendorf, S., Klemm, U., Marques, A. M., Bock, C. T., and Ho¨hne, M. (2016). Infection
with the persistent murine norovirus strain MNV-S99 suppresses IFN-Beta release and
activation of stat1 In vitro. PLoS ONE, 11(6).
Noel, J. S., Fankhauser, R. L., Ando, T., Monroe, S. S., and Glass, R. I. (1999). Identifica-
tion of a Distinct Common Strain of Norwalklike Viruses Having a Global Distribution.
The Journal of Infectious Diseases, 179(6):1334–1344.
Nordgren, J., Kindberg, E., Lindgren, P. E., Matussek, A., and Svensson, L. (2010).
Norovirus gastroenteritis outbreak with a secretor-independent susceptibility pattern,
Sweden. Emerging Infectious Diseases, 16(1):81–87.
Nordgren, J., Nitiema, L. W., Ouermi, D., Simpore, J., and Svensson, L. (2013). Host
Genetic Factors Affect Susceptibility to Norovirus Infections in Burkina Faso. PLoS
ONE, 8(7).
Nordgren, J., Sharma, S., Kambhampati, A., Lopman, B., Svensson, L., and Lynfield, R.
(2016). Innate Resistance and Susceptibility to Norovirus Infection. PLOS Pathogens,
12(4):e1005385.
O’Brien, S. J., Donaldson, A. L., Iturriza-Gomara, M., and Tam, C. C. (2016). Age-
Specific Incidence Rates for Norovirus in the Community and Presenting to Primary
Healthcare Facilities in the United Kingdom. Journal of Infectious Diseases, 213:S15–
S18.
Oliver, S. L., Dastjerdi, A. M., Wong, S., El-Attar, L., Gallimore, C., Brown, D. W. G.,
Green, J., and Bridger, J. C. (2003). Molecular Characterization of Bovine Enteric Cali-
civiruses: a Distinct Third Genogroup of Noroviruses (Norwalk-Like Viruses) Unlikely
To Be of Risk to Humans. Journal of Virology, 77(4):2789–2798.
Orchard, R. C., Wilen, C. B., Doench, J. G., Baldridge, M. T., McCune, B. T., Lee,
Y.-C. J., Lee, S., Pruett-Miller, S. M., Nelson, C. A., Fremont, D. H., and Virgin,
H. W. (2016). Discovery of a proteinaceous cellular receptor for a norovirus. Science,
353(6302):933–936.
BIBLIOGRAPHY 227
Otto, P. H., Clarke, I. N., Lambden, P. R., Salim, O., Reetz, J., and Liebler-Tenorio,
E. M. (2011). Infection of Calves with Bovine Norovirus GIII.1 Strain Jena Virus:
an Experimental Model To Study the Pathogenesis of Norovirus Infection. Journal of
Virology, 85(22):12013–12021.
Park, S. I., Jeong, C., Kim, H. H., Park, S. H., Park, S. J., Hyun, B. H., Yang, D. K.,
Kim, S. K., Kang, M. I., and Cho, K. O. (2007). Molecular epidemiology of bovine
noroviruses in South Korea. Veterinary Microbiology, 124(1-2):125–133.
Parra, G. I., Squires, R. B., Karangwa, C. K., Johnson, J. A., Lepore, C. J., Sosnovtsev,
S. V., and Green, K. Y. (2017). Static and Evolving Norovirus Genotypes: Implications
for Epidemiology and Immunity. PLoS Pathogens, 13(1).
Parrino, T. A., Schreiber, D. S., Trier, J. S., Kapikian, A. Z., and Blacklow, N. R. (1977).
Clinical immunity in acute gastroenteritis caused by Norwalk agent. The New England
journal of medicine, 297(2):86–9.
Patel, M. M., Hall, A. J., Vinje´, J., and Parashar, U. D. (2009). Noroviruses: A compre-
hensive review.
Patel, M. M., Widdowson, M. A., Glass, R. I., Akazawa, K., Vinje´, J., and Parashar, U. D.
(2008). Systematic literature review of role of noroviruses in sporadic gastroenteritis.
Payne, D. C., Vinje´, J., Szilagyi, P. G., Edwards, K. M., Staat, M. A., Weinberg, G. A.,
Hall, C. B., Chappell, J., Bernstein, D. I., Curns, A. T., Wikswo, M., Shirley, S. H., Hall,
A. J., Lopman, B., and Parashar, U. D. (2013). Norovirus and Medically Attended
Gastroenteritis in U.S. Children. New England Journal of Medicine, 368(12):1121–
1130.
Pires, S. M., Fischer-Walker, C. L., Lanata, C. F., Devleesschauwer, B., Hall, A. J., Kirk,
M. D., Duarte, A. S., Black, R. E., and Angulo, F. J. (2015). Aetiology-specific esti-
mates of the global and regional incidence and mortality of diarrhoeal diseases com-
monly transmitted through food. PLoS ONE, 10(12).
Pond, S. L. K., Posada, D., Gravenor, M. B., Woelk, C. H., and Frost, S. D. W. (2006). Au-
tomated phylogenetic detection of recombination using a genetic algorithm. Molecular
Biology and Evolution, 23(10):1891–1901.
228 BIBLIOGRAPHY
Prasad, B. V., Hardy, M. E., Dokland, T., Bella, J., Rossmann, M. G., and Estes,
M. K. (1999). X-ray crystallographic structure of the Norwalk virus capsid. Science,
286(October):287–290.
Qu, L., Murakami, K., Broughman, J. R., Lay, M. K., Guix, S., Tenge, V. R., Atmar, R. L.,
and Estes, M. K. (2016). Replication of Human Norovirus RNA in Mammalian Cells
Reveals Lack of Interferon Response. Journal of Virology, 90(19):8906–8923.
Ramani, S., Estes, M. K., and Atmar, R. L. (2016). Correlates of Protection against
Norovirus Infection and DiseaseWhere Are We Now, Where Do We Go?
Ramani, S., Neill, F. H., Opekun, A. R., Gilger, M. A., Graham, D. Y., Estes, M. K., and
Atmar, R. L. (2015). Mucosal and Cellular Immune Responses to Norwalk Virus. In
Journal of Infectious Diseases, volume 212, pages 397–405.
Rambaut, A., Lam, T. T., Max Carvalho, L., and Pybus, O. G. (2016). Exploring the
temporal structure of heterochronous sequences using TempEst (formerly Path-O-Gen).
Virus Evolution, 2(1):vew007.
Reeck, A., Kavanagh, O., Estes, M. K., Opekun, A. R., Gilger, M. a., Graham, D. Y.,
and Atmar, R. L. (2010). Serological correlate of protection against norovirus-induced
gastroenteritis. The Journal of infectious diseases, 202(8):1212–1218.
Robilotti, E., Deresinski, S., and Pinsky, B. A. (2015). Norovirus. Clinical Microbiology
Reviews, 28(1):134–164.
Rockx, B., Baric, R. S., De Grijs, I., Duizer, E., and Koopmans, M. P. G. (2005). Char-
acterization of the homo- and heterotypic immune responses after natural norovirus
infection. Journal of Medical Virology, 77(3):439–446.
Rohayem, J., Robel, I., Jager, K., Scheffler, U., and Rudolph, W. (2006). Protein-Primed
and De Novo Initiation of RNA Synthesis by Norovirus 3Dpol. Journal of Virology,
80(14):7060–7069.
Roth, A. N. and Karst, S. M. (2016). Norovirus mechanisms of immune antagonism.
BIBLIOGRAPHY 229
Ruvoe¨n-Clouet, N., Belliot, G., and Le Pendu, J. (2013). Noroviruses and histo-blood
groups: The impact of common host genetic polymorphisms on virus transmission and
evolution.
Sato, T., Stange, D. E., Ferrante, M., Vries, R. G. J., Van Es, J. H., Van Den Brink, S., Van
Houdt, W. J., Pronk, A., Van Gorp, J., Siersema, P. D., and Clevers, H. (2011). Long-
term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma,
and Barrett’s epithelium. Gastroenterology, 141(5):1762–1772.
Schuit, M., Miller, D. M., Reddick-Elick, M. S., Wlazlowski, C. B., Filone, C. M., Her-
zog, A., Colf, L. A., Wahl-Jensen, V., Hevey, M., and Noah, J. W. (2016). Differences
in the comparative stability of ebola virus makona-c05 and yambuku-mayinga in blood.
PLoS ONE, 11(2).
Sdiri-Loulizi, K., Ambert-Balay, K., Gharbi-Khelifi, H., Sakly, N., Hassine, M.,
Chouchane, S., Guediche, M. N., Pothier, P., and Aouni, M. (2009). Molecular epi-
demiology of norovirus gastroenteritis investigated using samples collected from chil-
dren in Tunisia during a four-year period: Detection of the norovirus variant GGII.4
hunter as early as January 2003. Journal of Clinical Microbiology, 47(2):421–429.
Seitz, S. R., Leon, J. S., Schwab, K. J., Lyon, G. M., Dowd, M., McDaniels, M., Abdul-
hafid, G., Fernandez, M. L., Lindesmith, L. C., Baric, R. S., and Moe, C. L. (2011).
Norovirus infectivity in humans and persistence in water. Applied and Environmental
Microbiology, 77(19):6884–6888.
Sharma, S., Carlsson, B., Czako´, R., Vene, S., Haglund, M., Ludvigsson, J., Larson, G.,
Hammarstro¨m, L., Sosnovtsev, S., Atmar, R., Green, K., Estes, M., and Svensson, L.
(2017). Human sera collected between 1979 and 2010 possess blocking-antibody titers
to pandemic GII.4 noroviruses isolated over three decades. Journal of Virology, 91(14).
Siebenga, J. J., Lemey, P., Pond, S. L. K., Rambaut, A., Vennema, H., and Koopmans, M.
(2010). Phylodynamic reconstruction reveals norovirus GII.4 epidemic expansions and
their molecular determinants. PLoS Pathogens, 6(5):1–13.
Siebenga, J. J., Vennema, H., Renckens, B., de Bruin, E., van der Veer, B., Siezen, R. J.,
230 BIBLIOGRAPHY
and Koopmans, M. (2007). Epochal evolution of GGII.4 norovirus capsid proteins from
1995 to 2006. Journal of virology, 81(18):9932–41.
Siebenga, J. J., Vennema, H., Zheng, D.-P., Vinje´, J., Lee, B. E., Pang, X.-L., Ho, E. C. M.,
Lim, W., Choudekar, A., Broor, S., Halperin, T., Rasool, N. B. G., Hewitt, J., Greening,
G. E., Jin, M., Duan, Z.-J., Lucero, Y., O’Ryan, M., Hoehne, M., Schreier, E., Ratcliff,
R. M., White, P. A., Iritani, N., Reuter, G., and Koopmans, M. (2009). Norovirus Illness
Is a Global Problem: Emergence and Spread of Norovirus GII.4 Variants, 20012007.
The Journal of Infectious Diseases, 200(5):802–812.
Simmonds, P., Karakasiliotis, I., Bailey, D., Chaudhry, Y., Evans, D. J., and Goodfel-
low, I. G. (2008). Bioinformatic and functional analysis of RNA secondary structure
elements among different genera of human and animal caliciviruses. Nucleic Acids
Research, 36(8):2530–2546.
Simmons, K., Gambhir, M., Leon, J., and Lopman, B. (2013). Duration of immunity to
norovirus gastroenteritis. Emerging Infectious Diseases, 19(8):1260–1267.
Singh, B. K., Koromyslova, A., Hefele, L., Gurth, C., and Hansman, G. S. (2016a). Struc-
tural Evolution of the Emerging 2014-2015 GII.17 Noroviruses. J Virol, 90(5):2710–
2715.
Singh, B. K., Leuthold, M. M., and Hansman, G. S. (2015). Human noroviruses’ fondness
for histo-blood group antigens. Journal of virology, 89(4):2024–40.
Singh, B. K., Leuthold, M. M., and Hansman, G. S. (2016b). Structural Constraints on
Human Norovirus Binding to Histo-Blood Group Antigens. MSphere, 1(2):1–7.
Siqueira, J. A. M., Bandeira, R. D. S., Oliveira, D. D. S., Dos Santos, L. F. P., and Gabbay,
Y. B. (2017). Genotype diversity and molecular evolution of noroviruses: A 30-year
(1982-2011) comprehensive study with children from Northern Brazil. PLoS ONE,
12(6).
Smits, S. L., Rahman, M., Schapendonk, C. M. E., van Leeuwen, M., Faruque, A. S. G.,
Haagmans, B. L., Endtz, H. P., and Osterhaus, A. D. M. E. (2012). Calicivirus from
novel recovirus genogroup in human diarrhea, Bangladesh. Emerging Infectious Dis-
eases, 18(7):1192–1195.
BIBLIOGRAPHY 231
Someya, Y., Takeda, N., and Miyamura, T. (2002). Identification of active-site amino acid
residues in the Chiba virus 3C-like protease. Journal of virology, 76(12):5949–58.
Someya, Y., Takeda, N., and Wakita, T. (2008). Saturation mutagenesis reveals that
GLU54 of norovirus 3C-like protease is not essential for the proteolytic activity. Jour-
nal of Biochemistry, 144(6):771–780.
Sosnovtsev, S. V., Belliot, G., Chang, K.-O., Prikhodko, V. G., Thackray, L. B., Wobus,
C. E., Karst, S. M., Virgin, H. W., and Green, K. Y. (2006). Cleavage map and pro-
teolytic processing of the murine norovirus nonstructural polyprotein in infected cells.
Journal of virology, 80(16):7816–7831.
Stamatakis, A. (2014). RAxML version 8: A tool for phylogenetic analysis and post-
analysis of large phylogenies. Bioinformatics, 30(9):1312–1313.
Subba-Reddy, C. V., Goodfellow, I., and Kao, C. C. (2011). VPg-Primed RNA Synthesis
of Norovirus RNA-Dependent RNA Polymerases by Using a Novel Cell-Based Assay.
Journal of Virology, 85(24):13027–13037.
Subba-Reddy, C. V., Yunus, M. a., Goodfellow, I. G., and Kao, C. C. (2012).
Norovirus RNA Synthesis Is Modulated by an Interaction between the Viral RNA-
Dependent RNA Polymerase and the Major Capsid Protein, VP1. Journal of Virology,
86(18):10138–10149.
Sugieda, M., Nagaoka, H., Kakishima, Y., Ohshita, T., Nakamura, S., and Nakajima, S.
(1998). Detection of Norwalk-like virus genes in the caecum contents of pigs. Brief
report. Archives of Virology, 143(6):1215–1221.
Summa, M., von Bonsdorff, C. H., and Maunula, L. (2012). Pet dogs-A transmission
route for human noroviruses? Journal of Clinical Virology, 53(3):244–247.
Tam, C. C., Rodrigues, L. C., Viviani, L., Dodds, J. P., Evans, M. R., Hunter, P. R., Gray,
J. J., Letley, L. H., Rait, G., Tompkins, D. S., and O’Brien, S. J. (2012). Longitu-
dinal study of infectious intestinal disease in the UK (IID2 study): incidence in the
community and presenting to general practice. Gut, 61(1):69–77.
232 BIBLIOGRAPHY
Tamuri, A. U., Dos Reis, M., Hay, A. J., and Goldstein, R. A. (2009). Identifying changes
in selective constraints: Host shifts in influenza. PLoS Computational Biology, 5(11).
Taube, S., Jiang, M., and Wobus, C. E. (2010). Glycosphingolipids as receptors for non-
enveloped viruses.
Taube, S., Kolawole, A. O., Ho¨hne, M., Wilkinson, J. E., Handley, S. A., Perry, J. W.,
Thackray, L. B., Akkina, R., and Wobus, C. E. (2013). A mouse model for human
norovirus. mBio, 4(4).
Teunis, P. F. M., Moe, C. L., Liu, P., Miller, S. E., Lindesmith, L., Baric, R. S., Le Pendu,
J., and Calderon, R. L. (2008). Norwalk virus: How infectious is it? Journal of Medical
Virology, 80(8):1468–1476.
Teunis, P. F. M., Sukhrie, F. H. A., Vennema, H., Bogerman, J., Beersma, M. F. C., and
Koopmans, M. P. G. (2015). Shedding of norovirus in symptomatic and asymptomatic
infections. Epidemiology and Infection, 143(08):1710–1717.
Thackray, L. B., Duan, E., Lazear, H. M., Kambal, A., Schreiber, R. D., Diamond, M. S.,
and Virgin, H. W. (2012). Critical role for interferon regulatory factor 3 (IRF-3) and
IRF-7 in type I interferon-mediated control of murine norovirus replication. Journal of
Virology, 86(24):13515–13523.
Thorne, L., Arias, A., and Goodfellow, I. (2016). Advances Toward a Norovirus Antivi-
ral: From Classical Inhibitors to Lethal Mutagenesis. Journal of Infectious Diseases,
213:S27–S31.
Thorne, L. G. and Goodfellow, I. G. (2014). Norovirus gene expression and replication.
Tomov, V. T., Osborne, L. C., Dolfi, D. V., Sonnenberg, G. F., Monticelli, L. A., Mans-
field, K., Virgin, H. W., Artis, D., and Wherry, E. J. (2013). Persistent Enteric Murine
Norovirus Infection Is Associated with Functionally Suboptimal Virus-Specific CD8 T
Cell Responses. Journal of Virology, 87(12):7015–7031.
Tse, H., Lau, S. K. P., Chan, W.-M., Choi, G. K. Y., Woo, P. C. Y., and Yuen, K.-Y. (2012).
Complete genome sequences of novel canine noroviruses in Hong Kong. Journal of
virology, 86(17):9531–2.
BIBLIOGRAPHY 233
Tu, E. T.-V., Bull, R. A., Greening, G. E., Hewitt, J., Lyon, M. J., Marshall, J. A., McIver,
C. J., Rawlinson, W. D., and White, P. A. (2008). Epidemics of Gastroenteritis during
2006 Were Associated with the Spread of Norovirus GII.4 Variants 2006a and 2006b.
Clinical Infectious Diseases, 46(3):413–420.
van Beek, J., Ambert-Balay, K., Botteldoorn, N., Eden, J. S., Fonager, J., Hewitt, J.,
Iritani, N., Kroneman, A., Vennema, H., Vinj??, J., White, P. A., Koopmans, M., and
NoroNet (2013). Indications for worldwide increased norovirus activity associated with
emergence of a new variant of genotype II.4, late 2012. Euro surveillance : bulletin
europ??en sur les maladies transmissibles = European communicable disease bulletin,
18(1):8–9.
Van Beek, J., De Graaf, M., Xia, M., Jiang, X., Vinje´, J., Beersma, M., De Bruin, E.,
Van De Vijver, D., Holwerda, M., Van Houten, M., Buisman, A. M., Van Binnendijk,
R., Osterhaus, A. D., Van Der Klis, F., Vennema, H., and Koopmans, M. P. (2016).
Comparison of norovirus genogroup I, II and IV seroprevalence among children in the
Netherlands, 1963, 1983 and 2006. Journal of General Virology, 97(9):2255–2264.
Vashist, S., Bailey, D., Putics, A., and Goodfellow, I. (2009). Model systems for the study
of human norovirus biology. Future Virology, 4(4):353–367.
Vega, E., Barclay, L., Gregoricus, N., Shirley, S. H., Lee, D., and Vinje´, J. (2014a).
Genotypic and epidemiologic trends of norovirus outbreaks in the united states, 2009
to 2013. Journal of Clinical Microbiology, 52(1):147–155.
Vega, E., Barclay, L., Gregoricus, N., Williams, K., Lee, D., and Vinje´, J. (2011). Novel
surveillance network for norovirus gastroenteritis outbreaks, United States. Emerging
Infectious Diseases, 17(8):1389–1395.
Vega, E., Donaldson, E., Huynh, J., Barclay, L., Lopman, B., Baric, R., Chen, L. F., and
Vinje´, J. (2014b). RNA populations in immunocompromised patients as reservoirs for
novel norovirus variants. Journal of virology, 88(24):14184–96.
Verhoef, L., Hewitt, J., Barclay, L., Ahmed, S. M., Lake, R., Hall, A. J., Lopman, B.,
Kroneman, A., Vennema, H., Vinje´, J., and Koopmans, M. (2015). Norovirus genotype
234 BIBLIOGRAPHY
profiles associated with foodborne transmission, 1999???2012. Emerging Infectious
Diseases, 21(4):592–599.
Vinje, J. (2015). Advances in Laboratory Methods for Detection and Typing of Norovirus.
J Clin Microbiol, 53(2):373–381.
Vongpunsawad, S., Venkataram Prasad, B. V., and Estes, M. K. (2013). Norwalk Virus
Minor Capsid Protein VP2 Associates within the VP1 Shell Domain. Journal of virol-
ogy, 87(9):4818–25.
Wang, Q. H., Myung, G. H., Cheetham, S., Souza, M., Funk, J. A., and Saif, L. J.
(2005). Porcine noroviruses related to human noroviruses. Emerging Infectious Dis-
eases, 11(12):1874–1881.
Ward, J. M., Wobus, C. E., Thackray, L. B., Erexson, C. R., Faucette, L. J., Belliot, G.,
Barron, E. L., Sosnovtsev, S. V., and Green, K. Y. (2006). Pathology of immunodefi-
cient mice with naturally occurring murine norovirus infection. Toxicologic Pathology,
34(6):708–715.
Wheeler, J. G., Sethi, D., Cowden, J. M., Wall, P. G., Rodrigues, L. C., Tompkins, D. S.,
Hudson, M. J., and Roderick, P. J. (1999). Study of infectious intestinal disease in
England: rates in the community, presenting to general practice, and reported to na-
tional surveillance. The Infectious Intestinal Disease Study Executive. BMJ (Clinical
research ed.), 318(7190):1046–50.
White, P. A. (2014). Evolution of norovirus.
Widdowson, M.-A., Monroe, S. S., and Glass, R. I. (2005). Are Noroviruses Emerging?
Emerging Infectious Diseases, 11(5):735–737.
Wobus, C. E., Karst, S. M., Thackray, L. B., Chang, K. O., Sosnovtsev, S. V., Belliot, G.,
Krug, A., Mackenzie, J. M., Green, K. Y., and Virgin IV, H. W. (2004). Replication of
Norovirus in cell culture reveals a tropism for dendritic cells and macrophages. PLoS
Biology, 2(12).
BIBLIOGRAPHY 235
Wobus, C. E., Thackray, L. B., and Virgin, H. W. (2006). Murine Norovirus: a Model Sys-
tem To Study Norovirus Biology and Pathogenesis. Journal of Virology, 80(11):5104–
5112.
Wolf, S., Williamson, W., Hewitt, J., Lin, S., Rivera-Aban, M., Ball, A., Scholes, P.,
Savill, M., and Greening, G. E. (2009). Molecular detection of norovirus in sheep and
pigs in New Zealand farms. Veterinary Microbiology, 133(1-2):184–189.
Wong, T. H. N., Dearlove, B. L., Hedge, J., Giess, A. P., Piazza, P., Trebes, A., Paul,
J., Smit, E., Smith, E. G., Sutton, J. K., Wilcox, M. H., Dingle, K. E., Peto, T. E. a.,
Crook, D. W., Wilson, D. J., and Wyllie, D. H. (2013). Whole genome sequencing and
de novo assembly identifies Sydney-like variant noroviruses and recombinants during
the winter 2012/2013 outbreak in England. Virology journal, 10:335.
Wright, P. J., Gunesekere, I. C., Doultree, J. C., and Marshall, J. A. (1998). Small
round-structued (Norwalk-like) viruses and classical human caliciviruses in Southeast-
ern Australia, 1980-1996. Journal of Medical Virology, 55(4):312–320.
Wu, Z., Yang, L., Ren, X., He, G., Zhang, J., Yang, J., Qian, Z., Dong, J., Sun, L., Zhu, Y.,
Du, J., Yang, F., Zhang, S., and Jin, Q. (2016). Deciphering the bat virome catalog to
better understand the ecological diversity of bat viruses and the bat origin of emerging
infectious diseases. The ISME Journal, 10(3):609–620.
Xi, J. N., Graham, D. Y., Wang, K. N., and Estes, M. K. (1990). Norwalk virus genome
cloning and characterization. Science, 250(4987):1580–1583.
Yang, Z. (2007). PAML 4: Phylogenetic analysis by maximum likelihood. Molecular
Biology and Evolution, 24(8):1586–1591.
Zahorsky, J. (1929). Hyperemesis Hiemis or the winter vomiting disease. Archives of
Pediatrics & Adolescent Medicine, 46:391–395.
Zakikhany, K., Allen, D. J., Brown, D., and Iturriza-Go´mara, M. (2012). Molecular
evolution of GII-4 norovirus strains. PLoS ONE, 7(7).
Zamyatkin, D. F., Parra, F., Alonso, J. M. M., Harki, D. a., Peterson, B. R., Grochulski, P.,
and Ng, K. K.-S. (2008). Structural insights into mechanisms of catalysis and inhibition
236 BIBLIOGRAPHY
in Norwalk virus polymerase. The Journal of biological chemistry, 283(12):7705–
7712.
Zeitler, C. E., Estes, M. K., and Venkataram Prasad, B. V. (2006). X-ray crystallo-
graphic structure of the Norwalk virus protease at 1.5-A resolution. Journal of virology,
80(10):5050–8.
Zhang, Y. (2008). I-TASSER server for protein 3D structure prediction. BMC Bioinfor-
matics, 9(1):40.
Zheng, D. P., Ando, T., Fankhauser, R. L., Beard, R. S., Glass, R. I., and Monroe,
S. S. (2006). Norovirus classification and proposed strain nomenclature. Virology,
346(2):312–323.
Zhu, S., Regev, D., Watanabe, M., Hickman, D., Moussatche, N., Jesus, D. M., Kahan,
S. M., Napthine, S., Brierley, I., Hunter, R. N., Devabhaktuni, D., Jones, M. K., and
Karst, S. M. (2013). Identification of Immune and Viral Correlates of Norovirus Pro-
tective Immunity through Comparative Study of Intra-Cluster Norovirus Strains. PLoS
Pathogens, 9(9).
Appendix A
Supplementary figures and tables
238 Appendix A. Supplementary figures and tables
A.1. Chapter 2 supplementary figures and tables 239
A.1 Chapter 2 supplementary figures and tables
1
2
3
4
5
6
7
8
9
10
20
30
40
50
60
70
80
90
100
200
1970 1975 1980 1985 1990 1995 2000 2005 2010 2015
Time
M
ed
ian
1
2
3
4
5
6
7
8
9
10
20
30
40
50
60
70
80
90
100
200
1970 1975 1980 1985 1990 1995 2000 2005 2010
Time
M
ed
ian
Pre-1990 increase in Neτ Post-1990 increase in Neτ 
1960 1970 1980 1990
0.
0
0.
1
0.
2
0.
3
0.
4
0.
5
0.
6
Ancestor
Value
D
en
si
ty
A 
Density 
0 
0.1 
0.2 
0.3 
0.4 
0.5 
0.6 
Year 
1960 1970 1980 1990 
Neτ 
1 
10 
10  
Year 
1970 1980 1990 2000 2010 
1 
10 
100 
Year 
1970 1980 1990 2000 2010 
B 
Within 95% HPD 
Outside 95% HPD 
0.0
0.2
0.4
0.6
1960 1970 1980 1990 2000
Ancestor
de
ns
ity
Density 
0 
0.2 
0.4 
0.6 
Year 
1960 1970 1980 1990 2000 
C 
Figure S2.1: The distribution of the time of GII.4 pandemic onset. (A) The distribution of the
time at which the Bayesian skyline plot first exhibits an increase in Neτ of more
the 100% relative to baseline. We calculated this time in each sampled step in the
MCMC chain. While most samples support the first increase occurring in the mid-
1990s, a small number of samples support the first increase occurring prior to 1990.
(B) Bayesian skyline plots for MCMC samples supporting the first increase in Neτ
prior to 1990 (red) and post-1990 (blue). The samples supporting an early increase
in Neτ have a small Neτ within the earliest time slice and exhibit a small increase in
Neτ prior to a large increase in the mid-1990s, coinciding with the first increase in
Neτ in the post-1990 increase samples. We therefore defined the time of pandemic
onset within the pre-1990 increase samples as the time at which Neτ increased by
more than 400%. (C) The distribution of the time of increase in GII.4 frequency,
calculated as the time at which Neτ increased by more than 100% relative to baseline
in the post-1990 increase samples or by more than 400% in the pre-1990 increase
samples. The black shaded region shows the 95% HPD of the time of pandemic
emergence.
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Figure S2.2: Comparison of the interaction network at site 459 in solved crystal structures.
The residue at site 459 is shown in red in each case and residues that hydrogen
bond with site 459 either directly or through a single intermediate water molecule
are shown in grey if they are in the same monomer or brown if they are in the other
monomer. Water molecules are shown as blue circles and each hydrogen bond is
shown as a dashed black line. (A) The hydrogen bond network formed by glu-
tamine 459 is shown for six solved P domain structures from the pandemic GII.4
clade: Farmington Hills 2002 unbound (PDB identifier 4OOV), Farmington Hills
2002 bound to Lewis B (4OPS), Den Haag 2006 bound to Lewis A (4WZL), Den
Haag 2006 bound to HBGA type B (4X06), Sydney 2012 bound to HBGA type A
(4WZT) and Sydney 2012 bound to HBGA type B (4OP7). The structures from
the same strain have the same viral sequence. (B) The hydrogen bond network
formed by serine 459 is shown for three solved P domain structures from a CHDC
1970s virus (pre-pandemic): unbound (PDB identifier 5IYN), bound to HBGA type
A (5IYP) and bound to HBGA type B (5IYQ). These three structures have the same
viral sequence. While there are differences in the exact hydrogen bond network
formed within different pandemic GII.4 structures and within different CHDC 1970s
structures, the network is consistently more extensive in the pandemic GII.4 struc-
tures compared with the pre-pandemic GII.4 structures.
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Figure S2.3: Convergent substitutions at sites 285 and 505. Coloured trees of the early GII.4
lineage for sites 285 and 505. Each site exhibits a convergent substitution leading to
the Kaiso 2003 strain and leading to the pandemic GII.4 clade.
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V710I,	R732K,	R738K,	E742D,	I750V,	R754K,	S768A,	N773S,	R778K,	V830A,	D837N,	D983E,	R1004K,	Q1045K,	
E1156G,	K1268R,	R1420K,	A1442D,	K1480Q,	N1484S,	N1515D,	N1575D	
2	 T699A,	S751A,	T883S,	S1270N	
3	 A13V,	L29F,	N118S,	V750I,	G760N,	T850M,	S852N,	P857L,	K927R,	N1193S,	I1364V,	K1425R,	S1616F	
4	 K511R,	G760S,	S762C,	S852N,	A1296T	
5	 A13V,	P79L,	T104A,	R189K,	M650A,	R729K,	A851T	
6	 K496R,	A650T,	N1006S,	N1193S,	M1314I	
7	 None	
8	 R190K,	R1004K	
9	 L79I,	D102E,	I342V,	V491L,	L508V,	I525V,	A586V,	D618E,	P642S,	Y693F,	T699A,	R754K,	T783S,	T850A,	V867I,	
Q1045K,	A1091V,	Q1291E,	I1314M,	V1404I,	P1456S,	I1463V,	M1474V	
p48 NTPase p22 VPg Protease RdRp Nonstructural polyprotein 
NS1/2 NS3 NS4 NS5 NS6 NS7 
1 330 696 875 1008 1189 1699 
A B 
C 
Figure S2.4: Nonsynonymous substitutions close to the GII.P4 and GII.Pe genotypes. (A)
Maximum likelihood phylogeny showing the evolutionary relationship between
GII.P4, GII.Pe and closely related genotypes. Branches are coloured by strain with
the colour matching that of the strain label. Bootstrap supports are shown at trunk
nodes. Part of the pandemic GII.P4 clade has been collapsed for clarity. This clade
was extracted from a nucleotide maximum likelihood tree reconstructed on all GII
and GIV ORF1 sequences. (B) Ancestral reconstruction was carried out to deter-
mine the substitutions occurring along each branch within ORF1. Branches 1-9
lead to the pandemic ORF1 clades following their divergence. Therefore the inde-
pendent evolution leading to these clades following their divergence occurred along
these branches. (C) The nonsynonymous substitutions inferred to occur along each
of the branches 1-9 are shown. Substitutions in red occurred convergently leading
to the pandemic GII.P4 clade (along any of the branches 4-9) and the pandemic
GII.Pe clade (along any of the branches 1-3). Substitutions in blue represent sites
that changed leading to both pandemic clades but the residue change was different
in each case. Note that while there are pairs of sites that are located close together
in the ORF1 sequence that change leading to each pandemic clade, the residues at
these sites are different in each case and there is therefore no reason to expect that
they would result in similar phenotypic changes. The nonstructural polyprotein is
shown with the residues delimiting each individual protein labelled (Belliot et al.,
2003)
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Figure S2.5: Convergent substitutions leading to the GII.P4 and GII.Pe genotypes. A
coloured tree is shown for each of the sites that exhibit convergent substitution lead-
ing to the pandemic GII.P4 and GII.Pe clades after their divergence (red substitu-
tions in figure S2.4 panel C). For each site, the substitution is listed along with the
branches on which the substitution occurred. We suggest that none of these substi-
tutions were essential for pandemic emergence due to either the residue also being
present in other, non-pandemic, genotypes, the substitution reverting in one or more
pandemic strains within the pandemic GII.P4 clade or, in the case of site 79, the site
undergoing a further substitution leading to the pandemic GII.P4 clade. The sites
where the residue present in both pandemic clades is also present in other genotypes
are typically highly variable between two or more residues, with multiple substitu-
tions occurring between these residues. The tree shown is the nucleotide maximum
likelihood tree reconstructed on all available ORF1 sequences from the GII and GIV
genogroups.
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Figure S2.6: Subclades within GII.6 exhibit accumulation of nucleotide change through
time. (A) Maximum likelihood tree of the GII.6 capsid genotype. The tree exhibits
three well diverged subclades, which we named subclade 1 (red), subclade 2 (green)
and subclade 3 (blue). (B) The correlation between root-to-tip distance and collec-
tion date within the GII.6 capsid genotype nucleotide maximum likelihood tree. The
points are coloured by subclade. While there is no correlation when including all
subclades, each subclade appears to exhibit a correlation. (C) We reconstructed a
nucleotide maximum likelihood tree on each GII.6 subclade independently. Plotted
here is the root-to-tip distance versus collection date for each subclade.
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Figure S2.7: Comparison of the magnitude of amino acid change within the pandemic GII.4
clade and pre-pandemic GII.4 lineages. We extracted the pandemic GII.4 clade
and the pre-pandemic GII.4 lineages from the phylogenetic tree in Figure 2.1 and
optimised branch lengths independently using the respective amino acid alignment
and the WAG substitution matrix. We then plotted the accumulation of amino acid
change versus collection date for each sequence within each clade and calculated the
best fit regression line. Both clades exhibit a correlation between amino acid root-
to-tip distance and collection date. Plotted here are the regression lines normalised
so the root of the respective phylogeny occurred at time zero. There is a greater
magnitude of amino acid change in the pandemic GII.4 clade compared with the
pre-pandemic GII.4 lineages.
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Genotype Putative breakpoint Number of samples Accession numbers of
removed removed samples
GII.12 846 2 EF547403.1, KC464498.1
GII.14 273 1 GU017903.2
GII.21 1014 6 AY675554.1, EU019230.2, GQ856468.1
KJ196284.1, JN899245.1, KU687014.1
Table S2.1: Putative recombinant samples removed from capsid genotype datasets. We
screened for recombination within each capsid genotype dataset using SBP. Where
a significant breakpoint was identified, we reconstructed a maximum likelihood tree
on either side of the putative breakpoint and classified sequences that clustered dif-
ferently on each side of the breakpoint with strong bootstrap support as being puta-
tively recombinant. These sequences were removed from further analyses. Putative
recombination was identified within the GII.12, GII.14 and GII.21 genotypes. The
breakpoint here is the most likely breakpoint position within the capsid identified by
SBP and may not be the true recombination breakpoint. Removal of the sequences in
this table resulted in loss of the recombination signal.
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Figure S3.1: Comparison of node and ancestor dates between subsampled datasets. (A) The
mean (circle) and 95% HPD is shown for the date of the root node of the GII.4
genotype and the node one downstream of the root node following the divergence
of a sequence collected in Malaysia in 1978. The date of the GII.4 root excluding
the Malaysia 1978 sequence is comparable to that obtained in a previous study (Bok
et al., 2009) where the Malaysia 1978 sequence was not included. (B) As in panel A,
but the date of the common ancestor of each GII.4 strain is shown. US - US95/96,
FH - Farmington Hills 2002, Hu - Hunter 2004, DH - Den Haag 2006, NO - New
Orleans 2009, Sy - Sydney 2012, As - Asia 2003, Ys - Yerseke 2006, Ap - Apeldoorn
2007, Os - Osaka 2007.
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Figure S3.2: Recombination events in the Apeldoorn lineage. Shown are two hypothetical sce-
narios for the acquisition of RdRp and VP2 genomic regions by the Apeldoorn lin-
eage capsid (consisting of Apeldoorn 2007, New Orleans 2009 and Sydney 2012)
that are consistent with the tree topologies and divergence dates in Figure 3.1. The
tree backbones are from the capsid tree in Figure 3.1 in which the relationship be-
tween Apeldoorn 2007, New Orleans 2009 and Sydney 2012 is uncertain. Therefore
each scenario depicts a hypothetical relationship between these strains that fits that
scenario. Arrows represent a recombination event in which a RdRp or VP2 genomic
region is obtained, with the arrow pointing from donor strain to recipient strain. Tri-
angles at the end of branches represent the remaining lineages within the strain. (A)
This scenario involves the acquisition of a Yerseke 2006-like VP2 prior to the diver-
gence of the strains within the lineage. The relationship between Apeldoorn 2007,
New Orleans 2009 and Sydney 2012 is the same as the well-supported relationship
within the VP2 tree, with Sydney 2012 diverging first. The Yerseke 2006 RdRp is
acquired prior to divergence of strains within the Apeldoorn lineage and Apeldoorn
2007 acquires a Hunter 2004-like RdRp after its divergence from New Orleans 2009.
(B) This scenario involves acquisition of the Yerseke 2006 VP2 and a Hunter 2004-
like RdRp prior to divergence of the strains within the Apeldoorn lineage. Here,
Apeldoorn 2007 branches first and the Yerseke 2006-like RdRp is acquired lead-
ing to the common ancestor of New Orleans 2009 and Sydney 2012. Sydney 2012
acquires its VP2 region from an early Apeldoorn lineage virus that has persisted,
explaining the divergence of Sydney 2012 in the VP2 tree. In both scenarios, Syd-
ney 2012 acquires the GII.Pe RdRp after divergence from Apeldoorn 2007 and New
Orleans 2009. Scenario B requires one more recombination event than scenario A
and requires the persistence of an unsampled early Apeldoorn lineage.
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Figure S3.3: Acquisition of the GII.Pe RdRp by the Sydney 2012 capsid. (A) The Sydney
2012 clade in the capsid MCC tree in Figure 3.1 is shown. Tip branches are coloured
by the RdRp found with that sequence; blue - GII.4 New Orleans 2009-like RdRp,
purple - GII.Pe RdRp. Acquisition of the GII.Pe RdRp by recombination has been
inferred to occur along the starred branches. (B) The GII.Pe-Sydney 2012 clade
in the RdRp MCC tree in Figure 3.1 is shown. While the sequences marked with
green and yellow rectangles each have the GII.Pe RdRp and are monophyletic in
the capsid tree, they are not monophyletic in the RdRp tree and therefore must have
been acquired in separate recombination events. As the GII.Pe RdRp marked with a
yellow rectangle clusters within the GII.Pe-Sydney 2012 clade in the RdRp tree, it
was likely acquired from a virus with a Sydney 2012 capsid. Posterior supports are
shown at key nodes.
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Figure S3.4: Example collection date distributions for pre-pandemic and pre-epidemic se-
quences. We identified 50 putative pre-pandemic and pre-epidemic GII.4 sequences
and estimated the collection date of each sequence using BEAST. The estimated
collection date overlapping with the reported collection date was taken as evidence
to support, but not confirm, the reported collection date, suggesting that these se-
quences are true pre-pandemic/pre-epidemic sequences. Shown here is the posterior
distribution of the estimated collection date for one sequence from each strain with a
pre-pandemic or pre-epidemic sequence. The median of this distribution is shown by
the magenta vertical line. The reported collection date is shown by the red line/red
area; where the collection date was reported to the day this is shown by a vertical
red line, while if the collection date was reported to the nearest month or year, the
red area shows this time span. The red reported collection date overlapping with the
black distribution of the estimated collection date was taken as evidence to support
the reported collection date. The start of the year in which the respective pandemic
or epidemic strain emerged is shown by the blue vertical line. The accession num-
ber of each sequence is shown next to the respective distribution and details of each
sequence are summarised in Table 3.6.
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Figure S3.5: Accumulation of nucleotide change by putative pre-pandemic/pre-epidemic se-
quences. We reconstructed a nucleotide maximum likelihood tree of the P2 domain
of all available GII.4 sequences and rooted the tree to minimise the heuristic resid-
ual mean squared score. Plotted for each strain with a putative pre-pandemic or
pre-epidemic sequence is the root-to-tip distance versus collection date for each se-
quence within the strain. The putative pre-pandemic/pre-epidemic sequences where
the collection date estimated with BEAST overlaps with the reported collection date
are coloured magenta, other sequences from the strain are coloured grey. Each of the
putative pre-pandemic/pre-epidemic sequences exhibits close to the expected level
of nucleotide change for their reported collection date, given the accumulation of
nucleotide change exhibited by other sequences within the same strain. The trend-
line shows the general rate of accumulation of change within the GII.4 genotype, as
calculated from the maximum likelihood phylogenetic tree.
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Most likely GII.4 strain 5’ GII.4 strain 3’ Number of Accession numbers
recombination to breakpoint to breakpoint sequences
breakpoint
537 Den Haag 2006 New Orleans 2009 12 KF712501.1, KF429790.1,
KF712491.1, KF429762.1,
KF712498.1, KF712505.1,
KF712495.1, KF429785.1,
KF429776.1, JX459900.1,
KF712502.1, AB933738.1
537 Den Haag 2006 Apeldoorn 2007 1 AB541362.1
537 New Orleans 2009 Apeldoorn 2007 1 JX448566.1
314 Den Haag 2006 Apeldoorn 2007 1 KF712492.1
314 New Orleans 2009 Den Haag 2006 3 KF196287.1, AB933682.1,
AB447434.1
314 Unclear Osaka 2007 1 GQ845368.2
Table S3.1: Summary of putative recombination events in the GII.4 capsid. Putative recombi-
nation events were identified using SBP. We identified the most likely recombination
breakpoint as the position with the greatest gain in AIC when splitting the alignment
at that position compared with the null model. As SBP can only examine recombi-
nation at variable positions, this may not be the true recombination breakpoint. The
number of sequences that cluster together but in different clades on either side of the
breakpoint is shown. Removal of the sequences in this table resulted in loss of the
recombination signal.
RdRp ancestor Capsid ancestor VP2 ancestor
GII.4 strain Sample 1 Sample 2 Sample 3 Sample 1 Sample 2 Sample 3 Sample 1 Sample 2 Sample 3
US95/96 1993 1993 1994 1994 1993 1993 1994 1994 1994
(1991,1995) (1991,1996) (1992,1996) (1991,1996) (1991,1996) (1991,1996) (1993,1996) (1993,1996) (1993,1996)
Farmington 2000 2000 2000 2001 2000 2001 1999 1999 2000
Hills 2002 (1999,2001) (1999,2001) (1999,2001) (2000,2001) (1999,2001) (2000,2001) (1998,2000) (1998,2000) (1998,2000)
Asia 2003 2002 2002 2002 2001 2001 2001 2001 2001 2001
(2001,2003) (2001,2003) (2001,2003) (1999,2002) (1999,2002) (1999,2002) (2000,2002) (1999,2002) (2000,2002)
Hunter 2004 2002 2002 2002 2003 2002 2002 2002 2002 2002
(2001,2003) (2001,2003) (2001,2003) (2002,2003) (2002,2003) (2002,2003) (2001,2003) (2001,2003) (2001,2003)
Yerseke 2006 2002 2002 2002 2003 2003 2003 2002 2002 2002
(2001,2003) (2001,2003) (2001,2003) (2002,2004) (2002,2004) (2002,2004) (2001,2003) (2001,2003) (2002,2004)
Den Haag 2006 2004 2004 2003 2004 2004 2004 2002 2002 2003
(2003,2005) (2003,2005) (2002,2004) (2002,2005) (2002,2005) (2003,2005) (2001,2003) (2001,2004) (2002,2004)
Osaka 2007 2006 2006 2006 2005 2005 2005 2005 2005 2005
(2005,2007) (2005,2007) (2005,2006) (2004,2006) (2004,2006) (2004,2006) (2004,2006) (2003,2006) (2004,2006)
Apeldoorn 2007 2005 2005 2005 2006 2005 2005 2005 2005 2005
(2004,2006) (2004,2006) (2004,2006) (2005,2007) (2004,2006) (2004,2006) (2004,2006) (2004,2006) (2004,2006)
New Orleans 2005 2005 2005 2006 2005 2005 2006 2005 2005
2009 (2003,2006) (2004,2006) (2003,2006) (2004,2007) (2004,2007) (2004,2006) (2005,2006) (2004,2006) (2005,2006)
Sydney 2012 2009 2009 2009 2007 2007 2006 2005 2005 2005
(2008,2010) (2008,2010) (2008,2010) (2005,2008) (2005,2008) (2005,2008) (2003,2007) (2003,2007) (2003,2007)
Table S3.2: Comparison of strain ancestor dates in each subsampled dataset. Samples 1, 2 and
3 contain a different subset of 41 sequences from Den Haag 2006 and 41 sequences
from New Orleans 2009. The Sydney 2012 RdRp ancestor date is the common an-
cestor of the GII.Pe RdRps associated with the Sydney 2012 capsid.
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Figure S4.1: The majority of viral lineages were imported into the continent of collection
more than a year prior to sampling. We collected each phylogeny tip belonging
to a continent and traced the phylogeographic history of that lineage back in time.
Shown is the average ancestry of viruses collected within each continent, averaged
across all tips from the region within a tree and across the posterior distribution of
trees. The average ancestry is shown as a stacked area plot. As an example, the
top left panel shows the average ancestry of New Orleans 2009 viruses collected
in Africa. At time 0, all viruses are by definition within the continent in which they
were collected. By one year prior to sampling, the majority of ancestors were already
in Africa, while a small number of ancestors were yet to migrate into Africa and at
that time were in Oceania or Asia. The grey vertical dashed lines represent one year
prior to sampling, at which time approximately 86% and 85% of New Orleans 2009
and Sydney 2012 lineages, respectively, had been imported into their continent of
sampling.
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Figure S4.2: Subsampling does not alter estimates of sample persistence. The mean duration
of persistence on each continent is plotted for each subsampled New Orleans 2009
dataset and a New Orleans 2009 dataset without subsampling.
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Figure S4.3: No correlation between the average persistence of viral lineages within conti-
nents between New Orleans 2009 and Sydney 2012. The mean persistence for
New Orleans 2009 lineages within each continent is plotted against the mean persis-
tence for Sydney 2012 viral lineages within the continent.
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Figure S4.4: Variable sites within US95/96. Coloured trees are shown for each of the sites iden-
tified as exhibiting high variability in the US95/96 pandemic GII.4 strain. Each tip
is coloured by the amino acid residue in that sequence at the corresponding site,
residues are shown next to the tree.
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Figure S4.5: Variable sites within Farmington Hills 2002. Coloured trees are shown for each of
the sites identified as exhibiting high variability in the Farmington Hills 2002 pan-
demic GII.4 strain. Each tip is coloured by the amino acid residue in that sequence
at the corresponding site, residues are shown next to the tree.
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Figure S4.6: Variable sites within Hunter 2004. Coloured trees are shown for each of the sites
identified as exhibiting high variability in the Hunter 2004 pandemic GII.4 strain.
Each tip is coloured by the amino acid residue in that sequence at the corresponding
site, residues are shown next to the tree.
256 Appendix A. Supplementary figures and tables
Site 6 Site 9 Site 23 Site 45 Site 171 
Site 193 Site 255 Site 298 Site 333 Site 340 
Site 357 Site 368 Site 372 Site 377 Site 393 
Site 412 Site 414 Site 425 Site 539 
N 
S 
N 
S 
N 
S 
Q 
T 
S 
T 
D 
E 
G 
S 
D 
N 
M 
V 
A 
E 
G 
R 
D 
P 
A 
E 
G 
S 
T 
D 
E 
A 
T 
G 
S 
D 
N 
H 
P 
Q 
N 
T 
 
A 
V 
 
Figure S4.7: Variable sites within Den Haag 2006. Coloured trees are shown for each of the sites
identified as exhibiting high variability in the Den Haag 2006 pandemic GII.4 strain.
Each tip is coloured by the amino acid residue in that sequence at the corresponding
site, residues are shown next to the tree.
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Figure S4.8: Variable sites within New Orleans 2009. Coloured trees are shown for each of
the sites identified as exhibiting high variability in the New Orleans 2009 pandemic
GII.4 strain. Each tip is coloured by the amino acid residue in that sequence at the
corresponding site, residues are shown next to the tree.
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Figure S4.9: Variable sites within Sydney 2012. Coloured trees are shown for each of the sites
identified as exhibiting high variability in the Sydney 2012 pandemic GII.4 strain.
Each tip is coloured by the amino acid residue in that sequence at the corresponding
site, residues are shown next to the tree.
